data_2fwl_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2fwl _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.427 ' HA3' ' HB2' ' A' ' 86' ' ' HIS . . . . . . . . 0 N--CA 1.448 -0.519 0 CA-C-O 120.115 -0.269 . . . . 0.0 113.52 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.06 -39.4 75.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 117.186 0.493 . . . . 0.0 111.165 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.06 -40.17 88.58 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.167 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.405 ' HB ' ' HB ' ' A' ' 83' ' ' VAL . 37.2 mm -80.3 -26.92 11.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.081 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -57.2 -29.34 63.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.923 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -59.57 -30.81 68.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.103 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 75.8 mt-30 -75.39 -36.16 60.93 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.284 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 20.6 m -67.42 -31.8 72.24 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-O 121.048 0.452 . . . . 0.0 110.516 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.51 -19.56 65.98 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.953 -179.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.95 -24.73 71.74 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.256 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 96.3 m -129.32 -40.2 1.46 Allowed 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -179.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -91.3 -7.2 51.72 Favored 'General case' 0 C--N 1.33 -0.253 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.341 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 16.1 mm-40 65.27 176.26 0.21 Allowed 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.892 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 20.3 mp0 -79.35 -8.57 59.17 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.631 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 23.8 p30 -90.93 -20.22 22.44 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.774 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 72.34 22.35 78.94 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.565 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 16.3 mt-30 -98.02 -32.29 11.71 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.978 0.418 . . . . 0.0 110.42 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.671 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.786 179.689 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.226 -0.175 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -128.29 123.91 22.68 Favored Pre-proline 0 C--N 1.327 -0.397 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.939 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.3 158.65 44.62 Favored 'Trans proline' 0 C--O 1.239 0.531 0 C-N-CA 122.889 2.393 . . . . 0.0 113.0 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -78.76 158.7 28.06 Favored 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.782 2.322 . . . . 0.0 112.351 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 65.8 mt -115.4 -38.04 3.88 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.347 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.39 120.3 11.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.127 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 73.43 33.45 58.63 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 -179.042 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 32.4 t60 -143.92 -32.99 0.43 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.585 -0.307 . . . . 0.0 110.548 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.6 t -63.45 -41.12 91.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.629 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -62.04 -35.38 78.42 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.847 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -61.65 -37.58 84.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.513 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.458 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 19.4 mt -79.95 -38.53 18.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.525 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 46.5 mt -62.67 -23.59 67.19 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.556 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -82.7 -10.1 59.06 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.419 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 65.9 mmtt -90.7 154.02 19.86 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.739 0.304 . . . . 0.0 110.35 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -75.42 105.31 6.38 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.71 7.67 55.28 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.458 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -64.44 -34.79 90.85 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 121.255 -0.498 . . . . 0.0 112.105 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 11.4 ptm85 -67.77 -35.17 78.21 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.614 0.245 . . . . 0.0 110.394 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -67.0 -40.09 87.28 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -61.96 -40.67 96.36 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.393 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 86.6 mt -59.43 -34.09 72.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.011 179.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.4 mt -78.98 -42.19 23.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.999 0.428 . . . . 0.0 110.08 179.104 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 42.8 mt -63.3 -37.93 89.17 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.11 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.568 ' O ' ' HA2' ' A' ' 53' ' ' GLY . 0.8 OUTLIER -71.06 -15.47 18.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.013 -179.631 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 3.0 mp -96.66 -44.5 7.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.852 0.358 . . . . 0.0 110.538 179.158 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.6 mt -66.69 -47.23 73.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.059 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 68.9 m-85 -111.92 -55.85 2.46 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.213 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.568 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 120.11 -158.46 15.36 Favored Glycine 0 N--CA 1.441 -1.009 0 C-N-CA 119.888 -1.148 . . . . 0.0 113.938 178.506 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.4 ' H ' ' HB2' ' A' ' 69' ' ' MET . 1.9 tp -152.52 150.01 29.12 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -179.192 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . 0.487 ' OE1' ' HB2' ' A' ' 118' ' ' PRO . 9.3 pt20 -151.09 111.16 4.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.864 0.364 . . . . 0.0 111.726 -179.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -177.37 -143.8 5.09 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.182 178.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.443 ' HA ' ' O ' ' A' ' 65' ' ' TYR . 19.8 mp0 -132.88 66.67 1.55 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' A' ' 64' ' ' LYS . 33.1 pt -66.87 155.07 7.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.247 -178.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 -124.62 100.63 6.73 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.215 0.531 . . . . 0.0 110.817 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 41.0 t -100.32 115.85 42.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.061 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 19.2 mmtp 62.96 23.82 14.22 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.508 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.91 -7.9 65.17 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.654 179.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -97.55 121.0 38.95 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.475 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 17.0 mttp -91.67 144.77 25.18 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.955 0.407 . . . . 0.0 110.914 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.443 ' O ' ' HA ' ' A' ' 57' ' ' GLN . 71.1 m-85 -120.96 177.43 5.11 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.058 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -156.38 71.98 0.73 Allowed 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -140.99 -161.99 8.92 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.766 179.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.666 ' HB ' ' CG ' ' B' ' 88' ' ' PHE . 41.4 t -146.77 136.39 16.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.222 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' MET . . . . . 0.4 ' HB2' ' H ' ' A' ' 54' ' ' LEU . 0.3 OUTLIER -71.19 142.07 50.66 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.527 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 6.5 m -78.52 123.84 27.5 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.719 0.295 . . . . 0.0 110.75 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.5 m -70.78 95.19 1.1 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.351 179.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -84.5 45.83 1.17 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.229 0.538 . . . . 0.0 111.375 -179.192 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -74.12 -16.67 61.0 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.84 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 19.4 pm0 -76.12 -18.65 59.06 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.68 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 65.2 mt -83.48 155.31 23.45 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.889 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 25.0 mtpt -72.69 154.71 40.58 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -55.41 -41.72 73.11 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.715 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -63.17 -37.96 89.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.005 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 51.5 mt-10 -67.07 -45.17 78.14 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.652 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 89.9 mt -60.45 -42.48 91.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.379 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.39 -35.61 73.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.635 179.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.83 -46.39 88.17 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.701 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.405 ' HB ' ' HB ' ' A' ' 7' ' ' ILE . 9.8 p -66.42 -34.94 73.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 C-N-CA 120.485 -0.486 . . . . 0.0 110.669 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 35.2 mt -65.55 -44.82 85.63 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.157 0.503 . . . . 0.0 110.155 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 82.4 m-20 -66.33 -39.06 89.0 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.21 179.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . 0.427 ' HB2' ' HA3' ' A' ' 4' ' ' GLY . 32.3 t60 -63.73 -50.73 67.98 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.516 -0.766 . . . . 0.0 111.597 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.42 HG13 ' N ' ' A' ' 88' ' ' ALA . 41.8 pt -64.39 -39.53 85.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.42 ' N ' HG13 ' A' ' 87' ' ' ILE . . . -63.62 -36.23 83.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.852 0.358 . . . . 0.0 111.663 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.5 p -89.28 -23.57 22.27 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.751 -179.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -61.43 -53.88 50.76 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.875 0.369 . . . . 0.0 111.527 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.411 ' CZ3' ' HB ' ' A' ' 87' ' ' ILE . 5.3 m-90 -86.32 -8.4 57.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.192 0.52 . . . . 0.0 110.566 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 77.56 17.89 78.4 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.493 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.59 -26.96 68.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.301 0.572 . . . . 0.0 110.187 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -73.53 -7.57 52.39 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.208 179.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -98.67 1.14 45.94 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.052 0.453 . . . . 0.0 110.476 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 39.4 mtpt -103.76 11.05 36.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.636 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 15.9 m -125.18 159.77 31.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.987 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.6 ptpt -93.1 112.91 25.02 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.823 0.344 . . . . 0.0 111.155 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 69.99 68.27 1.68 Allowed Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.85 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 65.1 t80 -73.17 124.68 26.09 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.827 0.346 . . . . 0.0 110.395 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 70.5 mttt -98.65 117.56 64.37 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.501 179.261 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -59.55 141.85 97.93 Favored 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.243 1.962 . . . . 0.0 111.374 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -69.83 126.64 30.3 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.306 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.6 p -109.15 152.52 25.01 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.663 -0.698 . . . . 0.0 110.457 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.05 -24.44 58.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 111.333 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 66.6 mm-40 -60.97 -43.21 99.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.894 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.454 ' O ' ' HG2' ' A' ' 110' ' ' LYS . 27.2 mt-10 -68.73 -29.64 68.1 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.006 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 24.3 t -76.98 -40.56 30.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-O 121.186 0.517 . . . . 0.0 109.919 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 9.2 tppt? -62.93 -44.21 96.7 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.814 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . 0.454 ' HG2' ' O ' ' A' ' 107' ' ' GLU . 62.7 pttt -60.49 -32.0 71.01 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.711 0.291 . . . . 0.0 111.361 -179.031 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 97.4 mt -87.61 -30.48 20.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.214 -179.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 46.6 ttm-85 -66.56 -31.05 71.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.051 0.453 . . . . 0.0 110.457 179.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -71.46 -29.99 65.48 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.621 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -89.16 92.65 9.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.729 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 27.3 tptp -66.09 113.71 4.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.415 0.626 . . . . 0.0 111.473 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 81.5 mt -126.63 -174.97 3.26 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.245 179.102 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.437 ' O ' HG21 ' A' ' 121' ' ' VAL . 75.3 p -131.13 147.94 68.26 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.091 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.487 ' HB2' ' OE1' ' A' ' 55' ' ' GLN . 32.4 Cg_exo -58.01 -26.77 76.56 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.6 2.2 . . . . 0.0 112.118 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 11.5 tp60 -71.29 -29.91 65.62 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.447 179.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -80.07 -33.0 39.3 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.073 179.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . 0.437 HG21 ' O ' ' A' ' 117' ' ' THR . 43.2 t -63.15 -25.72 39.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.344 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 26.7 tp . . . . . 0 C--O 1.232 0.163 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.215 178.785 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 86.4 t80 . . . . . 0 N--CA 1.481 1.105 0 CA-C-O 120.716 0.294 . . . . 0.0 110.932 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -35.35 80.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.86 0.362 . . . . 0.0 111.311 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 94.4 mt -76.79 -15.16 59.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.994 0.426 . . . . 0.0 110.675 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.81 13.02 30.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.824 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 1.8 p -139.89 178.04 7.54 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.314 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 40' ' ' HIS . . . . . . . . . . . . . 1.4 p80 -75.54 -6.43 50.21 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.349 0.595 . . . . 0.0 109.824 179.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 41' ' ' THR . . . . . 0.48 ' O ' HG22 ' B' ' 44' ' ' VAL . 0.3 OUTLIER -64.4 -19.71 65.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.07 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.28 -10.92 47.18 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.276 179.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -66.11 -25.78 72.27 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.312 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . 0.48 HG22 ' O ' ' B' ' 41' ' ' THR . 11.8 m -70.62 -12.24 15.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-O 120.987 0.422 . . . . 0.0 111.094 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 38.1 mt -92.16 133.2 30.59 Favored Pre-proline 0 C--N 1.322 -0.602 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 46' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -52.62 145.02 39.96 Favored 'Trans proline' 0 C--N 1.347 0.482 0 C-N-CA 122.831 2.354 . . . . 0.0 112.613 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -60.24 152.55 24.51 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.492 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -84.98 -18.99 60.09 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.947 -0.644 . . . . 0.0 111.911 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 29.8 tttt -75.85 138.42 41.1 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 50' ' ' LEU . . . . . . . . . . . . . 13.2 mt -83.19 134.27 34.98 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.01 0.433 . . . . 0.0 110.272 179.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 51' ' ' GLU . . . . . 0.421 ' HB3' ' HB ' ' B' ' 132' ' ' VAL . 1.6 tt0 -133.46 74.82 1.58 Allowed 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 52' ' ' ARG . . . . . . . . . . . . . 23.2 ttm180 -95.78 132.45 41.0 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.092 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 6.8 m -136.16 -172.0 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 115.668 -0.697 . . . . 0.0 109.909 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . 0.535 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 28.2 t70 -93.07 114.62 63.22 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 179.161 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -72.1 -11.83 27.49 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.541 2.16 . . . . 0.0 112.952 -178.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.17 -52.11 9.83 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 111.887 0.328 . . . . 0.0 111.887 -179.277 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 12.6 p -98.51 0.02 44.25 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 -178.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 58' ' ' VAL . . . . . 0.535 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 8.4 p -61.84 -22.58 28.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-O 121.136 0.494 . . . . 0.0 111.104 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 59' ' ' ARG . . . . . 0.454 ' NH1' ' HB2' ' B' ' 110' ' ' PRO . 12.2 ptt180 -95.77 3.12 54.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.435 -179.707 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -124.04 -31.2 3.4 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.85 0.357 . . . . 0.0 111.095 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -140.23 118.37 11.97 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.448 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 137.79 -177.76 19.68 Favored Glycine 0 N--CA 1.441 -0.969 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.298 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -63.88 -13.2 35.8 Favored 'Trans proline' 0 CA--C 1.53 0.306 0 C-N-CA 123.17 2.58 . . . . 0.0 113.103 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 30.2 m-90 -104.18 12.66 33.57 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.978 0.418 . . . . 0.0 110.328 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -100.42 2.54 42.35 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.563 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -145.14 114.93 4.97 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.472 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -72.61 -9.97 24.62 Favored 'Trans proline' 0 C--O 1.234 0.293 0 C-N-CA 122.64 2.227 . . . . 0.0 112.985 -179.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -81.93 -54.93 4.93 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.848 0.356 . . . . 0.0 110.581 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 69' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -88.07 44.23 1.18 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.051 0.453 . . . . 0.0 110.989 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . 0.426 ' O ' ' HA ' ' B' ' 81' ' ' VAL . . . -84.15 -29.36 26.74 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.383 179.374 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 41.6 t -102.21 106.84 20.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.697 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 40.7 t -120.94 125.03 73.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.136 -179.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -65.93 127.4 31.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.843 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -123.58 20.85 9.43 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.875 -178.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . 158.33 177.81 31.77 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.359 -0.924 . . . . 0.0 112.125 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -61.45 108.69 0.63 Allowed 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.961 2.441 . . . . 0.0 111.729 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 38.8 t30 63.47 25.56 14.53 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.401 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -122.19 123.15 40.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.587 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 24.8 m-85 -129.37 127.42 40.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.725 0.298 . . . . 0.0 110.823 -179.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 100.0 m -93.37 125.37 37.94 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 178.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' B' ' 70' ' ' ALA . 55.8 t -114.52 116.98 54.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.097 0.475 . . . . 0.0 110.825 -179.261 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -85.36 118.48 24.92 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.557 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 83' ' ' VAL . . . . . 0.536 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 20.2 t -116.16 124.82 72.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.138 0.494 . . . . 0.0 110.986 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 34.6 tp -101.05 115.2 29.92 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.524 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 85' ' ' ALA . . . . . 0.456 ' HB1' ' CE1' ' B' ' 90' ' ' TYR . . . -100.46 90.93 4.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.641 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 86' ' ' PHE . . . . . 0.456 ' HB2' ' H ' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -96.44 -163.82 1.09 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.011 0.434 . . . . 0.0 111.524 -179.535 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.456 ' H ' ' HB2' ' B' ' 86' ' ' PHE . . . -55.86 103.31 0.1 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.913 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . 0.666 ' CG ' ' HB ' ' A' ' 68' ' ' VAL . 9.2 m-85 56.34 27.66 12.27 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.085 -0.962 . . . . 0.0 113.071 177.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 89' ' ' GLY . . . . . . . . . . . . . . . -150.38 168.98 30.33 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 119.649 -1.262 . . . . 0.0 113.207 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 90' ' ' TYR . . . . . 0.456 ' CE1' ' HB1' ' B' ' 85' ' ' ALA . 83.8 m-85 -138.78 131.39 28.98 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 91' ' ' GLN . . . . . 0.408 ' HB2' ' CZ ' ' B' ' 86' ' ' PHE . 5.3 tt0 -122.34 130.28 24.75 Favored Pre-proline 0 C--N 1.323 -0.567 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -82.03 172.14 52.91 Favored 'Cis proline' 0 N--CA 1.461 -0.385 0 C-N-CA 123.512 -1.453 . . . . 0.0 112.269 -0.197 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 93' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -152.09 130.07 6.04 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.788 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 94' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -77.96 149.31 87.22 Favored 'Cis proline' 0 N--CA 1.461 -0.418 0 C-N-CA 122.925 -1.698 . . . . 0.0 111.481 -1.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.3 mt -75.65 96.22 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.472 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 96' ' ' GLU . . . . . 0.597 ' HA ' ' O ' ' B' ' 165' ' ' VAL . 41.2 mt-10 -88.32 120.5 29.75 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.449 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 3.2 m -138.29 149.82 64.57 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.692 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -78.99 149.07 22.39 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.747 2.298 . . . . 0.0 112.318 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -92.26 155.83 17.7 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.37 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.13 7.12 87.39 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.355 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -123.36 158.31 31.36 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.44 0.162 . . . . 0.0 110.847 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 102' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -86.26 111.71 20.7 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 103' ' ' ILE . . . . . . . . . . . . . 8.0 mt -100.51 116.42 43.89 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.631 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 20.0 t -90.5 95.66 5.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 105' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -79.83 122.74 27.01 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.204 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -121.02 92.55 3.78 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 107' ' ' ILE . . . . . 0.536 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.5 mp -100.85 137.65 27.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.493 -177.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 5.5 t -141.79 159.49 42.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.499 178.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 109' ' ' SER . . . . . . . . . . . . . 30.6 t -119.5 135.88 24.32 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-O 120.708 0.29 . . . . 0.0 111.18 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 110' ' ' PRO . . . . . 0.454 ' HB2' ' NH1' ' B' ' 59' ' ' ARG . 65.8 Cg_endo -96.67 -0.83 1.82 Allowed 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.212 2.608 . . . . 0.0 113.216 178.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 111' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -129.16 -97.71 0.37 Allowed 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -179.042 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 112' ' ' VAL . . . . . . . . . . . . . 14.6 m -107.7 -175.25 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.709 0.29 . . . . 0.0 111.469 -178.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.1 mt -68.26 144.19 14.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.707 0.765 . . . . 0.0 111.428 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 114' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -141.82 178.02 7.78 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.578 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 115' ' ' GLY . . . . . 0.433 ' HA3' ' OD1' ' B' ' 150' ' ' ASN . . . -141.79 141.81 11.33 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.537 -0.839 . . . . 0.0 111.579 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -110.66 76.66 0.99 Allowed 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.077 0.465 . . . . 0.0 110.343 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 117' ' ' HIS . . . . . 0.468 ' HA ' ' O ' ' B' ' 123' ' ' ILE . 15.1 t-160 -109.11 92.18 3.95 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.024 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . 0.561 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 22.0 t -75.26 114.63 15.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.728 -179.203 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -64.67 119.21 10.11 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.538 -179.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 106.84 1.7 36.63 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.151 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 121' ' ' THR . . . . . 0.561 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 51.0 p -132.4 -174.68 3.52 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.836 0.351 . . . . 0.0 110.777 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -103.01 14.14 32.64 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 178.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . 0.468 ' O ' ' HA ' ' B' ' 117' ' ' HIS . 33.7 mt -83.44 109.37 17.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.572 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -144.54 80.15 1.62 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.437 -0.801 . . . . 0.0 108.957 179.498 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 14.6 p -124.76 148.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.0 -179.047 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -83.47 142.78 30.69 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.304 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 127' ' ' VAL . . . . . . . . . . . . . 46.8 t -116.16 103.84 15.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 128' ' ' LEU . . . . . . . . . . . . . 6.4 mt -92.2 156.57 41.82 Favored Pre-proline 0 C--N 1.322 -0.592 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.135 -178.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -66.59 119.17 6.17 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.725 2.283 . . . . 0.0 112.289 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.71 7.48 87.29 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.708 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -112.48 126.05 54.9 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 132' ' ' VAL . . . . . 0.421 ' HB ' ' HB3' ' B' ' 51' ' ' GLU . 35.1 t -93.94 103.73 15.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.191 0.519 . . . . 0.0 111.137 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 6.3 m -81.97 111.71 18.39 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.653 179.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 134' ' ' THR . . . . . . . . . . . . . 24.3 m -97.99 124.16 42.33 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.543 -179.083 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 40.4 t -136.12 130.99 48.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.932 179.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 136' ' ' ARG . . . . . . . . . . . . . 51.5 mtt180 -99.91 115.98 30.9 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.941 0.401 . . . . 0.0 110.404 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 137' ' ' TYR . . . . . . . . . . . . . 7.7 t80 -121.07 156.54 32.01 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.167 0.508 . . . . 0.0 111.272 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 4.1 m -134.12 100.57 4.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.741 178.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 139' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -72.19 121.92 20.15 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.538 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -108.79 6.99 26.05 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.034 0.445 . . . . 0.0 110.444 179.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 141' ' ' ARG . . . . . . . . . . . . . 8.7 ptp180 -152.17 131.15 6.57 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.215 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 142' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -76.64 -177.33 3.68 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 123.134 2.556 . . . . 0.0 112.782 -179.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 143' ' ' GLY . . . . . . . . . . . . . . . 123.43 179.58 15.82 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.93 -0.653 . . . . 0.0 112.44 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 144' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -101.25 127.04 48.03 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -119.07 143.01 47.37 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.739 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 2.8 tpt180 -108.18 133.01 53.04 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.799 0.333 . . . . 0.0 110.301 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 147' ' ' ILE . . . . . 0.522 ' O ' ' HA ' ' B' ' 161' ' ' PHE . 13.5 mt -87.27 125.22 41.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.655 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 69.7 mt -102.19 116.01 45.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.086 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 149' ' ' CYS . . . . . . . . . . . . . 37.5 t -85.39 90.21 7.88 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.418 179.387 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 150' ' ' ASN . . . . . 0.433 ' OD1' ' HA3' ' B' ' 115' ' ' GLY . 26.5 p-10 -59.36 -38.47 80.49 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -179.185 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -70.95 136.01 48.24 Favored 'General case' 0 C--O 1.25 1.098 0 CA-C-O 121.128 0.489 . . . . 0.0 111.793 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -53.63 164.35 0.55 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.067 -0.969 . . . . 0.0 111.993 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 153' ' ' CYS . . . . . 0.648 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 5.9 p 170.52 89.67 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.996 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 71.07 -174.81 40.0 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.734 178.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 155' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -77.66 -18.36 56.77 Favored 'General case' 0 N--CA 1.463 0.208 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.044 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 156' ' ' GLY . . . . . 0.431 ' O ' HG21 ' A' ' 68' ' ' VAL . . . -108.33 31.27 8.01 Favored Glycine 0 CA--C 1.508 -0.349 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.321 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 157' ' ' HIS . . . . . 0.648 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 0.3 OUTLIER -66.41 -27.89 68.19 Favored 'General case' 0 C--N 1.318 -0.789 0 O-C-N 122.682 -0.305 . . . . 0.0 111.425 -179.337 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 2.6 pm0 -76.07 -17.67 59.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -178.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 159' ' ' ASN . . . . . . . . . . . . . 13.1 t30 -100.96 4.49 42.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.823 0.344 . . . . 0.0 111.038 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 160' ' ' MET . . . . . . . . . . . . . 26.8 ttt -77.5 77.48 4.02 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 161' ' ' PHE . . . . . 0.522 ' HA ' ' O ' ' B' ' 147' ' ' ILE . 8.6 m-30 -115.8 109.89 18.3 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.427 -178.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 162' ' ' GLY . . . . . . . . . . . . . . . -80.4 165.31 48.29 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.921 -0.657 . . . . 0.0 111.598 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.08 127.06 53.04 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 117.377 0.589 . . . . 0.0 112.084 -178.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 40.8 mt -120.15 130.41 74.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 178.55 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 165' ' ' VAL . . . . . 0.597 ' O ' ' HA ' ' B' ' 96' ' ' GLU . 58.0 t -126.3 104.78 13.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 120.869 0.366 . . . . 0.0 110.643 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 166' ' ' VAL . . . . . 0.403 ' HA ' ' O ' ' B' ' 97' ' ' VAL . 0.4 OUTLIER -86.74 127.56 40.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.563 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 30.5 mmtp -80.33 136.03 36.32 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.077 -178.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 168' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 . . . . . 0 C--O 1.248 0.995 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.129 179.63 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.336 0 CA-C-O 120.277 -0.18 . . . . 0.0 113.152 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.65 -38.65 77.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.997 0.398 . . . . 0.0 110.378 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.52 -34.44 77.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.55 179.186 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 50.7 mm -76.07 -35.16 28.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.358 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 68.3 t80 -65.71 -16.43 63.76 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.451 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -58.91 -26.98 64.82 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.978 0.418 . . . . 0.0 110.982 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 60.0 mt-30 -77.11 -30.49 55.27 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.535 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 2.0 m -76.02 -25.87 56.12 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.152 -179.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.29 -18.24 48.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.948 -179.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.15 -20.77 80.05 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.795 -0.717 . . . . 0.0 113.277 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 77.0 m -130.43 -43.58 1.14 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 117.329 0.564 . . . . 0.0 111.971 -179.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 92.1 m-70 -91.42 -5.4 54.44 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 59.47 -172.11 0.12 Allowed 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.617 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -92.47 -9.67 40.63 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.093 -179.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 39.1 p30 -84.63 -8.31 58.93 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.623 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 72.67 20.32 79.58 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.498 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 64.3 mt-30 -117.4 -51.05 2.53 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.941 0.401 . . . . 0.0 110.282 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.623 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.77 -179.675 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.283 0 CA-C-O 120.547 0.213 . . . . 0.0 111.12 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -121.89 137.81 27.81 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.071 -179.186 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -76.16 147.64 30.01 Favored 'Trans proline' 0 C--O 1.24 0.597 0 C-N-CA 122.857 2.371 . . . . 0.0 112.14 179.056 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -80.81 155.5 20.51 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.856 2.371 . . . . 0.0 112.263 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.527 ' O ' HG23 ' A' ' 33' ' ' VAL . 67.4 mt -105.57 -43.75 4.86 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.655 179.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.91 120.02 11.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.431 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.25 12.7 82.88 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.783 -0.722 . . . . 0.0 111.998 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 58.0 t60 -127.62 -22.53 3.59 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.692 0.282 . . . . 0.0 110.899 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 29' ' ' LEU . 60.2 t -65.53 -45.43 92.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.924 0.392 . . . . 0.0 109.945 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -63.05 -31.34 72.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.441 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -65.08 -38.13 89.76 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.198 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.506 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 63.8 mt -78.47 -40.11 24.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.705 -179.595 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 85.8 mt -64.32 -27.32 68.95 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.137 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -79.79 4.58 15.99 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.603 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 59.0 mmtt -109.74 154.79 22.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.629 0.252 . . . . 0.0 110.407 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -66.49 112.6 4.17 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.718 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.55 14.76 77.57 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.009 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.506 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -61.07 -40.75 98.95 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 121.226 -0.511 . . . . 0.0 112.648 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.431 ' O ' HG13 ' A' ' 47' ' ' ILE . 12.7 ptm85 -66.58 -36.31 82.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.679 0.276 . . . . 0.0 110.538 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -67.52 -41.85 83.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.373 0.606 . . . . 0.0 109.52 178.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.474 ' O ' HG23 ' A' ' 49' ' ' VAL . 26.7 t80 -60.0 -43.88 94.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.109 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 35.5 mt -56.06 -45.6 79.21 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.106 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.431 HG13 ' O ' ' A' ' 43' ' ' ARG . 59.2 mt -62.13 -43.39 97.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.802 -179.704 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 62.8 mt -60.93 -38.22 85.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.963 0.411 . . . . 0.0 110.739 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.474 HG23 ' O ' ' A' ' 45' ' ' TYR . 81.0 t -65.6 -31.68 54.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.183 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.0 mp -84.04 -34.65 24.21 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.958 0.409 . . . . 0.0 110.845 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.7 mt -71.54 -56.97 4.87 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.992 -0.549 . . . . 0.0 112.097 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.58 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 55.6 m-85 -103.71 -37.23 7.57 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -178.017 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 119.51 -167.61 13.4 Favored Glycine 0 N--CA 1.445 -0.728 0 C-N-CA 119.878 -1.153 . . . . 0.0 113.438 178.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.436 ' H ' ' HB3' ' A' ' 69' ' ' MET . 4.6 tp -163.33 134.62 4.81 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.867 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . 0.485 ' HB2' ' HB3' ' B' ' 159' ' ' ASN . 0.0 OUTLIER -154.38 116.27 4.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.06 0.457 . . . . 0.0 111.862 179.779 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -162.97 -148.3 5.32 Favored Glycine 0 N--CA 1.442 -0.904 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.462 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -130.52 68.19 1.47 Allowed 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.3 pt -83.39 165.49 2.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.357 -178.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -140.77 113.76 8.4 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.468 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 42.9 t -110.89 116.8 53.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.63 -179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 16.2 mttp 61.38 28.06 17.57 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.521 179.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.46 -20.22 51.59 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.753 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.78 110.87 18.68 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.882 0.372 . . . . 0.0 110.738 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 19.1 mttp -81.45 134.3 35.52 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.69 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -119.73 151.13 39.26 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -156.84 82.54 0.95 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.095 0.474 . . . . 0.0 110.268 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -139.73 -150.73 5.55 Favored Glycine 0 N--CA 1.44 -1.07 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 58.8 t -143.06 118.28 4.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.791 0.329 . . . . 0.0 110.574 179.172 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' MET . . . . . 0.436 ' HB3' ' H ' ' A' ' 54' ' ' LEU . 4.1 tpt -77.02 108.5 10.13 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -55.75 132.33 48.96 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.404 -0.816 . . . . 0.0 113.01 -178.214 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -71.14 121.4 18.25 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.896 178.795 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 36.6 m-85 -108.06 39.22 2.0 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.125 0.488 . . . . 0.0 111.034 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.02 -18.71 65.52 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.414 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.1 pm0 -68.23 -14.91 63.34 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.809 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 82.4 mt -87.35 147.69 25.37 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.888 179.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 53.4 mtpt -71.6 160.71 32.19 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.933 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 76.8 m-20 -53.97 -42.88 69.43 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.18 0.515 . . . . 0.0 110.356 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -63.6 -43.31 97.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.309 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 73.9 mt-10 -64.46 -42.79 95.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.368 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 97.6 mt -66.28 -40.45 86.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.969 0.414 . . . . 0.0 110.498 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.49 -35.85 75.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.884 179.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.32 -45.67 92.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.538 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 12.5 p -70.96 -34.49 55.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.619 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 15.7 mt -62.25 -45.49 93.05 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.263 0.554 . . . . 0.0 109.96 178.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 54.0 m-20 -69.32 -32.83 72.2 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.405 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 25.8 t60 -66.19 -51.09 61.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.749 -179.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 39.5 pt -63.63 -32.43 56.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -178.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -73.63 -33.39 64.53 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 112.034 0.383 . . . . 0.0 112.034 -179.397 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.9 p -91.47 -31.06 16.13 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 -178.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -52.25 -47.94 65.5 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 28.5 m-90 -100.38 10.28 41.45 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.902 0.382 . . . . 0.0 110.934 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 57.44 26.56 56.95 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.869 -0.605 . . . . 0.0 113.309 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -71.41 -29.11 64.53 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.202 0.525 . . . . 0.0 109.998 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -70.55 -15.44 62.77 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.162 179.328 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.2 mttm -80.63 -14.43 58.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.957 0.408 . . . . 0.0 110.632 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 40.6 mtpt -80.86 -21.04 41.04 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.377 -179.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 28.3 m -95.22 161.06 2.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 179.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -97.07 127.86 43.45 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.068 0.461 . . . . 0.0 110.967 -178.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 62.05 61.11 7.02 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.61 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 76.4 t80 -75.61 110.31 9.9 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.857 0.361 . . . . 0.0 110.457 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 95.6 mttt -84.56 124.08 73.75 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 115.683 -0.69 . . . . 0.0 109.737 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_exo -59.52 138.15 82.06 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.631 2.221 . . . . 0.0 111.923 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -65.77 129.28 39.23 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.258 179.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p -111.91 157.57 20.5 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.081 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -60.79 -32.03 71.38 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.484 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.0 mm-40 -66.54 -32.74 74.28 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.821 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -66.51 -38.55 87.45 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.167 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.1 t -71.21 -45.76 69.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.061 179.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.426 ' HZ2' ' HB2' ' A' ' 109' ' ' LYS . 4.2 ttmp? -58.68 -38.33 77.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.713 179.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 25.8 ttpt -58.75 -46.46 87.4 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.328 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 40.0 mt -83.63 -15.94 47.08 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.564 -178.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 48.1 ttm-85 -69.98 -16.86 63.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.379 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -80.34 -38.52 30.4 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.066 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 45.6 tttp -81.62 95.65 7.24 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 19.7 tptm -66.05 114.03 4.91 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.2 0.524 . . . . 0.0 111.532 -179.178 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 79.6 mt -125.35 176.66 6.64 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.005 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.432 ' O ' HG21 ' A' ' 121' ' ' VAL . 61.2 p -124.43 157.57 64.53 Favored Pre-proline 0 C--N 1.319 -0.744 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.359 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.58 ' HG3' ' O ' ' A' ' 52' ' ' TYR . 50.1 Cg_exo -55.1 -30.61 71.39 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.545 2.163 . . . . 0.0 111.745 179.298 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 42.8 tp60 -74.34 -39.92 62.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.881 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 44.8 mt-30 -67.02 -37.63 84.48 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.162 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . 0.432 HG21 ' O ' ' A' ' 117' ' ' THR . 60.8 t -60.37 -31.81 49.46 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 CA-C-O 121.137 0.494 . . . . 0.0 110.18 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 23.9 tp . . . . . 0 C--N 1.331 -0.23 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.543 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 45.9 t80 . . . . . 0 N--CA 1.479 0.991 0 CA-C-O 120.787 0.327 . . . . 0.0 110.926 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 1.6 p -60.96 -36.15 78.65 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -178.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 74.6 mt -69.18 -24.33 64.04 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.763 0.316 . . . . 0.0 111.339 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -93.48 -5.37 49.32 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.14 0.495 . . . . 0.0 111.072 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.9 m -106.82 167.73 9.68 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.887 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 40' ' ' HIS . . . . . . . . . . . . . 6.0 p80 -65.18 -10.38 30.84 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.73 0.3 . . . . 0.0 111.564 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.76 -17.63 64.76 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.932 0.396 . . . . 0.0 111.178 179.421 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.07 -4.35 24.62 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.611 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -66.36 -18.06 67.02 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.962 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 33.4 m -72.44 -12.11 15.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-O 120.927 0.394 . . . . 0.0 111.234 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 71.0 mt -88.72 125.78 61.84 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.727 179.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 46' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -58.08 149.11 73.6 Favored 'Trans proline' 0 C--O 1.234 0.301 0 C-N-CA 122.567 2.178 . . . . 0.0 112.197 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -62.51 142.82 57.76 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.749 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -73.37 -18.36 79.29 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.959 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 45.0 tttp -68.19 127.94 34.74 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.252 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 50' ' ' LEU . . . . . . . . . . . . . 84.2 mt -80.54 114.89 19.75 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.008 0.432 . . . . 0.0 110.488 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 51' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -116.82 103.53 10.41 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.772 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 52' ' ' ARG . . . . . 0.456 ' HD2' ' N ' ' B' ' 52' ' ' ARG . 0.4 OUTLIER -111.0 137.64 48.38 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.412 -178.981 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 10.4 m -133.02 170.47 19.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.886 179.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . 0.48 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 13.7 t70 -81.48 114.05 46.64 Favored Pre-proline 0 C--N 1.327 -0.408 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.371 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -80.18 19.32 1.06 Allowed 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 123.07 2.513 . . . . 0.0 113.576 -178.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.8 -47.94 3.1 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.238 0.542 . . . . 0.0 110.67 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 9.2 p -106.41 12.72 29.41 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.48 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 58' ' ' VAL . . . . . 0.48 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 14.7 p -60.63 -28.59 43.06 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.428 0 CA-C-O 120.944 0.402 . . . . 0.0 111.829 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 59' ' ' ARG . . . . . . . . . . . . . 29.3 ptt180 -97.05 13.19 29.92 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.843 0.354 . . . . 0.0 111.055 -179.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 79.0 mt-30 -130.9 -35.93 1.39 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.95 0.405 . . . . 0.0 110.813 -179.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -135.04 105.68 6.47 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.857 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 145.43 -179.22 22.67 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.862 -0.685 . . . . 0.0 111.884 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_exo -63.33 -27.54 71.61 Favored 'Trans proline' 0 CA--C 1.527 0.145 0 C-N-CA 122.834 2.356 . . . . 0.0 112.551 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 31.3 m-90 -85.03 6.4 25.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.534 -179.273 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -94.55 10.57 34.18 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.973 0.416 . . . . 0.0 110.951 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . 0.404 ' HB3' ' HB2' ' B' ' 69' ' ' GLN . 7.9 t70 -147.65 110.35 3.87 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.222 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_exo -62.39 -32.66 81.03 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.808 2.339 . . . . 0.0 112.915 -179.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.5 -46.13 20.35 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.539 -0.301 . . . . 0.0 111.086 -179.164 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 69' ' ' GLN . . . . . 0.404 ' HB2' ' HB3' ' B' ' 66' ' ' ASP . 13.6 mm100 -80.63 16.92 1.23 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.529 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -78.11 -24.56 47.43 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.992 0.425 . . . . 0.0 110.662 179.366 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 25.5 t -100.46 93.85 3.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.741 179.555 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 2.9 t -105.56 139.64 26.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -178.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 8.5 tt0 -81.51 122.86 28.08 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.023 179.496 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.18 -29.55 18.18 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.678 -179.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . 178.86 -162.54 29.64 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.438 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -61.7 107.72 0.55 Allowed 'Trans proline' 0 C--O 1.236 0.397 0 C-N-CA 123.077 2.518 . . . . 0.0 112.124 -179.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 45.2 t30 63.79 29.76 14.71 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.762 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -133.96 122.31 22.9 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.093 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -127.06 151.42 48.64 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.873 -179.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 91.4 m -119.82 121.58 39.41 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 50.0 t -110.56 117.2 54.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 121.053 0.454 . . . . 0.0 111.242 -178.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -86.39 106.09 17.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.647 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 83' ' ' VAL . . . . . 0.494 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 28.8 t -98.36 122.43 50.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.191 0.52 . . . . 0.0 110.697 -179.398 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 57.4 tp -102.09 109.39 21.08 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.797 179.621 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 85' ' ' ALA . . . . . . . . . . . . . . . -96.6 73.16 2.72 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.153 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 86' ' ' PHE . . . . . 0.51 ' CZ ' ' HB2' ' B' ' 91' ' ' GLN . 0.1 OUTLIER -75.01 -169.77 0.98 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.999 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . . . . . . . . . . . -39.66 93.75 0.01 OUTLIER 'General case' 0 N--CA 1.462 0.127 0 O-C-N 124.316 1.01 . . . . 0.0 113.724 -178.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 53.26 27.73 6.41 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.698 -1.137 . . . . 0.0 112.976 178.22 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 89' ' ' GLY . . . . . . . . . . . . . . . -139.62 -178.4 16.62 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.016 -1.088 . . . . 0.0 112.978 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 90' ' ' TYR . . . . . 0.508 ' OH ' ' HB2' ' B' ' 149' ' ' CYS . 41.2 m-85 -140.32 133.65 29.81 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 91' ' ' GLN . . . . . 0.51 ' HB2' ' CZ ' ' B' ' 86' ' ' PHE . 31.7 tt0 -135.48 128.34 18.11 Favored Pre-proline 0 C--N 1.322 -0.608 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 178.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -79.95 170.88 64.94 Favored 'Cis proline' 0 CA--C 1.53 0.293 0 C-N-CA 123.386 -1.506 . . . . 0.0 112.451 -0.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 93' ' ' ASN . . . . . . . . . . . . . 58.6 t30 -159.76 120.19 1.72 Allowed Pre-proline 0 C--N 1.326 -0.456 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 94' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -78.85 151.39 88.06 Favored 'Cis proline' 0 C--O 1.233 0.264 0 C-N-CA 123.47 -1.471 . . . . 0.0 112.755 -0.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 40.2 mt -81.7 127.27 39.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 96' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -104.52 124.63 49.63 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.516 0.198 . . . . 0.0 110.839 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . 0.458 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 4.8 m -141.22 153.7 66.79 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.101 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.49 161.45 14.77 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 122.718 2.279 . . . . 0.0 111.802 178.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.29 152.73 18.31 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.021 0.438 . . . . 0.0 111.378 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 78.03 8.72 87.32 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.564 -0.743 . . . . 0.0 113.135 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.29 155.26 26.53 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.838 0.351 . . . . 0.0 111.302 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 102' ' ' GLU . . . . . 0.546 ' OE2' ' HD3' ' B' ' 136' ' ' ARG . 77.8 tt0 -81.56 119.26 23.55 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 103' ' ' ILE . . . . . . . . . . . . . 7.8 mt -108.91 113.54 44.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.004 -179.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 21.5 t -91.98 101.14 12.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 105' ' ' PHE . . . . . 0.483 ' O ' ' HA ' ' B' ' 134' ' ' THR . 75.7 m-85 -82.24 122.18 27.59 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.09 -179.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -119.93 89.95 3.23 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 107' ' ' ILE . . . . . 0.494 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.2 mp -97.77 135.82 30.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.576 -178.111 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 4.9 t -133.8 154.21 51.17 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 109' ' ' SER . . . . . 0.688 ' O ' ' HA ' ' B' ' 129' ' ' PRO . 0.7 OUTLIER -122.7 126.28 26.15 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-O 120.652 0.263 . . . . 0.0 111.226 -178.932 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -89.24 -29.05 0.26 Allowed 'Trans proline' 0 N--CA 1.459 -0.547 0 C-N-CA 122.911 2.407 . . . . 0.0 112.808 178.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 111' ' ' ASP . . . . . 0.474 ' CG ' ' H ' ' B' ' 112' ' ' VAL . 8.2 p-10 -95.0 -111.76 0.12 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.863 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 112' ' ' VAL . . . . . 0.474 ' H ' ' CG ' ' B' ' 111' ' ' ASP . 17.0 m -99.86 -172.77 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 120.561 0.22 . . . . 0.0 110.533 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 21.0 mt -74.91 143.78 12.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-O 121.365 0.602 . . . . 0.0 111.543 -179.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 114' ' ' HIS . . . . . 0.467 ' HD2' ' OG ' ' B' ' 109' ' ' SER . 97.7 m-70 -136.95 179.39 6.41 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.461 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 115' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' B' ' 149' ' ' CYS . . . -134.06 134.78 7.61 Favored Glycine 0 N--CA 1.443 -0.845 0 C-N-CA 120.443 -0.885 . . . . 0.0 112.044 -179.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -104.56 85.28 2.3 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-O 121.028 0.442 . . . . 0.0 109.915 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 117' ' ' HIS . . . . . 0.45 ' HA ' ' O ' ' B' ' 123' ' ' ILE . 12.6 t-160 -113.82 109.97 19.39 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.635 179.228 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . 0.449 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 44.5 t -88.04 113.83 25.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.241 0.543 . . . . 0.0 111.119 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -63.38 115.93 5.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.6 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 110.46 0.06 29.39 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.462 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 121' ' ' THR . . . . . 0.449 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 40.9 p -139.65 175.5 9.52 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 179.407 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -92.96 18.24 9.43 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.94 0.4 . . . . 0.0 110.365 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . 0.45 ' O ' ' HA ' ' B' ' 117' ' ' HIS . 53.6 mt -81.9 106.72 13.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.033 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -146.1 100.33 3.37 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 178.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 7.1 p -137.63 144.57 30.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.485 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -82.56 145.63 29.63 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.373 179.122 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 127' ' ' VAL . . . . . . . . . . . . . 6.3 t -115.5 106.17 19.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.589 179.579 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 128' ' ' LEU . . . . . . . . . . . . . 7.7 mp -96.52 153.24 38.9 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.38 -178.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . 0.688 ' HA ' ' O ' ' B' ' 109' ' ' SER . 27.5 Cg_exo -62.65 120.52 8.08 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.693 2.262 . . . . 0.0 112.614 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.68 -13.68 65.04 Favored Glycine 0 N--CA 1.451 -0.312 0 CA-C-N 115.897 -0.592 . . . . 0.0 113.103 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -94.55 148.37 22.32 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 132' ' ' VAL . . . . . . . . . . . . . 22.6 t -112.82 89.27 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 121.026 0.441 . . . . 0.0 110.21 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 5.0 m -62.68 105.59 0.67 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.031 179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 134' ' ' THR . . . . . 0.483 ' HA ' ' O ' ' B' ' 105' ' ' PHE . 23.2 m -102.34 115.48 30.64 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.539 -179.26 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 78.6 t -127.85 136.28 60.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.834 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 136' ' ' ARG . . . . . 0.546 ' HD3' ' OE2' ' B' ' 102' ' ' GLU . 51.2 mtt180 -110.58 113.45 26.08 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.747 0.308 . . . . 0.0 111.056 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 137' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -128.98 166.83 18.42 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.675 -179.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 73.1 m -134.51 110.55 9.44 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 178.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 139' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -84.3 112.97 20.79 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.383 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 78.9 mttt -105.31 -11.0 16.68 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.183 0.516 . . . . 0.0 110.509 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 141' ' ' ARG . . . . . . . . . . . . . 61.5 mtt180 -110.67 114.27 54.84 Favored Pre-proline 0 C--N 1.324 -0.511 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.783 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 142' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -68.67 155.84 67.49 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.906 2.404 . . . . 0.0 112.852 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 143' ' ' GLY . . . . . . . . . . . . . . . 139.38 -168.66 24.83 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.681 179.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 144' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 -109.39 119.71 40.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.72 0.295 . . . . 0.0 110.71 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 31.1 m-85 -106.05 137.38 44.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.017 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.43 135.44 34.67 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.034 0.445 . . . . 0.0 111.636 -178.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 147' ' ' ILE . . . . . . . . . . . . . 40.3 mt -99.79 109.92 25.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 13.4 mt -103.11 119.22 51.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-O 120.817 0.341 . . . . 0.0 111.185 -179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 149' ' ' CYS . . . . . 0.508 ' HB2' ' OH ' ' B' ' 90' ' ' TYR . 3.9 t -85.57 84.05 7.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.093 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 150' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -58.89 -17.51 24.86 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -179.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 32.1 tp60 -80.33 140.06 36.3 Favored 'General case' 0 C--O 1.25 1.102 0 CA-C-O 121.162 0.506 . . . . 0.0 111.928 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -57.25 155.35 8.93 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 114.816 -1.084 . . . . 0.0 110.778 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 153' ' ' CYS . . . . . 0.548 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 1.6 p -176.55 78.34 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.733 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 55.65 -140.93 39.91 Favored Glycine 0 C--N 1.331 0.264 0 O-C-N 123.432 0.458 . . . . 0.0 112.73 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 155' ' ' LEU . . . . . . . . . . . . . 37.4 mt -92.58 -15.49 26.85 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.24 0.543 . . . . 0.0 110.318 179.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 156' ' ' GLY . . . . . . . . . . . . . . . -87.97 63.91 3.71 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.729 -0.668 . . . . 0.0 111.909 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 157' ' ' HIS . . . . . 0.548 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 62.9 t60 -131.71 -37.5 1.18 Allowed 'General case' 0 C--N 1.319 -0.752 0 O-C-N 122.61 -0.347 . . . . 0.0 111.212 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -64.99 -14.05 59.29 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 112.864 0.69 . . . . 0.0 112.864 -178.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 159' ' ' ASN . . . . . 0.485 ' HB3' ' HB2' ' A' ' 55' ' ' GLN . 8.5 t30 -132.99 15.09 4.25 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.879 0.371 . . . . 0.0 111.4 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 160' ' ' MET . . . . . . . . . . . . . 24.7 ttt -87.74 87.87 7.5 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 161' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -128.2 136.2 50.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.852 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 162' ' ' GLY . . . . . . . . . . . . . . . -105.87 176.37 22.05 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 11.7 m -144.38 131.51 20.57 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 117.762 0.781 . . . . 0.0 111.9 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 65.1 mt -114.44 113.11 42.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 165' ' ' VAL . . . . . . . . . . . . . 22.1 t -101.91 103.67 15.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.113 0.482 . . . . 0.0 110.746 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 166' ' ' VAL . . . . . 0.458 ' HA ' ' O ' ' B' ' 97' ' ' VAL . 1.3 p -90.88 123.63 43.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 178.69 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 28.4 mmtp -79.16 147.26 32.74 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.212 -178.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 168' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.245 0.827 0 CA-C-O 118.689 -0.672 . . . . 0.0 109.781 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.231 0 CA-C-O 120.475 -0.069 . . . . 0.0 113.165 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.01 -35.67 80.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.526 0.203 . . . . 0.0 111.128 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -66.17 -34.87 79.02 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.034 0.445 . . . . 0.0 110.533 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 31.9 mm -73.02 -38.06 54.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.054 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -63.08 -21.81 66.43 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.112 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -57.89 -31.85 67.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.989 0.424 . . . . 0.0 110.827 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 66.4 mt-30 -77.31 -32.19 55.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.06 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 15.7 m -70.87 -29.39 65.48 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.074 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.15 -17.58 64.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.415 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.31 5.98 39.84 Favored Glycine 0 N--CA 1.453 -0.21 0 C-N-CA 121.048 -0.596 . . . . 0.0 112.623 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.8 m -153.56 -51.13 0.1 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.602 0.239 . . . . 0.0 110.992 179.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.5 m-70 -85.96 7.01 26.01 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.87 -0.15 . . . . 0.0 111.094 -179.041 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 57.2 mm-40 61.41 -168.19 0.18 Allowed 'General case' 0 N--CA 1.465 0.275 0 O-C-N 123.492 0.495 . . . . 0.0 111.215 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 46.8 mt-30 -104.52 -5.56 21.43 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.908 0.385 . . . . 0.0 110.593 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 14.9 p30 -82.71 -4.46 57.89 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.091 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 75.74 19.18 79.25 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.468 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.504 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 44.6 mt-30 -124.73 -80.16 0.62 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.824 0.345 . . . . 0.0 110.561 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.786 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.905 -179.655 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.349 0 CA-C-O 120.686 0.279 . . . . 0.0 111.096 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -136.09 126.3 16.41 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.007 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -75.72 134.73 16.98 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.395 2.063 . . . . 0.0 111.276 178.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.504 ' HA ' ' HA ' ' A' ' 20' ' ' GLN . 17.1 Cg_exo -67.61 148.0 77.34 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.524 2.149 . . . . 0.0 112.599 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.468 ' O ' HG23 ' A' ' 33' ' ' VAL . 80.3 mt -97.22 -39.86 9.06 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.37 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.38 116.49 8.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.143 179.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.84 29.45 42.54 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.561 -0.828 . . . . 0.0 111.101 -178.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 43.9 t60 -146.06 -34.22 0.31 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.598 -0.301 . . . . 0.0 110.561 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.468 HG23 ' O ' ' A' ' 29' ' ' LEU . 97.2 t -62.48 -43.12 98.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.326 -0.397 . . . . 0.0 109.961 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -61.8 -35.9 79.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.541 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -63.45 -37.61 87.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.23 0.538 . . . . 0.0 110.278 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.498 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 61.7 mt -80.2 -39.32 19.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.142 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 45.9 mt -61.82 -25.27 67.4 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.376 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.5 -13.82 59.65 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.456 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -87.22 151.82 22.83 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.631 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -66.89 111.87 4.0 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.981 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.54 ' HA2' ' OE1' ' A' ' 44' ' ' GLU . . . 83.02 14.59 74.59 Favored Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 120.737 -0.744 . . . . 0.0 111.578 -178.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.498 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -61.58 -39.54 97.5 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.338 -0.458 . . . . 0.0 112.475 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.503 ' O ' HG13 ' A' ' 47' ' ' ILE . 12.7 ptm85 -65.12 -36.1 83.19 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.54 ' OE1' ' HA2' ' A' ' 41' ' ' GLY . 23.0 mp0 -67.66 -39.66 84.54 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.141 0.496 . . . . 0.0 109.775 178.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 31.5 t80 -60.16 -44.2 95.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.099 179.258 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 41.4 mt -60.67 -40.4 91.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.923 179.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.503 HG13 ' O ' ' A' ' 43' ' ' ARG . 71.9 mt -64.91 -42.12 93.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.158 179.63 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 92.2 mt -62.16 -35.42 78.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.873 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.478 ' O ' ' HA2' ' A' ' 53' ' ' GLY . 61.0 t -66.08 -33.35 62.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.733 179.448 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 8.2 mp -83.63 -33.31 25.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.949 0.404 . . . . 0.0 110.496 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 18.3 mt -72.18 -57.02 4.58 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.976 -0.556 . . . . 0.0 112.012 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 39.8 m-85 -105.12 -37.88 6.76 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.973 -177.635 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.478 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 117.59 -168.13 12.89 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.051 -1.071 . . . . 0.0 113.671 178.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.41 ' H ' ' HB3' ' A' ' 69' ' ' MET . 25.6 tp -152.85 150.2 29.09 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . 0.424 HE22 ' NE2' ' B' ' 158' ' ' GLN . 13.1 pt20 -163.94 157.49 18.63 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.672 0.272 . . . . 0.0 111.114 -178.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 138.25 -118.38 1.61 Allowed Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.727 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 6.0 tp60 -161.82 82.8 0.58 Allowed 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 4.0 pt -96.4 148.14 5.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.036 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -121.44 105.27 10.34 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.165 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.4 HG13 ' HG2' ' A' ' 61' ' ' LYS . 6.9 t -126.68 135.7 62.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 179.616 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.4 ' HG2' HG13 ' A' ' 60' ' ' VAL . 21.3 mmtp 60.11 28.14 17.66 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 121.079 0.466 . . . . 0.0 110.814 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.19 20.91 78.8 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.793 -0.639 . . . . 0.0 112.447 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 45.2 mtt -118.03 121.41 40.55 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -90.39 100.22 13.09 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.196 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -85.18 139.87 31.35 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.657 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -139.73 81.61 1.83 Allowed 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.434 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.9 -160.95 9.96 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.667 -0.777 . . . . 0.0 111.946 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 64.5 t -138.46 114.04 9.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.932 0.396 . . . . 0.0 110.29 179.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' MET . . . . . 0.41 ' HB3' ' H ' ' A' ' 54' ' ' LEU . 5.0 tpt -69.73 114.91 8.38 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 178.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.5 m -63.48 135.07 56.63 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.779 -177.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -72.09 126.87 30.86 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.412 179.23 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 37.1 m-85 -110.36 34.35 3.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.122 0.487 . . . . 0.0 110.661 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -69.02 -8.49 45.49 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.843 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 18.0 pm0 -72.22 -20.19 61.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.86 0.362 . . . . 0.0 110.721 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 22.9 mt -82.09 159.06 23.49 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.255 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.43 ' HB2' ' HG3' ' A' ' 79' ' ' GLU . 22.5 mtpt -70.29 155.11 41.11 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.255 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 40.3 m-20 -61.51 -37.05 82.28 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.002 0.43 . . . . 0.0 110.31 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -69.29 -19.99 63.9 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.952 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . 0.43 ' HG3' ' HB2' ' A' ' 76' ' ' LYS . 41.1 mt-10 -89.23 -41.85 11.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.371 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 81.9 mt -62.93 -38.84 82.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.857 179.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.55 -28.4 64.89 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.161 178.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.13 -46.46 67.6 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.327 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 14.2 p -65.27 -36.93 78.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 C-N-CA 120.81 -0.356 . . . . 0.0 110.161 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 41.1 mt -63.41 -44.02 95.85 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.168 0.509 . . . . 0.0 109.829 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 50.1 m-20 -64.51 -43.15 94.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.891 178.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 44.5 t60 -61.09 -55.23 34.96 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.354 -178.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 46.6 pt -60.6 -35.65 65.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.476 0.547 . . . . 0.0 112.476 -177.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -73.39 -34.2 65.4 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -178.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 22.1 p -89.85 -35.05 15.87 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.631 0.604 . . . . 0.0 112.631 -178.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -59.32 -44.51 92.58 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 15.8 m-90 -91.35 2.21 56.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.813 0.339 . . . . 0.0 111.014 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 64.44 23.99 68.93 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.9 -0.591 . . . . 0.0 113.273 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.435 ' HA ' ' HD3' ' A' ' 96' ' ' LYS . 0.2 OUTLIER -75.28 -28.73 59.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.191 0.52 . . . . 0.0 109.976 -179.913 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -73.47 -6.43 46.37 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.919 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -91.03 -7.12 52.78 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.175 179.362 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.435 ' HD3' ' HA ' ' A' ' 93' ' ' ASP . 34.3 mtpt -96.43 11.21 35.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.34 -179.211 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 13.0 m -126.1 151.04 32.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.017 178.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.3 ptpt -86.46 122.85 30.98 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.061 0.458 . . . . 0.0 111.967 -179.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 64.42 62.05 5.44 Favored Glycine 0 N--CA 1.453 -0.232 0 CA-C-N 115.617 -0.72 . . . . 0.0 113.424 178.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -72.46 122.7 21.71 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.778 0.323 . . . . 0.0 110.508 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 78.5 mttt -96.69 125.16 47.9 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.848 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -57.24 132.65 52.43 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.362 2.042 . . . . 0.0 111.393 179.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -61.95 132.57 53.42 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.581 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -113.36 153.83 27.89 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.733 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -63.33 -30.33 71.49 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.051 0.453 . . . . 0.0 110.774 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.0 mm-40 -61.24 -32.06 71.85 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.954 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -68.23 -45.72 72.48 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.176 0.512 . . . . 0.0 110.199 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 11.7 t -65.0 -46.4 91.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.527 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 26.0 ttpt -62.91 -36.01 81.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.747 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 32.9 ttpt -63.94 -47.7 79.45 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.124 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 80.3 mt -74.21 -25.69 59.82 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.046 0.45 . . . . 0.0 110.876 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 21.0 ttm-85 -72.74 -9.02 58.16 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.689 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -70.13 -37.45 75.29 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.032 0.444 . . . . 0.0 110.027 179.062 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -92.47 103.77 16.16 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.453 179.144 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 25.9 tptp -68.25 99.68 0.94 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.3 0.571 . . . . 0.0 111.009 -179.182 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 72.7 mt -108.86 -174.74 2.59 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.901 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 1.3 p -138.47 163.04 49.85 Favored Pre-proline 0 C--N 1.32 -0.699 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 179.442 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_exo -50.87 -41.66 54.61 Favored 'Trans proline' 0 CA--C 1.533 0.472 0 C-N-CA 122.686 2.257 . . . . 0.0 112.841 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 35.7 tp60 -65.63 -32.41 73.97 Favored 'General case' 0 CA--C 1.53 0.212 0 CA-C-O 120.767 0.318 . . . . 0.0 110.856 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 57.8 mt-30 -73.43 -35.24 65.76 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.182 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 50.1 t -66.46 -36.6 77.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 20.3 tp . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.963 178.827 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 61.5 t80 . . . . . 0 N--CA 1.48 1.049 0 CA-C-O 120.464 0.173 . . . . 0.0 111.024 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 4.1 m -59.83 -40.81 89.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.029 0.443 . . . . 0.0 111.436 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 94.9 mt -80.86 -3.46 51.33 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.455 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -103.53 -6.3 21.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.028 0.442 . . . . 0.0 110.993 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.0 p -116.31 179.97 3.84 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.651 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 40' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -68.09 -8.63 39.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.549 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 41' ' ' THR . . . . . 0.428 ' O ' HG21 ' B' ' 44' ' ' VAL . 0.2 OUTLIER -61.37 -20.67 63.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.329 -179.928 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -72.06 -8.86 57.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.198 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -70.3 -18.7 75.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.326 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . 0.428 HG21 ' O ' ' B' ' 41' ' ' THR . 8.9 m -74.61 -11.24 14.32 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-O 121.136 0.494 . . . . 0.0 110.905 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 38.1 mt -86.82 131.93 43.71 Favored Pre-proline 0 C--N 1.322 -0.625 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.596 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 46' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -53.56 134.62 58.72 Favored 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.797 2.331 . . . . 0.0 112.288 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -56.54 140.21 47.15 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.24 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -68.69 -23.59 75.52 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.914 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 80.0 tttt -64.08 116.87 6.33 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.933 0.397 . . . . 0.0 110.303 179.311 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 50' ' ' LEU . . . . . . . . . . . . . 80.2 mt -91.66 93.28 8.83 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.01 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 51' ' ' GLU . . . . . . . . . . . . . 21.0 mt-10 -89.19 103.7 16.3 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 52' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -90.7 114.79 27.2 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.797 0.332 . . . . 0.0 110.72 -179.792 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.19 -173.48 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.735 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . 0.579 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 17.3 t70 -96.04 111.41 56.16 Favored Pre-proline 0 C--N 1.326 -0.435 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -78.06 17.43 1.02 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.752 2.301 . . . . 0.0 113.755 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.6 -55.99 2.16 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.442 0.639 . . . . 0.0 110.609 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.8 -2.03 55.5 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.092 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 58' ' ' VAL . . . . . 0.579 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 12.1 p -56.22 -28.37 25.56 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -179.316 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 59' ' ' ARG . . . . . . . . . . . . . 37.3 ptt180 -98.43 12.0 36.37 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.068 0.461 . . . . 0.0 111.031 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 58.8 mt-30 -124.41 -39.35 2.33 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.214 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -140.63 133.87 29.63 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.995 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.07 170.86 12.94 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.027 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -60.46 -28.19 86.26 Favored 'Trans proline' 0 CA--C 1.529 0.229 0 C-N-CA 122.682 2.255 . . . . 0.0 112.712 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 32.3 m-90 -84.55 -2.62 57.63 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.154 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.92 -1.12 57.86 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.91 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -122.69 105.07 35.9 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.592 -179.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_exo -69.06 -23.76 33.65 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.888 2.392 . . . . 0.0 112.625 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -83.81 -47.55 11.01 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.134 0.492 . . . . 0.0 110.371 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 69' ' ' GLN . . . . . . . . . . . . . 17.6 mm100 -86.19 20.92 2.17 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.764 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . 0.439 ' O ' ' HA ' ' B' ' 81' ' ' VAL . . . -71.74 -24.25 61.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.141 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 33.9 t -112.21 103.35 15.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.261 179.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 9.6 t -122.06 130.39 74.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.435 -0.348 . . . . 0.0 111.049 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 6.2 tt0 -78.08 105.15 9.1 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 178.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -78.57 -23.76 45.89 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.152 -0.476 . . . . 0.0 112.041 -178.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . -164.17 177.39 39.91 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.366 -0.921 . . . . 0.0 112.242 -179.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -55.92 115.84 2.75 Favored 'Trans proline' 0 C--O 1.235 0.366 0 C-N-CA 122.85 2.367 . . . . 0.0 112.414 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 18.1 t30 65.27 28.18 11.99 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.533 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 34.4 tt0 -135.64 120.25 18.24 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.839 0.352 . . . . 0.0 110.69 179.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 34.3 m-85 -119.97 126.28 50.48 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.94 -178.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 59.4 m -97.85 124.65 42.34 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 81' ' ' VAL . . . . . 0.439 ' HA ' ' O ' ' B' ' 70' ' ' ALA . 44.7 t -115.15 117.76 56.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 121.09 0.471 . . . . 0.0 111.081 -179.342 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -88.86 95.51 10.32 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.2 178.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 83' ' ' VAL . . . . . 0.515 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 21.7 t -90.46 120.3 39.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.282 -179.152 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 58.0 tp -101.2 109.12 20.94 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.848 179.22 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.79 70.31 10.35 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 86' ' ' PHE . . . . . 0.468 ' CZ ' ' HA3' ' B' ' 89' ' ' GLY . 53.5 p90 -63.0 179.13 0.41 Allowed 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.952 -178.737 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.12 102.94 0.05 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.464 -178.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 64.11 26.96 14.05 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 114.845 -1.07 . . . . 0.0 113.005 178.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 89' ' ' GLY . . . . . 0.468 ' HA3' ' CZ ' ' B' ' 86' ' ' PHE . . . -156.53 -179.52 31.58 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 119.776 -1.202 . . . . 0.0 113.285 179.42 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 90' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -135.71 132.02 36.37 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 91' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -124.1 137.64 29.33 Favored Pre-proline 0 C--N 1.324 -0.525 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -80.12 174.46 48.54 Favored 'Cis proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.249 -1.563 . . . . 0.0 111.971 -0.362 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 93' ' ' ASN . . . . . 0.419 ' OD1' ' HA ' ' B' ' 94' ' ' PRO . 55.4 t30 -161.14 124.86 1.94 Allowed Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 94' ' ' PRO . . . . . 0.419 ' HA ' ' OD1' ' B' ' 93' ' ' ASN . 69.3 Cg_endo -74.55 151.82 97.45 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.371 -1.512 . . . . 0.0 113.162 0.182 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 66.0 mt -85.78 108.56 17.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.917 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 96' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -94.15 115.43 27.71 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.481 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 97' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 2.6 m -132.6 155.31 81.36 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.65 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -84.6 160.89 12.52 Favored 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.492 2.128 . . . . 0.0 112.524 179.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.05 146.02 27.98 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.836 0.35 . . . . 0.0 111.031 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.47 -5.32 84.83 Favored Glycine 0 N--CA 1.452 -0.266 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.497 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -105.07 157.45 17.24 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.762 0.315 . . . . 0.0 111.406 -179.341 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 102' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -84.86 116.61 23.41 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 103' ' ' ILE . . . . . . . . . . . . . 24.2 mt -104.02 120.65 54.54 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.092 0.472 . . . . 0.0 110.766 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 16.7 t -96.37 99.36 8.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.262 179.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 105' ' ' PHE . . . . . 0.451 ' O ' ' HA ' ' B' ' 134' ' ' THR . 66.0 m-85 -84.07 118.62 24.19 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.343 -178.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 54.7 mttm -115.76 95.69 5.25 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 177.678 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 107' ' ' ILE . . . . . 0.515 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.1 mp -102.46 137.01 32.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.173 -177.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 3.3 t -138.85 157.19 46.51 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 109' ' ' SER . . . . . 0.602 ' O ' ' HA ' ' B' ' 129' ' ' PRO . 39.4 t -125.69 138.05 31.18 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 111.846 0.314 . . . . 0.0 111.846 -178.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -93.52 -11.51 1.51 Allowed 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 123.118 2.546 . . . . 0.0 112.666 178.15 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 111' ' ' ASP . . . . . 0.58 ' CG ' ' H ' ' B' ' 112' ' ' VAL . 11.5 p-10 -115.84 -113.98 0.34 Allowed 'General case' 0 CA--C 1.537 0.454 0 O-C-N 122.271 -0.268 . . . . 0.0 111.493 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 112' ' ' VAL . . . . . 0.58 ' H ' ' CG ' ' B' ' 111' ' ' ASP . 20.1 m -93.11 -179.05 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.676 0.274 . . . . 0.0 110.544 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.1 mt -73.42 136.01 26.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.24 0.543 . . . . 0.0 110.554 179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 114' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -122.83 174.13 7.33 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 115' ' ' GLY . . . . . 0.544 ' O ' ' HA ' ' B' ' 149' ' ' CYS . . . -124.96 121.35 4.28 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.999 -179.613 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -96.83 80.57 3.04 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 117' ' ' HIS . . . . . . . . . . . . . 12.2 t-80 -113.79 110.27 19.88 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.57 179.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . 0.527 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 21.6 t -88.64 113.56 25.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-O 120.966 0.412 . . . . 0.0 110.316 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -63.02 115.47 4.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.957 -179.269 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 110.08 1.74 29.99 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.686 179.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 121' ' ' THR . . . . . 0.527 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 31.7 p -138.36 178.96 6.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.652 0.263 . . . . 0.0 110.658 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -96.52 20.58 10.45 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.129 0.49 . . . . 0.0 110.646 179.297 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 34.2 mt -86.95 109.38 19.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.246 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -150.28 103.82 3.19 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.761 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 9.0 p -143.41 151.78 16.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.275 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.75 134.68 34.04 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.145 0.498 . . . . 0.0 110.419 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 127' ' ' VAL . . . . . . . . . . . . . 5.1 t -99.17 96.98 5.41 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.884 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 128' ' ' LEU . . . . . . . . . . . . . 4.8 mp -87.93 147.18 40.32 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.773 -179.131 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . 0.602 ' HA ' ' O ' ' B' ' 109' ' ' SER . 28.5 Cg_endo -63.78 118.07 5.03 Favored 'Trans proline' 0 N--CA 1.462 -0.336 0 C-N-CA 122.52 2.147 . . . . 0.0 112.307 179.831 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.93 -4.29 85.67 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.832 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -102.58 139.87 37.61 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 132' ' ' VAL . . . . . . . . . . . . . 59.8 t -101.63 92.31 2.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.251 0.548 . . . . 0.0 110.756 179.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 5.3 m -73.29 105.59 4.76 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.842 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 134' ' ' THR . . . . . 0.451 ' HA ' ' O ' ' B' ' 105' ' ' PHE . 24.6 m -100.66 121.18 41.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.387 -179.024 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 48.2 t -128.13 137.3 57.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.177 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 136' ' ' ARG . . . . . . . . . . . . . 68.6 mtt-85 -108.74 120.26 41.96 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.899 0.38 . . . . 0.0 110.663 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 137' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -136.81 151.55 49.29 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.954 0.407 . . . . 0.0 111.081 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 8.3 m -120.48 100.17 6.99 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.806 179.077 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 139' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -73.27 96.87 2.35 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.344 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 83.5 mttt -91.78 -5.55 53.32 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.01 0.433 . . . . 0.0 110.668 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 141' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 -122.79 113.56 30.17 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.097 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 142' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -72.59 167.45 27.07 Favored 'Trans proline' 0 C--O 1.236 0.409 0 C-N-CA 122.591 2.194 . . . . 0.0 112.342 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 143' ' ' GLY . . . . . 0.463 ' N ' HG12 ' B' ' 166' ' ' VAL . . . 137.29 -159.56 24.79 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.245 -179.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 144' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -120.33 116.82 26.28 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.781 0.324 . . . . 0.0 110.349 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 51.4 m-85 -110.11 147.04 34.4 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.92 -179.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 12.5 mmt180 -110.22 133.12 53.55 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.064 0.459 . . . . 0.0 111.456 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 147' ' ' ILE . . . . . . . . . . . . . 40.5 mt -88.0 131.46 35.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.708 178.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 46.4 mt -115.53 115.14 48.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 120.951 0.405 . . . . 0.0 110.179 179.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 149' ' ' CYS . . . . . 0.544 ' HA ' ' O ' ' B' ' 115' ' ' GLY . 42.5 t -79.9 89.1 5.28 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.751 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 150' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -64.13 -25.09 67.94 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 10.2 tp60 -81.05 135.85 35.88 Favored 'General case' 0 C--O 1.247 0.94 0 CA-C-O 121.204 0.526 . . . . 0.0 111.764 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -53.53 161.85 0.94 Allowed 'General case' 0 N--CA 1.471 0.621 0 CA-C-N 114.893 -1.049 . . . . 0.0 112.386 -178.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 153' ' ' CYS . . . . . 0.407 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 1.6 p 176.44 65.17 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.914 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 52.79 -142.67 25.85 Favored Glycine 0 CA--C 1.518 0.262 0 O-C-N 123.464 0.478 . . . . 0.0 114.019 179.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 155' ' ' LEU . . . . . . . . . . . . . 91.4 mt -72.91 -27.1 61.67 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.741 0.305 . . . . 0.0 111.527 -179.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 156' ' ' GLY . . . . . . . . . . . . . . . -87.32 62.14 4.14 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.591 -0.814 . . . . 0.0 111.623 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 157' ' ' HIS . . . . . 0.407 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 69.2 t60 -127.78 -59.3 1.21 Allowed 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -178.831 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . 0.424 ' NE2' HE22 ' A' ' 55' ' ' GLN . 4.5 pm0 -57.71 -33.23 68.19 Favored 'General case' 0 C--N 1.328 -0.333 0 O-C-N 123.463 0.477 . . . . 0.0 112.188 -178.359 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 159' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -107.49 14.14 26.14 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.719 -0.392 . . . . 0.0 111.009 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 160' ' ' MET . . . . . . . . . . . . . 26.3 ttt -84.99 85.15 7.51 Favored 'General case' 0 C--O 1.237 0.426 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 161' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -112.66 -177.14 3.07 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.972 -179.282 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 162' ' ' GLY . . . . . . . . . . . . . . . -148.21 150.98 23.25 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 178.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 7.5 m -113.03 108.31 17.17 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 117.317 0.558 . . . . 0.0 111.659 -179.022 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 41.1 mt -102.5 111.86 33.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 165' ' ' VAL . . . . . . . . . . . . . 15.0 t -108.49 102.78 14.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 121.175 0.512 . . . . 0.0 110.451 -179.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 166' ' ' VAL . . . . . 0.463 HG12 ' N ' ' B' ' 143' ' ' GLY . 0.7 OUTLIER -88.06 120.75 37.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 179.209 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 51.9 mmtt -67.32 155.93 37.69 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.654 -178.354 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 168' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 . . . . . 0 C--O 1.249 1.035 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.094 -179.459 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.408 ' OD1' ' HB2' ' A' ' 6' ' ' LYS . 4.1 p-10 . . . . . 0 N--CA 1.481 1.095 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.427 ' HA3' ' HB2' ' A' ' 86' ' ' HIS . . . -71.72 -32.66 63.92 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.931 -0.652 . . . . 0.0 113.52 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.06 -39.4 75.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 117.186 0.493 . . . . 0.0 111.165 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.408 ' HB2' ' OD1' ' A' ' 3' ' ' ASP . 0.0 OUTLIER -60.06 -40.17 88.58 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.167 179.839 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.405 ' HB ' ' HB ' ' A' ' 83' ' ' VAL . 37.2 mm -80.3 -26.92 11.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.081 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -57.2 -29.34 63.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.923 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -59.57 -30.81 68.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.103 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.507 ' O ' HMC3 ' A' ' 132' ' ' HEC . 75.8 mt-30 -75.39 -36.16 60.93 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.284 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 20.6 m -67.42 -31.8 72.24 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-O 121.048 0.452 . . . . 0.0 110.516 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.51 -19.56 65.98 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.953 -179.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.95 -24.73 71.74 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.256 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 96.3 m -129.32 -40.2 1.46 Allowed 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -179.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -91.3 -7.2 51.72 Favored 'General case' 0 C--N 1.33 -0.253 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.341 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 16.1 mm-40 65.27 176.26 0.21 Allowed 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.892 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 20.3 mp0 -79.35 -8.57 59.17 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.631 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 23.8 p30 -90.93 -20.22 22.44 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.774 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 72.34 22.35 78.94 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.565 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 16.3 mt-30 -98.02 -32.29 11.71 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.978 0.418 . . . . 0.0 110.42 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 79.68 -154.65 38.24 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.786 179.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 43.2 mm -128.54 125.43 23.15 Favored Pre-proline 0 C--N 1.323 -0.552 0 C-N-CA 122.472 0.309 . . . . 0.0 110.587 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_exo -56.59 114.86 2.11 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.92 2.413 . . . . 0.0 112.573 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 92.27 4.35 66.51 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 116.037 -0.528 . . . . 0.0 113.334 179.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.484 ' O ' HMD3 ' A' ' 132' ' ' HEC . . . -139.81 -53.69 0.54 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.137 0.469 . . . . 0.0 112.125 -179.518 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -128.29 123.91 22.68 Favored Pre-proline 0 C--N 1.327 -0.397 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.939 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.3 158.65 44.62 Favored 'Trans proline' 0 C--O 1.239 0.531 0 C-N-CA 122.889 2.393 . . . . 0.0 113.0 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -78.76 158.7 28.06 Favored 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.782 2.322 . . . . 0.0 112.351 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 65.8 mt -115.4 -38.04 3.88 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.347 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.39 120.3 11.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.127 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 73.43 33.45 58.63 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 -179.042 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 32.4 t60 -143.92 -32.99 0.43 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.585 -0.307 . . . . 0.0 110.548 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.6 t -63.45 -41.12 91.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.629 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -62.04 -35.38 78.42 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.847 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -61.65 -37.58 84.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.513 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.458 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 19.4 mt -79.95 -38.53 18.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.525 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 46.5 mt -62.67 -23.59 67.19 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.556 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -82.7 -10.1 59.06 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.419 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 65.9 mmtt -90.7 154.02 19.86 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.739 0.304 . . . . 0.0 110.35 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -75.42 105.31 6.38 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.71 7.67 55.28 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.458 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -64.44 -34.79 90.85 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 121.255 -0.498 . . . . 0.0 112.105 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 11.4 ptm85 -67.77 -35.17 78.21 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.614 0.245 . . . . 0.0 110.394 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -67.0 -40.09 87.28 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -61.96 -40.67 96.36 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.393 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 86.6 mt -59.43 -34.09 72.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.011 179.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.4 mt -78.98 -42.19 23.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.999 0.428 . . . . 0.0 110.08 179.104 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 42.8 mt -63.3 -37.93 89.17 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.11 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.568 ' O ' ' HA2' ' A' ' 53' ' ' GLY . 0.8 OUTLIER -71.06 -15.47 18.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.013 -179.631 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 3.0 mp -96.66 -44.5 7.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.852 0.358 . . . . 0.0 110.538 179.158 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.6 mt -66.69 -47.23 73.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.059 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 68.9 m-85 -111.92 -55.85 2.46 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.213 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.568 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 120.11 -158.46 15.36 Favored Glycine 0 N--CA 1.441 -1.009 0 C-N-CA 119.888 -1.148 . . . . 0.0 113.938 178.506 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.4 ' H ' ' HB2' ' A' ' 69' ' ' MET . 1.9 tp -152.52 150.01 29.12 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -179.192 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . 0.487 ' OE1' ' HB2' ' A' ' 118' ' ' PRO . 9.3 pt20 -151.09 111.16 4.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.864 0.364 . . . . 0.0 111.726 -179.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -177.37 -143.8 5.09 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.182 178.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.443 ' HA ' ' O ' ' A' ' 65' ' ' TYR . 19.8 mp0 -132.88 66.67 1.55 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' A' ' 64' ' ' LYS . 33.1 pt -66.87 155.07 7.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.247 -178.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 -124.62 100.63 6.73 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.215 0.531 . . . . 0.0 110.817 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 41.0 t -100.32 115.85 42.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.061 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 19.2 mmtp 62.96 23.82 14.22 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.508 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.91 -7.9 65.17 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.654 179.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -97.55 121.0 38.95 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.475 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 17.0 mttp -91.67 144.77 25.18 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.955 0.407 . . . . 0.0 110.914 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.443 ' O ' ' HA ' ' A' ' 57' ' ' GLN . 71.1 m-85 -120.96 177.43 5.11 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.058 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -156.38 71.98 0.73 Allowed 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -140.99 -161.99 8.92 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.766 179.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.666 ' HB ' ' CG ' ' B' ' 88' ' ' PHE . 41.4 t -146.77 136.39 16.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.222 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' MET . . . . . 0.4 ' HB2' ' H ' ' A' ' 54' ' ' LEU . 0.3 OUTLIER -71.19 142.07 50.66 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.527 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 6.5 m -78.52 123.84 27.5 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.719 0.295 . . . . 0.0 110.75 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.5 m -70.78 95.19 1.1 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.351 179.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -84.5 45.83 1.17 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.229 0.538 . . . . 0.0 111.375 -179.192 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -74.12 -16.67 61.0 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.84 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 19.4 pm0 -76.12 -18.65 59.06 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.68 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 65.2 mt -83.48 155.31 23.45 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.889 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 25.0 mtpt -72.69 154.71 40.58 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -55.41 -41.72 73.11 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.715 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -63.17 -37.96 89.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.005 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 51.5 mt-10 -67.07 -45.17 78.14 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.652 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 89.9 mt -60.45 -42.48 91.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.379 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.39 -35.61 73.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.635 179.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.83 -46.39 88.17 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.701 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.405 ' HB ' ' HB ' ' A' ' 7' ' ' ILE . 9.8 p -66.42 -34.94 73.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 C-N-CA 120.485 -0.486 . . . . 0.0 110.669 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 35.2 mt -65.55 -44.82 85.63 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.157 0.503 . . . . 0.0 110.155 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 82.4 m-20 -66.33 -39.06 89.0 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.21 179.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . 0.427 ' HB2' ' HA3' ' A' ' 4' ' ' GLY . 32.3 t60 -63.73 -50.73 67.98 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.516 -0.766 . . . . 0.0 111.597 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.42 HG13 ' N ' ' A' ' 88' ' ' ALA . 41.8 pt -64.39 -39.53 85.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.42 ' N ' HG13 ' A' ' 87' ' ' ILE . . . -63.62 -36.23 83.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.852 0.358 . . . . 0.0 111.663 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.5 p -89.28 -23.57 22.27 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.751 -179.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -61.43 -53.88 50.76 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.875 0.369 . . . . 0.0 111.527 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.411 ' CZ3' ' HB ' ' A' ' 87' ' ' ILE . 5.3 m-90 -86.32 -8.4 57.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.192 0.52 . . . . 0.0 110.566 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 77.56 17.89 78.4 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.493 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.59 -26.96 68.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.301 0.572 . . . . 0.0 110.187 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -73.53 -7.57 52.39 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.208 179.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -98.67 1.14 45.94 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.052 0.453 . . . . 0.0 110.476 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 39.4 mtpt -103.76 11.05 36.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.636 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 15.9 m -125.18 159.77 31.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.987 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.6 ptpt -93.1 112.91 25.02 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.823 0.344 . . . . 0.0 111.155 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 69.99 68.27 1.68 Allowed Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.85 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 65.1 t80 -73.17 124.68 26.09 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.827 0.346 . . . . 0.0 110.395 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 70.5 mttt -98.65 117.56 64.37 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.501 179.261 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -59.55 141.85 97.93 Favored 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.243 1.962 . . . . 0.0 111.374 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -69.83 126.64 30.3 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.306 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.6 p -109.15 152.52 25.01 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.663 -0.698 . . . . 0.0 110.457 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.05 -24.44 58.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 111.333 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 66.6 mm-40 -60.97 -43.21 99.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.894 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.454 ' O ' ' HG2' ' A' ' 110' ' ' LYS . 27.2 mt-10 -68.73 -29.64 68.1 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.006 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 24.3 t -76.98 -40.56 30.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-O 121.186 0.517 . . . . 0.0 109.919 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 9.2 tppt? -62.93 -44.21 96.7 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.814 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.454 ' HG2' ' O ' ' A' ' 107' ' ' GLU . 62.7 pttt -60.49 -32.0 71.01 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.711 0.291 . . . . 0.0 111.361 -179.031 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 97.4 mt -87.61 -30.48 20.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.214 -179.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 46.6 ttm-85 -66.56 -31.05 71.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.051 0.453 . . . . 0.0 110.457 179.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -71.46 -29.99 65.48 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.621 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -89.16 92.65 9.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.729 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 27.3 tptp -66.09 113.71 4.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.415 0.626 . . . . 0.0 111.473 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 81.5 mt -126.63 -174.97 3.26 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.245 179.102 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.437 ' O ' HG21 ' A' ' 121' ' ' VAL . 75.3 p -131.13 147.94 68.26 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.091 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.487 ' HB2' ' OE1' ' A' ' 55' ' ' GLN . 32.4 Cg_exo -58.01 -26.77 76.56 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.6 2.2 . . . . 0.0 112.118 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 11.5 tp60 -71.29 -29.91 65.62 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.447 179.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -80.07 -33.0 39.3 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.073 179.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . 0.437 HG21 ' O ' ' A' ' 117' ' ' THR . 43.2 t -63.15 -25.72 39.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.344 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 26.7 tp -57.38 -40.67 78.65 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.215 178.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . 0.469 ' O ' ' HG3' ' A' ' 127' ' ' LYS . . . -67.88 -44.72 76.4 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.042 179.428 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 32.2 mm-40 -58.12 -40.55 81.53 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.698 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . 0.43 ' HG2' ' HB2' ' A' ' 130' ' ' LEU . 67.0 ttt-85 -65.24 -46.25 81.34 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.45 179.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.403 ' HA ' ' O ' ' A' ' 130' ' ' LEU . 65.7 mttm -67.89 -27.49 66.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.21 -179.657 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.469 ' HG3' ' O ' ' A' ' 123' ' ' ALA . 92.2 mttt -65.43 -29.66 70.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.071 0.462 . . . . 0.0 109.97 178.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 96.0 mt -76.77 -6.6 52.91 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.549 179.102 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.44 -1.44 57.2 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 121.018 -0.611 . . . . 0.0 111.589 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.43 ' HB2' ' HG2' ' A' ' 125' ' ' ARG . 64.4 mt -81.18 112.27 18.36 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.9 0.381 . . . . 0.0 110.343 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 8.8 mptt . . . . . 0 C--O 1.252 1.214 0 CA-C-O 118.32 -0.848 . . . . 0.0 111.139 -179.355 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 86.4 t80 . . . . . 0 N--CA 1.481 1.105 0 CA-C-O 120.716 0.294 . . . . 0.0 110.932 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -35.35 80.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.86 0.362 . . . . 0.0 111.311 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 94.4 mt -76.79 -15.16 59.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.994 0.426 . . . . 0.0 110.675 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.81 13.02 30.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.824 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 1.8 p -139.89 178.04 7.54 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.314 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' HIS . . . . . . . . . . . . . 1.4 p80 -75.54 -6.43 50.21 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.349 0.595 . . . . 0.0 109.824 179.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' THR . . . . . 0.48 ' O ' HG22 ' B' ' 44' ' ' VAL . 0.3 OUTLIER -64.4 -19.71 65.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.07 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.28 -10.92 47.18 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.276 179.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -66.11 -25.78 72.27 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.312 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . 0.48 HG22 ' O ' ' B' ' 41' ' ' THR . 11.8 m -70.62 -12.24 15.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-O 120.987 0.422 . . . . 0.0 111.094 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 38.1 mt -92.16 133.2 30.59 Favored Pre-proline 0 C--N 1.322 -0.602 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -52.62 145.02 39.96 Favored 'Trans proline' 0 C--N 1.347 0.482 0 C-N-CA 122.831 2.354 . . . . 0.0 112.613 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -60.24 152.55 24.51 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.492 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -84.98 -18.99 60.09 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.947 -0.644 . . . . 0.0 111.911 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 29.8 tttt -75.85 138.42 41.1 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 50' ' ' LEU . . . . . . . . . . . . . 13.2 mt -83.19 134.27 34.98 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.01 0.433 . . . . 0.0 110.272 179.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 51' ' ' GLU . . . . . 0.421 ' HB3' ' HB ' ' B' ' 132' ' ' VAL . 1.6 tt0 -133.46 74.82 1.58 Allowed 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 52' ' ' ARG . . . . . . . . . . . . . 23.2 ttm180 -95.78 132.45 41.0 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.092 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 6.8 m -136.16 -172.0 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 115.668 -0.697 . . . . 0.0 109.909 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . 0.535 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 28.2 t70 -93.07 114.62 63.22 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 179.161 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -72.1 -11.83 27.49 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.541 2.16 . . . . 0.0 112.952 -178.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.17 -52.11 9.83 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 111.887 0.328 . . . . 0.0 111.887 -179.277 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 12.6 p -98.51 0.02 44.25 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 -178.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 58' ' ' VAL . . . . . 0.535 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 8.4 p -61.84 -22.58 28.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-O 121.136 0.494 . . . . 0.0 111.104 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 59' ' ' ARG . . . . . 0.454 ' NH1' ' HB2' ' B' ' 110' ' ' PRO . 12.2 ptt180 -95.77 3.12 54.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.435 -179.707 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -124.04 -31.2 3.4 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.85 0.357 . . . . 0.0 111.095 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -140.23 118.37 11.97 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.448 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 137.79 -177.76 19.68 Favored Glycine 0 N--CA 1.441 -0.969 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.298 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -63.88 -13.2 35.8 Favored 'Trans proline' 0 CA--C 1.53 0.306 0 C-N-CA 123.17 2.58 . . . . 0.0 113.103 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 30.2 m-90 -104.18 12.66 33.57 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.978 0.418 . . . . 0.0 110.328 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -100.42 2.54 42.35 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.563 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -145.14 114.93 4.97 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.472 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -72.61 -9.97 24.62 Favored 'Trans proline' 0 C--O 1.234 0.293 0 C-N-CA 122.64 2.227 . . . . 0.0 112.985 -179.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -81.93 -54.93 4.93 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.848 0.356 . . . . 0.0 110.581 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 69' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -88.07 44.23 1.18 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.051 0.453 . . . . 0.0 110.989 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . 0.426 ' O ' ' HA ' ' B' ' 81' ' ' VAL . . . -84.15 -29.36 26.74 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.383 179.374 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 41.6 t -102.21 106.84 20.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.697 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 40.7 t -120.94 125.03 73.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.136 -179.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -65.93 127.4 31.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.843 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -123.58 20.85 9.43 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.875 -178.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . 158.33 177.81 31.77 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.359 -0.924 . . . . 0.0 112.125 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -61.45 108.69 0.63 Allowed 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.961 2.441 . . . . 0.0 111.729 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 38.8 t30 63.47 25.56 14.53 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.401 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -122.19 123.15 40.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.587 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 24.8 m-85 -129.37 127.42 40.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.725 0.298 . . . . 0.0 110.823 -179.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 100.0 m -93.37 125.37 37.94 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 178.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' B' ' 70' ' ' ALA . 55.8 t -114.52 116.98 54.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.097 0.475 . . . . 0.0 110.825 -179.261 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -85.36 118.48 24.92 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.557 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 83' ' ' VAL . . . . . 0.536 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 20.2 t -116.16 124.82 72.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.138 0.494 . . . . 0.0 110.986 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 34.6 tp -101.05 115.2 29.92 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.524 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 85' ' ' ALA . . . . . 0.456 ' HB1' ' CE1' ' B' ' 90' ' ' TYR . . . -100.46 90.93 4.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.641 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 86' ' ' PHE . . . . . 0.456 ' HB2' ' H ' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -96.44 -163.82 1.09 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.011 0.434 . . . . 0.0 111.524 -179.535 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.727 ' O ' HBC2 ' A' ' 132' ' ' HEC . . . -55.86 103.31 0.1 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.913 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . 0.666 ' CG ' ' HB ' ' A' ' 68' ' ' VAL . 9.2 m-85 56.34 27.66 12.27 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.085 -0.962 . . . . 0.0 113.071 177.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 89' ' ' GLY . . . . . . . . . . . . . . . -150.38 168.98 30.33 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 119.649 -1.262 . . . . 0.0 113.207 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 90' ' ' TYR . . . . . 0.456 ' CE1' ' HB1' ' B' ' 85' ' ' ALA . 83.8 m-85 -138.78 131.39 28.98 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 91' ' ' GLN . . . . . 0.408 ' HB2' ' CZ ' ' B' ' 86' ' ' PHE . 5.3 tt0 -122.34 130.28 24.75 Favored Pre-proline 0 C--N 1.323 -0.567 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -82.03 172.14 52.91 Favored 'Cis proline' 0 N--CA 1.461 -0.385 0 C-N-CA 123.512 -1.453 . . . . 0.0 112.269 -0.197 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 93' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -152.09 130.07 6.04 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.788 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 94' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -77.96 149.31 87.22 Favored 'Cis proline' 0 N--CA 1.461 -0.418 0 C-N-CA 122.925 -1.698 . . . . 0.0 111.481 -1.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.3 mt -75.65 96.22 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.472 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 96' ' ' GLU . . . . . 0.597 ' HA ' ' O ' ' B' ' 165' ' ' VAL . 41.2 mt-10 -88.32 120.5 29.75 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.449 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 3.2 m -138.29 149.82 64.57 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.692 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -78.99 149.07 22.39 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.747 2.298 . . . . 0.0 112.318 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -92.26 155.83 17.7 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.37 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.13 7.12 87.39 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.355 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -123.36 158.31 31.36 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.44 0.162 . . . . 0.0 110.847 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 102' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -86.26 111.71 20.7 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 103' ' ' ILE . . . . . . . . . . . . . 8.0 mt -100.51 116.42 43.89 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.631 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 20.0 t -90.5 95.66 5.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 105' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -79.83 122.74 27.01 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.204 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -121.02 92.55 3.78 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 107' ' ' ILE . . . . . 0.536 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.5 mp -100.85 137.65 27.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.493 -177.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 5.5 t -141.79 159.49 42.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.499 178.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 109' ' ' SER . . . . . . . . . . . . . 30.6 t -119.5 135.88 24.32 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-O 120.708 0.29 . . . . 0.0 111.18 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 110' ' ' PRO . . . . . 0.454 ' HB2' ' NH1' ' B' ' 59' ' ' ARG . 65.8 Cg_endo -96.67 -0.83 1.82 Allowed 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.212 2.608 . . . . 0.0 113.216 178.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 111' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -129.16 -97.71 0.37 Allowed 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -179.042 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 112' ' ' VAL . . . . . . . . . . . . . 14.6 m -107.7 -175.25 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.709 0.29 . . . . 0.0 111.469 -178.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.1 mt -68.26 144.19 14.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.707 0.765 . . . . 0.0 111.428 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 114' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -141.82 178.02 7.78 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.578 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 115' ' ' GLY . . . . . 0.433 ' HA3' ' OD1' ' B' ' 150' ' ' ASN . . . -141.79 141.81 11.33 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.537 -0.839 . . . . 0.0 111.579 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -110.66 76.66 0.99 Allowed 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.077 0.465 . . . . 0.0 110.343 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 117' ' ' HIS . . . . . 0.468 ' HA ' ' O ' ' B' ' 123' ' ' ILE . 15.1 t-160 -109.11 92.18 3.95 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.024 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . 0.561 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 22.0 t -75.26 114.63 15.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.728 -179.203 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -64.67 119.21 10.11 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.538 -179.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 106.84 1.7 36.63 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.151 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 121' ' ' THR . . . . . 0.561 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 51.0 p -132.4 -174.68 3.52 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.836 0.351 . . . . 0.0 110.777 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -103.01 14.14 32.64 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 178.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . 0.468 ' O ' ' HA ' ' B' ' 117' ' ' HIS . 33.7 mt -83.44 109.37 17.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.572 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -144.54 80.15 1.62 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.437 -0.801 . . . . 0.0 108.957 179.498 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 14.6 p -124.76 148.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.0 -179.047 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -83.47 142.78 30.69 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.304 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 127' ' ' VAL . . . . . . . . . . . . . 46.8 t -116.16 103.84 15.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 128' ' ' LEU . . . . . . . . . . . . . 6.4 mt -92.2 156.57 41.82 Favored Pre-proline 0 C--N 1.322 -0.592 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.135 -178.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -66.59 119.17 6.17 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.725 2.283 . . . . 0.0 112.289 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.71 7.48 87.29 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.708 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -112.48 126.05 54.9 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 132' ' ' VAL . . . . . 0.421 ' HB ' ' HB3' ' B' ' 51' ' ' GLU . 35.1 t -93.94 103.73 15.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.191 0.519 . . . . 0.0 111.137 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 6.3 m -81.97 111.71 18.39 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.653 179.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 134' ' ' THR . . . . . . . . . . . . . 24.3 m -97.99 124.16 42.33 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.543 -179.083 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 40.4 t -136.12 130.99 48.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.932 179.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 136' ' ' ARG . . . . . . . . . . . . . 51.5 mtt180 -99.91 115.98 30.9 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.941 0.401 . . . . 0.0 110.404 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 137' ' ' TYR . . . . . . . . . . . . . 7.7 t80 -121.07 156.54 32.01 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.167 0.508 . . . . 0.0 111.272 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 4.1 m -134.12 100.57 4.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.741 178.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 139' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -72.19 121.92 20.15 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.538 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -108.79 6.99 26.05 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.034 0.445 . . . . 0.0 110.444 179.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 141' ' ' ARG . . . . . . . . . . . . . 8.7 ptp180 -152.17 131.15 6.57 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.215 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 142' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -76.64 -177.33 3.68 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 123.134 2.556 . . . . 0.0 112.782 -179.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 143' ' ' GLY . . . . . . . . . . . . . . . 123.43 179.58 15.82 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.93 -0.653 . . . . 0.0 112.44 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 144' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -101.25 127.04 48.03 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -119.07 143.01 47.37 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.739 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 2.8 tpt180 -108.18 133.01 53.04 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.799 0.333 . . . . 0.0 110.301 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 147' ' ' ILE . . . . . 0.522 ' O ' ' HA ' ' B' ' 161' ' ' PHE . 13.5 mt -87.27 125.22 41.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.655 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 69.7 mt -102.19 116.01 45.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.086 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 149' ' ' CYS . . . . . . . . . . . . . 37.5 t -85.39 90.21 7.88 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.418 179.387 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 150' ' ' ASN . . . . . 0.433 ' OD1' ' HA3' ' B' ' 115' ' ' GLY . 26.5 p-10 -59.36 -38.47 80.49 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -179.185 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -70.95 136.01 48.24 Favored 'General case' 0 C--O 1.25 1.098 0 CA-C-O 121.128 0.489 . . . . 0.0 111.793 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -53.63 164.35 0.55 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.067 -0.969 . . . . 0.0 111.993 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 153' ' ' CYS . . . . . 0.648 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 5.9 p 170.52 89.67 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.996 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 71.07 -174.81 40.0 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.734 178.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 155' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -77.66 -18.36 56.77 Favored 'General case' 0 N--CA 1.463 0.208 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.044 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 156' ' ' GLY . . . . . 0.431 ' O ' HG21 ' A' ' 68' ' ' VAL . . . -108.33 31.27 8.01 Favored Glycine 0 CA--C 1.508 -0.349 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.321 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 157' ' ' HIS . . . . . 0.648 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 0.3 OUTLIER -66.41 -27.89 68.19 Favored 'General case' 0 C--N 1.318 -0.789 0 O-C-N 122.682 -0.305 . . . . 0.0 111.425 -179.337 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 2.6 pm0 -76.07 -17.67 59.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -178.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 159' ' ' ASN . . . . . . . . . . . . . 13.1 t30 -100.96 4.49 42.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.823 0.344 . . . . 0.0 111.038 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 160' ' ' MET . . . . . . . . . . . . . 26.8 ttt -77.5 77.48 4.02 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 161' ' ' PHE . . . . . 0.522 ' HA ' ' O ' ' B' ' 147' ' ' ILE . 8.6 m-30 -115.8 109.89 18.3 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.427 -178.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 162' ' ' GLY . . . . . . . . . . . . . . . -80.4 165.31 48.29 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.921 -0.657 . . . . 0.0 111.598 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.08 127.06 53.04 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 117.377 0.589 . . . . 0.0 112.084 -178.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 40.8 mt -120.15 130.41 74.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 178.55 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 165' ' ' VAL . . . . . 0.597 ' O ' ' HA ' ' B' ' 96' ' ' GLU . 58.0 t -126.3 104.78 13.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 120.869 0.366 . . . . 0.0 110.643 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 166' ' ' VAL . . . . . 0.403 ' HA ' ' O ' ' B' ' 97' ' ' VAL . 0.4 OUTLIER -86.74 127.56 40.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.563 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 30.5 mmtp -80.33 136.03 36.32 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.077 -178.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 168' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 . . . . . 0 C--O 1.248 0.995 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.129 179.63 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' HEC . . . . . 0.727 HBC2 ' O ' ' B' ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 169' ' ' CUA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.407 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.7 OUTLIER . . . . . 0 N--CA 1.481 1.123 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 . . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.49 -37.05 91.55 Favored Glycine 0 C--N 1.334 0.453 0 C-N-CA 121.45 -0.405 . . . . 0.0 113.152 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.65 -38.65 77.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.997 0.398 . . . . 0.0 110.378 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.52 -34.44 77.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.55 179.186 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.407 HG12 ' O ' ' A' ' 3' ' ' ASP . 50.7 mm -76.07 -35.16 28.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.358 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 68.3 t80 -65.71 -16.43 63.76 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.451 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -58.91 -26.98 64.82 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.978 0.418 . . . . 0.0 110.982 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 60.0 mt-30 -77.11 -30.49 55.27 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.535 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 2.0 m -76.02 -25.87 56.12 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.152 -179.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.29 -18.24 48.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.948 -179.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.15 -20.77 80.05 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.795 -0.717 . . . . 0.0 113.277 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 77.0 m -130.43 -43.58 1.14 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 117.329 0.564 . . . . 0.0 111.971 -179.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 92.1 m-70 -91.42 -5.4 54.44 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 59.47 -172.11 0.12 Allowed 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.617 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -92.47 -9.67 40.63 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.093 -179.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 39.1 p30 -84.63 -8.31 58.93 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.623 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 72.67 20.32 79.58 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.498 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 64.3 mt-30 -117.4 -51.05 2.53 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.941 0.401 . . . . 0.0 110.282 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.32 -154.45 28.7 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.77 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 42.3 mm -94.92 115.33 65.27 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-O 120.623 0.249 . . . . 0.0 110.452 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -59.45 128.56 27.7 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.739 2.292 . . . . 0.0 112.089 179.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.07 3.69 69.78 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.169 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -138.27 -48.43 0.54 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.547 0.213 . . . . 0.0 111.12 179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -121.89 137.81 27.81 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.071 -179.186 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -76.16 147.64 30.01 Favored 'Trans proline' 0 C--O 1.24 0.597 0 C-N-CA 122.857 2.371 . . . . 0.0 112.14 179.056 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -80.81 155.5 20.51 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.856 2.371 . . . . 0.0 112.263 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.527 ' O ' HG23 ' A' ' 33' ' ' VAL . 67.4 mt -105.57 -43.75 4.86 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.655 179.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.91 120.02 11.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.431 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.25 12.7 82.88 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.783 -0.722 . . . . 0.0 111.998 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 58.0 t60 -127.62 -22.53 3.59 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.692 0.282 . . . . 0.0 110.899 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 29' ' ' LEU . 60.2 t -65.53 -45.43 92.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.924 0.392 . . . . 0.0 109.945 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -63.05 -31.34 72.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.441 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -65.08 -38.13 89.76 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.198 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.506 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 63.8 mt -78.47 -40.11 24.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.705 -179.595 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 85.8 mt -64.32 -27.32 68.95 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.137 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -79.79 4.58 15.99 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.603 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 59.0 mmtt -109.74 154.79 22.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.629 0.252 . . . . 0.0 110.407 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -66.49 112.6 4.17 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.718 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.55 14.76 77.57 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.009 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.506 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -61.07 -40.75 98.95 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 121.226 -0.511 . . . . 0.0 112.648 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.431 ' O ' HG13 ' A' ' 47' ' ' ILE . 12.7 ptm85 -66.58 -36.31 82.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.679 0.276 . . . . 0.0 110.538 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -67.52 -41.85 83.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.373 0.606 . . . . 0.0 109.52 178.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.474 ' O ' HG23 ' A' ' 49' ' ' VAL . 26.7 t80 -60.0 -43.88 94.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.109 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 35.5 mt -56.06 -45.6 79.21 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.106 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.431 HG13 ' O ' ' A' ' 43' ' ' ARG . 59.2 mt -62.13 -43.39 97.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.802 -179.704 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 62.8 mt -60.93 -38.22 85.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.963 0.411 . . . . 0.0 110.739 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.474 HG23 ' O ' ' A' ' 45' ' ' TYR . 81.0 t -65.6 -31.68 54.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.183 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.0 mp -84.04 -34.65 24.21 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.958 0.409 . . . . 0.0 110.845 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.7 mt -71.54 -56.97 4.87 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.992 -0.549 . . . . 0.0 112.097 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.58 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 55.6 m-85 -103.71 -37.23 7.57 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -178.017 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 119.51 -167.61 13.4 Favored Glycine 0 N--CA 1.445 -0.728 0 C-N-CA 119.878 -1.153 . . . . 0.0 113.438 178.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.436 ' H ' ' HB3' ' A' ' 69' ' ' MET . 4.6 tp -163.33 134.62 4.81 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.867 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . 0.485 ' HB2' ' HB3' ' B' ' 159' ' ' ASN . 0.0 OUTLIER -154.38 116.27 4.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.06 0.457 . . . . 0.0 111.862 179.779 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -162.97 -148.3 5.32 Favored Glycine 0 N--CA 1.442 -0.904 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.462 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -130.52 68.19 1.47 Allowed 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.3 pt -83.39 165.49 2.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.357 -178.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -140.77 113.76 8.4 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.468 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 42.9 t -110.89 116.8 53.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.63 -179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 16.2 mttp 61.38 28.06 17.57 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.521 179.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.46 -20.22 51.59 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.753 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.78 110.87 18.68 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.882 0.372 . . . . 0.0 110.738 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 19.1 mttp -81.45 134.3 35.52 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.69 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -119.73 151.13 39.26 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -156.84 82.54 0.95 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.095 0.474 . . . . 0.0 110.268 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -139.73 -150.73 5.55 Favored Glycine 0 N--CA 1.44 -1.07 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.537 ' N ' HMD2 ' A' ' 132' ' ' HEC . 58.8 t -143.06 118.28 4.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.791 0.329 . . . . 0.0 110.574 179.172 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' MET . . . . . 0.607 ' HB2' ' C4D' ' A' ' 132' ' ' HEC . 4.1 tpt -77.02 108.5 10.13 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -55.75 132.33 48.96 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.404 -0.816 . . . . 0.0 113.01 -178.214 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -71.14 121.4 18.25 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.896 178.795 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . 0.449 ' HE2' ' CHC' ' A' ' 132' ' ' HEC . 36.6 m-85 -108.06 39.22 2.0 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.125 0.488 . . . . 0.0 111.034 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.02 -18.71 65.52 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.414 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.1 pm0 -68.23 -14.91 63.34 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.809 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 82.4 mt -87.35 147.69 25.37 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.888 179.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 53.4 mtpt -71.6 160.71 32.19 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.933 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 76.8 m-20 -53.97 -42.88 69.43 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.18 0.515 . . . . 0.0 110.356 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -63.6 -43.31 97.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.309 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 73.9 mt-10 -64.46 -42.79 95.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.368 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 97.6 mt -66.28 -40.45 86.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.969 0.414 . . . . 0.0 110.498 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.49 -35.85 75.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.884 179.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.32 -45.67 92.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.538 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 12.5 p -70.96 -34.49 55.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.619 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 15.7 mt -62.25 -45.49 93.05 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.263 0.554 . . . . 0.0 109.96 178.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 54.0 m-20 -69.32 -32.83 72.2 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.405 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 25.8 t60 -66.19 -51.09 61.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.749 -179.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 39.5 pt -63.63 -32.43 56.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -178.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -73.63 -33.39 64.53 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 112.034 0.383 . . . . 0.0 112.034 -179.397 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.9 p -91.47 -31.06 16.13 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 -178.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -52.25 -47.94 65.5 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 28.5 m-90 -100.38 10.28 41.45 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.902 0.382 . . . . 0.0 110.934 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 57.44 26.56 56.95 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.869 -0.605 . . . . 0.0 113.309 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -71.41 -29.11 64.53 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.202 0.525 . . . . 0.0 109.998 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -70.55 -15.44 62.77 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.162 179.328 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.2 mttm -80.63 -14.43 58.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.957 0.408 . . . . 0.0 110.632 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 40.6 mtpt -80.86 -21.04 41.04 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.377 -179.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 28.3 m -95.22 161.06 2.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 179.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -97.07 127.86 43.45 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.068 0.461 . . . . 0.0 110.967 -178.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 62.05 61.11 7.02 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.61 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 76.4 t80 -75.61 110.31 9.9 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.857 0.361 . . . . 0.0 110.457 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 95.6 mttt -84.56 124.08 73.75 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 115.683 -0.69 . . . . 0.0 109.737 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_exo -59.52 138.15 82.06 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.631 2.221 . . . . 0.0 111.923 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -65.77 129.28 39.23 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.258 179.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p -111.91 157.57 20.5 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.081 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -60.79 -32.03 71.38 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.484 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.0 mm-40 -66.54 -32.74 74.28 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.821 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -66.51 -38.55 87.45 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.167 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.1 t -71.21 -45.76 69.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.061 179.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.426 ' HZ2' ' HB2' ' A' ' 109' ' ' LYS . 4.2 ttmp? -58.68 -38.33 77.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.713 179.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 25.8 ttpt -58.75 -46.46 87.4 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.328 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 40.0 mt -83.63 -15.94 47.08 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.564 -178.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 48.1 ttm-85 -69.98 -16.86 63.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.379 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -80.34 -38.52 30.4 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.066 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 45.6 tttp -81.62 95.65 7.24 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 19.7 tptm -66.05 114.03 4.91 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.2 0.524 . . . . 0.0 111.532 -179.178 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 79.6 mt -125.35 176.66 6.64 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.005 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.432 ' O ' HG21 ' A' ' 121' ' ' VAL . 61.2 p -124.43 157.57 64.53 Favored Pre-proline 0 C--N 1.319 -0.744 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.359 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.58 ' HG3' ' O ' ' A' ' 52' ' ' TYR . 50.1 Cg_exo -55.1 -30.61 71.39 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.545 2.163 . . . . 0.0 111.745 179.298 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 42.8 tp60 -74.34 -39.92 62.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.881 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' GLN . . . . . 0.474 ' O ' ' HG2' ' A' ' 124' ' ' GLU . 44.8 mt-30 -67.02 -37.63 84.48 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.162 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . 0.432 HG21 ' O ' ' A' ' 117' ' ' THR . 60.8 t -60.37 -31.81 49.46 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 CA-C-O 121.137 0.494 . . . . 0.0 110.18 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 23.9 tp -64.91 -38.33 90.61 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.543 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -68.52 -39.74 81.06 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.753 178.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.474 ' HG2' ' O ' ' A' ' 120' ' ' GLN . 10.9 mm-40 -59.97 -38.03 81.34 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.656 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . 0.415 HH11 ' HD3' ' A' ' 125' ' ' ARG . 6.4 ttm-85 -61.01 -46.27 91.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.964 178.372 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.517 ' HA ' ' O ' ' A' ' 130' ' ' LEU . 67.0 mttm -68.57 -28.41 66.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.911 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -69.01 -29.24 67.38 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.096 0.474 . . . . 0.0 110.006 178.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 70.0 mt -78.28 0.92 23.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.821 179.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 89.46 18.39 52.61 Favored Glycine 0 N--CA 1.446 -0.697 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.209 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.517 ' O ' ' HA ' ' A' ' 126' ' ' LYS . 18.1 mt -105.7 169.26 8.58 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 12.1 mptt . . . . . 0 C--O 1.246 0.891 0 CA-C-O 118.863 -0.589 . . . . 0.0 109.836 179.521 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 45.9 t80 . . . . . 0 N--CA 1.479 0.991 0 CA-C-O 120.787 0.327 . . . . 0.0 110.926 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 1.6 p -60.96 -36.15 78.65 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -178.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 74.6 mt -69.18 -24.33 64.04 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.763 0.316 . . . . 0.0 111.339 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -93.48 -5.37 49.32 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.14 0.495 . . . . 0.0 111.072 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 3.9 m -106.82 167.73 9.68 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.887 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 40' ' ' HIS . . . . . . . . . . . . . 6.0 p80 -65.18 -10.38 30.84 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.73 0.3 . . . . 0.0 111.564 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.76 -17.63 64.76 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.932 0.396 . . . . 0.0 111.178 179.421 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.07 -4.35 24.62 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.611 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -66.36 -18.06 67.02 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.962 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 33.4 m -72.44 -12.11 15.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-O 120.927 0.394 . . . . 0.0 111.234 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 71.0 mt -88.72 125.78 61.84 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.727 179.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 46' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -58.08 149.11 73.6 Favored 'Trans proline' 0 C--O 1.234 0.301 0 C-N-CA 122.567 2.178 . . . . 0.0 112.197 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -62.51 142.82 57.76 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.749 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -73.37 -18.36 79.29 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.959 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 45.0 tttp -68.19 127.94 34.74 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.252 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 50' ' ' LEU . . . . . . . . . . . . . 84.2 mt -80.54 114.89 19.75 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.008 0.432 . . . . 0.0 110.488 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 51' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -116.82 103.53 10.41 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.772 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 52' ' ' ARG . . . . . 0.456 ' HD2' ' N ' ' B' ' 52' ' ' ARG . 0.4 OUTLIER -111.0 137.64 48.38 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.412 -178.981 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 10.4 m -133.02 170.47 19.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.886 179.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . 0.48 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 13.7 t70 -81.48 114.05 46.64 Favored Pre-proline 0 C--N 1.327 -0.408 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.371 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -80.18 19.32 1.06 Allowed 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 123.07 2.513 . . . . 0.0 113.576 -178.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.8 -47.94 3.1 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.238 0.542 . . . . 0.0 110.67 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 9.2 p -106.41 12.72 29.41 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.48 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 58' ' ' VAL . . . . . 0.48 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 14.7 p -60.63 -28.59 43.06 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.428 0 CA-C-O 120.944 0.402 . . . . 0.0 111.829 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 59' ' ' ARG . . . . . . . . . . . . . 29.3 ptt180 -97.05 13.19 29.92 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.843 0.354 . . . . 0.0 111.055 -179.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 79.0 mt-30 -130.9 -35.93 1.39 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.95 0.405 . . . . 0.0 110.813 -179.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -135.04 105.68 6.47 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.857 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 145.43 -179.22 22.67 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.862 -0.685 . . . . 0.0 111.884 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_exo -63.33 -27.54 71.61 Favored 'Trans proline' 0 CA--C 1.527 0.145 0 C-N-CA 122.834 2.356 . . . . 0.0 112.551 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 31.3 m-90 -85.03 6.4 25.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.534 -179.273 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -94.55 10.57 34.18 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.973 0.416 . . . . 0.0 110.951 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . 0.404 ' HB3' ' HB2' ' B' ' 69' ' ' GLN . 7.9 t70 -147.65 110.35 3.87 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.222 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_exo -62.39 -32.66 81.03 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.808 2.339 . . . . 0.0 112.915 -179.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.5 -46.13 20.35 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.539 -0.301 . . . . 0.0 111.086 -179.164 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 69' ' ' GLN . . . . . 0.404 ' HB2' ' HB3' ' B' ' 66' ' ' ASP . 13.6 mm100 -80.63 16.92 1.23 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.529 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -78.11 -24.56 47.43 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.992 0.425 . . . . 0.0 110.662 179.366 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 25.5 t -100.46 93.85 3.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.741 179.555 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 2.9 t -105.56 139.64 26.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -178.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 8.5 tt0 -81.51 122.86 28.08 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.023 179.496 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.18 -29.55 18.18 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.678 -179.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . 178.86 -162.54 29.64 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.438 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -61.7 107.72 0.55 Allowed 'Trans proline' 0 C--O 1.236 0.397 0 C-N-CA 123.077 2.518 . . . . 0.0 112.124 -179.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 45.2 t30 63.79 29.76 14.71 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.762 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -133.96 122.31 22.9 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.093 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -127.06 151.42 48.64 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.873 -179.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 91.4 m -119.82 121.58 39.41 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 50.0 t -110.56 117.2 54.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 121.053 0.454 . . . . 0.0 111.242 -178.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -86.39 106.09 17.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.647 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 83' ' ' VAL . . . . . 0.494 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 28.8 t -98.36 122.43 50.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.191 0.52 . . . . 0.0 110.697 -179.398 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 57.4 tp -102.09 109.39 21.08 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.797 179.621 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 85' ' ' ALA . . . . . . . . . . . . . . . -96.6 73.16 2.72 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.153 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 86' ' ' PHE . . . . . 0.51 ' CZ ' ' HB2' ' B' ' 91' ' ' GLN . 0.1 OUTLIER -75.01 -169.77 0.98 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.999 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.447 ' O ' HBC3 ' A' ' 132' ' ' HEC . . . -39.66 93.75 0.01 OUTLIER 'General case' 0 N--CA 1.462 0.127 0 O-C-N 124.316 1.01 . . . . 0.0 113.724 -178.46 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 53.26 27.73 6.41 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.698 -1.137 . . . . 0.0 112.976 178.22 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 89' ' ' GLY . . . . . . . . . . . . . . . -139.62 -178.4 16.62 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.016 -1.088 . . . . 0.0 112.978 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 90' ' ' TYR . . . . . 0.508 ' OH ' ' HB2' ' B' ' 149' ' ' CYS . 41.2 m-85 -140.32 133.65 29.81 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 91' ' ' GLN . . . . . 0.51 ' HB2' ' CZ ' ' B' ' 86' ' ' PHE . 31.7 tt0 -135.48 128.34 18.11 Favored Pre-proline 0 C--N 1.322 -0.608 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 178.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -79.95 170.88 64.94 Favored 'Cis proline' 0 CA--C 1.53 0.293 0 C-N-CA 123.386 -1.506 . . . . 0.0 112.451 -0.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 93' ' ' ASN . . . . . . . . . . . . . 58.6 t30 -159.76 120.19 1.72 Allowed Pre-proline 0 C--N 1.326 -0.456 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 94' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -78.85 151.39 88.06 Favored 'Cis proline' 0 C--O 1.233 0.264 0 C-N-CA 123.47 -1.471 . . . . 0.0 112.755 -0.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 40.2 mt -81.7 127.27 39.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 96' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -104.52 124.63 49.63 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.516 0.198 . . . . 0.0 110.839 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . 0.458 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 4.8 m -141.22 153.7 66.79 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.101 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.49 161.45 14.77 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 122.718 2.279 . . . . 0.0 111.802 178.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.29 152.73 18.31 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.021 0.438 . . . . 0.0 111.378 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 78.03 8.72 87.32 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.564 -0.743 . . . . 0.0 113.135 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.29 155.26 26.53 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.838 0.351 . . . . 0.0 111.302 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 102' ' ' GLU . . . . . 0.546 ' OE2' ' HD3' ' B' ' 136' ' ' ARG . 77.8 tt0 -81.56 119.26 23.55 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 103' ' ' ILE . . . . . . . . . . . . . 7.8 mt -108.91 113.54 44.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.004 -179.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 21.5 t -91.98 101.14 12.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 105' ' ' PHE . . . . . 0.483 ' O ' ' HA ' ' B' ' 134' ' ' THR . 75.7 m-85 -82.24 122.18 27.59 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.09 -179.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -119.93 89.95 3.23 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 107' ' ' ILE . . . . . 0.494 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.2 mp -97.77 135.82 30.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.576 -178.111 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 4.9 t -133.8 154.21 51.17 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 109' ' ' SER . . . . . 0.688 ' O ' ' HA ' ' B' ' 129' ' ' PRO . 0.7 OUTLIER -122.7 126.28 26.15 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-O 120.652 0.263 . . . . 0.0 111.226 -178.932 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -89.24 -29.05 0.26 Allowed 'Trans proline' 0 N--CA 1.459 -0.547 0 C-N-CA 122.911 2.407 . . . . 0.0 112.808 178.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 111' ' ' ASP . . . . . 0.474 ' CG ' ' H ' ' B' ' 112' ' ' VAL . 8.2 p-10 -95.0 -111.76 0.12 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.863 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 112' ' ' VAL . . . . . 0.474 ' H ' ' CG ' ' B' ' 111' ' ' ASP . 17.0 m -99.86 -172.77 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 120.561 0.22 . . . . 0.0 110.533 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 21.0 mt -74.91 143.78 12.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-O 121.365 0.602 . . . . 0.0 111.543 -179.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 114' ' ' HIS . . . . . 0.467 ' HD2' ' OG ' ' B' ' 109' ' ' SER . 97.7 m-70 -136.95 179.39 6.41 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.461 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 115' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' B' ' 149' ' ' CYS . . . -134.06 134.78 7.61 Favored Glycine 0 N--CA 1.443 -0.845 0 C-N-CA 120.443 -0.885 . . . . 0.0 112.044 -179.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -104.56 85.28 2.3 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-O 121.028 0.442 . . . . 0.0 109.915 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 117' ' ' HIS . . . . . 0.45 ' HA ' ' O ' ' B' ' 123' ' ' ILE . 12.6 t-160 -113.82 109.97 19.39 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.635 179.228 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . 0.449 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 44.5 t -88.04 113.83 25.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.241 0.543 . . . . 0.0 111.119 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -63.38 115.93 5.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.6 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 110.46 0.06 29.39 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.462 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 121' ' ' THR . . . . . 0.449 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 40.9 p -139.65 175.5 9.52 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 179.407 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -92.96 18.24 9.43 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.94 0.4 . . . . 0.0 110.365 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . 0.45 ' O ' ' HA ' ' B' ' 117' ' ' HIS . 53.6 mt -81.9 106.72 13.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.033 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -146.1 100.33 3.37 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 178.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 7.1 p -137.63 144.57 30.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.485 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -82.56 145.63 29.63 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.373 179.122 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 127' ' ' VAL . . . . . . . . . . . . . 6.3 t -115.5 106.17 19.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.589 179.579 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 128' ' ' LEU . . . . . . . . . . . . . 7.7 mp -96.52 153.24 38.9 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.38 -178.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . 0.688 ' HA ' ' O ' ' B' ' 109' ' ' SER . 27.5 Cg_exo -62.65 120.52 8.08 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.693 2.262 . . . . 0.0 112.614 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.68 -13.68 65.04 Favored Glycine 0 N--CA 1.451 -0.312 0 CA-C-N 115.897 -0.592 . . . . 0.0 113.103 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -94.55 148.37 22.32 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 132' ' ' VAL . . . . . . . . . . . . . 22.6 t -112.82 89.27 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 121.026 0.441 . . . . 0.0 110.21 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 5.0 m -62.68 105.59 0.67 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.031 179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 134' ' ' THR . . . . . 0.483 ' HA ' ' O ' ' B' ' 105' ' ' PHE . 23.2 m -102.34 115.48 30.64 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.539 -179.26 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 78.6 t -127.85 136.28 60.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.834 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 136' ' ' ARG . . . . . 0.546 ' HD3' ' OE2' ' B' ' 102' ' ' GLU . 51.2 mtt180 -110.58 113.45 26.08 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.747 0.308 . . . . 0.0 111.056 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 137' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -128.98 166.83 18.42 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.675 -179.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 73.1 m -134.51 110.55 9.44 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 178.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 139' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -84.3 112.97 20.79 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.383 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 78.9 mttt -105.31 -11.0 16.68 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.183 0.516 . . . . 0.0 110.509 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 141' ' ' ARG . . . . . . . . . . . . . 61.5 mtt180 -110.67 114.27 54.84 Favored Pre-proline 0 C--N 1.324 -0.511 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.783 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 142' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -68.67 155.84 67.49 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.906 2.404 . . . . 0.0 112.852 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 143' ' ' GLY . . . . . . . . . . . . . . . 139.38 -168.66 24.83 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.681 179.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 144' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 -109.39 119.71 40.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.72 0.295 . . . . 0.0 110.71 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 31.1 m-85 -106.05 137.38 44.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.017 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.43 135.44 34.67 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.034 0.445 . . . . 0.0 111.636 -178.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 147' ' ' ILE . . . . . . . . . . . . . 40.3 mt -99.79 109.92 25.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 13.4 mt -103.11 119.22 51.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-O 120.817 0.341 . . . . 0.0 111.185 -179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 149' ' ' CYS . . . . . 0.508 ' HB2' ' OH ' ' B' ' 90' ' ' TYR . 3.9 t -85.57 84.05 7.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.093 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 150' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -58.89 -17.51 24.86 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -179.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 32.1 tp60 -80.33 140.06 36.3 Favored 'General case' 0 C--O 1.25 1.102 0 CA-C-O 121.162 0.506 . . . . 0.0 111.928 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -57.25 155.35 8.93 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 114.816 -1.084 . . . . 0.0 110.778 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 153' ' ' CYS . . . . . 0.548 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 1.6 p -176.55 78.34 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.733 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 55.65 -140.93 39.91 Favored Glycine 0 C--N 1.331 0.264 0 O-C-N 123.432 0.458 . . . . 0.0 112.73 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 155' ' ' LEU . . . . . . . . . . . . . 37.4 mt -92.58 -15.49 26.85 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.24 0.543 . . . . 0.0 110.318 179.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 156' ' ' GLY . . . . . . . . . . . . . . . -87.97 63.91 3.71 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.729 -0.668 . . . . 0.0 111.909 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 157' ' ' HIS . . . . . 0.548 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 62.9 t60 -131.71 -37.5 1.18 Allowed 'General case' 0 C--N 1.319 -0.752 0 O-C-N 122.61 -0.347 . . . . 0.0 111.212 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -64.99 -14.05 59.29 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 112.864 0.69 . . . . 0.0 112.864 -178.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 159' ' ' ASN . . . . . 0.485 ' HB3' ' HB2' ' A' ' 55' ' ' GLN . 8.5 t30 -132.99 15.09 4.25 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.879 0.371 . . . . 0.0 111.4 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 160' ' ' MET . . . . . . . . . . . . . 24.7 ttt -87.74 87.87 7.5 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 161' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -128.2 136.2 50.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.852 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 162' ' ' GLY . . . . . . . . . . . . . . . -105.87 176.37 22.05 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 11.7 m -144.38 131.51 20.57 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 117.762 0.781 . . . . 0.0 111.9 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 65.1 mt -114.44 113.11 42.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 165' ' ' VAL . . . . . . . . . . . . . 22.1 t -101.91 103.67 15.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.113 0.482 . . . . 0.0 110.746 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 166' ' ' VAL . . . . . 0.458 ' HA ' ' O ' ' B' ' 97' ' ' VAL . 1.3 p -90.88 123.63 43.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 178.69 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 28.4 mmtp -79.16 147.26 32.74 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.212 -178.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 168' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.245 0.827 0 CA-C-O 118.689 -0.672 . . . . 0.0 109.781 179.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' HEC . . . . . 0.607 ' C4D' ' HB2' ' A' ' 69' ' ' MET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 169' ' ' CUA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.421 ' O ' HG12 ' A' ' 7' ' ' ILE . 6.1 p-10 . . . . . 0 N--CA 1.478 0.97 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.16 -37.39 92.82 Favored Glycine 0 C--N 1.333 0.379 0 C-N-CA 121.136 -0.554 . . . . 0.0 113.165 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.01 -35.67 80.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.526 0.203 . . . . 0.0 111.128 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -66.17 -34.87 79.02 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.034 0.445 . . . . 0.0 110.533 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.421 HG12 ' O ' ' A' ' 3' ' ' ASP . 31.9 mm -73.02 -38.06 54.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.054 179.557 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -63.08 -21.81 66.43 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.112 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -57.89 -31.85 67.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.989 0.424 . . . . 0.0 110.827 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 66.4 mt-30 -77.31 -32.19 55.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.06 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 15.7 m -70.87 -29.39 65.48 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.074 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.15 -17.58 64.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.415 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.31 5.98 39.84 Favored Glycine 0 N--CA 1.453 -0.21 0 C-N-CA 121.048 -0.596 . . . . 0.0 112.623 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.8 m -153.56 -51.13 0.1 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.602 0.239 . . . . 0.0 110.992 179.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.5 m-70 -85.96 7.01 26.01 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.87 -0.15 . . . . 0.0 111.094 -179.041 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 57.2 mm-40 61.41 -168.19 0.18 Allowed 'General case' 0 N--CA 1.465 0.275 0 O-C-N 123.492 0.495 . . . . 0.0 111.215 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 46.8 mt-30 -104.52 -5.56 21.43 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.908 0.385 . . . . 0.0 110.593 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 14.9 p30 -82.71 -4.46 57.89 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.091 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 75.74 19.18 79.25 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.468 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.504 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 44.6 mt-30 -124.73 -80.16 0.62 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.824 0.345 . . . . 0.0 110.561 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 116.39 -123.07 5.72 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.905 -179.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 36.9 mm -129.25 115.91 18.67 Favored Pre-proline 0 C--N 1.323 -0.572 0 N-CA-C 110.554 -0.165 . . . . 0.0 110.554 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -57.77 99.38 0.09 OUTLIER 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.884 2.39 . . . . 0.0 111.443 178.561 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 126.59 -15.29 6.71 Favored Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 -179.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -124.41 -36.45 2.64 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.686 0.279 . . . . 0.0 111.096 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -136.09 126.3 16.41 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.007 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -75.72 134.73 16.98 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.395 2.063 . . . . 0.0 111.276 178.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.504 ' HA ' ' HA ' ' A' ' 20' ' ' GLN . 17.1 Cg_exo -67.61 148.0 77.34 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.524 2.149 . . . . 0.0 112.599 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.468 ' O ' HG23 ' A' ' 33' ' ' VAL . 80.3 mt -97.22 -39.86 9.06 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.37 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.38 116.49 8.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.143 179.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.84 29.45 42.54 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.561 -0.828 . . . . 0.0 111.101 -178.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 43.9 t60 -146.06 -34.22 0.31 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.598 -0.301 . . . . 0.0 110.561 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.468 HG23 ' O ' ' A' ' 29' ' ' LEU . 97.2 t -62.48 -43.12 98.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.326 -0.397 . . . . 0.0 109.961 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -61.8 -35.9 79.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.541 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -63.45 -37.61 87.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.23 0.538 . . . . 0.0 110.278 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.498 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 61.7 mt -80.2 -39.32 19.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.142 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 45.9 mt -61.82 -25.27 67.4 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.376 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.5 -13.82 59.65 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.456 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -87.22 151.82 22.83 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.631 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -66.89 111.87 4.0 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.981 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.54 ' HA2' ' OE1' ' A' ' 44' ' ' GLU . . . 83.02 14.59 74.59 Favored Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 120.737 -0.744 . . . . 0.0 111.578 -178.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.498 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -61.58 -39.54 97.5 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.338 -0.458 . . . . 0.0 112.475 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.503 ' O ' HG13 ' A' ' 47' ' ' ILE . 12.7 ptm85 -65.12 -36.1 83.19 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.54 ' OE1' ' HA2' ' A' ' 41' ' ' GLY . 23.0 mp0 -67.66 -39.66 84.54 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.141 0.496 . . . . 0.0 109.775 178.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 31.5 t80 -60.16 -44.2 95.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.099 179.258 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 41.4 mt -60.67 -40.4 91.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.923 179.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.503 HG13 ' O ' ' A' ' 43' ' ' ARG . 71.9 mt -64.91 -42.12 93.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.158 179.63 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 92.2 mt -62.16 -35.42 78.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.873 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.478 ' O ' ' HA2' ' A' ' 53' ' ' GLY . 61.0 t -66.08 -33.35 62.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.733 179.448 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 8.2 mp -83.63 -33.31 25.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.949 0.404 . . . . 0.0 110.496 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 18.3 mt -72.18 -57.02 4.58 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.976 -0.556 . . . . 0.0 112.012 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 39.8 m-85 -105.12 -37.88 6.76 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.973 -177.635 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.478 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 117.59 -168.13 12.89 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.051 -1.071 . . . . 0.0 113.671 178.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.41 ' H ' ' HB3' ' A' ' 69' ' ' MET . 25.6 tp -152.85 150.2 29.09 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . 0.424 HE22 ' NE2' ' B' ' 158' ' ' GLN . 13.1 pt20 -163.94 157.49 18.63 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.672 0.272 . . . . 0.0 111.114 -178.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 138.25 -118.38 1.61 Allowed Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.727 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 6.0 tp60 -161.82 82.8 0.58 Allowed 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 4.0 pt -96.4 148.14 5.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.036 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -121.44 105.27 10.34 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.165 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.4 HG13 ' HG2' ' A' ' 61' ' ' LYS . 6.9 t -126.68 135.7 62.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 179.616 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.4 ' HG2' HG13 ' A' ' 60' ' ' VAL . 21.3 mmtp 60.11 28.14 17.66 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 121.079 0.466 . . . . 0.0 110.814 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.19 20.91 78.8 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.793 -0.639 . . . . 0.0 112.447 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 45.2 mtt -118.03 121.41 40.55 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -90.39 100.22 13.09 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.196 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -85.18 139.87 31.35 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.657 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -139.73 81.61 1.83 Allowed 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.434 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.9 -160.95 9.96 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.667 -0.777 . . . . 0.0 111.946 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 64.5 t -138.46 114.04 9.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.932 0.396 . . . . 0.0 110.29 179.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' MET . . . . . 0.609 ' HB2' ' C4D' ' A' ' 132' ' ' HEC . 5.0 tpt -69.73 114.91 8.38 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 178.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.5 m -63.48 135.07 56.63 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.779 -177.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -72.09 126.87 30.86 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.412 179.23 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 37.1 m-85 -110.36 34.35 3.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.122 0.487 . . . . 0.0 110.661 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -69.02 -8.49 45.49 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.843 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 18.0 pm0 -72.22 -20.19 61.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.86 0.362 . . . . 0.0 110.721 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 22.9 mt -82.09 159.06 23.49 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.255 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.43 ' HB2' ' HG3' ' A' ' 79' ' ' GLU . 22.5 mtpt -70.29 155.11 41.11 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.255 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 40.3 m-20 -61.51 -37.05 82.28 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.002 0.43 . . . . 0.0 110.31 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -69.29 -19.99 63.9 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.952 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . 0.43 ' HG3' ' HB2' ' A' ' 76' ' ' LYS . 41.1 mt-10 -89.23 -41.85 11.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.371 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 81.9 mt -62.93 -38.84 82.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.857 179.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.55 -28.4 64.89 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.161 178.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.13 -46.46 67.6 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.327 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 14.2 p -65.27 -36.93 78.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 C-N-CA 120.81 -0.356 . . . . 0.0 110.161 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 41.1 mt -63.41 -44.02 95.85 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.168 0.509 . . . . 0.0 109.829 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 50.1 m-20 -64.51 -43.15 94.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.891 178.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 44.5 t60 -61.09 -55.23 34.96 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.354 -178.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 46.6 pt -60.6 -35.65 65.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.476 0.547 . . . . 0.0 112.476 -177.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -73.39 -34.2 65.4 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -178.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 22.1 p -89.85 -35.05 15.87 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.631 0.604 . . . . 0.0 112.631 -178.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -59.32 -44.51 92.58 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 15.8 m-90 -91.35 2.21 56.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.813 0.339 . . . . 0.0 111.014 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 64.44 23.99 68.93 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.9 -0.591 . . . . 0.0 113.273 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.435 ' HA ' ' HD3' ' A' ' 96' ' ' LYS . 0.2 OUTLIER -75.28 -28.73 59.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.191 0.52 . . . . 0.0 109.976 -179.913 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -73.47 -6.43 46.37 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.919 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -91.03 -7.12 52.78 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.175 179.362 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.435 ' HD3' ' HA ' ' A' ' 93' ' ' ASP . 34.3 mtpt -96.43 11.21 35.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.34 -179.211 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 13.0 m -126.1 151.04 32.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.017 178.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.3 ptpt -86.46 122.85 30.98 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.061 0.458 . . . . 0.0 111.967 -179.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 64.42 62.05 5.44 Favored Glycine 0 N--CA 1.453 -0.232 0 CA-C-N 115.617 -0.72 . . . . 0.0 113.424 178.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -72.46 122.7 21.71 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.778 0.323 . . . . 0.0 110.508 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 78.5 mttt -96.69 125.16 47.9 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.848 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -57.24 132.65 52.43 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.362 2.042 . . . . 0.0 111.393 179.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -61.95 132.57 53.42 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.581 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -113.36 153.83 27.89 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.733 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -63.33 -30.33 71.49 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.051 0.453 . . . . 0.0 110.774 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.0 mm-40 -61.24 -32.06 71.85 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.954 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -68.23 -45.72 72.48 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.176 0.512 . . . . 0.0 110.199 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 11.7 t -65.0 -46.4 91.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.527 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 26.0 ttpt -62.91 -36.01 81.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.747 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 32.9 ttpt -63.94 -47.7 79.45 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.124 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 80.3 mt -74.21 -25.69 59.82 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.046 0.45 . . . . 0.0 110.876 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 21.0 ttm-85 -72.74 -9.02 58.16 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.689 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -70.13 -37.45 75.29 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.032 0.444 . . . . 0.0 110.027 179.062 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -92.47 103.77 16.16 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.453 179.144 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 25.9 tptp -68.25 99.68 0.94 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.3 0.571 . . . . 0.0 111.009 -179.182 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 72.7 mt -108.86 -174.74 2.59 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.901 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 1.3 p -138.47 163.04 49.85 Favored Pre-proline 0 C--N 1.32 -0.699 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 179.442 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_exo -50.87 -41.66 54.61 Favored 'Trans proline' 0 CA--C 1.533 0.472 0 C-N-CA 122.686 2.257 . . . . 0.0 112.841 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 35.7 tp60 -65.63 -32.41 73.97 Favored 'General case' 0 CA--C 1.53 0.212 0 CA-C-O 120.767 0.318 . . . . 0.0 110.856 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 57.8 mt-30 -73.43 -35.24 65.76 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.182 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 50.1 t -66.46 -36.6 77.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 20.3 tp -61.14 -36.56 80.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.963 178.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.87 -38.72 91.92 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.408 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.455 ' O ' ' HG ' ' A' ' 128' ' ' LEU . 58.4 mm-40 -62.98 -39.13 93.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.33 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 55.4 ttt-85 -61.89 -42.18 98.76 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.986 179.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.456 ' HA ' ' O ' ' A' ' 130' ' ' LEU . 68.1 mttm -68.64 -27.71 66.25 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.469 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 91.1 mttt -73.67 -15.26 61.24 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.236 0.541 . . . . 0.0 110.252 179.307 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.455 ' HG ' ' O ' ' A' ' 124' ' ' GLU . 59.8 mt -88.4 -1.42 58.03 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.578 178.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.21 -10.42 61.64 Favored Glycine 0 N--CA 1.449 -0.463 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.942 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.456 ' O ' ' HA ' ' A' ' 126' ' ' LYS . 20.7 mt -88.25 106.58 18.3 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.9 0.381 . . . . 0.0 110.82 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 9.2 mptt . . . . . 0 C--O 1.246 0.904 0 CA-C-O 118.416 -0.802 . . . . 0.0 110.12 -179.773 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 61.5 t80 . . . . . 0 N--CA 1.48 1.049 0 CA-C-O 120.464 0.173 . . . . 0.0 111.024 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 4.1 m -59.83 -40.81 89.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.029 0.443 . . . . 0.0 111.436 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 94.9 mt -80.86 -3.46 51.33 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.455 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -103.53 -6.3 21.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.028 0.442 . . . . 0.0 110.993 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.0 p -116.31 179.97 3.84 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.651 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 40' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -68.09 -8.63 39.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.549 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 41' ' ' THR . . . . . 0.428 ' O ' HG21 ' B' ' 44' ' ' VAL . 0.2 OUTLIER -61.37 -20.67 63.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.329 -179.928 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -72.06 -8.86 57.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.198 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -70.3 -18.7 75.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.326 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . 0.428 HG21 ' O ' ' B' ' 41' ' ' THR . 8.9 m -74.61 -11.24 14.32 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-O 121.136 0.494 . . . . 0.0 110.905 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 38.1 mt -86.82 131.93 43.71 Favored Pre-proline 0 C--N 1.322 -0.625 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.596 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 46' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -53.56 134.62 58.72 Favored 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.797 2.331 . . . . 0.0 112.288 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -56.54 140.21 47.15 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.24 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -68.69 -23.59 75.52 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.914 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 80.0 tttt -64.08 116.87 6.33 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.933 0.397 . . . . 0.0 110.303 179.311 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 50' ' ' LEU . . . . . . . . . . . . . 80.2 mt -91.66 93.28 8.83 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.01 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 51' ' ' GLU . . . . . . . . . . . . . 21.0 mt-10 -89.19 103.7 16.3 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 52' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -90.7 114.79 27.2 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.797 0.332 . . . . 0.0 110.72 -179.792 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.19 -173.48 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.735 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . 0.579 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 17.3 t70 -96.04 111.41 56.16 Favored Pre-proline 0 C--N 1.326 -0.435 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -78.06 17.43 1.02 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.752 2.301 . . . . 0.0 113.755 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.6 -55.99 2.16 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.442 0.639 . . . . 0.0 110.609 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.8 -2.03 55.5 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.092 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 58' ' ' VAL . . . . . 0.579 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 12.1 p -56.22 -28.37 25.56 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -179.316 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 59' ' ' ARG . . . . . . . . . . . . . 37.3 ptt180 -98.43 12.0 36.37 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.068 0.461 . . . . 0.0 111.031 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 58.8 mt-30 -124.41 -39.35 2.33 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.214 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -140.63 133.87 29.63 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.995 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.07 170.86 12.94 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.027 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -60.46 -28.19 86.26 Favored 'Trans proline' 0 CA--C 1.529 0.229 0 C-N-CA 122.682 2.255 . . . . 0.0 112.712 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 32.3 m-90 -84.55 -2.62 57.63 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.154 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.92 -1.12 57.86 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.91 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -122.69 105.07 35.9 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.592 -179.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_exo -69.06 -23.76 33.65 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.888 2.392 . . . . 0.0 112.625 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -83.81 -47.55 11.01 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.134 0.492 . . . . 0.0 110.371 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 69' ' ' GLN . . . . . . . . . . . . . 17.6 mm100 -86.19 20.92 2.17 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.764 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . 0.439 ' O ' ' HA ' ' B' ' 81' ' ' VAL . . . -71.74 -24.25 61.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.141 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 33.9 t -112.21 103.35 15.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.261 179.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 9.6 t -122.06 130.39 74.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.435 -0.348 . . . . 0.0 111.049 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 6.2 tt0 -78.08 105.15 9.1 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 178.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -78.57 -23.76 45.89 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.152 -0.476 . . . . 0.0 112.041 -178.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . -164.17 177.39 39.91 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.366 -0.921 . . . . 0.0 112.242 -179.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -55.92 115.84 2.75 Favored 'Trans proline' 0 C--O 1.235 0.366 0 C-N-CA 122.85 2.367 . . . . 0.0 112.414 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 18.1 t30 65.27 28.18 11.99 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.533 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 34.4 tt0 -135.64 120.25 18.24 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.839 0.352 . . . . 0.0 110.69 179.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 34.3 m-85 -119.97 126.28 50.48 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.94 -178.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 59.4 m -97.85 124.65 42.34 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 81' ' ' VAL . . . . . 0.439 ' HA ' ' O ' ' B' ' 70' ' ' ALA . 44.7 t -115.15 117.76 56.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 121.09 0.471 . . . . 0.0 111.081 -179.342 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -88.86 95.51 10.32 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.2 178.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 83' ' ' VAL . . . . . 0.515 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 21.7 t -90.46 120.3 39.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.282 -179.152 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 58.0 tp -101.2 109.12 20.94 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.848 179.22 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.79 70.31 10.35 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 86' ' ' PHE . . . . . 0.468 ' CZ ' ' HA3' ' B' ' 89' ' ' GLY . 53.5 p90 -63.0 179.13 0.41 Allowed 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.952 -178.737 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.461 ' HB2' ' CBC' ' A' ' 132' ' ' HEC . . . -52.12 102.94 0.05 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.464 -178.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 64.11 26.96 14.05 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 114.845 -1.07 . . . . 0.0 113.005 178.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 89' ' ' GLY . . . . . 0.468 ' HA3' ' CZ ' ' B' ' 86' ' ' PHE . . . -156.53 -179.52 31.58 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 119.776 -1.202 . . . . 0.0 113.285 179.42 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 90' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -135.71 132.02 36.37 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 91' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -124.1 137.64 29.33 Favored Pre-proline 0 C--N 1.324 -0.525 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -80.12 174.46 48.54 Favored 'Cis proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.249 -1.563 . . . . 0.0 111.971 -0.362 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 93' ' ' ASN . . . . . 0.419 ' OD1' ' HA ' ' B' ' 94' ' ' PRO . 55.4 t30 -161.14 124.86 1.94 Allowed Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 94' ' ' PRO . . . . . 0.419 ' HA ' ' OD1' ' B' ' 93' ' ' ASN . 69.3 Cg_endo -74.55 151.82 97.45 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.371 -1.512 . . . . 0.0 113.162 0.182 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 66.0 mt -85.78 108.56 17.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.917 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 96' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -94.15 115.43 27.71 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.481 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 2.6 m -132.6 155.31 81.36 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.65 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -84.6 160.89 12.52 Favored 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.492 2.128 . . . . 0.0 112.524 179.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.05 146.02 27.98 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.836 0.35 . . . . 0.0 111.031 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.47 -5.32 84.83 Favored Glycine 0 N--CA 1.452 -0.266 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.497 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -105.07 157.45 17.24 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.762 0.315 . . . . 0.0 111.406 -179.341 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 102' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -84.86 116.61 23.41 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 103' ' ' ILE . . . . . . . . . . . . . 24.2 mt -104.02 120.65 54.54 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.092 0.472 . . . . 0.0 110.766 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 16.7 t -96.37 99.36 8.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.262 179.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 105' ' ' PHE . . . . . 0.451 ' O ' ' HA ' ' B' ' 134' ' ' THR . 66.0 m-85 -84.07 118.62 24.19 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.343 -178.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 54.7 mttm -115.76 95.69 5.25 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 177.678 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 107' ' ' ILE . . . . . 0.515 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.1 mp -102.46 137.01 32.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.173 -177.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 3.3 t -138.85 157.19 46.51 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 109' ' ' SER . . . . . 0.602 ' O ' ' HA ' ' B' ' 129' ' ' PRO . 39.4 t -125.69 138.05 31.18 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 111.846 0.314 . . . . 0.0 111.846 -178.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -93.52 -11.51 1.51 Allowed 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 123.118 2.546 . . . . 0.0 112.666 178.15 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 111' ' ' ASP . . . . . 0.58 ' CG ' ' H ' ' B' ' 112' ' ' VAL . 11.5 p-10 -115.84 -113.98 0.34 Allowed 'General case' 0 CA--C 1.537 0.454 0 O-C-N 122.271 -0.268 . . . . 0.0 111.493 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 112' ' ' VAL . . . . . 0.58 ' H ' ' CG ' ' B' ' 111' ' ' ASP . 20.1 m -93.11 -179.05 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.676 0.274 . . . . 0.0 110.544 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.1 mt -73.42 136.01 26.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.24 0.543 . . . . 0.0 110.554 179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 114' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -122.83 174.13 7.33 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 115' ' ' GLY . . . . . 0.544 ' O ' ' HA ' ' B' ' 149' ' ' CYS . . . -124.96 121.35 4.28 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.999 -179.613 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -96.83 80.57 3.04 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 117' ' ' HIS . . . . . . . . . . . . . 12.2 t-80 -113.79 110.27 19.88 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.57 179.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . 0.527 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 21.6 t -88.64 113.56 25.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-O 120.966 0.412 . . . . 0.0 110.316 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -63.02 115.47 4.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.957 -179.269 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 110.08 1.74 29.99 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.686 179.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 121' ' ' THR . . . . . 0.527 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 31.7 p -138.36 178.96 6.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.652 0.263 . . . . 0.0 110.658 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -96.52 20.58 10.45 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.129 0.49 . . . . 0.0 110.646 179.297 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 34.2 mt -86.95 109.38 19.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.246 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -150.28 103.82 3.19 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.761 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 9.0 p -143.41 151.78 16.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.275 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.75 134.68 34.04 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.145 0.498 . . . . 0.0 110.419 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 127' ' ' VAL . . . . . . . . . . . . . 5.1 t -99.17 96.98 5.41 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.884 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 128' ' ' LEU . . . . . . . . . . . . . 4.8 mp -87.93 147.18 40.32 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.773 -179.131 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . 0.602 ' HA ' ' O ' ' B' ' 109' ' ' SER . 28.5 Cg_endo -63.78 118.07 5.03 Favored 'Trans proline' 0 N--CA 1.462 -0.336 0 C-N-CA 122.52 2.147 . . . . 0.0 112.307 179.831 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.93 -4.29 85.67 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.832 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -102.58 139.87 37.61 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 132' ' ' VAL . . . . . . . . . . . . . 59.8 t -101.63 92.31 2.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.251 0.548 . . . . 0.0 110.756 179.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 5.3 m -73.29 105.59 4.76 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.842 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 134' ' ' THR . . . . . 0.451 ' HA ' ' O ' ' B' ' 105' ' ' PHE . 24.6 m -100.66 121.18 41.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.387 -179.024 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 48.2 t -128.13 137.3 57.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.177 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 136' ' ' ARG . . . . . . . . . . . . . 68.6 mtt-85 -108.74 120.26 41.96 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.899 0.38 . . . . 0.0 110.663 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 137' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -136.81 151.55 49.29 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.954 0.407 . . . . 0.0 111.081 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 8.3 m -120.48 100.17 6.99 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.806 179.077 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 139' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -73.27 96.87 2.35 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.344 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 83.5 mttt -91.78 -5.55 53.32 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.01 0.433 . . . . 0.0 110.668 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 141' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 -122.79 113.56 30.17 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.097 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 142' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -72.59 167.45 27.07 Favored 'Trans proline' 0 C--O 1.236 0.409 0 C-N-CA 122.591 2.194 . . . . 0.0 112.342 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 143' ' ' GLY . . . . . 0.463 ' N ' HG12 ' B' ' 166' ' ' VAL . . . 137.29 -159.56 24.79 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.245 -179.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 144' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -120.33 116.82 26.28 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.781 0.324 . . . . 0.0 110.349 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 51.4 m-85 -110.11 147.04 34.4 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.92 -179.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 12.5 mmt180 -110.22 133.12 53.55 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.064 0.459 . . . . 0.0 111.456 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 147' ' ' ILE . . . . . . . . . . . . . 40.5 mt -88.0 131.46 35.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.708 178.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 46.4 mt -115.53 115.14 48.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 120.951 0.405 . . . . 0.0 110.179 179.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 149' ' ' CYS . . . . . 0.544 ' HA ' ' O ' ' B' ' 115' ' ' GLY . 42.5 t -79.9 89.1 5.28 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.751 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 150' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -64.13 -25.09 67.94 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 10.2 tp60 -81.05 135.85 35.88 Favored 'General case' 0 C--O 1.247 0.94 0 CA-C-O 121.204 0.526 . . . . 0.0 111.764 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -53.53 161.85 0.94 Allowed 'General case' 0 N--CA 1.471 0.621 0 CA-C-N 114.893 -1.049 . . . . 0.0 112.386 -178.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 153' ' ' CYS . . . . . 0.407 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 1.6 p 176.44 65.17 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.914 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 52.79 -142.67 25.85 Favored Glycine 0 CA--C 1.518 0.262 0 O-C-N 123.464 0.478 . . . . 0.0 114.019 179.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 155' ' ' LEU . . . . . . . . . . . . . 91.4 mt -72.91 -27.1 61.67 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.741 0.305 . . . . 0.0 111.527 -179.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 156' ' ' GLY . . . . . . . . . . . . . . . -87.32 62.14 4.14 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.591 -0.814 . . . . 0.0 111.623 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 157' ' ' HIS . . . . . 0.407 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 69.2 t60 -127.78 -59.3 1.21 Allowed 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -178.831 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . 0.424 ' NE2' HE22 ' A' ' 55' ' ' GLN . 4.5 pm0 -57.71 -33.23 68.19 Favored 'General case' 0 C--N 1.328 -0.333 0 O-C-N 123.463 0.477 . . . . 0.0 112.188 -178.359 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 159' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -107.49 14.14 26.14 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.719 -0.392 . . . . 0.0 111.009 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 160' ' ' MET . . . . . . . . . . . . . 26.3 ttt -84.99 85.15 7.51 Favored 'General case' 0 C--O 1.237 0.426 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 161' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -112.66 -177.14 3.07 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.972 -179.282 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 162' ' ' GLY . . . . . . . . . . . . . . . -148.21 150.98 23.25 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 178.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 7.5 m -113.03 108.31 17.17 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 117.317 0.558 . . . . 0.0 111.659 -179.022 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 41.1 mt -102.5 111.86 33.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 165' ' ' VAL . . . . . . . . . . . . . 15.0 t -108.49 102.78 14.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 121.175 0.512 . . . . 0.0 110.451 -179.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 166' ' ' VAL . . . . . 0.463 HG12 ' N ' ' B' ' 143' ' ' GLY . 0.7 OUTLIER -88.06 120.75 37.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 179.209 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 51.9 mmtt -67.32 155.93 37.69 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.654 -178.354 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 168' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 . . . . . 0 C--O 1.249 1.035 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.094 -179.459 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' HEC . . . . . 0.609 ' C4D' ' HB2' ' A' ' 69' ' ' MET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 169' ' ' CUA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.452 ' HA3' ' HB2' ' A' ' 86' ' ' HIS . . . . . . . . 0 N--CA 1.448 -0.519 0 CA-C-O 120.115 -0.269 . . . . 0.0 113.52 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.06 -39.4 75.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 117.186 0.493 . . . . 0.0 111.165 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.06 -40.17 88.58 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.167 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.402 ' HB ' ' HB ' ' A' ' 83' ' ' VAL . 37.2 mm -80.3 -26.92 11.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.081 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -57.2 -29.34 63.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.923 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -59.57 -30.81 68.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.103 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 75.8 mt-30 -75.39 -36.16 60.93 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.284 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 20.6 m -67.42 -31.8 72.24 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-O 121.048 0.452 . . . . 0.0 110.516 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.51 -19.56 65.98 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.953 -179.409 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.95 -24.73 71.74 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.256 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 96.3 m -129.32 -40.2 1.46 Allowed 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -179.425 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -91.3 -7.2 51.72 Favored 'General case' 0 C--N 1.33 -0.253 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.341 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 16.1 mm-40 65.27 176.26 0.21 Allowed 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.892 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 20.3 mp0 -79.35 -8.57 59.17 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.631 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 23.8 p30 -90.93 -20.22 22.44 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.774 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 72.34 22.35 78.94 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.565 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 16.3 mt-30 -98.02 -32.29 11.71 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.978 0.418 . . . . 0.0 110.42 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.671 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.786 179.689 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.226 -0.175 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -128.29 123.91 22.68 Favored Pre-proline 0 C--N 1.327 -0.397 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.939 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.3 158.65 44.62 Favored 'Trans proline' 0 C--O 1.239 0.531 0 C-N-CA 122.889 2.393 . . . . 0.0 113.0 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -78.76 158.7 28.06 Favored 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.782 2.322 . . . . 0.0 112.351 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.409 ' O ' HG23 ' A' ' 33' ' ' VAL . 65.8 mt -115.4 -38.04 3.88 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.347 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.39 120.3 11.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.127 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 73.43 33.45 58.63 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 -179.042 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 32.4 t60 -143.92 -32.99 0.43 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.585 -0.307 . . . . 0.0 110.548 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 29' ' ' LEU . 59.6 t -63.45 -41.12 91.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -62.04 -35.38 78.42 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.847 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -61.65 -37.58 84.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.513 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.47 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 19.4 mt -79.95 -38.53 18.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.525 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 46.5 mt -62.67 -23.59 67.19 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.556 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -82.7 -10.1 59.06 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.419 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 65.9 mmtt -90.7 154.02 19.86 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.739 0.304 . . . . 0.0 110.35 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -75.42 105.31 6.38 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.71 7.67 55.28 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.149 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -64.44 -34.79 90.85 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 121.255 -0.498 . . . . 0.0 112.105 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 11.4 ptm85 -67.77 -35.17 78.21 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.614 0.245 . . . . 0.0 110.394 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -67.0 -40.09 87.28 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -61.96 -40.67 96.36 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.393 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 86.6 mt -59.43 -34.09 72.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.011 179.644 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.4 mt -78.98 -42.19 23.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.999 0.428 . . . . 0.0 110.08 179.104 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.51 ' HG ' HD13 ' A' ' 111' ' ' LEU . 42.8 mt -63.3 -37.93 89.17 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.11 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.577 ' O ' ' HA2' ' A' ' 53' ' ' GLY . 0.8 OUTLIER -71.06 -15.47 18.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.013 -179.631 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 3.0 mp -96.66 -44.5 7.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.852 0.358 . . . . 0.0 110.538 179.158 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.6 mt -66.69 -47.23 73.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.059 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 68.9 m-85 -111.92 -55.85 2.46 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.213 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.577 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 120.11 -158.46 15.36 Favored Glycine 0 N--CA 1.441 -1.009 0 C-N-CA 119.888 -1.148 . . . . 0.0 113.938 178.506 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.431 ' H ' ' HB2' ' A' ' 69' ' ' MET . 1.9 tp -152.52 150.01 29.12 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -179.192 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLN . . . . . 0.495 ' OE1' ' HB2' ' A' ' 118' ' ' PRO . 9.3 pt20 -151.09 111.16 4.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.864 0.364 . . . . 0.0 111.726 -179.66 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -177.37 -143.8 5.09 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.182 178.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.463 ' HA ' ' O ' ' A' ' 65' ' ' TYR . 19.8 mp0 -132.88 66.67 1.55 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.479 ' O ' ' HA ' ' A' ' 64' ' ' LYS . 33.1 pt -66.87 155.07 7.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.247 -178.89 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.408 ' OE1' ' HG3' ' A' ' 64' ' ' LYS . 23.7 tt0 -124.62 100.63 6.73 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.215 0.531 . . . . 0.0 110.817 -179.422 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 41.0 t -100.32 115.85 42.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.061 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 19.2 mmtp 62.96 23.82 14.22 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.508 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.91 -7.9 65.17 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.654 179.652 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -97.55 121.0 38.95 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 17.0 mttp -91.67 144.77 25.18 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.955 0.407 . . . . 0.0 110.914 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.463 ' O ' ' HA ' ' A' ' 57' ' ' GLN . 71.1 m-85 -120.96 177.43 5.11 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.058 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -156.38 71.98 0.73 Allowed 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -140.99 -161.99 8.92 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.766 179.602 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.67 ' HB ' ' CG ' ' B' ' 88' ' ' PHE . 41.4 t -146.77 136.39 16.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.222 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' MET . . . . . 0.517 ' HG3' HG22 ' A' ' 49' ' ' VAL . 0.3 OUTLIER -71.19 142.07 50.66 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.527 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 6.5 m -78.52 123.84 27.5 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.719 0.295 . . . . 0.0 110.75 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.5 m -70.78 95.19 1.1 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.351 179.418 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -84.5 45.83 1.17 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.229 0.538 . . . . 0.0 111.375 -179.192 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -74.12 -16.67 61.0 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.84 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 19.4 pm0 -76.12 -18.65 59.06 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.68 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 65.2 mt -83.48 155.31 23.45 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.889 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 25.0 mtpt -72.69 154.71 40.58 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -55.41 -41.72 73.11 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.715 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -63.17 -37.96 89.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.005 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 51.5 mt-10 -67.07 -45.17 78.14 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.652 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 89.9 mt -60.45 -42.48 91.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.379 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.39 -35.61 73.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.635 179.049 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.83 -46.39 88.17 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.701 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.402 ' HB ' ' HB ' ' A' ' 7' ' ' ILE . 9.8 p -66.42 -34.94 73.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 C-N-CA 120.485 -0.486 . . . . 0.0 110.669 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 35.2 mt -65.55 -44.82 85.63 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.157 0.503 . . . . 0.0 110.155 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 82.4 m-20 -66.33 -39.06 89.0 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.21 179.129 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' HIS . . . . . 0.452 ' HB2' ' HA3' ' A' ' 4' ' ' GLY . 32.3 t60 -63.73 -50.73 67.98 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.516 -0.766 . . . . 0.0 111.597 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.438 HG13 ' N ' ' A' ' 88' ' ' ALA . 41.8 pt -64.39 -39.53 85.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.561 ' HB1' ' HB2' ' A' ' 94' ' ' ALA . . . -63.62 -36.23 83.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.852 0.358 . . . . 0.0 111.663 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.5 p -89.28 -23.57 22.27 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.751 -179.333 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -61.43 -53.88 50.76 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.875 0.369 . . . . 0.0 111.527 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.415 ' CZ3' ' HB ' ' A' ' 87' ' ' ILE . 5.3 m-90 -86.32 -8.4 57.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.192 0.52 . . . . 0.0 110.566 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 77.56 17.89 78.4 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.493 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.59 -26.96 68.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.301 0.572 . . . . 0.0 110.187 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.561 ' HB2' ' HB1' ' A' ' 88' ' ' ALA . . . -73.53 -7.57 52.39 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.208 179.233 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -98.67 1.14 45.94 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.052 0.453 . . . . 0.0 110.476 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 39.4 mtpt -103.76 11.05 36.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.636 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 15.9 m -125.18 159.77 31.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.987 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.6 ptpt -93.1 112.91 25.02 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.823 0.344 . . . . 0.0 111.155 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 69.99 68.27 1.68 Allowed Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.85 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 65.1 t80 -73.17 124.68 26.09 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.827 0.346 . . . . 0.0 110.395 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 70.5 mttt -98.65 117.56 64.37 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.501 179.261 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -59.55 141.85 97.93 Favored 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.243 1.962 . . . . 0.0 111.374 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -69.83 126.64 30.3 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.306 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.6 p -109.15 152.52 25.01 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.663 -0.698 . . . . 0.0 110.457 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.05 -24.44 58.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 111.333 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 66.6 mm-40 -60.97 -43.21 99.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.894 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.473 ' O ' ' HG2' ' A' ' 110' ' ' LYS . 27.2 mt-10 -68.73 -29.64 68.1 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.006 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 24.3 t -76.98 -40.56 30.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-O 121.186 0.517 . . . . 0.0 109.919 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 9.2 tppt? -62.93 -44.21 96.7 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.814 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' LYS . . . . . 0.473 ' HG2' ' O ' ' A' ' 107' ' ' GLU . 62.7 pttt -60.49 -32.0 71.01 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.711 0.291 . . . . 0.0 111.361 -179.031 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.51 HD13 ' HG ' ' A' ' 48' ' ' LEU . 97.4 mt -87.61 -30.48 20.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.214 -179.342 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 46.6 ttm-85 -66.56 -31.05 71.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.051 0.453 . . . . 0.0 110.457 179.464 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -71.46 -29.99 65.48 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.621 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -89.16 92.65 9.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.729 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 27.3 tptp -66.09 113.71 4.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.415 0.626 . . . . 0.0 111.473 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 81.5 mt -126.63 -174.97 3.26 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.245 179.102 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.45 ' O ' HG23 ' A' ' 121' ' ' VAL . 75.3 p -131.13 147.94 68.26 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.091 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.495 ' HB2' ' OE1' ' A' ' 55' ' ' GLN . 32.4 Cg_exo -58.01 -26.77 76.56 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.6 2.2 . . . . 0.0 112.118 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 11.5 tp60 -71.29 -29.91 65.62 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.447 179.665 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -80.07 -33.0 39.3 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.073 179.209 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.45 HG23 ' O ' ' A' ' 117' ' ' THR . 43.2 t -63.15 -25.72 39.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.344 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.416 ' HA ' HD11 ' A' ' 54' ' ' LEU . 26.7 tp . . . . . 0 C--O 1.232 0.163 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.215 178.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 86.4 t80 . . . . . 0 N--CA 1.481 1.105 0 CA-C-O 120.716 0.294 . . . . 0.0 110.932 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -35.35 80.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.86 0.362 . . . . 0.0 111.311 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 94.4 mt -76.79 -15.16 59.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.994 0.426 . . . . 0.0 110.675 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.81 13.02 30.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.824 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 1.8 p -139.89 178.04 7.54 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.314 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 40' ' ' HIS . . . . . . . . . . . . . 1.4 p80 -75.54 -6.43 50.21 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.349 0.595 . . . . 0.0 109.824 179.171 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 41' ' ' THR . . . . . 0.476 ' O ' HG22 ' B' ' 44' ' ' VAL . 0.3 OUTLIER -64.4 -19.71 65.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.07 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.28 -10.92 47.18 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.276 179.445 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -66.11 -25.78 72.27 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.312 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 44' ' ' VAL . . . . . 0.476 HG22 ' O ' ' B' ' 41' ' ' THR . 11.8 m -70.62 -12.24 15.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-O 120.987 0.422 . . . . 0.0 111.094 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 38.1 mt -92.16 133.2 30.59 Favored Pre-proline 0 C--N 1.322 -0.602 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 46' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -52.62 145.02 39.96 Favored 'Trans proline' 0 C--N 1.347 0.482 0 C-N-CA 122.831 2.354 . . . . 0.0 112.613 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -60.24 152.55 24.51 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.492 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -84.98 -18.99 60.09 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.947 -0.644 . . . . 0.0 111.911 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 29.8 tttt -75.85 138.42 41.1 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 50' ' ' LEU . . . . . 0.427 HD23 ' HA ' ' B' ' 50' ' ' LEU . 13.2 mt -83.19 134.27 34.98 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.01 0.433 . . . . 0.0 110.272 179.322 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 51' ' ' GLU . . . . . 0.435 ' HB3' ' HB ' ' B' ' 132' ' ' VAL . 1.6 tt0 -133.46 74.82 1.58 Allowed 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 52' ' ' ARG . . . . . . . . . . . . . 23.2 ttm180 -95.78 132.45 41.0 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.092 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 6.8 m -136.16 -172.0 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 115.668 -0.697 . . . . 0.0 109.909 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 54' ' ' ASP . . . . . 0.549 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 28.2 t70 -93.07 114.62 63.22 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 179.161 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -72.1 -11.83 27.49 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.541 2.16 . . . . 0.0 112.952 -178.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.17 -52.11 9.83 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 111.887 0.328 . . . . 0.0 111.887 -179.277 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 12.6 p -98.51 0.02 44.25 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 -178.367 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 58' ' ' VAL . . . . . 0.549 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 8.4 p -61.84 -22.58 28.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-O 121.136 0.494 . . . . 0.0 111.104 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 59' ' ' ARG . . . . . 0.456 ' NH1' ' HB2' ' B' ' 110' ' ' PRO . 12.2 ptt180 -95.77 3.12 54.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.435 -179.707 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -124.04 -31.2 3.4 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.85 0.357 . . . . 0.0 111.095 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -140.23 118.37 11.97 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.448 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 137.79 -177.76 19.68 Favored Glycine 0 N--CA 1.441 -0.969 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.298 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -63.88 -13.2 35.8 Favored 'Trans proline' 0 CA--C 1.53 0.306 0 C-N-CA 123.17 2.58 . . . . 0.0 113.103 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 30.2 m-90 -104.18 12.66 33.57 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.978 0.418 . . . . 0.0 110.328 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -100.42 2.54 42.35 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.563 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -145.14 114.93 4.97 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.472 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -72.61 -9.97 24.62 Favored 'Trans proline' 0 C--O 1.234 0.293 0 C-N-CA 122.64 2.227 . . . . 0.0 112.985 -179.644 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -81.93 -54.93 4.93 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.848 0.356 . . . . 0.0 110.581 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 69' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -88.07 44.23 1.18 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.051 0.453 . . . . 0.0 110.989 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 70' ' ' ALA . . . . . 0.429 ' O ' ' HA ' ' B' ' 81' ' ' VAL . . . -84.15 -29.36 26.74 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.383 179.374 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 41.6 t -102.21 106.84 20.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.697 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 40.7 t -120.94 125.03 73.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.136 -179.453 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 58.0 tt0 -65.93 127.4 31.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.843 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -123.58 20.85 9.43 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.875 -178.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . 158.33 177.81 31.77 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.359 -0.924 . . . . 0.0 112.125 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -61.45 108.69 0.63 Allowed 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.961 2.441 . . . . 0.0 111.729 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 38.8 t30 63.47 25.56 14.53 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.401 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -122.19 123.15 40.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.587 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 24.8 m-85 -129.37 127.42 40.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.725 0.298 . . . . 0.0 110.823 -179.085 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 100.0 m -93.37 125.37 37.94 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 178.695 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 81' ' ' VAL . . . . . 0.429 ' HA ' ' O ' ' B' ' 70' ' ' ALA . 55.8 t -114.52 116.98 54.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.097 0.475 . . . . 0.0 110.825 -179.261 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -85.36 118.48 24.92 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.557 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 83' ' ' VAL . . . . . 0.531 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 20.2 t -116.16 124.82 72.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.138 0.494 . . . . 0.0 110.986 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 34.6 tp -101.05 115.2 29.92 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.524 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 85' ' ' ALA . . . . . . . . . . . . . . . -100.46 90.93 4.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.641 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 86' ' ' PHE . . . . . 0.414 ' CZ ' ' HB2' ' B' ' 91' ' ' GLN . 0.2 OUTLIER -96.44 -163.82 1.09 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.011 0.434 . . . . 0.0 111.524 -179.535 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.41 ' H ' ' HB2' ' B' ' 86' ' ' PHE . . . -55.86 103.31 0.1 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.913 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 88' ' ' PHE . . . . . 0.67 ' CG ' ' HB ' ' A' ' 68' ' ' VAL . 9.2 m-85 56.34 27.66 12.27 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.085 -0.962 . . . . 0.0 113.071 177.795 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 89' ' ' GLY . . . . . . . . . . . . . . . -150.38 168.98 30.33 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 119.649 -1.262 . . . . 0.0 113.207 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 90' ' ' TYR . . . . . 0.408 ' O ' ' HB2' ' B' ' 93' ' ' ASN . 83.8 m-85 -138.78 131.39 28.98 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 91' ' ' GLN . . . . . 0.414 ' HB2' ' CZ ' ' B' ' 86' ' ' PHE . 5.3 tt0 -122.34 130.28 24.75 Favored Pre-proline 0 C--N 1.323 -0.567 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -82.03 172.14 52.91 Favored 'Cis proline' 0 N--CA 1.461 -0.385 0 C-N-CA 123.512 -1.453 . . . . 0.0 112.269 -0.197 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 93' ' ' ASN . . . . . 0.408 ' HB2' ' O ' ' B' ' 90' ' ' TYR . 3.7 t30 -152.09 130.07 6.04 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.788 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 94' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' B' ' 93' ' ' ASN . 73.0 Cg_endo -77.96 149.31 87.22 Favored 'Cis proline' 0 N--CA 1.461 -0.418 0 C-N-CA 122.925 -1.698 . . . . 0.0 111.481 -1.33 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.3 mt -75.65 96.22 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.472 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 96' ' ' GLU . . . . . 0.61 ' HA ' ' O ' ' B' ' 165' ' ' VAL . 41.2 mt-10 -88.32 120.5 29.75 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.449 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 97' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 3.2 m -138.29 149.82 64.57 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.692 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -78.99 149.07 22.39 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.747 2.298 . . . . 0.0 112.318 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -92.26 155.83 17.7 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.37 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.13 7.12 87.39 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.355 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -123.36 158.31 31.36 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.44 0.162 . . . . 0.0 110.847 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 102' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -86.26 111.71 20.7 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 103' ' ' ILE . . . . . . . . . . . . . 8.0 mt -100.51 116.42 43.89 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.631 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 20.0 t -90.5 95.66 5.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 105' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -79.83 122.74 27.01 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.204 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -121.02 92.55 3.78 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.347 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 107' ' ' ILE . . . . . 0.531 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.5 mp -100.85 137.65 27.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.493 -177.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 5.5 t -141.79 159.49 42.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.499 178.465 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 109' ' ' SER . . . . . . . . . . . . . 30.6 t -119.5 135.88 24.32 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-O 120.708 0.29 . . . . 0.0 111.18 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 110' ' ' PRO . . . . . 0.456 ' HB2' ' NH1' ' B' ' 59' ' ' ARG . 65.8 Cg_endo -96.67 -0.83 1.82 Allowed 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.212 2.608 . . . . 0.0 113.216 178.889 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 111' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -129.16 -97.71 0.37 Allowed 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -179.042 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 112' ' ' VAL . . . . . . . . . . . . . 14.6 m -107.7 -175.25 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.709 0.29 . . . . 0.0 111.469 -178.758 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.1 mt -68.26 144.19 14.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.707 0.765 . . . . 0.0 111.428 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 114' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -141.82 178.02 7.78 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.578 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 115' ' ' GLY . . . . . 0.446 ' HA3' ' OD1' ' B' ' 150' ' ' ASN . . . -141.79 141.81 11.33 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.537 -0.839 . . . . 0.0 111.579 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -110.66 76.66 0.99 Allowed 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.077 0.465 . . . . 0.0 110.343 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 117' ' ' HIS . . . . . 0.475 ' HA ' ' O ' ' B' ' 123' ' ' ILE . 15.1 t-160 -109.11 92.18 3.95 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.024 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.571 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 22.0 t -75.26 114.63 15.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.728 -179.203 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -64.67 119.21 10.11 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.538 -179.717 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 106.84 1.7 36.63 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.151 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 121' ' ' THR . . . . . 0.571 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 51.0 p -132.4 -174.68 3.52 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.836 0.351 . . . . 0.0 110.777 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -103.01 14.14 32.64 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 178.551 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 123' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' B' ' 117' ' ' HIS . 33.7 mt -83.44 109.37 17.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.572 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -144.54 80.15 1.62 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.437 -0.801 . . . . 0.0 108.957 179.498 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 14.6 p -124.76 148.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.0 -179.047 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -83.47 142.78 30.69 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.304 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 127' ' ' VAL . . . . . . . . . . . . . 46.8 t -116.16 103.84 15.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 128' ' ' LEU . . . . . . . . . . . . . 6.4 mt -92.2 156.57 41.82 Favored Pre-proline 0 C--N 1.322 -0.592 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.135 -178.839 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -66.59 119.17 6.17 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.725 2.283 . . . . 0.0 112.289 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.71 7.48 87.29 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.708 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -112.48 126.05 54.9 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 132' ' ' VAL . . . . . 0.435 ' HB ' ' HB3' ' B' ' 51' ' ' GLU . 35.1 t -93.94 103.73 15.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.191 0.519 . . . . 0.0 111.137 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 6.3 m -81.97 111.71 18.39 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.653 179.234 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 134' ' ' THR . . . . . . . . . . . . . 24.3 m -97.99 124.16 42.33 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.543 -179.083 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 40.4 t -136.12 130.99 48.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.932 179.561 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 136' ' ' ARG . . . . . . . . . . . . . 51.5 mtt180 -99.91 115.98 30.9 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.941 0.401 . . . . 0.0 110.404 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 137' ' ' TYR . . . . . 0.413 ' CZ ' ' HB ' ' B' ' 121' ' ' THR . 7.7 t80 -121.07 156.54 32.01 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.167 0.508 . . . . 0.0 111.272 -179.311 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 4.1 m -134.12 100.57 4.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.741 178.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 139' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -72.19 121.92 20.15 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.538 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -108.79 6.99 26.05 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.034 0.445 . . . . 0.0 110.444 179.525 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 141' ' ' ARG . . . . . . . . . . . . . 8.7 ptp180 -152.17 131.15 6.57 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.215 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 142' ' ' PRO . . . . . 0.626 ' HA ' HG13 ' B' ' 166' ' ' VAL . 92.1 Cg_endo -76.64 -177.33 3.68 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 123.134 2.556 . . . . 0.0 112.782 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 143' ' ' GLY . . . . . . . . . . . . . . . 123.43 179.58 15.82 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.93 -0.653 . . . . 0.0 112.44 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 144' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -101.25 127.04 48.03 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -119.07 143.01 47.37 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.739 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 2.8 tpt180 -108.18 133.01 53.04 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.799 0.333 . . . . 0.0 110.301 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 147' ' ' ILE . . . . . 0.53 ' O ' ' HA ' ' B' ' 161' ' ' PHE . 13.5 mt -87.27 125.22 41.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.655 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 69.7 mt -102.19 116.01 45.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.086 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 149' ' ' CYS . . . . . . . . . . . . . 37.5 t -85.39 90.21 7.88 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.418 179.387 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 150' ' ' ASN . . . . . 0.446 ' OD1' ' HA3' ' B' ' 115' ' ' GLY . 26.5 p-10 -59.36 -38.47 80.49 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -179.185 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -70.95 136.01 48.24 Favored 'General case' 0 C--O 1.25 1.098 0 CA-C-O 121.128 0.489 . . . . 0.0 111.793 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -53.63 164.35 0.55 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.067 -0.969 . . . . 0.0 111.993 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 153' ' ' CYS . . . . . 0.646 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 5.9 p 170.52 89.67 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.996 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 71.07 -174.81 40.0 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.734 178.876 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 155' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -77.66 -18.36 56.77 Favored 'General case' 0 N--CA 1.463 0.208 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.044 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 156' ' ' GLY . . . . . 0.451 ' O ' HG21 ' A' ' 68' ' ' VAL . . . -108.33 31.27 8.01 Favored Glycine 0 CA--C 1.508 -0.349 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.321 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 157' ' ' HIS . . . . . 0.646 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 0.3 OUTLIER -66.41 -27.89 68.19 Favored 'General case' 0 C--N 1.318 -0.789 0 O-C-N 122.682 -0.305 . . . . 0.0 111.425 -179.337 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 2.6 pm0 -76.07 -17.67 59.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -178.325 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 159' ' ' ASN . . . . . 0.411 ' HB3' ' CG2' ' A' ' 68' ' ' VAL . 13.1 t30 -100.96 4.49 42.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.823 0.344 . . . . 0.0 111.038 -179.514 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 160' ' ' MET . . . . . . . . . . . . . 26.8 ttt -77.5 77.48 4.02 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 161' ' ' PHE . . . . . 0.53 ' HA ' ' O ' ' B' ' 147' ' ' ILE . 8.6 m-30 -115.8 109.89 18.3 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.427 -178.766 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 162' ' ' GLY . . . . . . . . . . . . . . . -80.4 165.31 48.29 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.921 -0.657 . . . . 0.0 111.598 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.08 127.06 53.04 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 117.377 0.589 . . . . 0.0 112.084 -178.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 40.8 mt -120.15 130.41 74.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 178.55 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 165' ' ' VAL . . . . . 0.61 ' O ' ' HA ' ' B' ' 96' ' ' GLU . 58.0 t -126.3 104.78 13.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 120.869 0.366 . . . . 0.0 110.643 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 166' ' ' VAL . . . . . 0.626 HG13 ' HA ' ' B' ' 142' ' ' PRO . 0.4 OUTLIER -86.74 127.56 40.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.563 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 30.5 mmtp -80.33 136.03 36.32 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.077 -178.419 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 168' ' ' GLU . . . . . 0.433 ' H ' ' CD ' ' B' ' 168' ' ' GLU . 1.3 pm0 . . . . . 0 C--O 1.248 0.995 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.129 179.63 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.336 0 CA-C-O 120.277 -0.18 . . . . 0.0 113.152 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.65 -38.65 77.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.997 0.398 . . . . 0.0 110.378 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.52 -34.44 77.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.55 179.186 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 50.7 mm -76.07 -35.16 28.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.358 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.402 ' HA ' ' SG ' ' A' ' 11' ' ' CYS . 68.3 t80 -65.71 -16.43 63.76 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.451 -179.726 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -58.91 -26.98 64.82 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.978 0.418 . . . . 0.0 110.982 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 15.3 mt-30 -77.11 -30.49 55.27 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.535 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.402 ' SG ' ' HA ' ' A' ' 8' ' ' TYR . 2.0 m -76.02 -25.87 56.12 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.152 -179.35 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.29 -18.24 48.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.948 -179.359 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.15 -20.77 80.05 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.795 -0.717 . . . . 0.0 113.277 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 77.0 m -130.43 -43.58 1.14 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 117.329 0.564 . . . . 0.0 111.971 -179.264 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 92.1 m-70 -91.42 -5.4 54.44 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 59.47 -172.11 0.12 Allowed 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.617 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -92.47 -9.67 40.63 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.093 -179.59 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 39.1 p30 -84.63 -8.31 58.93 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.623 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 72.67 20.32 79.58 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.498 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 64.3 mt-30 -117.4 -51.05 2.53 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.941 0.401 . . . . 0.0 110.282 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.623 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.77 -179.675 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.283 0 CA-C-O 120.547 0.213 . . . . 0.0 111.12 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -121.89 137.81 27.81 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.071 -179.186 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -76.16 147.64 30.01 Favored 'Trans proline' 0 C--O 1.24 0.597 0 C-N-CA 122.857 2.371 . . . . 0.0 112.14 179.056 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -80.81 155.5 20.51 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.856 2.371 . . . . 0.0 112.263 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.552 ' O ' HG23 ' A' ' 33' ' ' VAL . 67.4 mt -105.57 -43.75 4.86 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.655 179.44 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.91 120.02 11.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.431 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.25 12.7 82.88 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.783 -0.722 . . . . 0.0 111.998 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 58.0 t60 -127.62 -22.53 3.59 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.692 0.282 . . . . 0.0 110.899 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.552 HG23 ' O ' ' A' ' 29' ' ' LEU . 60.2 t -65.53 -45.43 92.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.924 0.392 . . . . 0.0 109.945 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -63.05 -31.34 72.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.441 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -65.08 -38.13 89.76 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.198 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.523 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 63.8 mt -78.47 -40.11 24.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.705 -179.595 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 85.8 mt -64.32 -27.32 68.95 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.137 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -79.79 4.58 15.99 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.603 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 59.0 mmtt -109.74 154.79 22.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.629 0.252 . . . . 0.0 110.407 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -66.49 112.6 4.17 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.718 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.55 14.76 77.57 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.009 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.523 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -61.07 -40.75 98.95 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 121.226 -0.511 . . . . 0.0 112.648 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.432 ' O ' HG13 ' A' ' 47' ' ' ILE . 12.7 ptm85 -66.58 -36.31 82.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.679 0.276 . . . . 0.0 110.538 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -67.52 -41.85 83.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.373 0.606 . . . . 0.0 109.52 178.681 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.485 ' O ' HG23 ' A' ' 49' ' ' VAL . 26.7 t80 -60.0 -43.88 94.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.109 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 35.5 mt -56.06 -45.6 79.21 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.106 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.432 HG13 ' O ' ' A' ' 43' ' ' ARG . 59.2 mt -62.13 -43.39 97.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.802 -179.704 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 62.8 mt -60.93 -38.22 85.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.963 0.411 . . . . 0.0 110.739 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.485 HG23 ' O ' ' A' ' 45' ' ' TYR . 81.0 t -65.6 -31.68 54.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.183 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.0 mp -84.04 -34.65 24.21 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.958 0.409 . . . . 0.0 110.845 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.7 mt -71.54 -56.97 4.87 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.992 -0.549 . . . . 0.0 112.097 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.576 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 55.6 m-85 -103.71 -37.23 7.57 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -178.017 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.457 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 119.51 -167.61 13.4 Favored Glycine 0 N--CA 1.445 -0.728 0 C-N-CA 119.878 -1.153 . . . . 0.0 113.438 178.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.469 ' H ' ' HB3' ' A' ' 69' ' ' MET . 4.6 tp -163.33 134.62 4.81 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.867 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLN . . . . . 0.523 ' HB2' ' HB3' ' B' ' 159' ' ' ASN . 0.0 OUTLIER -154.38 116.27 4.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.06 0.457 . . . . 0.0 111.862 179.779 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -162.97 -148.3 5.32 Favored Glycine 0 N--CA 1.442 -0.904 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.462 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -130.52 68.19 1.47 Allowed 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.931 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.3 pt -83.39 165.49 2.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.357 -178.539 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -140.77 113.76 8.4 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.468 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 42.9 t -110.89 116.8 53.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.63 -179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 16.2 mttp 61.38 28.06 17.57 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.521 179.268 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.46 -20.22 51.59 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.753 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.78 110.87 18.68 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.882 0.372 . . . . 0.0 110.738 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 19.1 mttp -81.45 134.3 35.52 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.69 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -119.73 151.13 39.26 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -156.84 82.54 0.95 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.095 0.474 . . . . 0.0 110.268 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -139.73 -150.73 5.55 Favored Glycine 0 N--CA 1.44 -1.07 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.427 ' HA ' ' HB3' ' A' ' 55' ' ' GLN . 58.8 t -143.06 118.28 4.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.791 0.329 . . . . 0.0 110.574 179.172 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' MET . . . . . 0.469 ' HB3' ' H ' ' A' ' 54' ' ' LEU . 4.1 tpt -77.02 108.5 10.13 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.063 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -55.75 132.33 48.96 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.404 -0.816 . . . . 0.0 113.01 -178.214 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -71.14 121.4 18.25 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.896 178.795 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 36.6 m-85 -108.06 39.22 2.0 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.125 0.488 . . . . 0.0 111.034 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.02 -18.71 65.52 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.414 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.1 pm0 -68.23 -14.91 63.34 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.809 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 82.4 mt -87.35 147.69 25.37 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.888 179.298 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 53.4 mtpt -71.6 160.71 32.19 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.933 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 76.8 m-20 -53.97 -42.88 69.43 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.18 0.515 . . . . 0.0 110.356 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -63.6 -43.31 97.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.309 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 73.9 mt-10 -64.46 -42.79 95.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.368 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 97.6 mt -66.28 -40.45 86.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.969 0.414 . . . . 0.0 110.498 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.49 -35.85 75.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.884 179.448 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.32 -45.67 92.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.538 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 12.5 p -70.96 -34.49 55.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.619 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 15.7 mt -62.25 -45.49 93.05 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.263 0.554 . . . . 0.0 109.96 178.619 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 54.0 m-20 -69.32 -32.83 72.2 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.405 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 25.8 t60 -66.19 -51.09 61.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.749 -179.089 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 39.5 pt -63.63 -32.43 56.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -178.642 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.703 ' HB1' ' HB2' ' A' ' 94' ' ' ALA . . . -73.63 -33.39 64.53 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 112.034 0.383 . . . . 0.0 112.034 -179.397 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.9 p -91.47 -31.06 16.13 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 -178.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -52.25 -47.94 65.5 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 28.5 m-90 -100.38 10.28 41.45 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.902 0.382 . . . . 0.0 110.934 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 57.44 26.56 56.95 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.869 -0.605 . . . . 0.0 113.309 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.435 ' HA ' ' HD3' ' A' ' 96' ' ' LYS . 0.5 OUTLIER -71.41 -29.11 64.53 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.202 0.525 . . . . 0.0 109.998 -179.412 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.703 ' HB2' ' HB1' ' A' ' 88' ' ' ALA . . . -70.55 -15.44 62.77 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.162 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.2 mttm -80.63 -14.43 58.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.957 0.408 . . . . 0.0 110.632 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.435 ' HD3' ' HA ' ' A' ' 93' ' ' ASP . 40.6 mtpt -80.86 -21.04 41.04 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.377 -179.46 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 28.3 m -95.22 161.06 2.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 179.316 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -97.07 127.86 43.45 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.068 0.461 . . . . 0.0 110.967 -178.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 62.05 61.11 7.02 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.61 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 76.4 t80 -75.61 110.31 9.9 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.857 0.361 . . . . 0.0 110.457 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 95.6 mttt -84.56 124.08 73.75 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 115.683 -0.69 . . . . 0.0 109.737 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_exo -59.52 138.15 82.06 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.631 2.221 . . . . 0.0 111.923 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -65.77 129.28 39.23 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.258 179.509 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p -111.91 157.57 20.5 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.081 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -60.79 -32.03 71.38 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.484 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.0 mm-40 -66.54 -32.74 74.28 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.821 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -66.51 -38.55 87.45 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.167 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.408 ' HA ' HG21 ' A' ' 47' ' ' ILE . 21.1 t -71.21 -45.76 69.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.061 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 4.2 ttmp? -58.68 -38.33 77.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.713 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 25.8 ttpt -58.75 -46.46 87.4 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.328 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 40.0 mt -83.63 -15.94 47.08 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.564 -178.848 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 48.1 ttm-85 -69.98 -16.86 63.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.379 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -80.34 -38.52 30.4 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.066 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 45.6 tttp -81.62 95.65 7.24 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 19.7 tptm -66.05 114.03 4.91 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.2 0.524 . . . . 0.0 111.532 -179.178 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 79.6 mt -125.35 176.66 6.64 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.005 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.441 ' O ' HG23 ' A' ' 121' ' ' VAL . 61.2 p -124.43 157.57 64.53 Favored Pre-proline 0 C--N 1.319 -0.744 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.359 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.576 ' HG3' ' O ' ' A' ' 52' ' ' TYR . 50.1 Cg_exo -55.1 -30.61 71.39 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.545 2.163 . . . . 0.0 111.745 179.298 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 42.8 tp60 -74.34 -39.92 62.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.881 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' GLN . . . . . 0.423 ' HB2' ' H ' ' A' ' 117' ' ' THR . 44.8 mt-30 -67.02 -37.63 84.48 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.162 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 117' ' ' THR . 60.8 t -60.37 -31.81 49.46 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 CA-C-O 121.137 0.494 . . . . 0.0 110.18 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 23.9 tp . . . . . 0 C--N 1.331 -0.23 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.543 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 45.9 t80 . . . . . 0 N--CA 1.479 0.991 0 CA-C-O 120.787 0.327 . . . . 0.0 110.926 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 1.6 p -60.96 -36.15 78.65 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -178.622 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 74.6 mt -69.18 -24.33 64.04 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.763 0.316 . . . . 0.0 111.339 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -93.48 -5.37 49.32 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.14 0.495 . . . . 0.0 111.072 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 39' ' ' THR . . . . . 0.403 HG22 ' H ' ' B' ' 40' ' ' HIS . 3.9 m -106.82 167.73 9.68 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.887 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 40' ' ' HIS . . . . . 0.403 ' H ' HG22 ' B' ' 39' ' ' THR . 6.0 p80 -65.18 -10.38 30.84 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.73 0.3 . . . . 0.0 111.564 -179.678 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.76 -17.63 64.76 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.932 0.396 . . . . 0.0 111.178 179.421 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.07 -4.35 24.62 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.611 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -66.36 -18.06 67.02 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.962 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 33.4 m -72.44 -12.11 15.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-O 120.927 0.394 . . . . 0.0 111.234 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 71.0 mt -88.72 125.78 61.84 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.727 179.587 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 46' ' ' PRO . . . . . 0.405 ' HA ' ' O ' ' B' ' 134' ' ' THR . 32.2 Cg_exo -58.08 149.11 73.6 Favored 'Trans proline' 0 C--O 1.234 0.301 0 C-N-CA 122.567 2.178 . . . . 0.0 112.197 179.736 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -62.51 142.82 57.76 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.749 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -73.37 -18.36 79.29 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.959 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 45.0 tttp -68.19 127.94 34.74 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.252 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 50' ' ' LEU . . . . . . . . . . . . . 84.2 mt -80.54 114.89 19.75 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.008 0.432 . . . . 0.0 110.488 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 51' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -116.82 103.53 10.41 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.772 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 52' ' ' ARG . . . . . 0.454 ' HD2' ' N ' ' B' ' 52' ' ' ARG . 0.4 OUTLIER -111.0 137.64 48.38 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.412 -178.981 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 10.4 m -133.02 170.47 19.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.886 179.076 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 54' ' ' ASP . . . . . 0.493 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 13.7 t70 -81.48 114.05 46.64 Favored Pre-proline 0 C--N 1.327 -0.408 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.371 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -80.18 19.32 1.06 Allowed 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 123.07 2.513 . . . . 0.0 113.576 -178.695 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.8 -47.94 3.1 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.238 0.542 . . . . 0.0 110.67 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 9.2 p -106.41 12.72 29.41 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.48 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 58' ' ' VAL . . . . . 0.493 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 14.7 p -60.63 -28.59 43.06 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.428 0 CA-C-O 120.944 0.402 . . . . 0.0 111.829 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 59' ' ' ARG . . . . . . . . . . . . . 29.3 ptt180 -97.05 13.19 29.92 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.843 0.354 . . . . 0.0 111.055 -179.535 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 79.0 mt-30 -130.9 -35.93 1.39 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.95 0.405 . . . . 0.0 110.813 -179.332 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -135.04 105.68 6.47 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.857 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 145.43 -179.22 22.67 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.862 -0.685 . . . . 0.0 111.884 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_exo -63.33 -27.54 71.61 Favored 'Trans proline' 0 CA--C 1.527 0.145 0 C-N-CA 122.834 2.356 . . . . 0.0 112.551 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 31.3 m-90 -85.03 6.4 25.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.534 -179.273 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -94.55 10.57 34.18 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.973 0.416 . . . . 0.0 110.951 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 66' ' ' ASP . . . . . 0.416 ' HB3' ' HB2' ' B' ' 69' ' ' GLN . 7.9 t70 -147.65 110.35 3.87 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.222 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_exo -62.39 -32.66 81.03 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.808 2.339 . . . . 0.0 112.915 -179.443 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.5 -46.13 20.35 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.539 -0.301 . . . . 0.0 111.086 -179.164 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 69' ' ' GLN . . . . . 0.416 ' HB2' ' HB3' ' B' ' 66' ' ' ASP . 13.6 mm100 -80.63 16.92 1.23 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.529 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -78.11 -24.56 47.43 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.992 0.425 . . . . 0.0 110.662 179.366 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 25.5 t -100.46 93.85 3.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.741 179.555 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 2.9 t -105.56 139.64 26.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -178.864 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -81.51 122.86 28.08 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.023 179.496 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.18 -29.55 18.18 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.678 -179.325 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . 178.86 -162.54 29.64 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.438 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -61.7 107.72 0.55 Allowed 'Trans proline' 0 C--O 1.236 0.397 0 C-N-CA 123.077 2.518 . . . . 0.0 112.124 -179.577 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 45.2 t30 63.79 29.76 14.71 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.762 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -133.96 122.31 22.9 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.093 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -127.06 151.42 48.64 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.873 -179.411 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 91.4 m -119.82 121.58 39.41 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.332 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 50.0 t -110.56 117.2 54.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 121.053 0.454 . . . . 0.0 111.242 -178.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -86.39 106.09 17.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.647 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 83' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 28.8 t -98.36 122.43 50.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.191 0.52 . . . . 0.0 110.697 -179.398 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 57.4 tp -102.09 109.39 21.08 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.797 179.621 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 85' ' ' ALA . . . . . . . . . . . . . . . -96.6 73.16 2.72 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.153 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 86' ' ' PHE . . . . . 0.52 ' CZ ' ' HB2' ' B' ' 91' ' ' GLN . 0.1 OUTLIER -75.01 -169.77 0.98 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.999 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 87' ' ' ALA . . . . . . . . . . . . . . . -39.66 93.75 0.01 OUTLIER 'General case' 0 N--CA 1.462 0.127 0 O-C-N 124.316 1.01 . . . . 0.0 113.724 -178.46 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 88' ' ' PHE . . . . . 0.402 ' HA ' ' SD ' ' B' ' 160' ' ' MET . 4.9 m-85 53.26 27.73 6.41 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.698 -1.137 . . . . 0.0 112.976 178.22 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 89' ' ' GLY . . . . . . . . . . . . . . . -139.62 -178.4 16.62 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.016 -1.088 . . . . 0.0 112.978 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 90' ' ' TYR . . . . . 0.517 ' OH ' ' HB2' ' B' ' 149' ' ' CYS . 41.2 m-85 -140.32 133.65 29.81 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 91' ' ' GLN . . . . . 0.52 ' HB2' ' CZ ' ' B' ' 86' ' ' PHE . 31.7 tt0 -135.48 128.34 18.11 Favored Pre-proline 0 C--N 1.322 -0.608 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 178.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -79.95 170.88 64.94 Favored 'Cis proline' 0 CA--C 1.53 0.293 0 C-N-CA 123.386 -1.506 . . . . 0.0 112.451 -0.146 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 93' ' ' ASN . . . . . 0.405 ' HA ' ' HA ' ' B' ' 94' ' ' PRO . 58.6 t30 -159.76 120.19 1.72 Allowed Pre-proline 0 C--N 1.326 -0.456 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 94' ' ' PRO . . . . . 0.405 ' HA ' ' HA ' ' B' ' 93' ' ' ASN . 98.2 Cg_endo -78.85 151.39 88.06 Favored 'Cis proline' 0 C--O 1.233 0.264 0 C-N-CA 123.47 -1.471 . . . . 0.0 112.755 -0.363 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 40.2 mt -81.7 127.27 39.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.611 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 96' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -104.52 124.63 49.63 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.516 0.198 . . . . 0.0 110.839 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 97' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 4.8 m -141.22 153.7 66.79 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.101 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.49 161.45 14.77 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 122.718 2.279 . . . . 0.0 111.802 178.632 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.29 152.73 18.31 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.021 0.438 . . . . 0.0 111.378 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 78.03 8.72 87.32 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.564 -0.743 . . . . 0.0 113.135 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.29 155.26 26.53 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.838 0.351 . . . . 0.0 111.302 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 102' ' ' GLU . . . . . 0.556 ' OE2' ' HD3' ' B' ' 136' ' ' ARG . 77.8 tt0 -81.56 119.26 23.55 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.739 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 103' ' ' ILE . . . . . 0.437 HD12 ' HD1' ' B' ' 139' ' ' PHE . 7.8 mt -108.91 113.54 44.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.004 -179.107 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 21.5 t -91.98 101.14 12.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.764 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 105' ' ' PHE . . . . . 0.503 ' O ' ' HA ' ' B' ' 134' ' ' THR . 75.7 m-85 -82.24 122.18 27.59 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.09 -179.235 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -119.93 89.95 3.23 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 107' ' ' ILE . . . . . 0.491 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.2 mp -97.77 135.82 30.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.576 -178.111 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 4.9 t -133.8 154.21 51.17 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.515 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 109' ' ' SER . . . . . 0.702 ' O ' ' HA ' ' B' ' 129' ' ' PRO . 0.7 OUTLIER -122.7 126.28 26.15 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-O 120.652 0.263 . . . . 0.0 111.226 -178.932 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -89.24 -29.05 0.26 Allowed 'Trans proline' 0 N--CA 1.459 -0.547 0 C-N-CA 122.911 2.407 . . . . 0.0 112.808 178.455 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 111' ' ' ASP . . . . . 0.43 ' CG ' ' H ' ' B' ' 112' ' ' VAL . 8.2 p-10 -95.0 -111.76 0.12 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.863 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 112' ' ' VAL . . . . . 0.43 ' H ' ' CG ' ' B' ' 111' ' ' ASP . 17.0 m -99.86 -172.77 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 120.561 0.22 . . . . 0.0 110.533 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 21.0 mt -74.91 143.78 12.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-O 121.365 0.602 . . . . 0.0 111.543 -179.208 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 114' ' ' HIS . . . . . 0.466 ' HD2' ' OG ' ' B' ' 109' ' ' SER . 97.7 m-70 -136.95 179.39 6.41 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.461 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 115' ' ' GLY . . . . . 0.505 ' O ' ' HA ' ' B' ' 149' ' ' CYS . . . -134.06 134.78 7.61 Favored Glycine 0 N--CA 1.443 -0.845 0 C-N-CA 120.443 -0.885 . . . . 0.0 112.044 -179.644 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -104.56 85.28 2.3 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-O 121.028 0.442 . . . . 0.0 109.915 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 117' ' ' HIS . . . . . 0.462 ' HA ' ' O ' ' B' ' 123' ' ' ILE . 12.6 t-160 -113.82 109.97 19.39 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.635 179.228 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.457 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 44.5 t -88.04 113.83 25.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.241 0.543 . . . . 0.0 111.119 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -63.38 115.93 5.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.6 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 110.46 0.06 29.39 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.462 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 121' ' ' THR . . . . . 0.457 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 40.9 p -139.65 175.5 9.52 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 179.407 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -92.96 18.24 9.43 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.94 0.4 . . . . 0.0 110.365 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 123' ' ' ILE . . . . . 0.462 ' O ' ' HA ' ' B' ' 117' ' ' HIS . 53.6 mt -81.9 106.72 13.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.033 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -146.1 100.33 3.37 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 178.796 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 7.1 p -137.63 144.57 30.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.485 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -82.56 145.63 29.63 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.373 179.122 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 127' ' ' VAL . . . . . 0.503 HG12 ' HB2' ' B' ' 109' ' ' SER . 6.3 t -115.5 106.17 19.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.589 179.579 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 128' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' B' ' 129' ' ' PRO . 7.7 mp -96.52 153.24 38.9 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.38 -178.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 129' ' ' PRO . . . . . 0.702 ' HA ' ' O ' ' B' ' 109' ' ' SER . 27.5 Cg_exo -62.65 120.52 8.08 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.693 2.262 . . . . 0.0 112.614 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.68 -13.68 65.04 Favored Glycine 0 N--CA 1.451 -0.312 0 CA-C-N 115.897 -0.592 . . . . 0.0 113.103 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -94.55 148.37 22.32 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 132' ' ' VAL . . . . . . . . . . . . . 22.6 t -112.82 89.27 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 121.026 0.441 . . . . 0.0 110.21 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 5.0 m -62.68 105.59 0.67 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.031 179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 134' ' ' THR . . . . . 0.503 ' HA ' ' O ' ' B' ' 105' ' ' PHE . 23.2 m -102.34 115.48 30.64 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.539 -179.26 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 78.6 t -127.85 136.28 60.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.834 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 136' ' ' ARG . . . . . 0.556 ' HD3' ' OE2' ' B' ' 102' ' ' GLU . 51.2 mtt180 -110.58 113.45 26.08 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.747 0.308 . . . . 0.0 111.056 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 137' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -128.98 166.83 18.42 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.675 -179.61 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 73.1 m -134.51 110.55 9.44 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 178.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 139' ' ' PHE . . . . . 0.437 ' HD1' HD12 ' B' ' 103' ' ' ILE . 39.6 m-85 -84.3 112.97 20.79 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.383 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 78.9 mttt -105.31 -11.0 16.68 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.183 0.516 . . . . 0.0 110.509 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 141' ' ' ARG . . . . . 0.413 ' HB2' ' OH ' ' B' ' 145' ' ' TYR . 61.5 mtt180 -110.67 114.27 54.84 Favored Pre-proline 0 C--N 1.324 -0.511 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.783 179.493 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 142' ' ' PRO . . . . . 0.475 ' HA ' HG13 ' B' ' 166' ' ' VAL . 15.5 Cg_exo -68.67 155.84 67.49 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.906 2.404 . . . . 0.0 112.852 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 143' ' ' GLY . . . . . . . . . . . . . . . 139.38 -168.66 24.83 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.681 179.647 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 144' ' ' GLU . . . . . 0.413 ' HG2' HG22 ' B' ' 165' ' ' VAL . 49.3 mt-10 -109.39 119.71 40.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.72 0.295 . . . . 0.0 110.71 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 145' ' ' TYR . . . . . 0.413 ' OH ' ' HB2' ' B' ' 141' ' ' ARG . 31.1 m-85 -106.05 137.38 44.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.017 179.66 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.43 135.44 34.67 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.034 0.445 . . . . 0.0 111.636 -178.869 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 147' ' ' ILE . . . . . . . . . . . . . 40.3 mt -99.79 109.92 25.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.443 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 13.4 mt -103.11 119.22 51.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-O 120.817 0.341 . . . . 0.0 111.185 -179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 149' ' ' CYS . . . . . 0.517 ' HB2' ' OH ' ' B' ' 90' ' ' TYR . 3.9 t -85.57 84.05 7.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.093 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 150' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -58.89 -17.51 24.86 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -179.393 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 32.1 tp60 -80.33 140.06 36.3 Favored 'General case' 0 C--O 1.25 1.102 0 CA-C-O 121.162 0.506 . . . . 0.0 111.928 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -57.25 155.35 8.93 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 114.816 -1.084 . . . . 0.0 110.778 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 153' ' ' CYS . . . . . 0.547 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 1.6 p -176.55 78.34 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.733 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 55.65 -140.93 39.91 Favored Glycine 0 C--N 1.331 0.264 0 O-C-N 123.432 0.458 . . . . 0.0 112.73 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 155' ' ' LEU . . . . . 0.434 HD13 HG22 ' A' ' 117' ' ' THR . 37.4 mt -92.58 -15.49 26.85 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.24 0.543 . . . . 0.0 110.318 179.303 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 156' ' ' GLY . . . . . . . . . . . . . . . -87.97 63.91 3.71 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.729 -0.668 . . . . 0.0 111.909 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 157' ' ' HIS . . . . . 0.547 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 62.9 t60 -131.71 -37.5 1.18 Allowed 'General case' 0 C--N 1.319 -0.752 0 O-C-N 122.61 -0.347 . . . . 0.0 111.212 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -64.99 -14.05 59.29 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 112.864 0.69 . . . . 0.0 112.864 -178.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 159' ' ' ASN . . . . . 0.523 ' HB3' ' HB2' ' A' ' 55' ' ' GLN . 8.5 t30 -132.99 15.09 4.25 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.879 0.371 . . . . 0.0 111.4 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 160' ' ' MET . . . . . 0.402 ' SD ' ' HA ' ' B' ' 88' ' ' PHE . 24.7 ttt -87.74 87.87 7.5 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 161' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -128.2 136.2 50.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.852 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 162' ' ' GLY . . . . . . . . . . . . . . . -105.87 176.37 22.05 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 11.7 m -144.38 131.51 20.57 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 117.762 0.781 . . . . 0.0 111.9 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 65.1 mt -114.44 113.11 42.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.303 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 165' ' ' VAL . . . . . 0.413 HG22 ' HG2' ' B' ' 144' ' ' GLU . 22.1 t -101.91 103.67 15.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.113 0.482 . . . . 0.0 110.746 -179.345 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 166' ' ' VAL . . . . . 0.475 HG13 ' HA ' ' B' ' 142' ' ' PRO . 1.3 p -90.88 123.63 43.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 178.69 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 28.4 mmtp -79.16 147.26 32.74 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.212 -178.346 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 168' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.245 0.827 0 CA-C-O 118.689 -0.672 . . . . 0.0 109.781 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.231 0 CA-C-O 120.475 -0.069 . . . . 0.0 113.165 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.01 -35.67 80.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.526 0.203 . . . . 0.0 111.128 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -66.17 -34.87 79.02 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.034 0.445 . . . . 0.0 110.533 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 31.9 mm -73.02 -38.06 54.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.054 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -63.08 -21.81 66.43 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.112 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -57.89 -31.85 67.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.989 0.424 . . . . 0.0 110.827 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 66.4 mt-30 -77.31 -32.19 55.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.06 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 15.7 m -70.87 -29.39 65.48 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.074 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.15 -17.58 64.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.415 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.31 5.98 39.84 Favored Glycine 0 N--CA 1.453 -0.21 0 C-N-CA 121.048 -0.596 . . . . 0.0 112.623 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.8 m -153.56 -51.13 0.1 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.602 0.239 . . . . 0.0 110.992 179.422 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.5 m-70 -85.96 7.01 26.01 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.87 -0.15 . . . . 0.0 111.094 -179.041 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 57.2 mm-40 61.41 -168.19 0.18 Allowed 'General case' 0 N--CA 1.465 0.275 0 O-C-N 123.492 0.495 . . . . 0.0 111.215 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 46.8 mt-30 -104.52 -5.56 21.43 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.908 0.385 . . . . 0.0 110.593 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 14.9 p30 -82.71 -4.46 57.89 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.091 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 75.74 19.18 79.25 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.468 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.468 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 44.6 mt-30 -124.73 -80.16 0.62 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.824 0.345 . . . . 0.0 110.561 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.786 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.905 -179.655 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.349 0 CA-C-O 120.686 0.279 . . . . 0.0 111.096 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -136.09 126.3 16.41 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.007 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.428 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 60.0 Cg_endo -75.72 134.73 16.98 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.395 2.063 . . . . 0.0 111.276 178.061 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 20' ' ' GLN . 17.1 Cg_exo -67.61 148.0 77.34 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.524 2.149 . . . . 0.0 112.599 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.482 ' O ' HG23 ' A' ' 33' ' ' VAL . 80.3 mt -97.22 -39.86 9.06 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.37 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.38 116.49 8.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.143 179.418 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.84 29.45 42.54 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.561 -0.828 . . . . 0.0 111.101 -178.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 43.9 t60 -146.06 -34.22 0.31 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.598 -0.301 . . . . 0.0 110.561 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.482 HG23 ' O ' ' A' ' 29' ' ' LEU . 97.2 t -62.48 -43.12 98.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.326 -0.397 . . . . 0.0 109.961 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -61.8 -35.9 79.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.541 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -63.45 -37.61 87.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.23 0.538 . . . . 0.0 110.278 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.51 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 61.7 mt -80.2 -39.32 19.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.142 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 45.9 mt -61.82 -25.27 67.4 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.376 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.5 -13.82 59.65 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.456 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -87.22 151.82 22.83 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.631 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -66.89 111.87 4.0 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.981 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.549 ' HA2' ' OE1' ' A' ' 44' ' ' GLU . . . 83.02 14.59 74.59 Favored Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 120.737 -0.744 . . . . 0.0 111.578 -178.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.51 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -61.58 -39.54 97.5 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.338 -0.458 . . . . 0.0 112.475 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.502 ' O ' HG13 ' A' ' 47' ' ' ILE . 12.7 ptm85 -65.12 -36.1 83.19 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.549 ' OE1' ' HA2' ' A' ' 41' ' ' GLY . 23.0 mp0 -67.66 -39.66 84.54 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.141 0.496 . . . . 0.0 109.775 178.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.415 ' O ' HG23 ' A' ' 49' ' ' VAL . 31.5 t80 -60.16 -44.2 95.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.099 179.258 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 41.4 mt -60.67 -40.4 91.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.923 179.619 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.502 HG13 ' O ' ' A' ' 43' ' ' ARG . 71.9 mt -64.91 -42.12 93.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.158 179.63 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 92.2 mt -62.16 -35.42 78.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.873 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.475 ' O ' ' HA2' ' A' ' 53' ' ' GLY . 61.0 t -66.08 -33.35 62.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.733 179.448 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 8.2 mp -83.63 -33.31 25.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.949 0.404 . . . . 0.0 110.496 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 18.3 mt -72.18 -57.02 4.58 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.976 -0.556 . . . . 0.0 112.012 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 39.8 m-85 -105.12 -37.88 6.76 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.973 -177.635 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 117.59 -168.13 12.89 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.051 -1.071 . . . . 0.0 113.671 178.756 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.466 ' H ' ' HB3' ' A' ' 69' ' ' MET . 25.6 tp -152.85 150.2 29.09 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.857 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLN . . . . . 0.401 ' CD ' ' HB2' ' A' ' 118' ' ' PRO . 3.2 pt20 -163.94 157.49 18.63 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.672 0.272 . . . . 0.0 111.114 -178.902 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 138.25 -118.38 1.61 Allowed Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.727 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.417 HE22 ' HB2' ' A' ' 66' ' ' ASN . 6.0 tp60 -161.82 82.8 0.58 Allowed 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 4.0 pt -96.4 148.14 5.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.036 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.407 ' HA ' ' O ' ' A' ' 63' ' ' MET . 1.8 tt0 -121.44 105.27 10.34 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.165 179.82 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.424 HG12 ' HG2' ' A' ' 61' ' ' LYS . 6.9 t -126.68 135.7 62.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 179.616 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.424 ' HG2' HG12 ' A' ' 60' ' ' VAL . 21.3 mmtp 60.11 28.14 17.66 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 121.079 0.466 . . . . 0.0 110.814 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.19 20.91 78.8 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.793 -0.639 . . . . 0.0 112.447 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' MET . . . . . 0.407 ' O ' ' HA ' ' A' ' 59' ' ' GLU . 45.2 mtt -118.03 121.41 40.55 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -90.39 100.22 13.09 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.196 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -85.18 139.87 31.35 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.657 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ASN . . . . . 0.417 ' HB2' HE22 ' A' ' 57' ' ' GLN . 49.8 t30 -139.73 81.61 1.83 Allowed 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.434 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.9 -160.95 9.96 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.667 -0.777 . . . . 0.0 111.946 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 64.5 t -138.46 114.04 9.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.932 0.396 . . . . 0.0 110.29 179.18 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' MET . . . . . 0.466 ' HB3' ' H ' ' A' ' 54' ' ' LEU . 5.0 tpt -69.73 114.91 8.38 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 178.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.5 m -63.48 135.07 56.63 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.779 -177.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -72.09 126.87 30.86 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.412 179.23 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 37.1 m-85 -110.36 34.35 3.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.122 0.487 . . . . 0.0 110.661 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -69.02 -8.49 45.49 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.843 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 18.0 pm0 -72.22 -20.19 61.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.86 0.362 . . . . 0.0 110.721 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 22.9 mt -82.09 159.06 23.49 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.255 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.449 ' HB2' ' HG3' ' A' ' 79' ' ' GLU . 22.5 mtpt -70.29 155.11 41.11 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.255 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 40.3 m-20 -61.51 -37.05 82.28 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.002 0.43 . . . . 0.0 110.31 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -69.29 -19.99 63.9 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.952 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLU . . . . . 0.449 ' HG3' ' HB2' ' A' ' 76' ' ' LYS . 41.1 mt-10 -89.23 -41.85 11.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.371 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 81.9 mt -62.93 -38.84 82.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.857 179.364 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.55 -28.4 64.89 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.161 178.46 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.13 -46.46 67.6 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.327 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 14.2 p -65.27 -36.93 78.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 C-N-CA 120.81 -0.356 . . . . 0.0 110.161 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 41.1 mt -63.41 -44.02 95.85 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.168 0.509 . . . . 0.0 109.829 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 50.1 m-20 -64.51 -43.15 94.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.891 178.793 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 44.5 t60 -61.09 -55.23 34.96 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.354 -178.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 46.6 pt -60.6 -35.65 65.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.476 0.547 . . . . 0.0 112.476 -177.851 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.62 ' HB1' ' HB2' ' A' ' 94' ' ' ALA . . . -73.39 -34.2 65.4 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 22.1 p -89.85 -35.05 15.87 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.631 0.604 . . . . 0.0 112.631 -178.387 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -59.32 -44.51 92.58 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 15.8 m-90 -91.35 2.21 56.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.813 0.339 . . . . 0.0 111.014 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 64.44 23.99 68.93 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.9 -0.591 . . . . 0.0 113.273 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.454 ' HA ' ' HD3' ' A' ' 96' ' ' LYS . 0.2 OUTLIER -75.28 -28.73 59.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.191 0.52 . . . . 0.0 109.976 -179.913 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.62 ' HB2' ' HB1' ' A' ' 88' ' ' ALA . . . -73.47 -6.43 46.37 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.919 179.416 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -91.03 -7.12 52.78 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.175 179.362 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.454 ' HD3' ' HA ' ' A' ' 93' ' ' ASP . 34.3 mtpt -96.43 11.21 35.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.34 -179.211 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 13.0 m -126.1 151.04 32.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.017 178.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.3 ptpt -86.46 122.85 30.98 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.061 0.458 . . . . 0.0 111.967 -179.208 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 64.42 62.05 5.44 Favored Glycine 0 N--CA 1.453 -0.232 0 CA-C-N 115.617 -0.72 . . . . 0.0 113.424 178.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -72.46 122.7 21.71 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.778 0.323 . . . . 0.0 110.508 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 78.5 mttt -96.69 125.16 47.9 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.848 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -57.24 132.65 52.43 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.362 2.042 . . . . 0.0 111.393 179.137 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -61.95 132.57 53.42 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.581 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -113.36 153.83 27.89 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.733 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -63.33 -30.33 71.49 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.051 0.453 . . . . 0.0 110.774 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.0 mm-40 -61.24 -32.06 71.85 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.954 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -68.23 -45.72 72.48 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.176 0.512 . . . . 0.0 110.199 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 11.7 t -65.0 -46.4 91.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.527 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 26.0 ttpt -62.91 -36.01 81.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.747 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 32.9 ttpt -63.94 -47.7 79.45 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.124 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 80.3 mt -74.21 -25.69 59.82 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.046 0.45 . . . . 0.0 110.876 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 21.0 ttm-85 -72.74 -9.02 58.16 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.689 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -70.13 -37.45 75.29 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.032 0.444 . . . . 0.0 110.027 179.062 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -92.47 103.77 16.16 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.453 179.144 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 25.9 tptp -68.25 99.68 0.94 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.3 0.571 . . . . 0.0 111.009 -179.182 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 72.7 mt -108.86 -174.74 2.59 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.901 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.423 HG22 HD13 ' B' ' 155' ' ' LEU . 1.3 p -138.47 163.04 49.85 Favored Pre-proline 0 C--N 1.32 -0.699 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.401 ' HB2' ' CD ' ' A' ' 55' ' ' GLN . 77.9 Cg_exo -50.87 -41.66 54.61 Favored 'Trans proline' 0 CA--C 1.533 0.472 0 C-N-CA 122.686 2.257 . . . . 0.0 112.841 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -65.63 -32.41 73.97 Favored 'General case' 0 CA--C 1.53 0.212 0 CA-C-O 120.767 0.318 . . . . 0.0 110.856 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 57.8 mt-30 -73.43 -35.24 65.76 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.182 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 50.1 t -66.46 -36.6 77.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 20.3 tp . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.963 178.827 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 61.5 t80 . . . . . 0 N--CA 1.48 1.049 0 CA-C-O 120.464 0.173 . . . . 0.0 111.024 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 4.1 m -59.83 -40.81 89.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.029 0.443 . . . . 0.0 111.436 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 94.9 mt -80.86 -3.46 51.33 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.455 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -103.53 -6.3 21.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.028 0.442 . . . . 0.0 110.993 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.0 p -116.31 179.97 3.84 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.651 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 40' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -68.09 -8.63 39.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.549 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -61.37 -20.67 63.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.329 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -72.06 -8.86 57.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.198 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -70.3 -18.7 75.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.326 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 8.9 m -74.61 -11.24 14.32 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-O 121.136 0.494 . . . . 0.0 110.905 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 38.1 mt -86.82 131.93 43.71 Favored Pre-proline 0 C--N 1.322 -0.625 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.596 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 46' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -53.56 134.62 58.72 Favored 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.797 2.331 . . . . 0.0 112.288 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -56.54 140.21 47.15 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.24 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -68.69 -23.59 75.52 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.914 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 80.0 tttt -64.08 116.87 6.33 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.933 0.397 . . . . 0.0 110.303 179.311 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 50' ' ' LEU . . . . . . . . . . . . . 80.2 mt -91.66 93.28 8.83 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.01 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 51' ' ' GLU . . . . . 0.41 ' HB2' ' HB ' ' B' ' 132' ' ' VAL . 21.0 mt-10 -89.19 103.7 16.3 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 52' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -90.7 114.79 27.2 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.797 0.332 . . . . 0.0 110.72 -179.792 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.19 -173.48 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.735 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 54' ' ' ASP . . . . . 0.59 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 17.3 t70 -96.04 111.41 56.16 Favored Pre-proline 0 C--N 1.326 -0.435 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -78.06 17.43 1.02 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.752 2.301 . . . . 0.0 113.755 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.6 -55.99 2.16 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.442 0.639 . . . . 0.0 110.609 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.8 -2.03 55.5 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.092 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 58' ' ' VAL . . . . . 0.59 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 12.1 p -56.22 -28.37 25.56 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -179.316 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 59' ' ' ARG . . . . . . . . . . . . . 37.3 ptt180 -98.43 12.0 36.37 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.068 0.461 . . . . 0.0 111.031 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 58.8 mt-30 -124.41 -39.35 2.33 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.214 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -140.63 133.87 29.63 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.995 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.07 170.86 12.94 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.027 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -60.46 -28.19 86.26 Favored 'Trans proline' 0 CA--C 1.529 0.229 0 C-N-CA 122.682 2.255 . . . . 0.0 112.712 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 32.3 m-90 -84.55 -2.62 57.63 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.154 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.92 -1.12 57.86 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.91 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -122.69 105.07 35.9 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.592 -179.608 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_exo -69.06 -23.76 33.65 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.888 2.392 . . . . 0.0 112.625 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -83.81 -47.55 11.01 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.134 0.492 . . . . 0.0 110.371 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 69' ' ' GLN . . . . . . . . . . . . . 85.3 mm-40 -86.19 20.92 2.17 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.764 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 70' ' ' ALA . . . . . 0.442 ' O ' ' HA ' ' B' ' 81' ' ' VAL . . . -71.74 -24.25 61.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.141 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 33.9 t -112.21 103.35 15.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.261 179.615 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 9.6 t -122.06 130.39 74.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.435 -0.348 . . . . 0.0 111.049 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 30.8 tt0 -78.08 105.15 9.1 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 178.708 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -78.57 -23.76 45.89 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.152 -0.476 . . . . 0.0 112.041 -178.532 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . -164.17 177.39 39.91 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.366 -0.921 . . . . 0.0 112.242 -179.644 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -55.92 115.84 2.75 Favored 'Trans proline' 0 C--O 1.235 0.366 0 C-N-CA 122.85 2.367 . . . . 0.0 112.414 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 18.1 t30 65.27 28.18 11.99 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.533 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 34.4 tt0 -135.64 120.25 18.24 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.839 0.352 . . . . 0.0 110.69 179.379 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 34.3 m-85 -119.97 126.28 50.48 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.94 -178.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 59.4 m -97.85 124.65 42.34 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.852 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 81' ' ' VAL . . . . . 0.442 ' HA ' ' O ' ' B' ' 70' ' ' ALA . 44.7 t -115.15 117.76 56.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 121.09 0.471 . . . . 0.0 111.081 -179.342 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -88.86 95.51 10.32 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.2 178.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 83' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 21.7 t -90.46 120.3 39.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.282 -179.152 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 58.0 tp -101.2 109.12 20.94 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.848 179.22 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.79 70.31 10.35 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.808 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 86' ' ' PHE . . . . . 0.472 ' CZ ' ' HA3' ' B' ' 89' ' ' GLY . 53.5 p90 -63.0 179.13 0.41 Allowed 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.952 -178.737 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.12 102.94 0.05 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.464 -178.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 64.11 26.96 14.05 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 114.845 -1.07 . . . . 0.0 113.005 178.17 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 89' ' ' GLY . . . . . 0.472 ' HA3' ' CZ ' ' B' ' 86' ' ' PHE . . . -156.53 -179.52 31.58 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 119.776 -1.202 . . . . 0.0 113.285 179.42 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 90' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -135.71 132.02 36.37 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 91' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -124.1 137.64 29.33 Favored Pre-proline 0 C--N 1.324 -0.525 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -80.12 174.46 48.54 Favored 'Cis proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.249 -1.563 . . . . 0.0 111.971 -0.362 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 93' ' ' ASN . . . . . 0.432 ' OD1' ' HA ' ' B' ' 94' ' ' PRO . 55.4 t30 -161.14 124.86 1.94 Allowed Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 94' ' ' PRO . . . . . 0.432 ' HA ' ' OD1' ' B' ' 93' ' ' ASN . 69.3 Cg_endo -74.55 151.82 97.45 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.371 -1.512 . . . . 0.0 113.162 0.182 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 66.0 mt -85.78 108.56 17.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.917 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 96' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -94.15 115.43 27.71 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.481 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 97' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 2.6 m -132.6 155.31 81.36 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.65 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -84.6 160.89 12.52 Favored 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.492 2.128 . . . . 0.0 112.524 179.46 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.05 146.02 27.98 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.836 0.35 . . . . 0.0 111.031 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.47 -5.32 84.83 Favored Glycine 0 N--CA 1.452 -0.266 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.497 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -105.07 157.45 17.24 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.762 0.315 . . . . 0.0 111.406 -179.341 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 102' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -84.86 116.61 23.41 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 103' ' ' ILE . . . . . . . . . . . . . 24.2 mt -104.02 120.65 54.54 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.092 0.472 . . . . 0.0 110.766 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 16.7 t -96.37 99.36 8.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.262 179.654 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 105' ' ' PHE . . . . . 0.466 ' O ' ' HA ' ' B' ' 134' ' ' THR . 66.0 m-85 -84.07 118.62 24.19 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.343 -178.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 54.7 mttm -115.76 95.69 5.25 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 177.678 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 107' ' ' ILE . . . . . 0.508 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.1 mp -102.46 137.01 32.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.173 -177.584 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 3.3 t -138.85 157.19 46.51 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 109' ' ' SER . . . . . 0.616 ' O ' ' HA ' ' B' ' 129' ' ' PRO . 39.4 t -125.69 138.05 31.18 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 111.846 0.314 . . . . 0.0 111.846 -178.573 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -93.52 -11.51 1.51 Allowed 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 123.118 2.546 . . . . 0.0 112.666 178.15 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 111' ' ' ASP . . . . . 0.544 ' CG ' ' H ' ' B' ' 112' ' ' VAL . 11.5 p-10 -115.84 -113.98 0.34 Allowed 'General case' 0 CA--C 1.537 0.454 0 O-C-N 122.271 -0.268 . . . . 0.0 111.493 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 112' ' ' VAL . . . . . 0.544 ' H ' ' CG ' ' B' ' 111' ' ' ASP . 20.1 m -93.11 -179.05 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.676 0.274 . . . . 0.0 110.544 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.1 mt -73.42 136.01 26.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.24 0.543 . . . . 0.0 110.554 179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 114' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -122.83 174.13 7.33 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 115' ' ' GLY . . . . . 0.556 ' O ' ' HA ' ' B' ' 149' ' ' CYS . . . -124.96 121.35 4.28 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.999 -179.613 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -96.83 80.57 3.04 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 117' ' ' HIS . . . . . . . . . . . . . 12.2 t-80 -113.79 110.27 19.88 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.57 179.367 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.536 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 21.6 t -88.64 113.56 25.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-O 120.966 0.412 . . . . 0.0 110.316 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -63.02 115.47 4.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.957 -179.269 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 110.08 1.74 29.99 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.686 179.607 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 121' ' ' THR . . . . . 0.536 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 31.7 p -138.36 178.96 6.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.652 0.263 . . . . 0.0 110.658 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -96.52 20.58 10.45 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.129 0.49 . . . . 0.0 110.646 179.297 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 34.2 mt -86.95 109.38 19.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.246 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -150.28 103.82 3.19 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.761 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 9.0 p -143.41 151.78 16.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.275 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.75 134.68 34.04 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.145 0.498 . . . . 0.0 110.419 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 127' ' ' VAL . . . . . . . . . . . . . 5.1 t -99.17 96.98 5.41 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.884 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 128' ' ' LEU . . . . . . . . . . . . . 4.8 mp -87.93 147.18 40.32 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.773 -179.131 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 129' ' ' PRO . . . . . 0.616 ' HA ' ' O ' ' B' ' 109' ' ' SER . 28.5 Cg_endo -63.78 118.07 5.03 Favored 'Trans proline' 0 N--CA 1.462 -0.336 0 C-N-CA 122.52 2.147 . . . . 0.0 112.307 179.831 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.93 -4.29 85.67 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.832 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -102.58 139.87 37.61 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 132' ' ' VAL . . . . . 0.41 ' HB ' ' HB2' ' B' ' 51' ' ' GLU . 59.8 t -101.63 92.31 2.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.251 0.548 . . . . 0.0 110.756 179.363 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 5.3 m -73.29 105.59 4.76 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.842 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 134' ' ' THR . . . . . 0.466 ' HA ' ' O ' ' B' ' 105' ' ' PHE . 24.6 m -100.66 121.18 41.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.387 -179.024 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 48.2 t -128.13 137.3 57.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.177 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 136' ' ' ARG . . . . . 0.402 HH11 ' HD3' ' B' ' 136' ' ' ARG . 68.6 mtt-85 -108.74 120.26 41.96 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.899 0.38 . . . . 0.0 110.663 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 137' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -136.81 151.55 49.29 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.954 0.407 . . . . 0.0 111.081 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 8.3 m -120.48 100.17 6.99 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.806 179.077 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 139' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -73.27 96.87 2.35 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.344 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 83.5 mttt -91.78 -5.55 53.32 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.01 0.433 . . . . 0.0 110.668 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 141' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 -122.79 113.56 30.17 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.097 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 142' ' ' PRO . . . . . 0.468 ' HA ' HG13 ' B' ' 166' ' ' VAL . 64.4 Cg_endo -72.59 167.45 27.07 Favored 'Trans proline' 0 C--O 1.236 0.409 0 C-N-CA 122.591 2.194 . . . . 0.0 112.342 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 143' ' ' GLY . . . . . 0.487 ' N ' HG13 ' B' ' 166' ' ' VAL . . . 137.29 -159.56 24.79 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.245 -179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 144' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -120.33 116.82 26.28 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.781 0.324 . . . . 0.0 110.349 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 51.4 m-85 -110.11 147.04 34.4 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.92 -179.653 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 12.5 mmt180 -110.22 133.12 53.55 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.064 0.459 . . . . 0.0 111.456 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 147' ' ' ILE . . . . . 0.431 HD12 ' HA3' ' B' ' 162' ' ' GLY . 40.5 mt -88.0 131.46 35.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.708 178.922 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 46.4 mt -115.53 115.14 48.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 120.951 0.405 . . . . 0.0 110.179 179.488 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 149' ' ' CYS . . . . . 0.556 ' HA ' ' O ' ' B' ' 115' ' ' GLY . 42.5 t -79.9 89.1 5.28 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.751 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 150' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -64.13 -25.09 67.94 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 10.2 tp60 -81.05 135.85 35.88 Favored 'General case' 0 C--O 1.247 0.94 0 CA-C-O 121.204 0.526 . . . . 0.0 111.764 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -53.53 161.85 0.94 Allowed 'General case' 0 N--CA 1.471 0.621 0 CA-C-N 114.893 -1.049 . . . . 0.0 112.386 -178.81 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 153' ' ' CYS . . . . . 0.403 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 1.6 p 176.44 65.17 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.914 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 52.79 -142.67 25.85 Favored Glycine 0 CA--C 1.518 0.262 0 O-C-N 123.464 0.478 . . . . 0.0 114.019 179.349 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 155' ' ' LEU . . . . . 0.423 HD13 HG22 ' A' ' 117' ' ' THR . 91.4 mt -72.91 -27.1 61.67 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.741 0.305 . . . . 0.0 111.527 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 156' ' ' GLY . . . . . . . . . . . . . . . -87.32 62.14 4.14 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.591 -0.814 . . . . 0.0 111.623 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 157' ' ' HIS . . . . . 0.403 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 69.2 t60 -127.78 -59.3 1.21 Allowed 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -178.831 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 4.5 pm0 -57.71 -33.23 68.19 Favored 'General case' 0 C--N 1.328 -0.333 0 O-C-N 123.463 0.477 . . . . 0.0 112.188 -178.359 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 159' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -107.49 14.14 26.14 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.719 -0.392 . . . . 0.0 111.009 -179.588 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 160' ' ' MET . . . . . . . . . . . . . 26.3 ttt -84.99 85.15 7.51 Favored 'General case' 0 C--O 1.237 0.426 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 161' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -112.66 -177.14 3.07 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.972 -179.282 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 162' ' ' GLY . . . . . 0.431 ' HA3' HD12 ' B' ' 147' ' ' ILE . . . -148.21 150.98 23.25 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 178.795 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 7.5 m -113.03 108.31 17.17 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 117.317 0.558 . . . . 0.0 111.659 -179.022 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 41.1 mt -102.5 111.86 33.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.34 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 165' ' ' VAL . . . . . . . . . . . . . 15.0 t -108.49 102.78 14.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 121.175 0.512 . . . . 0.0 110.451 -179.364 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 166' ' ' VAL . . . . . 0.487 HG13 ' N ' ' B' ' 143' ' ' GLY . 0.7 OUTLIER -88.06 120.75 37.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 179.209 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 51.9 mmtt -67.32 155.93 37.69 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.654 -178.354 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 168' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 . . . . . 0 C--O 1.249 1.035 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.094 -179.459 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.408 ' OD1' ' HB2' ' A' ' 6' ' ' LYS . 4.1 p-10 . . . . . 0 N--CA 1.481 1.095 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.452 ' HA3' ' HB2' ' A' ' 86' ' ' HIS . . . -71.72 -32.66 63.92 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.931 -0.652 . . . . 0.0 113.52 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.06 -39.4 75.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 117.186 0.493 . . . . 0.0 111.165 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.408 ' HB2' ' OD1' ' A' ' 3' ' ' ASP . 0.0 OUTLIER -60.06 -40.17 88.58 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.167 179.839 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.402 ' HB ' ' HB ' ' A' ' 83' ' ' VAL . 37.2 mm -80.3 -26.92 11.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.081 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -57.2 -29.34 63.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.923 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -59.57 -30.81 68.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.103 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.467 ' O ' HMC3 ' A' ' 132' ' ' HEC . 75.8 mt-30 -75.39 -36.16 60.93 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.284 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 20.6 m -67.42 -31.8 72.24 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-O 121.048 0.452 . . . . 0.0 110.516 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.51 -19.56 65.98 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.953 -179.409 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.95 -24.73 71.74 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.256 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 96.3 m -129.32 -40.2 1.46 Allowed 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -179.425 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -91.3 -7.2 51.72 Favored 'General case' 0 C--N 1.33 -0.253 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.341 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 16.1 mm-40 65.27 176.26 0.21 Allowed 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.892 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 20.3 mp0 -79.35 -8.57 59.17 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.631 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 23.8 p30 -90.93 -20.22 22.44 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.774 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 72.34 22.35 78.94 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.565 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 16.3 mt-30 -98.02 -32.29 11.71 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.978 0.418 . . . . 0.0 110.42 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 79.68 -154.65 38.24 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.786 179.689 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 43.2 mm -128.54 125.43 23.15 Favored Pre-proline 0 C--N 1.323 -0.552 0 C-N-CA 122.472 0.309 . . . . 0.0 110.587 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_exo -56.59 114.86 2.11 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.92 2.413 . . . . 0.0 112.573 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 92.27 4.35 66.51 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 116.037 -0.528 . . . . 0.0 113.334 179.153 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -139.81 -53.69 0.54 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.137 0.469 . . . . 0.0 112.125 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.613 ' CD1' HMD3 ' A' ' 132' ' ' HEC . 29.8 m-85 -128.29 123.91 22.68 Favored Pre-proline 0 C--N 1.327 -0.397 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.939 -178.757 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.3 158.65 44.62 Favored 'Trans proline' 0 C--O 1.239 0.531 0 C-N-CA 122.889 2.393 . . . . 0.0 113.0 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -78.76 158.7 28.06 Favored 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.782 2.322 . . . . 0.0 112.351 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.409 ' O ' HG23 ' A' ' 33' ' ' VAL . 65.8 mt -115.4 -38.04 3.88 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.347 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.39 120.3 11.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.127 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 73.43 33.45 58.63 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 -179.042 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 32.4 t60 -143.92 -32.99 0.43 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.585 -0.307 . . . . 0.0 110.548 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 29' ' ' LEU . 59.6 t -63.45 -41.12 91.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -62.04 -35.38 78.42 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.847 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -61.65 -37.58 84.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.513 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.47 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 19.4 mt -79.95 -38.53 18.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.525 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 46.5 mt -62.67 -23.59 67.19 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.556 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -82.7 -10.1 59.06 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.419 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 65.9 mmtt -90.7 154.02 19.86 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.739 0.304 . . . . 0.0 110.35 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -75.42 105.31 6.38 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.71 7.67 55.28 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.149 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -64.44 -34.79 90.85 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 121.255 -0.498 . . . . 0.0 112.105 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 11.4 ptm85 -67.77 -35.17 78.21 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.614 0.245 . . . . 0.0 110.394 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -67.0 -40.09 87.28 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -61.96 -40.67 96.36 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.393 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 86.6 mt -59.43 -34.09 72.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.011 179.644 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.4 mt -78.98 -42.19 23.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.999 0.428 . . . . 0.0 110.08 179.104 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.51 ' HG ' HD13 ' A' ' 111' ' ' LEU . 42.8 mt -63.3 -37.93 89.17 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.11 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.577 ' O ' ' HA2' ' A' ' 53' ' ' GLY . 0.8 OUTLIER -71.06 -15.47 18.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.013 -179.631 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.59 HD11 HMB2 ' A' ' 132' ' ' HEC . 3.0 mp -96.66 -44.5 7.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.852 0.358 . . . . 0.0 110.538 179.158 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.6 mt -66.69 -47.23 73.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.059 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 68.9 m-85 -111.92 -55.85 2.46 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.213 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.577 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 120.11 -158.46 15.36 Favored Glycine 0 N--CA 1.441 -1.009 0 C-N-CA 119.888 -1.148 . . . . 0.0 113.938 178.506 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.431 ' H ' ' HB2' ' A' ' 69' ' ' MET . 1.9 tp -152.52 150.01 29.12 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -179.192 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLN . . . . . 0.495 ' OE1' ' HB2' ' A' ' 118' ' ' PRO . 9.3 pt20 -151.09 111.16 4.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.864 0.364 . . . . 0.0 111.726 -179.66 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -177.37 -143.8 5.09 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.182 178.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.463 ' HA ' ' O ' ' A' ' 65' ' ' TYR . 19.8 mp0 -132.88 66.67 1.55 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.479 ' O ' ' HA ' ' A' ' 64' ' ' LYS . 33.1 pt -66.87 155.07 7.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.247 -178.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.408 ' OE1' ' HG3' ' A' ' 64' ' ' LYS . 23.7 tt0 -124.62 100.63 6.73 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.215 0.531 . . . . 0.0 110.817 -179.422 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 41.0 t -100.32 115.85 42.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.061 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 19.2 mmtp 62.96 23.82 14.22 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.508 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.91 -7.9 65.17 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.654 179.652 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -97.55 121.0 38.95 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 17.0 mttp -91.67 144.77 25.18 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.955 0.407 . . . . 0.0 110.914 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.463 ' O ' ' HA ' ' A' ' 57' ' ' GLN . 71.1 m-85 -120.96 177.43 5.11 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.058 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -156.38 71.98 0.73 Allowed 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -140.99 -161.99 8.92 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.766 179.602 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.67 ' HB ' ' CG ' ' B' ' 88' ' ' PHE . 41.4 t -146.77 136.39 16.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.222 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' MET . . . . . 0.517 ' HG3' HG22 ' A' ' 49' ' ' VAL . 0.3 OUTLIER -71.19 142.07 50.66 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.527 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.451 ' OG ' HBC2 ' A' ' 132' ' ' HEC . 6.5 m -78.52 123.84 27.5 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.719 0.295 . . . . 0.0 110.75 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.5 m -70.78 95.19 1.1 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.351 179.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.466 ' CE2' HBB2 ' A' ' 132' ' ' HEC . 41.5 m-85 -84.5 45.83 1.17 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.229 0.538 . . . . 0.0 111.375 -179.192 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -74.12 -16.67 61.0 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.84 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 19.4 pm0 -76.12 -18.65 59.06 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.68 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 65.2 mt -83.48 155.31 23.45 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.889 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 25.0 mtpt -72.69 154.71 40.58 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -55.41 -41.72 73.11 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.715 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -63.17 -37.96 89.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.005 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 51.5 mt-10 -67.07 -45.17 78.14 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.652 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 89.9 mt -60.45 -42.48 91.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.379 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.39 -35.61 73.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.635 179.049 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.83 -46.39 88.17 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.701 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.402 ' HB ' ' HB ' ' A' ' 7' ' ' ILE . 9.8 p -66.42 -34.94 73.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 C-N-CA 120.485 -0.486 . . . . 0.0 110.669 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 35.2 mt -65.55 -44.82 85.63 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.157 0.503 . . . . 0.0 110.155 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 82.4 m-20 -66.33 -39.06 89.0 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.21 179.129 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' HIS . . . . . 0.452 ' HB2' ' HA3' ' A' ' 4' ' ' GLY . 32.3 t60 -63.73 -50.73 67.98 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.516 -0.766 . . . . 0.0 111.597 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.438 HG13 ' N ' ' A' ' 88' ' ' ALA . 41.8 pt -64.39 -39.53 85.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.561 ' HB1' ' HB2' ' A' ' 94' ' ' ALA . . . -63.62 -36.23 83.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.852 0.358 . . . . 0.0 111.663 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.5 p -89.28 -23.57 22.27 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.751 -179.333 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -61.43 -53.88 50.76 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.875 0.369 . . . . 0.0 111.527 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.415 ' CZ3' ' HB ' ' A' ' 87' ' ' ILE . 5.3 m-90 -86.32 -8.4 57.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.192 0.52 . . . . 0.0 110.566 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 77.56 17.89 78.4 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.493 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.59 -26.96 68.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.301 0.572 . . . . 0.0 110.187 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.561 ' HB2' ' HB1' ' A' ' 88' ' ' ALA . . . -73.53 -7.57 52.39 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.208 179.233 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -98.67 1.14 45.94 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.052 0.453 . . . . 0.0 110.476 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 39.4 mtpt -103.76 11.05 36.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.636 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 15.9 m -125.18 159.77 31.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.987 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.6 ptpt -93.1 112.91 25.02 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.823 0.344 . . . . 0.0 111.155 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 69.99 68.27 1.68 Allowed Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.85 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 65.1 t80 -73.17 124.68 26.09 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.827 0.346 . . . . 0.0 110.395 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 70.5 mttt -98.65 117.56 64.37 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.501 179.261 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -59.55 141.85 97.93 Favored 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.243 1.962 . . . . 0.0 111.374 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -69.83 126.64 30.3 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.306 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.6 p -109.15 152.52 25.01 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.663 -0.698 . . . . 0.0 110.457 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.05 -24.44 58.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 111.333 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 66.6 mm-40 -60.97 -43.21 99.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.894 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.473 ' O ' ' HG2' ' A' ' 110' ' ' LYS . 27.2 mt-10 -68.73 -29.64 68.1 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.006 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 24.3 t -76.98 -40.56 30.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-O 121.186 0.517 . . . . 0.0 109.919 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 9.2 tppt? -62.93 -44.21 96.7 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.814 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.473 ' HG2' ' O ' ' A' ' 107' ' ' GLU . 62.7 pttt -60.49 -32.0 71.01 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.711 0.291 . . . . 0.0 111.361 -179.031 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.51 HD13 ' HG ' ' A' ' 48' ' ' LEU . 97.4 mt -87.61 -30.48 20.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.214 -179.342 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 46.6 ttm-85 -66.56 -31.05 71.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.051 0.453 . . . . 0.0 110.457 179.464 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -71.46 -29.99 65.48 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.621 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -89.16 92.65 9.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.729 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 27.3 tptp -66.09 113.71 4.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.415 0.626 . . . . 0.0 111.473 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 81.5 mt -126.63 -174.97 3.26 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.245 179.102 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.45 ' O ' HG23 ' A' ' 121' ' ' VAL . 75.3 p -131.13 147.94 68.26 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.091 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.495 ' HB2' ' OE1' ' A' ' 55' ' ' GLN . 32.4 Cg_exo -58.01 -26.77 76.56 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.6 2.2 . . . . 0.0 112.118 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 11.5 tp60 -71.29 -29.91 65.62 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.447 179.665 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -80.07 -33.0 39.3 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.073 179.209 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.45 HG23 ' O ' ' A' ' 117' ' ' THR . 43.2 t -63.15 -25.72 39.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.344 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.416 ' HA ' HD11 ' A' ' 54' ' ' LEU . 26.7 tp -57.38 -40.67 78.65 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.215 178.785 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ALA . . . . . 0.464 ' O ' ' HG3' ' A' ' 127' ' ' LYS . . . -67.88 -44.72 76.4 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.042 179.428 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 32.2 mm-40 -58.12 -40.55 81.53 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.698 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.473 ' HG2' ' HB2' ' A' ' 130' ' ' LEU . 67.0 ttt-85 -65.24 -46.25 81.34 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.45 179.564 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.409 ' HA ' ' O ' ' A' ' 130' ' ' LEU . 65.7 mttm -67.89 -27.49 66.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.21 -179.657 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.464 ' HG3' ' O ' ' A' ' 123' ' ' ALA . 92.2 mttt -65.43 -29.66 70.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.071 0.462 . . . . 0.0 109.97 178.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 96.0 mt -76.77 -6.6 52.91 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.549 179.102 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.44 -1.44 57.2 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 121.018 -0.611 . . . . 0.0 111.589 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.473 ' HB2' ' HG2' ' A' ' 125' ' ' ARG . 64.4 mt -81.18 112.27 18.36 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.9 0.381 . . . . 0.0 110.343 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 8.8 mptt . . . . . 0 C--O 1.252 1.214 0 CA-C-O 118.32 -0.848 . . . . 0.0 111.139 -179.355 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 86.4 t80 . . . . . 0 N--CA 1.481 1.105 0 CA-C-O 120.716 0.294 . . . . 0.0 110.932 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -35.35 80.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.86 0.362 . . . . 0.0 111.311 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 94.4 mt -76.79 -15.16 59.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.994 0.426 . . . . 0.0 110.675 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.81 13.02 30.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.824 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 1.8 p -139.89 178.04 7.54 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.314 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 40' ' ' HIS . . . . . . . . . . . . . 1.4 p80 -75.54 -6.43 50.21 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.349 0.595 . . . . 0.0 109.824 179.171 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 41' ' ' THR . . . . . 0.476 ' O ' HG22 ' B' ' 44' ' ' VAL . 0.3 OUTLIER -64.4 -19.71 65.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.07 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.28 -10.92 47.18 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.276 179.445 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -66.11 -25.78 72.27 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.312 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 44' ' ' VAL . . . . . 0.476 HG22 ' O ' ' B' ' 41' ' ' THR . 11.8 m -70.62 -12.24 15.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-O 120.987 0.422 . . . . 0.0 111.094 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 38.1 mt -92.16 133.2 30.59 Favored Pre-proline 0 C--N 1.322 -0.602 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 46' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -52.62 145.02 39.96 Favored 'Trans proline' 0 C--N 1.347 0.482 0 C-N-CA 122.831 2.354 . . . . 0.0 112.613 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -60.24 152.55 24.51 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.492 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -84.98 -18.99 60.09 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.947 -0.644 . . . . 0.0 111.911 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 29.8 tttt -75.85 138.42 41.1 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 50' ' ' LEU . . . . . 0.427 HD23 ' HA ' ' B' ' 50' ' ' LEU . 13.2 mt -83.19 134.27 34.98 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.01 0.433 . . . . 0.0 110.272 179.322 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 51' ' ' GLU . . . . . 0.435 ' HB3' ' HB ' ' B' ' 132' ' ' VAL . 1.6 tt0 -133.46 74.82 1.58 Allowed 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 52' ' ' ARG . . . . . . . . . . . . . 23.2 ttm180 -95.78 132.45 41.0 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.092 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 6.8 m -136.16 -172.0 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 115.668 -0.697 . . . . 0.0 109.909 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 54' ' ' ASP . . . . . 0.549 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 28.2 t70 -93.07 114.62 63.22 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 179.161 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -72.1 -11.83 27.49 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.541 2.16 . . . . 0.0 112.952 -178.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.17 -52.11 9.83 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 111.887 0.328 . . . . 0.0 111.887 -179.277 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 12.6 p -98.51 0.02 44.25 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 -178.367 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 58' ' ' VAL . . . . . 0.549 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 8.4 p -61.84 -22.58 28.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-O 121.136 0.494 . . . . 0.0 111.104 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 59' ' ' ARG . . . . . 0.456 ' NH1' ' HB2' ' B' ' 110' ' ' PRO . 12.2 ptt180 -95.77 3.12 54.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.435 -179.707 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -124.04 -31.2 3.4 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.85 0.357 . . . . 0.0 111.095 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -140.23 118.37 11.97 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.448 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 137.79 -177.76 19.68 Favored Glycine 0 N--CA 1.441 -0.969 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.298 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -63.88 -13.2 35.8 Favored 'Trans proline' 0 CA--C 1.53 0.306 0 C-N-CA 123.17 2.58 . . . . 0.0 113.103 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 30.2 m-90 -104.18 12.66 33.57 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.978 0.418 . . . . 0.0 110.328 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -100.42 2.54 42.35 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.563 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -145.14 114.93 4.97 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.472 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -72.61 -9.97 24.62 Favored 'Trans proline' 0 C--O 1.234 0.293 0 C-N-CA 122.64 2.227 . . . . 0.0 112.985 -179.644 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -81.93 -54.93 4.93 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.848 0.356 . . . . 0.0 110.581 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 69' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -88.07 44.23 1.18 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.051 0.453 . . . . 0.0 110.989 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 70' ' ' ALA . . . . . 0.429 ' O ' ' HA ' ' B' ' 81' ' ' VAL . . . -84.15 -29.36 26.74 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.383 179.374 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 41.6 t -102.21 106.84 20.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.697 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 40.7 t -120.94 125.03 73.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.136 -179.453 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 58.0 tt0 -65.93 127.4 31.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.843 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -123.58 20.85 9.43 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.875 -178.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . 158.33 177.81 31.77 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.359 -0.924 . . . . 0.0 112.125 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -61.45 108.69 0.63 Allowed 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.961 2.441 . . . . 0.0 111.729 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 38.8 t30 63.47 25.56 14.53 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.401 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -122.19 123.15 40.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.587 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 24.8 m-85 -129.37 127.42 40.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.725 0.298 . . . . 0.0 110.823 -179.085 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 100.0 m -93.37 125.37 37.94 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 178.695 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 81' ' ' VAL . . . . . 0.429 ' HA ' ' O ' ' B' ' 70' ' ' ALA . 55.8 t -114.52 116.98 54.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.097 0.475 . . . . 0.0 110.825 -179.261 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -85.36 118.48 24.92 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.557 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 83' ' ' VAL . . . . . 0.531 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 20.2 t -116.16 124.82 72.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.138 0.494 . . . . 0.0 110.986 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 34.6 tp -101.05 115.2 29.92 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.524 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 85' ' ' ALA . . . . . . . . . . . . . . . -100.46 90.93 4.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.641 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 86' ' ' PHE . . . . . 0.414 ' CZ ' ' HB2' ' B' ' 91' ' ' GLN . 0.2 OUTLIER -96.44 -163.82 1.09 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.011 0.434 . . . . 0.0 111.524 -179.535 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.41 ' H ' ' HB2' ' B' ' 86' ' ' PHE . . . -55.86 103.31 0.1 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.913 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 88' ' ' PHE . . . . . 0.67 ' CG ' ' HB ' ' A' ' 68' ' ' VAL . 9.2 m-85 56.34 27.66 12.27 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.085 -0.962 . . . . 0.0 113.071 177.795 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 89' ' ' GLY . . . . . . . . . . . . . . . -150.38 168.98 30.33 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 119.649 -1.262 . . . . 0.0 113.207 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 90' ' ' TYR . . . . . 0.408 ' O ' ' HB2' ' B' ' 93' ' ' ASN . 83.8 m-85 -138.78 131.39 28.98 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 91' ' ' GLN . . . . . 0.414 ' HB2' ' CZ ' ' B' ' 86' ' ' PHE . 5.3 tt0 -122.34 130.28 24.75 Favored Pre-proline 0 C--N 1.323 -0.567 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -82.03 172.14 52.91 Favored 'Cis proline' 0 N--CA 1.461 -0.385 0 C-N-CA 123.512 -1.453 . . . . 0.0 112.269 -0.197 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 93' ' ' ASN . . . . . 0.408 ' HB2' ' O ' ' B' ' 90' ' ' TYR . 3.7 t30 -152.09 130.07 6.04 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.788 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 94' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' B' ' 93' ' ' ASN . 73.0 Cg_endo -77.96 149.31 87.22 Favored 'Cis proline' 0 N--CA 1.461 -0.418 0 C-N-CA 122.925 -1.698 . . . . 0.0 111.481 -1.33 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.3 mt -75.65 96.22 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.472 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 96' ' ' GLU . . . . . 0.61 ' HA ' ' O ' ' B' ' 165' ' ' VAL . 41.2 mt-10 -88.32 120.5 29.75 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.449 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 97' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 3.2 m -138.29 149.82 64.57 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.692 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -78.99 149.07 22.39 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.747 2.298 . . . . 0.0 112.318 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -92.26 155.83 17.7 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.37 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.13 7.12 87.39 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.355 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -123.36 158.31 31.36 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.44 0.162 . . . . 0.0 110.847 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 102' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -86.26 111.71 20.7 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 103' ' ' ILE . . . . . . . . . . . . . 8.0 mt -100.51 116.42 43.89 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.631 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 20.0 t -90.5 95.66 5.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 105' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -79.83 122.74 27.01 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.204 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -121.02 92.55 3.78 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.347 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 107' ' ' ILE . . . . . 0.531 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.5 mp -100.85 137.65 27.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.493 -177.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 5.5 t -141.79 159.49 42.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.499 178.465 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 109' ' ' SER . . . . . . . . . . . . . 30.6 t -119.5 135.88 24.32 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-O 120.708 0.29 . . . . 0.0 111.18 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 110' ' ' PRO . . . . . 0.456 ' HB2' ' NH1' ' B' ' 59' ' ' ARG . 65.8 Cg_endo -96.67 -0.83 1.82 Allowed 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.212 2.608 . . . . 0.0 113.216 178.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 111' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -129.16 -97.71 0.37 Allowed 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -179.042 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 112' ' ' VAL . . . . . . . . . . . . . 14.6 m -107.7 -175.25 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.709 0.29 . . . . 0.0 111.469 -178.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.1 mt -68.26 144.19 14.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.707 0.765 . . . . 0.0 111.428 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 114' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -141.82 178.02 7.78 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.578 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 115' ' ' GLY . . . . . 0.446 ' HA3' ' OD1' ' B' ' 150' ' ' ASN . . . -141.79 141.81 11.33 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.537 -0.839 . . . . 0.0 111.579 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -110.66 76.66 0.99 Allowed 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.077 0.465 . . . . 0.0 110.343 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 117' ' ' HIS . . . . . 0.475 ' HA ' ' O ' ' B' ' 123' ' ' ILE . 15.1 t-160 -109.11 92.18 3.95 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.024 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.571 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 22.0 t -75.26 114.63 15.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.728 -179.203 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -64.67 119.21 10.11 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.538 -179.717 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 106.84 1.7 36.63 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.151 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 121' ' ' THR . . . . . 0.571 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 51.0 p -132.4 -174.68 3.52 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.836 0.351 . . . . 0.0 110.777 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -103.01 14.14 32.64 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 178.551 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 123' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' B' ' 117' ' ' HIS . 33.7 mt -83.44 109.37 17.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.572 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -144.54 80.15 1.62 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.437 -0.801 . . . . 0.0 108.957 179.498 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 14.6 p -124.76 148.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.0 -179.047 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -83.47 142.78 30.69 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.304 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 127' ' ' VAL . . . . . . . . . . . . . 46.8 t -116.16 103.84 15.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 128' ' ' LEU . . . . . . . . . . . . . 6.4 mt -92.2 156.57 41.82 Favored Pre-proline 0 C--N 1.322 -0.592 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.135 -178.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -66.59 119.17 6.17 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.725 2.283 . . . . 0.0 112.289 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.71 7.48 87.29 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.708 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -112.48 126.05 54.9 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 132' ' ' VAL . . . . . 0.435 ' HB ' ' HB3' ' B' ' 51' ' ' GLU . 35.1 t -93.94 103.73 15.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.191 0.519 . . . . 0.0 111.137 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 6.3 m -81.97 111.71 18.39 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.653 179.234 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 134' ' ' THR . . . . . . . . . . . . . 24.3 m -97.99 124.16 42.33 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.543 -179.083 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 40.4 t -136.12 130.99 48.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.932 179.561 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 136' ' ' ARG . . . . . . . . . . . . . 51.5 mtt180 -99.91 115.98 30.9 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.941 0.401 . . . . 0.0 110.404 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 137' ' ' TYR . . . . . 0.413 ' CZ ' ' HB ' ' B' ' 121' ' ' THR . 7.7 t80 -121.07 156.54 32.01 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.167 0.508 . . . . 0.0 111.272 -179.311 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 4.1 m -134.12 100.57 4.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.741 178.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 139' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -72.19 121.92 20.15 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.538 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -108.79 6.99 26.05 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.034 0.445 . . . . 0.0 110.444 179.525 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 141' ' ' ARG . . . . . . . . . . . . . 8.7 ptp180 -152.17 131.15 6.57 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.215 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 142' ' ' PRO . . . . . 0.626 ' HA ' HG13 ' B' ' 166' ' ' VAL . 92.1 Cg_endo -76.64 -177.33 3.68 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 123.134 2.556 . . . . 0.0 112.782 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 143' ' ' GLY . . . . . . . . . . . . . . . 123.43 179.58 15.82 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.93 -0.653 . . . . 0.0 112.44 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 144' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -101.25 127.04 48.03 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -119.07 143.01 47.37 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.739 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 2.8 tpt180 -108.18 133.01 53.04 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.799 0.333 . . . . 0.0 110.301 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 147' ' ' ILE . . . . . 0.53 ' O ' ' HA ' ' B' ' 161' ' ' PHE . 13.5 mt -87.27 125.22 41.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.655 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 69.7 mt -102.19 116.01 45.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.086 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 149' ' ' CYS . . . . . . . . . . . . . 37.5 t -85.39 90.21 7.88 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.418 179.387 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 150' ' ' ASN . . . . . 0.446 ' OD1' ' HA3' ' B' ' 115' ' ' GLY . 26.5 p-10 -59.36 -38.47 80.49 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -179.185 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -70.95 136.01 48.24 Favored 'General case' 0 C--O 1.25 1.098 0 CA-C-O 121.128 0.489 . . . . 0.0 111.793 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -53.63 164.35 0.55 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.067 -0.969 . . . . 0.0 111.993 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 153' ' ' CYS . . . . . 0.646 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 5.9 p 170.52 89.67 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.996 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 71.07 -174.81 40.0 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.734 178.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 155' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -77.66 -18.36 56.77 Favored 'General case' 0 N--CA 1.463 0.208 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.044 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 156' ' ' GLY . . . . . 0.451 ' O ' HG21 ' A' ' 68' ' ' VAL . . . -108.33 31.27 8.01 Favored Glycine 0 CA--C 1.508 -0.349 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.321 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 157' ' ' HIS . . . . . 0.646 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 0.3 OUTLIER -66.41 -27.89 68.19 Favored 'General case' 0 C--N 1.318 -0.789 0 O-C-N 122.682 -0.305 . . . . 0.0 111.425 -179.337 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 2.6 pm0 -76.07 -17.67 59.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -178.325 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 159' ' ' ASN . . . . . 0.411 ' HB3' ' CG2' ' A' ' 68' ' ' VAL . 13.1 t30 -100.96 4.49 42.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.823 0.344 . . . . 0.0 111.038 -179.514 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 160' ' ' MET . . . . . . . . . . . . . 26.8 ttt -77.5 77.48 4.02 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 161' ' ' PHE . . . . . 0.53 ' HA ' ' O ' ' B' ' 147' ' ' ILE . 8.6 m-30 -115.8 109.89 18.3 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.427 -178.766 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 162' ' ' GLY . . . . . . . . . . . . . . . -80.4 165.31 48.29 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.921 -0.657 . . . . 0.0 111.598 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.08 127.06 53.04 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 117.377 0.589 . . . . 0.0 112.084 -178.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 40.8 mt -120.15 130.41 74.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 178.55 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 165' ' ' VAL . . . . . 0.61 ' O ' ' HA ' ' B' ' 96' ' ' GLU . 58.0 t -126.3 104.78 13.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 120.869 0.366 . . . . 0.0 110.643 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 166' ' ' VAL . . . . . 0.626 HG13 ' HA ' ' B' ' 142' ' ' PRO . 0.4 OUTLIER -86.74 127.56 40.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.563 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 30.5 mmtp -80.33 136.03 36.32 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.077 -178.419 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 168' ' ' GLU . . . . . 0.433 ' H ' ' CD ' ' B' ' 168' ' ' GLU . 1.3 pm0 . . . . . 0 C--O 1.248 0.995 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.129 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' HEC . . . . . 0.97 HMC1 HBC3 ' A' ' 132' ' ' HEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 169' ' ' CUA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.421 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.7 OUTLIER . . . . . 0 N--CA 1.481 1.123 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 . . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.49 -37.05 91.55 Favored Glycine 0 C--N 1.334 0.453 0 C-N-CA 121.45 -0.405 . . . . 0.0 113.152 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.65 -38.65 77.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.997 0.398 . . . . 0.0 110.378 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.52 -34.44 77.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.55 179.186 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.421 HG12 ' O ' ' A' ' 3' ' ' ASP . 50.7 mm -76.07 -35.16 28.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.358 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.402 ' HA ' ' SG ' ' A' ' 11' ' ' CYS . 68.3 t80 -65.71 -16.43 63.76 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.451 -179.726 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -58.91 -26.98 64.82 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.978 0.418 . . . . 0.0 110.982 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 15.3 mt-30 -77.11 -30.49 55.27 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.535 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.402 ' SG ' ' HA ' ' A' ' 8' ' ' TYR . 2.0 m -76.02 -25.87 56.12 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.152 -179.35 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.29 -18.24 48.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.948 -179.359 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.15 -20.77 80.05 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.795 -0.717 . . . . 0.0 113.277 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 77.0 m -130.43 -43.58 1.14 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 117.329 0.564 . . . . 0.0 111.971 -179.264 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 92.1 m-70 -91.42 -5.4 54.44 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 59.47 -172.11 0.12 Allowed 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.617 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -92.47 -9.67 40.63 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.093 -179.59 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 39.1 p30 -84.63 -8.31 58.93 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.623 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 72.67 20.32 79.58 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.498 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 64.3 mt-30 -117.4 -51.05 2.53 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.941 0.401 . . . . 0.0 110.282 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.32 -154.45 28.7 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.77 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 42.3 mm -94.92 115.33 65.27 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-O 120.623 0.249 . . . . 0.0 110.452 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -59.45 128.56 27.7 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.739 2.292 . . . . 0.0 112.089 179.782 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.07 3.69 69.78 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.169 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -138.27 -48.43 0.54 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.547 0.213 . . . . 0.0 111.12 179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.642 ' CD1' HMD3 ' A' ' 132' ' ' HEC . 56.6 m-85 -121.89 137.81 27.81 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.071 -179.186 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -76.16 147.64 30.01 Favored 'Trans proline' 0 C--O 1.24 0.597 0 C-N-CA 122.857 2.371 . . . . 0.0 112.14 179.056 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -80.81 155.5 20.51 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.856 2.371 . . . . 0.0 112.263 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.552 ' O ' HG23 ' A' ' 33' ' ' VAL . 67.4 mt -105.57 -43.75 4.86 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.655 179.44 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.91 120.02 11.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.431 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.25 12.7 82.88 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.783 -0.722 . . . . 0.0 111.998 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 58.0 t60 -127.62 -22.53 3.59 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.692 0.282 . . . . 0.0 110.899 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.552 HG23 ' O ' ' A' ' 29' ' ' LEU . 60.2 t -65.53 -45.43 92.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.924 0.392 . . . . 0.0 109.945 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -63.05 -31.34 72.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.441 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -65.08 -38.13 89.76 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.198 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.523 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 63.8 mt -78.47 -40.11 24.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.705 -179.595 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 85.8 mt -64.32 -27.32 68.95 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.137 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -79.79 4.58 15.99 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.603 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 59.0 mmtt -109.74 154.79 22.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.629 0.252 . . . . 0.0 110.407 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -66.49 112.6 4.17 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.718 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.55 14.76 77.57 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.009 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.523 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -61.07 -40.75 98.95 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 121.226 -0.511 . . . . 0.0 112.648 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.432 ' O ' HG13 ' A' ' 47' ' ' ILE . 12.7 ptm85 -66.58 -36.31 82.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.679 0.276 . . . . 0.0 110.538 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -67.52 -41.85 83.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.373 0.606 . . . . 0.0 109.52 178.681 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.485 ' O ' HG23 ' A' ' 49' ' ' VAL . 26.7 t80 -60.0 -43.88 94.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.109 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 35.5 mt -56.06 -45.6 79.21 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.106 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.432 HG13 ' O ' ' A' ' 43' ' ' ARG . 59.2 mt -62.13 -43.39 97.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.802 -179.704 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 62.8 mt -60.93 -38.22 85.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.963 0.411 . . . . 0.0 110.739 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.485 HG23 ' O ' ' A' ' 45' ' ' TYR . 81.0 t -65.6 -31.68 54.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.183 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.627 HD21 HMB2 ' A' ' 132' ' ' HEC . 7.0 mp -84.04 -34.65 24.21 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.958 0.409 . . . . 0.0 110.845 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.7 mt -71.54 -56.97 4.87 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.992 -0.549 . . . . 0.0 112.097 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.576 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 55.6 m-85 -103.71 -37.23 7.57 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -178.017 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.457 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 119.51 -167.61 13.4 Favored Glycine 0 N--CA 1.445 -0.728 0 C-N-CA 119.878 -1.153 . . . . 0.0 113.438 178.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.469 ' H ' ' HB3' ' A' ' 69' ' ' MET . 4.6 tp -163.33 134.62 4.81 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.867 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLN . . . . . 0.523 ' HB2' ' HB3' ' B' ' 159' ' ' ASN . 0.0 OUTLIER -154.38 116.27 4.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.06 0.457 . . . . 0.0 111.862 179.779 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -162.97 -148.3 5.32 Favored Glycine 0 N--CA 1.442 -0.904 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.462 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -130.52 68.19 1.47 Allowed 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.3 pt -83.39 165.49 2.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.357 -178.539 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -140.77 113.76 8.4 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.468 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 42.9 t -110.89 116.8 53.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.63 -179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 16.2 mttp 61.38 28.06 17.57 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.521 179.268 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.46 -20.22 51.59 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.753 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.78 110.87 18.68 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.882 0.372 . . . . 0.0 110.738 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 19.1 mttp -81.45 134.3 35.52 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.69 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -119.73 151.13 39.26 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -156.84 82.54 0.95 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.095 0.474 . . . . 0.0 110.268 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -139.73 -150.73 5.55 Favored Glycine 0 N--CA 1.44 -1.07 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.515 ' N ' HMD2 ' A' ' 132' ' ' HEC . 58.8 t -143.06 118.28 4.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.791 0.329 . . . . 0.0 110.574 179.172 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' MET . . . . . 0.606 ' HB2' ' C4D' ' A' ' 132' ' ' HEC . 4.1 tpt -77.02 108.5 10.13 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.063 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -55.75 132.33 48.96 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.404 -0.816 . . . . 0.0 113.01 -178.214 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -71.14 121.4 18.25 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.896 178.795 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.45 ' HE2' ' CHC' ' A' ' 132' ' ' HEC . 36.6 m-85 -108.06 39.22 2.0 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.125 0.488 . . . . 0.0 111.034 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.02 -18.71 65.52 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.414 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.1 pm0 -68.23 -14.91 63.34 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.809 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 82.4 mt -87.35 147.69 25.37 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.888 179.298 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 53.4 mtpt -71.6 160.71 32.19 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.933 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 76.8 m-20 -53.97 -42.88 69.43 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.18 0.515 . . . . 0.0 110.356 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -63.6 -43.31 97.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.309 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 73.9 mt-10 -64.46 -42.79 95.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.368 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 97.6 mt -66.28 -40.45 86.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.969 0.414 . . . . 0.0 110.498 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.49 -35.85 75.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.884 179.448 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.32 -45.67 92.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.538 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 12.5 p -70.96 -34.49 55.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.619 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 15.7 mt -62.25 -45.49 93.05 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.263 0.554 . . . . 0.0 109.96 178.619 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 54.0 m-20 -69.32 -32.83 72.2 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.405 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 25.8 t60 -66.19 -51.09 61.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.749 -179.089 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 39.5 pt -63.63 -32.43 56.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -178.642 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.703 ' HB1' ' HB2' ' A' ' 94' ' ' ALA . . . -73.63 -33.39 64.53 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 112.034 0.383 . . . . 0.0 112.034 -179.397 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.9 p -91.47 -31.06 16.13 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 -178.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -52.25 -47.94 65.5 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 28.5 m-90 -100.38 10.28 41.45 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.902 0.382 . . . . 0.0 110.934 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 57.44 26.56 56.95 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.869 -0.605 . . . . 0.0 113.309 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.435 ' HA ' ' HD3' ' A' ' 96' ' ' LYS . 0.5 OUTLIER -71.41 -29.11 64.53 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.202 0.525 . . . . 0.0 109.998 -179.412 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.703 ' HB2' ' HB1' ' A' ' 88' ' ' ALA . . . -70.55 -15.44 62.77 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.162 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.2 mttm -80.63 -14.43 58.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.957 0.408 . . . . 0.0 110.632 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.435 ' HD3' ' HA ' ' A' ' 93' ' ' ASP . 40.6 mtpt -80.86 -21.04 41.04 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.377 -179.46 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 28.3 m -95.22 161.06 2.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 179.316 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -97.07 127.86 43.45 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.068 0.461 . . . . 0.0 110.967 -178.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 62.05 61.11 7.02 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.61 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 76.4 t80 -75.61 110.31 9.9 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.857 0.361 . . . . 0.0 110.457 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 95.6 mttt -84.56 124.08 73.75 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 115.683 -0.69 . . . . 0.0 109.737 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_exo -59.52 138.15 82.06 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.631 2.221 . . . . 0.0 111.923 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -65.77 129.28 39.23 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.258 179.509 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p -111.91 157.57 20.5 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.081 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -60.79 -32.03 71.38 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.484 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.0 mm-40 -66.54 -32.74 74.28 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.821 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -66.51 -38.55 87.45 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.167 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.408 ' HA ' HG21 ' A' ' 47' ' ' ILE . 21.1 t -71.21 -45.76 69.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.061 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 4.2 ttmp? -58.68 -38.33 77.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.713 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 25.8 ttpt -58.75 -46.46 87.4 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.328 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 40.0 mt -83.63 -15.94 47.08 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.564 -178.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 48.1 ttm-85 -69.98 -16.86 63.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.379 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -80.34 -38.52 30.4 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.066 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 45.6 tttp -81.62 95.65 7.24 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 19.7 tptm -66.05 114.03 4.91 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.2 0.524 . . . . 0.0 111.532 -179.178 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 79.6 mt -125.35 176.66 6.64 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.005 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.441 ' O ' HG23 ' A' ' 121' ' ' VAL . 61.2 p -124.43 157.57 64.53 Favored Pre-proline 0 C--N 1.319 -0.744 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.359 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.576 ' HG3' ' O ' ' A' ' 52' ' ' TYR . 50.1 Cg_exo -55.1 -30.61 71.39 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.545 2.163 . . . . 0.0 111.745 179.298 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 42.8 tp60 -74.34 -39.92 62.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.881 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' GLN . . . . . 0.478 ' O ' ' HG2' ' A' ' 124' ' ' GLU . 44.8 mt-30 -67.02 -37.63 84.48 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.162 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 117' ' ' THR . 60.8 t -60.37 -31.81 49.46 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 CA-C-O 121.137 0.494 . . . . 0.0 110.18 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 23.9 tp -64.91 -38.33 90.61 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.543 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -68.52 -39.74 81.06 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.753 178.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.478 ' HG2' ' O ' ' A' ' 120' ' ' GLN . 10.9 mm-40 -59.97 -38.03 81.34 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.656 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.426 HH11 ' HD3' ' A' ' 125' ' ' ARG . 6.4 ttm-85 -61.01 -46.27 91.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.964 178.372 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.526 ' HA ' ' O ' ' A' ' 130' ' ' LEU . 67.0 mttm -68.57 -28.41 66.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.911 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -69.01 -29.24 67.38 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.096 0.474 . . . . 0.0 110.006 178.741 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 70.0 mt -78.28 0.92 23.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.821 179.658 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 89.46 18.39 52.61 Favored Glycine 0 N--CA 1.446 -0.697 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.209 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.526 ' O ' ' HA ' ' A' ' 126' ' ' LYS . 18.1 mt -105.7 169.26 8.58 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 12.1 mptt . . . . . 0 C--O 1.246 0.891 0 CA-C-O 118.863 -0.589 . . . . 0.0 109.836 179.521 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 45.9 t80 . . . . . 0 N--CA 1.479 0.991 0 CA-C-O 120.787 0.327 . . . . 0.0 110.926 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 1.6 p -60.96 -36.15 78.65 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -178.622 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 74.6 mt -69.18 -24.33 64.04 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.763 0.316 . . . . 0.0 111.339 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -93.48 -5.37 49.32 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.14 0.495 . . . . 0.0 111.072 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 39' ' ' THR . . . . . 0.403 HG22 ' H ' ' B' ' 40' ' ' HIS . 3.9 m -106.82 167.73 9.68 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.887 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 40' ' ' HIS . . . . . 0.403 ' H ' HG22 ' B' ' 39' ' ' THR . 6.0 p80 -65.18 -10.38 30.84 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.73 0.3 . . . . 0.0 111.564 -179.678 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.76 -17.63 64.76 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.932 0.396 . . . . 0.0 111.178 179.421 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.07 -4.35 24.62 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.611 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -66.36 -18.06 67.02 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.962 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 33.4 m -72.44 -12.11 15.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-O 120.927 0.394 . . . . 0.0 111.234 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 71.0 mt -88.72 125.78 61.84 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.727 179.587 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 46' ' ' PRO . . . . . 0.405 ' HA ' ' O ' ' B' ' 134' ' ' THR . 32.2 Cg_exo -58.08 149.11 73.6 Favored 'Trans proline' 0 C--O 1.234 0.301 0 C-N-CA 122.567 2.178 . . . . 0.0 112.197 179.736 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -62.51 142.82 57.76 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.749 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -73.37 -18.36 79.29 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.959 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 45.0 tttp -68.19 127.94 34.74 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.252 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 50' ' ' LEU . . . . . . . . . . . . . 84.2 mt -80.54 114.89 19.75 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.008 0.432 . . . . 0.0 110.488 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 51' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -116.82 103.53 10.41 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.772 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 52' ' ' ARG . . . . . 0.454 ' HD2' ' N ' ' B' ' 52' ' ' ARG . 0.4 OUTLIER -111.0 137.64 48.38 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.412 -178.981 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 10.4 m -133.02 170.47 19.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.886 179.076 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 54' ' ' ASP . . . . . 0.493 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 13.7 t70 -81.48 114.05 46.64 Favored Pre-proline 0 C--N 1.327 -0.408 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.371 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -80.18 19.32 1.06 Allowed 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 123.07 2.513 . . . . 0.0 113.576 -178.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.8 -47.94 3.1 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.238 0.542 . . . . 0.0 110.67 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 9.2 p -106.41 12.72 29.41 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.48 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 58' ' ' VAL . . . . . 0.493 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 14.7 p -60.63 -28.59 43.06 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.428 0 CA-C-O 120.944 0.402 . . . . 0.0 111.829 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 59' ' ' ARG . . . . . . . . . . . . . 29.3 ptt180 -97.05 13.19 29.92 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.843 0.354 . . . . 0.0 111.055 -179.535 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 79.0 mt-30 -130.9 -35.93 1.39 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.95 0.405 . . . . 0.0 110.813 -179.332 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -135.04 105.68 6.47 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.857 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 145.43 -179.22 22.67 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.862 -0.685 . . . . 0.0 111.884 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_exo -63.33 -27.54 71.61 Favored 'Trans proline' 0 CA--C 1.527 0.145 0 C-N-CA 122.834 2.356 . . . . 0.0 112.551 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 31.3 m-90 -85.03 6.4 25.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.534 -179.273 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -94.55 10.57 34.18 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.973 0.416 . . . . 0.0 110.951 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 66' ' ' ASP . . . . . 0.416 ' HB3' ' HB2' ' B' ' 69' ' ' GLN . 7.9 t70 -147.65 110.35 3.87 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.222 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_exo -62.39 -32.66 81.03 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.808 2.339 . . . . 0.0 112.915 -179.443 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.5 -46.13 20.35 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.539 -0.301 . . . . 0.0 111.086 -179.164 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 69' ' ' GLN . . . . . 0.416 ' HB2' ' HB3' ' B' ' 66' ' ' ASP . 13.6 mm100 -80.63 16.92 1.23 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.529 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -78.11 -24.56 47.43 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.992 0.425 . . . . 0.0 110.662 179.366 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 25.5 t -100.46 93.85 3.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.741 179.555 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 2.9 t -105.56 139.64 26.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -178.864 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -81.51 122.86 28.08 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.023 179.496 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.18 -29.55 18.18 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.678 -179.325 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . 178.86 -162.54 29.64 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.438 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -61.7 107.72 0.55 Allowed 'Trans proline' 0 C--O 1.236 0.397 0 C-N-CA 123.077 2.518 . . . . 0.0 112.124 -179.577 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 45.2 t30 63.79 29.76 14.71 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.762 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -133.96 122.31 22.9 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.093 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -127.06 151.42 48.64 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.873 -179.411 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 91.4 m -119.82 121.58 39.41 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.332 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 50.0 t -110.56 117.2 54.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 121.053 0.454 . . . . 0.0 111.242 -178.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -86.39 106.09 17.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.647 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 83' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 28.8 t -98.36 122.43 50.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.191 0.52 . . . . 0.0 110.697 -179.398 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 57.4 tp -102.09 109.39 21.08 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.797 179.621 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 85' ' ' ALA . . . . . . . . . . . . . . . -96.6 73.16 2.72 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.153 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 86' ' ' PHE . . . . . 0.52 ' CZ ' ' HB2' ' B' ' 91' ' ' GLN . 0.1 OUTLIER -75.01 -169.77 0.98 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.999 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 87' ' ' ALA . . . . . . . . . . . . . . . -39.66 93.75 0.01 OUTLIER 'General case' 0 N--CA 1.462 0.127 0 O-C-N 124.316 1.01 . . . . 0.0 113.724 -178.46 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 88' ' ' PHE . . . . . 0.402 ' HA ' ' SD ' ' B' ' 160' ' ' MET . 4.9 m-85 53.26 27.73 6.41 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.698 -1.137 . . . . 0.0 112.976 178.22 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 89' ' ' GLY . . . . . . . . . . . . . . . -139.62 -178.4 16.62 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.016 -1.088 . . . . 0.0 112.978 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 90' ' ' TYR . . . . . 0.517 ' OH ' ' HB2' ' B' ' 149' ' ' CYS . 41.2 m-85 -140.32 133.65 29.81 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 91' ' ' GLN . . . . . 0.52 ' HB2' ' CZ ' ' B' ' 86' ' ' PHE . 31.7 tt0 -135.48 128.34 18.11 Favored Pre-proline 0 C--N 1.322 -0.608 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 178.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -79.95 170.88 64.94 Favored 'Cis proline' 0 CA--C 1.53 0.293 0 C-N-CA 123.386 -1.506 . . . . 0.0 112.451 -0.146 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 93' ' ' ASN . . . . . 0.405 ' HA ' ' HA ' ' B' ' 94' ' ' PRO . 58.6 t30 -159.76 120.19 1.72 Allowed Pre-proline 0 C--N 1.326 -0.456 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 94' ' ' PRO . . . . . 0.405 ' HA ' ' HA ' ' B' ' 93' ' ' ASN . 98.2 Cg_endo -78.85 151.39 88.06 Favored 'Cis proline' 0 C--O 1.233 0.264 0 C-N-CA 123.47 -1.471 . . . . 0.0 112.755 -0.363 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 40.2 mt -81.7 127.27 39.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.611 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 96' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -104.52 124.63 49.63 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.516 0.198 . . . . 0.0 110.839 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 97' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 4.8 m -141.22 153.7 66.79 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.101 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.49 161.45 14.77 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 122.718 2.279 . . . . 0.0 111.802 178.632 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.29 152.73 18.31 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.021 0.438 . . . . 0.0 111.378 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 78.03 8.72 87.32 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.564 -0.743 . . . . 0.0 113.135 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.29 155.26 26.53 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.838 0.351 . . . . 0.0 111.302 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 102' ' ' GLU . . . . . 0.556 ' OE2' ' HD3' ' B' ' 136' ' ' ARG . 77.8 tt0 -81.56 119.26 23.55 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.739 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 103' ' ' ILE . . . . . 0.437 HD12 ' HD1' ' B' ' 139' ' ' PHE . 7.8 mt -108.91 113.54 44.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.004 -179.107 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 21.5 t -91.98 101.14 12.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.764 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 105' ' ' PHE . . . . . 0.503 ' O ' ' HA ' ' B' ' 134' ' ' THR . 75.7 m-85 -82.24 122.18 27.59 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.09 -179.235 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -119.93 89.95 3.23 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 107' ' ' ILE . . . . . 0.491 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.2 mp -97.77 135.82 30.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.576 -178.111 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 4.9 t -133.8 154.21 51.17 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.515 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 109' ' ' SER . . . . . 0.702 ' O ' ' HA ' ' B' ' 129' ' ' PRO . 0.7 OUTLIER -122.7 126.28 26.15 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-O 120.652 0.263 . . . . 0.0 111.226 -178.932 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -89.24 -29.05 0.26 Allowed 'Trans proline' 0 N--CA 1.459 -0.547 0 C-N-CA 122.911 2.407 . . . . 0.0 112.808 178.455 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 111' ' ' ASP . . . . . 0.43 ' CG ' ' H ' ' B' ' 112' ' ' VAL . 8.2 p-10 -95.0 -111.76 0.12 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.863 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 112' ' ' VAL . . . . . 0.43 ' H ' ' CG ' ' B' ' 111' ' ' ASP . 17.0 m -99.86 -172.77 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 120.561 0.22 . . . . 0.0 110.533 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 21.0 mt -74.91 143.78 12.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-O 121.365 0.602 . . . . 0.0 111.543 -179.208 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 114' ' ' HIS . . . . . 0.466 ' HD2' ' OG ' ' B' ' 109' ' ' SER . 97.7 m-70 -136.95 179.39 6.41 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.461 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 115' ' ' GLY . . . . . 0.505 ' O ' ' HA ' ' B' ' 149' ' ' CYS . . . -134.06 134.78 7.61 Favored Glycine 0 N--CA 1.443 -0.845 0 C-N-CA 120.443 -0.885 . . . . 0.0 112.044 -179.644 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -104.56 85.28 2.3 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-O 121.028 0.442 . . . . 0.0 109.915 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 117' ' ' HIS . . . . . 0.462 ' HA ' ' O ' ' B' ' 123' ' ' ILE . 12.6 t-160 -113.82 109.97 19.39 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.635 179.228 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.457 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 44.5 t -88.04 113.83 25.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.241 0.543 . . . . 0.0 111.119 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -63.38 115.93 5.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.6 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 110.46 0.06 29.39 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.462 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 121' ' ' THR . . . . . 0.457 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 40.9 p -139.65 175.5 9.52 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 179.407 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -92.96 18.24 9.43 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.94 0.4 . . . . 0.0 110.365 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 123' ' ' ILE . . . . . 0.462 ' O ' ' HA ' ' B' ' 117' ' ' HIS . 53.6 mt -81.9 106.72 13.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.033 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -146.1 100.33 3.37 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 178.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 7.1 p -137.63 144.57 30.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.485 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -82.56 145.63 29.63 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.373 179.122 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 127' ' ' VAL . . . . . 0.503 HG12 ' HB2' ' B' ' 109' ' ' SER . 6.3 t -115.5 106.17 19.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.589 179.579 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 128' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' B' ' 129' ' ' PRO . 7.7 mp -96.52 153.24 38.9 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.38 -178.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 129' ' ' PRO . . . . . 0.702 ' HA ' ' O ' ' B' ' 109' ' ' SER . 27.5 Cg_exo -62.65 120.52 8.08 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.693 2.262 . . . . 0.0 112.614 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.68 -13.68 65.04 Favored Glycine 0 N--CA 1.451 -0.312 0 CA-C-N 115.897 -0.592 . . . . 0.0 113.103 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -94.55 148.37 22.32 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 132' ' ' VAL . . . . . . . . . . . . . 22.6 t -112.82 89.27 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 121.026 0.441 . . . . 0.0 110.21 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 5.0 m -62.68 105.59 0.67 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.031 179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 134' ' ' THR . . . . . 0.503 ' HA ' ' O ' ' B' ' 105' ' ' PHE . 23.2 m -102.34 115.48 30.64 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.539 -179.26 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 78.6 t -127.85 136.28 60.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.834 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 136' ' ' ARG . . . . . 0.556 ' HD3' ' OE2' ' B' ' 102' ' ' GLU . 51.2 mtt180 -110.58 113.45 26.08 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.747 0.308 . . . . 0.0 111.056 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 137' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -128.98 166.83 18.42 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.675 -179.61 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 73.1 m -134.51 110.55 9.44 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 178.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 139' ' ' PHE . . . . . 0.437 ' HD1' HD12 ' B' ' 103' ' ' ILE . 39.6 m-85 -84.3 112.97 20.79 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.383 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 78.9 mttt -105.31 -11.0 16.68 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.183 0.516 . . . . 0.0 110.509 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 141' ' ' ARG . . . . . 0.413 ' HB2' ' OH ' ' B' ' 145' ' ' TYR . 61.5 mtt180 -110.67 114.27 54.84 Favored Pre-proline 0 C--N 1.324 -0.511 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.783 179.493 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 142' ' ' PRO . . . . . 0.475 ' HA ' HG13 ' B' ' 166' ' ' VAL . 15.5 Cg_exo -68.67 155.84 67.49 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.906 2.404 . . . . 0.0 112.852 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 143' ' ' GLY . . . . . . . . . . . . . . . 139.38 -168.66 24.83 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.681 179.647 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 144' ' ' GLU . . . . . 0.413 ' HG2' HG22 ' B' ' 165' ' ' VAL . 49.3 mt-10 -109.39 119.71 40.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.72 0.295 . . . . 0.0 110.71 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 145' ' ' TYR . . . . . 0.413 ' OH ' ' HB2' ' B' ' 141' ' ' ARG . 31.1 m-85 -106.05 137.38 44.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.017 179.66 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.43 135.44 34.67 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.034 0.445 . . . . 0.0 111.636 -178.869 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 147' ' ' ILE . . . . . . . . . . . . . 40.3 mt -99.79 109.92 25.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.443 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 13.4 mt -103.11 119.22 51.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-O 120.817 0.341 . . . . 0.0 111.185 -179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 149' ' ' CYS . . . . . 0.517 ' HB2' ' OH ' ' B' ' 90' ' ' TYR . 3.9 t -85.57 84.05 7.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.093 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 150' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -58.89 -17.51 24.86 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -179.393 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 32.1 tp60 -80.33 140.06 36.3 Favored 'General case' 0 C--O 1.25 1.102 0 CA-C-O 121.162 0.506 . . . . 0.0 111.928 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -57.25 155.35 8.93 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 114.816 -1.084 . . . . 0.0 110.778 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 153' ' ' CYS . . . . . 0.547 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 1.6 p -176.55 78.34 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.733 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 55.65 -140.93 39.91 Favored Glycine 0 C--N 1.331 0.264 0 O-C-N 123.432 0.458 . . . . 0.0 112.73 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 155' ' ' LEU . . . . . 0.434 HD13 HG22 ' A' ' 117' ' ' THR . 37.4 mt -92.58 -15.49 26.85 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.24 0.543 . . . . 0.0 110.318 179.303 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 156' ' ' GLY . . . . . . . . . . . . . . . -87.97 63.91 3.71 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.729 -0.668 . . . . 0.0 111.909 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 157' ' ' HIS . . . . . 0.547 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 62.9 t60 -131.71 -37.5 1.18 Allowed 'General case' 0 C--N 1.319 -0.752 0 O-C-N 122.61 -0.347 . . . . 0.0 111.212 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -64.99 -14.05 59.29 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 112.864 0.69 . . . . 0.0 112.864 -178.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 159' ' ' ASN . . . . . 0.523 ' HB3' ' HB2' ' A' ' 55' ' ' GLN . 8.5 t30 -132.99 15.09 4.25 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.879 0.371 . . . . 0.0 111.4 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 160' ' ' MET . . . . . 0.402 ' SD ' ' HA ' ' B' ' 88' ' ' PHE . 24.7 ttt -87.74 87.87 7.5 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 161' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -128.2 136.2 50.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.852 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 162' ' ' GLY . . . . . . . . . . . . . . . -105.87 176.37 22.05 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 11.7 m -144.38 131.51 20.57 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 117.762 0.781 . . . . 0.0 111.9 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 65.1 mt -114.44 113.11 42.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.303 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 165' ' ' VAL . . . . . 0.413 HG22 ' HG2' ' B' ' 144' ' ' GLU . 22.1 t -101.91 103.67 15.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.113 0.482 . . . . 0.0 110.746 -179.345 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 166' ' ' VAL . . . . . 0.475 HG13 ' HA ' ' B' ' 142' ' ' PRO . 1.3 p -90.88 123.63 43.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 178.69 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 28.4 mmtp -79.16 147.26 32.74 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.212 -178.346 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 168' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.245 0.827 0 CA-C-O 118.689 -0.672 . . . . 0.0 109.781 179.767 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' HEC . . . . . 0.906 HMC1 HBC3 ' A' ' 132' ' ' HEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 169' ' ' CUA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ASP . . . . . 0.434 ' O ' HG12 ' A' ' 7' ' ' ILE . 6.1 p-10 . . . . . 0 N--CA 1.478 0.97 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.16 -37.39 92.82 Favored Glycine 0 C--N 1.333 0.379 0 C-N-CA 121.136 -0.554 . . . . 0.0 113.165 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.01 -35.67 80.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.526 0.203 . . . . 0.0 111.128 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -66.17 -34.87 79.02 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.034 0.445 . . . . 0.0 110.533 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.434 HG12 ' O ' ' A' ' 3' ' ' ASP . 31.9 mm -73.02 -38.06 54.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.054 179.557 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -63.08 -21.81 66.43 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.112 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -57.89 -31.85 67.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.989 0.424 . . . . 0.0 110.827 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 66.4 mt-30 -77.31 -32.19 55.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.06 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 15.7 m -70.87 -29.39 65.48 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.074 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.15 -17.58 64.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.415 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.31 5.98 39.84 Favored Glycine 0 N--CA 1.453 -0.21 0 C-N-CA 121.048 -0.596 . . . . 0.0 112.623 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.8 m -153.56 -51.13 0.1 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.602 0.239 . . . . 0.0 110.992 179.422 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.5 m-70 -85.96 7.01 26.01 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.87 -0.15 . . . . 0.0 111.094 -179.041 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 57.2 mm-40 61.41 -168.19 0.18 Allowed 'General case' 0 N--CA 1.465 0.275 0 O-C-N 123.492 0.495 . . . . 0.0 111.215 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 46.8 mt-30 -104.52 -5.56 21.43 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.908 0.385 . . . . 0.0 110.593 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 14.9 p30 -82.71 -4.46 57.89 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.091 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 75.74 19.18 79.25 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.468 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.468 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 44.6 mt-30 -124.73 -80.16 0.62 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.824 0.345 . . . . 0.0 110.561 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 116.39 -123.07 5.72 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.905 -179.655 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 36.9 mm -129.25 115.91 18.67 Favored Pre-proline 0 C--N 1.323 -0.572 0 N-CA-C 110.554 -0.165 . . . . 0.0 110.554 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -57.77 99.38 0.09 OUTLIER 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.884 2.39 . . . . 0.0 111.443 178.561 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 126.59 -15.29 6.71 Favored Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 -179.264 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -124.41 -36.45 2.64 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.686 0.279 . . . . 0.0 111.096 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -136.09 126.3 16.41 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.007 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.428 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 60.0 Cg_endo -75.72 134.73 16.98 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.395 2.063 . . . . 0.0 111.276 178.061 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 20' ' ' GLN . 17.1 Cg_exo -67.61 148.0 77.34 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.524 2.149 . . . . 0.0 112.599 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.482 ' O ' HG23 ' A' ' 33' ' ' VAL . 80.3 mt -97.22 -39.86 9.06 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.37 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.38 116.49 8.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.143 179.418 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.84 29.45 42.54 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.561 -0.828 . . . . 0.0 111.101 -178.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 43.9 t60 -146.06 -34.22 0.31 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.598 -0.301 . . . . 0.0 110.561 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.482 HG23 ' O ' ' A' ' 29' ' ' LEU . 97.2 t -62.48 -43.12 98.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.326 -0.397 . . . . 0.0 109.961 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -61.8 -35.9 79.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.541 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -63.45 -37.61 87.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.23 0.538 . . . . 0.0 110.278 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.51 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 61.7 mt -80.2 -39.32 19.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.142 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 45.9 mt -61.82 -25.27 67.4 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.376 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.5 -13.82 59.65 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.456 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -87.22 151.82 22.83 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.631 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -66.89 111.87 4.0 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.981 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.549 ' HA2' ' OE1' ' A' ' 44' ' ' GLU . . . 83.02 14.59 74.59 Favored Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 120.737 -0.744 . . . . 0.0 111.578 -178.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.51 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -61.58 -39.54 97.5 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.338 -0.458 . . . . 0.0 112.475 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.502 ' O ' HG13 ' A' ' 47' ' ' ILE . 12.7 ptm85 -65.12 -36.1 83.19 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.549 ' OE1' ' HA2' ' A' ' 41' ' ' GLY . 23.0 mp0 -67.66 -39.66 84.54 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.141 0.496 . . . . 0.0 109.775 178.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.415 ' O ' HG23 ' A' ' 49' ' ' VAL . 31.5 t80 -60.16 -44.2 95.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.099 179.258 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 41.4 mt -60.67 -40.4 91.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.923 179.619 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.502 HG13 ' O ' ' A' ' 43' ' ' ARG . 71.9 mt -64.91 -42.12 93.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.158 179.63 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 92.2 mt -62.16 -35.42 78.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.873 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.486 HG11 HAA1 ' A' ' 132' ' ' HEC . 61.0 t -66.08 -33.35 62.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.733 179.448 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 8.2 mp -83.63 -33.31 25.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.949 0.404 . . . . 0.0 110.496 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 18.3 mt -72.18 -57.02 4.58 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.976 -0.556 . . . . 0.0 112.012 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 39.8 m-85 -105.12 -37.88 6.76 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.973 -177.635 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 117.59 -168.13 12.89 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.051 -1.071 . . . . 0.0 113.671 178.756 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.466 ' H ' ' HB3' ' A' ' 69' ' ' MET . 25.6 tp -152.85 150.2 29.09 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.857 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLN . . . . . 0.401 ' CD ' ' HB2' ' A' ' 118' ' ' PRO . 3.2 pt20 -163.94 157.49 18.63 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.672 0.272 . . . . 0.0 111.114 -178.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 138.25 -118.38 1.61 Allowed Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.727 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.417 HE22 ' HB2' ' A' ' 66' ' ' ASN . 6.0 tp60 -161.82 82.8 0.58 Allowed 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 4.0 pt -96.4 148.14 5.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.036 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.407 ' HA ' ' O ' ' A' ' 63' ' ' MET . 1.8 tt0 -121.44 105.27 10.34 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.165 179.82 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.424 HG12 ' HG2' ' A' ' 61' ' ' LYS . 6.9 t -126.68 135.7 62.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 179.616 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.424 ' HG2' HG12 ' A' ' 60' ' ' VAL . 21.3 mmtp 60.11 28.14 17.66 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 121.079 0.466 . . . . 0.0 110.814 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.19 20.91 78.8 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.793 -0.639 . . . . 0.0 112.447 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' MET . . . . . 0.407 ' O ' ' HA ' ' A' ' 59' ' ' GLU . 45.2 mtt -118.03 121.41 40.55 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -90.39 100.22 13.09 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.196 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -85.18 139.87 31.35 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.657 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ASN . . . . . 0.417 ' HB2' HE22 ' A' ' 57' ' ' GLN . 49.8 t30 -139.73 81.61 1.83 Allowed 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.434 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.9 -160.95 9.96 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.667 -0.777 . . . . 0.0 111.946 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 64.5 t -138.46 114.04 9.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.932 0.396 . . . . 0.0 110.29 179.18 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' MET . . . . . 0.608 ' HB2' ' C4D' ' A' ' 132' ' ' HEC . 5.0 tpt -69.73 114.91 8.38 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 178.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.5 m -63.48 135.07 56.63 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.779 -177.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -72.09 126.87 30.86 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.412 179.23 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 37.1 m-85 -110.36 34.35 3.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.122 0.487 . . . . 0.0 110.661 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -69.02 -8.49 45.49 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.843 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 18.0 pm0 -72.22 -20.19 61.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.86 0.362 . . . . 0.0 110.721 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 22.9 mt -82.09 159.06 23.49 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.255 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.449 ' HB2' ' HG3' ' A' ' 79' ' ' GLU . 22.5 mtpt -70.29 155.11 41.11 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.255 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 40.3 m-20 -61.51 -37.05 82.28 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.002 0.43 . . . . 0.0 110.31 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -69.29 -19.99 63.9 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.952 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLU . . . . . 0.449 ' HG3' ' HB2' ' A' ' 76' ' ' LYS . 41.1 mt-10 -89.23 -41.85 11.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.371 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 81.9 mt -62.93 -38.84 82.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.857 179.364 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.55 -28.4 64.89 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.161 178.46 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.13 -46.46 67.6 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.327 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 14.2 p -65.27 -36.93 78.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 C-N-CA 120.81 -0.356 . . . . 0.0 110.161 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 41.1 mt -63.41 -44.02 95.85 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.168 0.509 . . . . 0.0 109.829 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 50.1 m-20 -64.51 -43.15 94.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.891 178.793 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 44.5 t60 -61.09 -55.23 34.96 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.354 -178.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 46.6 pt -60.6 -35.65 65.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.476 0.547 . . . . 0.0 112.476 -177.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.62 ' HB1' ' HB2' ' A' ' 94' ' ' ALA . . . -73.39 -34.2 65.4 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 22.1 p -89.85 -35.05 15.87 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.631 0.604 . . . . 0.0 112.631 -178.387 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -59.32 -44.51 92.58 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 15.8 m-90 -91.35 2.21 56.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.813 0.339 . . . . 0.0 111.014 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 64.44 23.99 68.93 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.9 -0.591 . . . . 0.0 113.273 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.454 ' HA ' ' HD3' ' A' ' 96' ' ' LYS . 0.2 OUTLIER -75.28 -28.73 59.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.191 0.52 . . . . 0.0 109.976 -179.913 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.62 ' HB2' ' HB1' ' A' ' 88' ' ' ALA . . . -73.47 -6.43 46.37 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.919 179.416 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -91.03 -7.12 52.78 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.175 179.362 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.454 ' HD3' ' HA ' ' A' ' 93' ' ' ASP . 34.3 mtpt -96.43 11.21 35.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.34 -179.211 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 13.0 m -126.1 151.04 32.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.017 178.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.3 ptpt -86.46 122.85 30.98 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.061 0.458 . . . . 0.0 111.967 -179.208 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 64.42 62.05 5.44 Favored Glycine 0 N--CA 1.453 -0.232 0 CA-C-N 115.617 -0.72 . . . . 0.0 113.424 178.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -72.46 122.7 21.71 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.778 0.323 . . . . 0.0 110.508 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 78.5 mttt -96.69 125.16 47.9 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.848 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -57.24 132.65 52.43 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.362 2.042 . . . . 0.0 111.393 179.137 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -61.95 132.57 53.42 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.581 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -113.36 153.83 27.89 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.733 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -63.33 -30.33 71.49 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.051 0.453 . . . . 0.0 110.774 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.0 mm-40 -61.24 -32.06 71.85 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.954 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -68.23 -45.72 72.48 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.176 0.512 . . . . 0.0 110.199 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 11.7 t -65.0 -46.4 91.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.527 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 26.0 ttpt -62.91 -36.01 81.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.747 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 32.9 ttpt -63.94 -47.7 79.45 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.124 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 80.3 mt -74.21 -25.69 59.82 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.046 0.45 . . . . 0.0 110.876 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 21.0 ttm-85 -72.74 -9.02 58.16 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.689 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -70.13 -37.45 75.29 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.032 0.444 . . . . 0.0 110.027 179.062 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -92.47 103.77 16.16 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.453 179.144 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 25.9 tptp -68.25 99.68 0.94 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.3 0.571 . . . . 0.0 111.009 -179.182 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 72.7 mt -108.86 -174.74 2.59 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.901 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.423 HG22 HD13 ' B' ' 155' ' ' LEU . 1.3 p -138.47 163.04 49.85 Favored Pre-proline 0 C--N 1.32 -0.699 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.401 ' HB2' ' CD ' ' A' ' 55' ' ' GLN . 77.9 Cg_exo -50.87 -41.66 54.61 Favored 'Trans proline' 0 CA--C 1.533 0.472 0 C-N-CA 122.686 2.257 . . . . 0.0 112.841 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -65.63 -32.41 73.97 Favored 'General case' 0 CA--C 1.53 0.212 0 CA-C-O 120.767 0.318 . . . . 0.0 110.856 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 57.8 mt-30 -73.43 -35.24 65.76 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.182 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 50.1 t -66.46 -36.6 77.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 20.3 tp -61.14 -36.56 80.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.963 178.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.87 -38.72 91.92 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.408 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.465 ' O ' ' HG ' ' A' ' 128' ' ' LEU . 58.4 mm-40 -62.98 -39.13 93.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.33 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 55.4 ttt-85 -61.89 -42.18 98.76 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.986 179.309 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.457 ' HA ' ' O ' ' A' ' 130' ' ' LEU . 68.1 mttm -68.64 -27.71 66.25 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.469 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 91.1 mttt -73.67 -15.26 61.24 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.236 0.541 . . . . 0.0 110.252 179.307 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.465 ' HG ' ' O ' ' A' ' 124' ' ' GLU . 59.8 mt -88.4 -1.42 58.03 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.578 178.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.21 -10.42 61.64 Favored Glycine 0 N--CA 1.449 -0.463 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.942 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.457 ' O ' ' HA ' ' A' ' 126' ' ' LYS . 20.7 mt -88.25 106.58 18.3 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.9 0.381 . . . . 0.0 110.82 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.443 ' H ' ' HD2' ' A' ' 131' ' ' LYS . 9.2 mptt . . . . . 0 C--O 1.246 0.904 0 CA-C-O 118.416 -0.802 . . . . 0.0 110.12 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 61.5 t80 . . . . . 0 N--CA 1.48 1.049 0 CA-C-O 120.464 0.173 . . . . 0.0 111.024 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 4.1 m -59.83 -40.81 89.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.029 0.443 . . . . 0.0 111.436 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 94.9 mt -80.86 -3.46 51.33 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.455 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -103.53 -6.3 21.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.028 0.442 . . . . 0.0 110.993 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.0 p -116.31 179.97 3.84 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.651 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 40' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -68.09 -8.63 39.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.549 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -61.37 -20.67 63.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.329 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -72.06 -8.86 57.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.198 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -70.3 -18.7 75.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.326 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 8.9 m -74.61 -11.24 14.32 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-O 121.136 0.494 . . . . 0.0 110.905 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 38.1 mt -86.82 131.93 43.71 Favored Pre-proline 0 C--N 1.322 -0.625 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.596 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 46' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -53.56 134.62 58.72 Favored 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.797 2.331 . . . . 0.0 112.288 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -56.54 140.21 47.15 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.24 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -68.69 -23.59 75.52 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.914 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 80.0 tttt -64.08 116.87 6.33 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.933 0.397 . . . . 0.0 110.303 179.311 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 50' ' ' LEU . . . . . . . . . . . . . 80.2 mt -91.66 93.28 8.83 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.01 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 51' ' ' GLU . . . . . 0.41 ' HB2' ' HB ' ' B' ' 132' ' ' VAL . 21.0 mt-10 -89.19 103.7 16.3 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 52' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -90.7 114.79 27.2 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.797 0.332 . . . . 0.0 110.72 -179.792 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.19 -173.48 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.735 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 54' ' ' ASP . . . . . 0.59 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 17.3 t70 -96.04 111.41 56.16 Favored Pre-proline 0 C--N 1.326 -0.435 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -78.06 17.43 1.02 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.752 2.301 . . . . 0.0 113.755 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.6 -55.99 2.16 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.442 0.639 . . . . 0.0 110.609 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.8 -2.03 55.5 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.092 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 58' ' ' VAL . . . . . 0.59 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 12.1 p -56.22 -28.37 25.56 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -179.316 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 59' ' ' ARG . . . . . . . . . . . . . 37.3 ptt180 -98.43 12.0 36.37 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.068 0.461 . . . . 0.0 111.031 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 58.8 mt-30 -124.41 -39.35 2.33 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.214 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -140.63 133.87 29.63 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.995 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.07 170.86 12.94 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.027 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -60.46 -28.19 86.26 Favored 'Trans proline' 0 CA--C 1.529 0.229 0 C-N-CA 122.682 2.255 . . . . 0.0 112.712 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 32.3 m-90 -84.55 -2.62 57.63 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.154 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.92 -1.12 57.86 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.91 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -122.69 105.07 35.9 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.592 -179.608 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_exo -69.06 -23.76 33.65 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.888 2.392 . . . . 0.0 112.625 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -83.81 -47.55 11.01 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.134 0.492 . . . . 0.0 110.371 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 69' ' ' GLN . . . . . . . . . . . . . 85.3 mm-40 -86.19 20.92 2.17 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.764 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 70' ' ' ALA . . . . . 0.442 ' O ' ' HA ' ' B' ' 81' ' ' VAL . . . -71.74 -24.25 61.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.141 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 33.9 t -112.21 103.35 15.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.261 179.615 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 9.6 t -122.06 130.39 74.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.435 -0.348 . . . . 0.0 111.049 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 30.8 tt0 -78.08 105.15 9.1 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 178.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -78.57 -23.76 45.89 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.152 -0.476 . . . . 0.0 112.041 -178.532 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . -164.17 177.39 39.91 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.366 -0.921 . . . . 0.0 112.242 -179.644 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -55.92 115.84 2.75 Favored 'Trans proline' 0 C--O 1.235 0.366 0 C-N-CA 122.85 2.367 . . . . 0.0 112.414 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 18.1 t30 65.27 28.18 11.99 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.533 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 34.4 tt0 -135.64 120.25 18.24 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.839 0.352 . . . . 0.0 110.69 179.379 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 34.3 m-85 -119.97 126.28 50.48 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.94 -178.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 59.4 m -97.85 124.65 42.34 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.852 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 81' ' ' VAL . . . . . 0.442 ' HA ' ' O ' ' B' ' 70' ' ' ALA . 44.7 t -115.15 117.76 56.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 121.09 0.471 . . . . 0.0 111.081 -179.342 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -88.86 95.51 10.32 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.2 178.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 83' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 21.7 t -90.46 120.3 39.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.282 -179.152 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 58.0 tp -101.2 109.12 20.94 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.848 179.22 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.79 70.31 10.35 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.808 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 86' ' ' PHE . . . . . 0.472 ' CZ ' ' HA3' ' B' ' 89' ' ' GLY . 53.5 p90 -63.0 179.13 0.41 Allowed 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.952 -178.737 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.475 ' HB3' ' CBC' ' A' ' 132' ' ' HEC . . . -52.12 102.94 0.05 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.464 -178.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 64.11 26.96 14.05 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 114.845 -1.07 . . . . 0.0 113.005 178.17 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 89' ' ' GLY . . . . . 0.472 ' HA3' ' CZ ' ' B' ' 86' ' ' PHE . . . -156.53 -179.52 31.58 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 119.776 -1.202 . . . . 0.0 113.285 179.42 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 90' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -135.71 132.02 36.37 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 91' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -124.1 137.64 29.33 Favored Pre-proline 0 C--N 1.324 -0.525 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -80.12 174.46 48.54 Favored 'Cis proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.249 -1.563 . . . . 0.0 111.971 -0.362 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 93' ' ' ASN . . . . . 0.432 ' OD1' ' HA ' ' B' ' 94' ' ' PRO . 55.4 t30 -161.14 124.86 1.94 Allowed Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 94' ' ' PRO . . . . . 0.432 ' HA ' ' OD1' ' B' ' 93' ' ' ASN . 69.3 Cg_endo -74.55 151.82 97.45 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.371 -1.512 . . . . 0.0 113.162 0.182 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 66.0 mt -85.78 108.56 17.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.917 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 96' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -94.15 115.43 27.71 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.481 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 97' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 2.6 m -132.6 155.31 81.36 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.65 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -84.6 160.89 12.52 Favored 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.492 2.128 . . . . 0.0 112.524 179.46 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.05 146.02 27.98 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.836 0.35 . . . . 0.0 111.031 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.47 -5.32 84.83 Favored Glycine 0 N--CA 1.452 -0.266 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.497 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -105.07 157.45 17.24 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.762 0.315 . . . . 0.0 111.406 -179.341 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 102' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -84.86 116.61 23.41 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 103' ' ' ILE . . . . . . . . . . . . . 24.2 mt -104.02 120.65 54.54 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.092 0.472 . . . . 0.0 110.766 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 16.7 t -96.37 99.36 8.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.262 179.654 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 105' ' ' PHE . . . . . 0.466 ' O ' ' HA ' ' B' ' 134' ' ' THR . 66.0 m-85 -84.07 118.62 24.19 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.343 -178.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 54.7 mttm -115.76 95.69 5.25 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 177.678 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 107' ' ' ILE . . . . . 0.508 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.1 mp -102.46 137.01 32.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.173 -177.584 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 3.3 t -138.85 157.19 46.51 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 109' ' ' SER . . . . . 0.616 ' O ' ' HA ' ' B' ' 129' ' ' PRO . 39.4 t -125.69 138.05 31.18 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 111.846 0.314 . . . . 0.0 111.846 -178.573 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -93.52 -11.51 1.51 Allowed 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 123.118 2.546 . . . . 0.0 112.666 178.15 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 111' ' ' ASP . . . . . 0.544 ' CG ' ' H ' ' B' ' 112' ' ' VAL . 11.5 p-10 -115.84 -113.98 0.34 Allowed 'General case' 0 CA--C 1.537 0.454 0 O-C-N 122.271 -0.268 . . . . 0.0 111.493 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 112' ' ' VAL . . . . . 0.544 ' H ' ' CG ' ' B' ' 111' ' ' ASP . 20.1 m -93.11 -179.05 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.676 0.274 . . . . 0.0 110.544 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.1 mt -73.42 136.01 26.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.24 0.543 . . . . 0.0 110.554 179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 114' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -122.83 174.13 7.33 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 115' ' ' GLY . . . . . 0.556 ' O ' ' HA ' ' B' ' 149' ' ' CYS . . . -124.96 121.35 4.28 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.999 -179.613 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -96.83 80.57 3.04 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 117' ' ' HIS . . . . . . . . . . . . . 12.2 t-80 -113.79 110.27 19.88 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.57 179.367 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.536 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 21.6 t -88.64 113.56 25.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-O 120.966 0.412 . . . . 0.0 110.316 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -63.02 115.47 4.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.957 -179.269 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 110.08 1.74 29.99 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.686 179.607 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 121' ' ' THR . . . . . 0.536 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 31.7 p -138.36 178.96 6.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.652 0.263 . . . . 0.0 110.658 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -96.52 20.58 10.45 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.129 0.49 . . . . 0.0 110.646 179.297 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 34.2 mt -86.95 109.38 19.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.246 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -150.28 103.82 3.19 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.761 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 9.0 p -143.41 151.78 16.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.275 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.75 134.68 34.04 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.145 0.498 . . . . 0.0 110.419 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 127' ' ' VAL . . . . . . . . . . . . . 5.1 t -99.17 96.98 5.41 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.884 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 128' ' ' LEU . . . . . . . . . . . . . 4.8 mp -87.93 147.18 40.32 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.773 -179.131 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 129' ' ' PRO . . . . . 0.616 ' HA ' ' O ' ' B' ' 109' ' ' SER . 28.5 Cg_endo -63.78 118.07 5.03 Favored 'Trans proline' 0 N--CA 1.462 -0.336 0 C-N-CA 122.52 2.147 . . . . 0.0 112.307 179.831 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.93 -4.29 85.67 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.832 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -102.58 139.87 37.61 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 132' ' ' VAL . . . . . 0.41 ' HB ' ' HB2' ' B' ' 51' ' ' GLU . 59.8 t -101.63 92.31 2.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.251 0.548 . . . . 0.0 110.756 179.363 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 5.3 m -73.29 105.59 4.76 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.842 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 134' ' ' THR . . . . . 0.466 ' HA ' ' O ' ' B' ' 105' ' ' PHE . 24.6 m -100.66 121.18 41.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.387 -179.024 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 48.2 t -128.13 137.3 57.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.177 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 136' ' ' ARG . . . . . 0.402 HH11 ' HD3' ' B' ' 136' ' ' ARG . 68.6 mtt-85 -108.74 120.26 41.96 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.899 0.38 . . . . 0.0 110.663 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 137' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -136.81 151.55 49.29 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.954 0.407 . . . . 0.0 111.081 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 8.3 m -120.48 100.17 6.99 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.806 179.077 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 139' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -73.27 96.87 2.35 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.344 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 83.5 mttt -91.78 -5.55 53.32 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.01 0.433 . . . . 0.0 110.668 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 141' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 -122.79 113.56 30.17 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.097 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 142' ' ' PRO . . . . . 0.468 ' HA ' HG13 ' B' ' 166' ' ' VAL . 64.4 Cg_endo -72.59 167.45 27.07 Favored 'Trans proline' 0 C--O 1.236 0.409 0 C-N-CA 122.591 2.194 . . . . 0.0 112.342 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 143' ' ' GLY . . . . . 0.487 ' N ' HG13 ' B' ' 166' ' ' VAL . . . 137.29 -159.56 24.79 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.245 -179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 144' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -120.33 116.82 26.28 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.781 0.324 . . . . 0.0 110.349 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 51.4 m-85 -110.11 147.04 34.4 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.92 -179.653 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 12.5 mmt180 -110.22 133.12 53.55 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.064 0.459 . . . . 0.0 111.456 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 147' ' ' ILE . . . . . 0.431 HD12 ' HA3' ' B' ' 162' ' ' GLY . 40.5 mt -88.0 131.46 35.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.708 178.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 46.4 mt -115.53 115.14 48.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 120.951 0.405 . . . . 0.0 110.179 179.488 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 149' ' ' CYS . . . . . 0.556 ' HA ' ' O ' ' B' ' 115' ' ' GLY . 42.5 t -79.9 89.1 5.28 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.751 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 150' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -64.13 -25.09 67.94 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 10.2 tp60 -81.05 135.85 35.88 Favored 'General case' 0 C--O 1.247 0.94 0 CA-C-O 121.204 0.526 . . . . 0.0 111.764 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -53.53 161.85 0.94 Allowed 'General case' 0 N--CA 1.471 0.621 0 CA-C-N 114.893 -1.049 . . . . 0.0 112.386 -178.81 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 153' ' ' CYS . . . . . 0.403 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 1.6 p 176.44 65.17 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.914 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 52.79 -142.67 25.85 Favored Glycine 0 CA--C 1.518 0.262 0 O-C-N 123.464 0.478 . . . . 0.0 114.019 179.349 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 155' ' ' LEU . . . . . 0.423 HD13 HG22 ' A' ' 117' ' ' THR . 91.4 mt -72.91 -27.1 61.67 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.741 0.305 . . . . 0.0 111.527 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 156' ' ' GLY . . . . . . . . . . . . . . . -87.32 62.14 4.14 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.591 -0.814 . . . . 0.0 111.623 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 157' ' ' HIS . . . . . 0.403 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 69.2 t60 -127.78 -59.3 1.21 Allowed 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -178.831 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 4.5 pm0 -57.71 -33.23 68.19 Favored 'General case' 0 C--N 1.328 -0.333 0 O-C-N 123.463 0.477 . . . . 0.0 112.188 -178.359 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 159' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -107.49 14.14 26.14 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.719 -0.392 . . . . 0.0 111.009 -179.588 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 160' ' ' MET . . . . . . . . . . . . . 26.3 ttt -84.99 85.15 7.51 Favored 'General case' 0 C--O 1.237 0.426 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 161' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -112.66 -177.14 3.07 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.972 -179.282 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 162' ' ' GLY . . . . . 0.431 ' HA3' HD12 ' B' ' 147' ' ' ILE . . . -148.21 150.98 23.25 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 178.795 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 7.5 m -113.03 108.31 17.17 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 117.317 0.558 . . . . 0.0 111.659 -179.022 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 41.1 mt -102.5 111.86 33.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.34 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 165' ' ' VAL . . . . . . . . . . . . . 15.0 t -108.49 102.78 14.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 121.175 0.512 . . . . 0.0 110.451 -179.364 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 166' ' ' VAL . . . . . 0.487 HG13 ' N ' ' B' ' 143' ' ' GLY . 0.7 OUTLIER -88.06 120.75 37.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 179.209 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 51.9 mmtt -67.32 155.93 37.69 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.654 -178.354 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 168' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 . . . . . 0 C--O 1.249 1.035 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.094 -179.459 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 132' ' ' HEC . . . . . 0.827 HMC1 HBC3 ' A' ' 132' ' ' HEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 169' ' ' CUA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.452 ' HA3' ' HB2' ' A' ' 86' ' ' HIS . . . . . . . . 0 N--CA 1.448 -0.519 0 CA-C-O 120.115 -0.269 . . . . 0.0 113.52 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.06 -39.4 75.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 117.186 0.493 . . . . 0.0 111.165 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.06 -40.17 88.58 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.167 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.402 ' HB ' ' HB ' ' A' ' 83' ' ' VAL . 37.2 mm -80.3 -26.92 11.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.081 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -57.2 -29.34 63.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.923 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -59.57 -30.81 68.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.103 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 75.8 mt-30 -75.39 -36.16 60.93 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.284 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 20.6 m -67.42 -31.8 72.24 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-O 121.048 0.452 . . . . 0.0 110.516 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.51 -19.56 65.98 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.953 -179.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.95 -24.73 71.74 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.256 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 96.3 m -129.32 -40.2 1.46 Allowed 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -179.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -91.3 -7.2 51.72 Favored 'General case' 0 C--N 1.33 -0.253 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.341 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 16.1 mm-40 65.27 176.26 0.21 Allowed 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.892 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 20.3 mp0 -79.35 -8.57 59.17 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.631 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 23.8 p30 -90.93 -20.22 22.44 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.774 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 72.34 22.35 78.94 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.565 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 16.3 mt-30 -98.02 -32.29 11.71 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.978 0.418 . . . . 0.0 110.42 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.671 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.786 179.689 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.226 -0.175 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -128.29 123.91 22.68 Favored Pre-proline 0 C--N 1.327 -0.397 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.939 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.3 158.65 44.62 Favored 'Trans proline' 0 C--O 1.239 0.531 0 C-N-CA 122.889 2.393 . . . . 0.0 113.0 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -78.76 158.7 28.06 Favored 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.782 2.322 . . . . 0.0 112.351 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.409 ' O ' HG23 ' A' ' 33' ' ' VAL . 65.8 mt -115.4 -38.04 3.88 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.347 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.39 120.3 11.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.127 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 73.43 33.45 58.63 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 -179.042 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 32.4 t60 -143.92 -32.99 0.43 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.585 -0.307 . . . . 0.0 110.548 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 29' ' ' LEU . 59.6 t -63.45 -41.12 91.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -62.04 -35.38 78.42 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.847 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -61.65 -37.58 84.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.513 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.47 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 19.4 mt -79.95 -38.53 18.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.525 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 46.5 mt -62.67 -23.59 67.19 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.556 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -82.7 -10.1 59.06 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.419 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 65.9 mmtt -90.7 154.02 19.86 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.739 0.304 . . . . 0.0 110.35 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -75.42 105.31 6.38 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.71 7.67 55.28 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -64.44 -34.79 90.85 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 121.255 -0.498 . . . . 0.0 112.105 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 11.4 ptm85 -67.77 -35.17 78.21 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.614 0.245 . . . . 0.0 110.394 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -67.0 -40.09 87.28 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -61.96 -40.67 96.36 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.393 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 86.6 mt -59.43 -34.09 72.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.011 179.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.4 mt -78.98 -42.19 23.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.999 0.428 . . . . 0.0 110.08 179.104 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.51 ' HG ' HD13 ' A' ' 111' ' ' LEU . 42.8 mt -63.3 -37.93 89.17 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.11 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.577 ' O ' ' HA2' ' A' ' 53' ' ' GLY . 0.8 OUTLIER -71.06 -15.47 18.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.013 -179.631 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 3.0 mp -96.66 -44.5 7.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.852 0.358 . . . . 0.0 110.538 179.158 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.6 mt -66.69 -47.23 73.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.059 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 68.9 m-85 -111.92 -55.85 2.46 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.213 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.577 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 120.11 -158.46 15.36 Favored Glycine 0 N--CA 1.441 -1.009 0 C-N-CA 119.888 -1.148 . . . . 0.0 113.938 178.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.431 ' H ' ' HB2' ' A' ' 69' ' ' MET . 1.9 tp -152.52 150.01 29.12 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -179.192 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . 0.495 ' OE1' ' HB2' ' A' ' 118' ' ' PRO . 9.3 pt20 -151.09 111.16 4.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.864 0.364 . . . . 0.0 111.726 -179.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -177.37 -143.8 5.09 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.182 178.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.463 ' HA ' ' O ' ' A' ' 65' ' ' TYR . 19.8 mp0 -132.88 66.67 1.55 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.479 ' O ' ' HA ' ' A' ' 64' ' ' LYS . 33.1 pt -66.87 155.07 7.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.247 -178.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.408 ' OE1' ' HG3' ' A' ' 64' ' ' LYS . 23.7 tt0 -124.62 100.63 6.73 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.215 0.531 . . . . 0.0 110.817 -179.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 41.0 t -100.32 115.85 42.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.061 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 19.2 mmtp 62.96 23.82 14.22 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.508 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.91 -7.9 65.17 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.654 179.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -97.55 121.0 38.95 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 17.0 mttp -91.67 144.77 25.18 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.955 0.407 . . . . 0.0 110.914 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.463 ' O ' ' HA ' ' A' ' 57' ' ' GLN . 71.1 m-85 -120.96 177.43 5.11 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.058 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -156.38 71.98 0.73 Allowed 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -140.99 -161.99 8.92 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.766 179.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.67 ' HB ' ' CG ' ' B' ' 88' ' ' PHE . 41.4 t -146.77 136.39 16.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.222 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . 0.517 ' HG3' HG22 ' A' ' 49' ' ' VAL . 0.3 OUTLIER -71.19 142.07 50.66 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.527 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 6.5 m -78.52 123.84 27.5 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.719 0.295 . . . . 0.0 110.75 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.5 m -70.78 95.19 1.1 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.351 179.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -84.5 45.83 1.17 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.229 0.538 . . . . 0.0 111.375 -179.192 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -74.12 -16.67 61.0 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.84 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 19.4 pm0 -76.12 -18.65 59.06 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.68 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 65.2 mt -83.48 155.31 23.45 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.889 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 25.0 mtpt -72.69 154.71 40.58 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -55.41 -41.72 73.11 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.715 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -63.17 -37.96 89.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.005 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 51.5 mt-10 -67.07 -45.17 78.14 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.652 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 89.9 mt -60.45 -42.48 91.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.379 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.39 -35.61 73.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.635 179.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.83 -46.39 88.17 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.701 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.402 ' HB ' ' HB ' ' A' ' 7' ' ' ILE . 9.8 p -66.42 -34.94 73.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 C-N-CA 120.485 -0.486 . . . . 0.0 110.669 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 35.2 mt -65.55 -44.82 85.63 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.157 0.503 . . . . 0.0 110.155 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 82.4 m-20 -66.33 -39.06 89.0 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.21 179.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . 0.452 ' HB2' ' HA3' ' A' ' 4' ' ' GLY . 32.3 t60 -63.73 -50.73 67.98 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.516 -0.766 . . . . 0.0 111.597 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.438 HG13 ' N ' ' A' ' 88' ' ' ALA . 41.8 pt -64.39 -39.53 85.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.561 ' HB1' ' HB2' ' A' ' 94' ' ' ALA . . . -63.62 -36.23 83.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.852 0.358 . . . . 0.0 111.663 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.5 p -89.28 -23.57 22.27 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.751 -179.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -61.43 -53.88 50.76 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.875 0.369 . . . . 0.0 111.527 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.415 ' CZ3' ' HB ' ' A' ' 87' ' ' ILE . 5.3 m-90 -86.32 -8.4 57.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.192 0.52 . . . . 0.0 110.566 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 77.56 17.89 78.4 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.493 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.59 -26.96 68.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.301 0.572 . . . . 0.0 110.187 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.561 ' HB2' ' HB1' ' A' ' 88' ' ' ALA . . . -73.53 -7.57 52.39 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.208 179.233 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -98.67 1.14 45.94 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.052 0.453 . . . . 0.0 110.476 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 39.4 mtpt -103.76 11.05 36.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.636 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 15.9 m -125.18 159.77 31.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.987 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.6 ptpt -93.1 112.91 25.02 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.823 0.344 . . . . 0.0 111.155 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 69.99 68.27 1.68 Allowed Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.85 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 65.1 t80 -73.17 124.68 26.09 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.827 0.346 . . . . 0.0 110.395 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 70.5 mttt -98.65 117.56 64.37 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.501 179.261 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -59.55 141.85 97.93 Favored 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.243 1.962 . . . . 0.0 111.374 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -69.83 126.64 30.3 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.306 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.6 p -109.15 152.52 25.01 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.663 -0.698 . . . . 0.0 110.457 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.05 -24.44 58.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 111.333 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 66.6 mm-40 -60.97 -43.21 99.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.894 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.473 ' O ' ' HG2' ' A' ' 110' ' ' LYS . 27.2 mt-10 -68.73 -29.64 68.1 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.006 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 24.3 t -76.98 -40.56 30.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-O 121.186 0.517 . . . . 0.0 109.919 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 9.2 tppt? -62.93 -44.21 96.7 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.814 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . 0.473 ' HG2' ' O ' ' A' ' 107' ' ' GLU . 62.7 pttt -60.49 -32.0 71.01 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.711 0.291 . . . . 0.0 111.361 -179.031 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.51 HD13 ' HG ' ' A' ' 48' ' ' LEU . 97.4 mt -87.61 -30.48 20.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.214 -179.342 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 46.6 ttm-85 -66.56 -31.05 71.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.051 0.453 . . . . 0.0 110.457 179.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -71.46 -29.99 65.48 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.621 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -89.16 92.65 9.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.729 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 27.3 tptp -66.09 113.71 4.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.415 0.626 . . . . 0.0 111.473 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 81.5 mt -126.63 -174.97 3.26 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.245 179.102 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.45 ' O ' HG23 ' A' ' 121' ' ' VAL . 75.3 p -131.13 147.94 68.26 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.091 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.495 ' HB2' ' OE1' ' A' ' 55' ' ' GLN . 32.4 Cg_exo -58.01 -26.77 76.56 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.6 2.2 . . . . 0.0 112.118 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 11.5 tp60 -71.29 -29.91 65.62 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.447 179.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -80.07 -33.0 39.3 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.073 179.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.45 HG23 ' O ' ' A' ' 117' ' ' THR . 43.2 t -63.15 -25.72 39.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.344 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.416 ' HA ' HD11 ' A' ' 54' ' ' LEU . 26.7 tp . . . . . 0 C--O 1.232 0.163 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.215 178.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 86.4 t80 . . . . . 0 N--CA 1.481 1.105 0 CA-C-O 120.716 0.294 . . . . 0.0 110.932 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -35.35 80.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.86 0.362 . . . . 0.0 111.311 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 94.4 mt -76.79 -15.16 59.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.994 0.426 . . . . 0.0 110.675 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.81 13.02 30.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.824 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 1.8 p -139.89 178.04 7.54 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.314 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 40' ' ' HIS . . . . . . . . . . . . . 1.4 p80 -75.54 -6.43 50.21 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.349 0.595 . . . . 0.0 109.824 179.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . 0.476 ' O ' HG22 ' B' ' 44' ' ' VAL . 0.3 OUTLIER -64.4 -19.71 65.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.07 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.28 -10.92 47.18 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.276 179.445 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -66.11 -25.78 72.27 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.312 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . 0.476 HG22 ' O ' ' B' ' 41' ' ' THR . 11.8 m -70.62 -12.24 15.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-O 120.987 0.422 . . . . 0.0 111.094 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 38.1 mt -92.16 133.2 30.59 Favored Pre-proline 0 C--N 1.322 -0.602 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 46' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -52.62 145.02 39.96 Favored 'Trans proline' 0 C--N 1.347 0.482 0 C-N-CA 122.831 2.354 . . . . 0.0 112.613 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -60.24 152.55 24.51 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.492 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -84.98 -18.99 60.09 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.947 -0.644 . . . . 0.0 111.911 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 29.8 tttt -75.85 138.42 41.1 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 50' ' ' LEU . . . . . 0.427 HD23 ' HA ' ' B' ' 50' ' ' LEU . 13.2 mt -83.19 134.27 34.98 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.01 0.433 . . . . 0.0 110.272 179.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 51' ' ' GLU . . . . . 0.435 ' HB3' ' HB ' ' B' ' 132' ' ' VAL . 1.6 tt0 -133.46 74.82 1.58 Allowed 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 52' ' ' ARG . . . . . . . . . . . . . 23.2 ttm180 -95.78 132.45 41.0 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.092 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 6.8 m -136.16 -172.0 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 115.668 -0.697 . . . . 0.0 109.909 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . 0.549 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 28.2 t70 -93.07 114.62 63.22 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 179.161 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -72.1 -11.83 27.49 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.541 2.16 . . . . 0.0 112.952 -178.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.17 -52.11 9.83 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 111.887 0.328 . . . . 0.0 111.887 -179.277 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 12.6 p -98.51 0.02 44.25 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 -178.367 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 58' ' ' VAL . . . . . 0.549 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 8.4 p -61.84 -22.58 28.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-O 121.136 0.494 . . . . 0.0 111.104 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 59' ' ' ARG . . . . . 0.456 ' NH1' ' HB2' ' B' ' 110' ' ' PRO . 12.2 ptt180 -95.77 3.12 54.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.435 -179.707 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -124.04 -31.2 3.4 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.85 0.357 . . . . 0.0 111.095 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -140.23 118.37 11.97 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.448 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 137.79 -177.76 19.68 Favored Glycine 0 N--CA 1.441 -0.969 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.298 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -63.88 -13.2 35.8 Favored 'Trans proline' 0 CA--C 1.53 0.306 0 C-N-CA 123.17 2.58 . . . . 0.0 113.103 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 30.2 m-90 -104.18 12.66 33.57 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.978 0.418 . . . . 0.0 110.328 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -100.42 2.54 42.35 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.563 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -145.14 114.93 4.97 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.472 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -72.61 -9.97 24.62 Favored 'Trans proline' 0 C--O 1.234 0.293 0 C-N-CA 122.64 2.227 . . . . 0.0 112.985 -179.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -81.93 -54.93 4.93 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.848 0.356 . . . . 0.0 110.581 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 69' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -88.07 44.23 1.18 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.051 0.453 . . . . 0.0 110.989 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . 0.429 ' O ' ' HA ' ' B' ' 81' ' ' VAL . . . -84.15 -29.36 26.74 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.383 179.374 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 41.6 t -102.21 106.84 20.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.697 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 40.7 t -120.94 125.03 73.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.136 -179.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -65.93 127.4 31.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.843 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -123.58 20.85 9.43 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.875 -178.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . 158.33 177.81 31.77 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.359 -0.924 . . . . 0.0 112.125 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -61.45 108.69 0.63 Allowed 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.961 2.441 . . . . 0.0 111.729 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 38.8 t30 63.47 25.56 14.53 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.401 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -122.19 123.15 40.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.587 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 24.8 m-85 -129.37 127.42 40.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.725 0.298 . . . . 0.0 110.823 -179.085 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 100.0 m -93.37 125.37 37.94 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 178.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . 0.429 ' HA ' ' O ' ' B' ' 70' ' ' ALA . 55.8 t -114.52 116.98 54.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.097 0.475 . . . . 0.0 110.825 -179.261 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -85.36 118.48 24.92 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.557 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 83' ' ' VAL . . . . . 0.531 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 20.2 t -116.16 124.82 72.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.138 0.494 . . . . 0.0 110.986 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 34.6 tp -101.05 115.2 29.92 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.524 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 85' ' ' ALA . . . . . . . . . . . . . . . -100.46 90.93 4.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.641 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 86' ' ' PHE . . . . . 0.414 ' CZ ' ' HB2' ' B' ' 91' ' ' GLN . 0.2 OUTLIER -96.44 -163.82 1.09 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.011 0.434 . . . . 0.0 111.524 -179.535 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.41 ' H ' ' HB2' ' B' ' 86' ' ' PHE . . . -55.86 103.31 0.1 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.913 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . 0.67 ' CG ' ' HB ' ' A' ' 68' ' ' VAL . 9.2 m-85 56.34 27.66 12.27 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.085 -0.962 . . . . 0.0 113.071 177.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 89' ' ' GLY . . . . . . . . . . . . . . . -150.38 168.98 30.33 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 119.649 -1.262 . . . . 0.0 113.207 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 90' ' ' TYR . . . . . 0.408 ' O ' ' HB2' ' B' ' 93' ' ' ASN . 83.8 m-85 -138.78 131.39 28.98 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 91' ' ' GLN . . . . . 0.414 ' HB2' ' CZ ' ' B' ' 86' ' ' PHE . 5.3 tt0 -122.34 130.28 24.75 Favored Pre-proline 0 C--N 1.323 -0.567 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -82.03 172.14 52.91 Favored 'Cis proline' 0 N--CA 1.461 -0.385 0 C-N-CA 123.512 -1.453 . . . . 0.0 112.269 -0.197 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 93' ' ' ASN . . . . . 0.408 ' HB2' ' O ' ' B' ' 90' ' ' TYR . 3.7 t30 -152.09 130.07 6.04 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.788 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 94' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' B' ' 93' ' ' ASN . 73.0 Cg_endo -77.96 149.31 87.22 Favored 'Cis proline' 0 N--CA 1.461 -0.418 0 C-N-CA 122.925 -1.698 . . . . 0.0 111.481 -1.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.3 mt -75.65 96.22 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.472 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 96' ' ' GLU . . . . . 0.61 ' HA ' ' O ' ' B' ' 165' ' ' VAL . 41.2 mt-10 -88.32 120.5 29.75 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.449 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 3.2 m -138.29 149.82 64.57 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.692 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -78.99 149.07 22.39 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.747 2.298 . . . . 0.0 112.318 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -92.26 155.83 17.7 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.37 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.13 7.12 87.39 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.355 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -123.36 158.31 31.36 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.44 0.162 . . . . 0.0 110.847 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 102' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -86.26 111.71 20.7 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 103' ' ' ILE . . . . . . . . . . . . . 8.0 mt -100.51 116.42 43.89 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.631 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 20.0 t -90.5 95.66 5.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 105' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -79.83 122.74 27.01 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.204 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -121.02 92.55 3.78 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 107' ' ' ILE . . . . . 0.531 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.5 mp -100.85 137.65 27.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.493 -177.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 5.5 t -141.79 159.49 42.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.499 178.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 109' ' ' SER . . . . . . . . . . . . . 30.6 t -119.5 135.88 24.32 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-O 120.708 0.29 . . . . 0.0 111.18 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 110' ' ' PRO . . . . . 0.456 ' HB2' ' NH1' ' B' ' 59' ' ' ARG . 65.8 Cg_endo -96.67 -0.83 1.82 Allowed 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.212 2.608 . . . . 0.0 113.216 178.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 111' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -129.16 -97.71 0.37 Allowed 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -179.042 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 112' ' ' VAL . . . . . . . . . . . . . 14.6 m -107.7 -175.25 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.709 0.29 . . . . 0.0 111.469 -178.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.1 mt -68.26 144.19 14.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.707 0.765 . . . . 0.0 111.428 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 114' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -141.82 178.02 7.78 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.578 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 115' ' ' GLY . . . . . 0.446 ' HA3' ' OD1' ' B' ' 150' ' ' ASN . . . -141.79 141.81 11.33 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.537 -0.839 . . . . 0.0 111.579 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -110.66 76.66 0.99 Allowed 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.077 0.465 . . . . 0.0 110.343 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 117' ' ' HIS . . . . . 0.475 ' HA ' ' O ' ' B' ' 123' ' ' ILE . 15.1 t-160 -109.11 92.18 3.95 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.024 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.571 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 22.0 t -75.26 114.63 15.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.728 -179.203 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -64.67 119.21 10.11 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.538 -179.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 106.84 1.7 36.63 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.151 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 121' ' ' THR . . . . . 0.571 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 51.0 p -132.4 -174.68 3.52 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.836 0.351 . . . . 0.0 110.777 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -103.01 14.14 32.64 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 178.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' B' ' 117' ' ' HIS . 33.7 mt -83.44 109.37 17.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.572 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -144.54 80.15 1.62 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.437 -0.801 . . . . 0.0 108.957 179.498 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 14.6 p -124.76 148.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.0 -179.047 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -83.47 142.78 30.69 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.304 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 127' ' ' VAL . . . . . . . . . . . . . 46.8 t -116.16 103.84 15.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 128' ' ' LEU . . . . . . . . . . . . . 6.4 mt -92.2 156.57 41.82 Favored Pre-proline 0 C--N 1.322 -0.592 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.135 -178.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -66.59 119.17 6.17 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.725 2.283 . . . . 0.0 112.289 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.71 7.48 87.29 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.708 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -112.48 126.05 54.9 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 132' ' ' VAL . . . . . 0.435 ' HB ' ' HB3' ' B' ' 51' ' ' GLU . 35.1 t -93.94 103.73 15.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.191 0.519 . . . . 0.0 111.137 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 6.3 m -81.97 111.71 18.39 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.653 179.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 134' ' ' THR . . . . . . . . . . . . . 24.3 m -97.99 124.16 42.33 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.543 -179.083 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 40.4 t -136.12 130.99 48.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.932 179.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 136' ' ' ARG . . . . . . . . . . . . . 51.5 mtt180 -99.91 115.98 30.9 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.941 0.401 . . . . 0.0 110.404 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 137' ' ' TYR . . . . . 0.413 ' CZ ' ' HB ' ' B' ' 121' ' ' THR . 7.7 t80 -121.07 156.54 32.01 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.167 0.508 . . . . 0.0 111.272 -179.311 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 4.1 m -134.12 100.57 4.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.741 178.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 139' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -72.19 121.92 20.15 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.538 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -108.79 6.99 26.05 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.034 0.445 . . . . 0.0 110.444 179.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 141' ' ' ARG . . . . . . . . . . . . . 8.7 ptp180 -152.17 131.15 6.57 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.215 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 142' ' ' PRO . . . . . 0.626 ' HA ' HG13 ' B' ' 166' ' ' VAL . 92.1 Cg_endo -76.64 -177.33 3.68 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 123.134 2.556 . . . . 0.0 112.782 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 143' ' ' GLY . . . . . . . . . . . . . . . 123.43 179.58 15.82 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.93 -0.653 . . . . 0.0 112.44 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 144' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -101.25 127.04 48.03 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -119.07 143.01 47.37 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.739 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 2.8 tpt180 -108.18 133.01 53.04 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.799 0.333 . . . . 0.0 110.301 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 147' ' ' ILE . . . . . 0.53 ' O ' ' HA ' ' B' ' 161' ' ' PHE . 13.5 mt -87.27 125.22 41.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.655 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 69.7 mt -102.19 116.01 45.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.086 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 149' ' ' CYS . . . . . . . . . . . . . 37.5 t -85.39 90.21 7.88 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.418 179.387 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 150' ' ' ASN . . . . . 0.446 ' OD1' ' HA3' ' B' ' 115' ' ' GLY . 26.5 p-10 -59.36 -38.47 80.49 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -179.185 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -70.95 136.01 48.24 Favored 'General case' 0 C--O 1.25 1.098 0 CA-C-O 121.128 0.489 . . . . 0.0 111.793 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -53.63 164.35 0.55 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.067 -0.969 . . . . 0.0 111.993 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 153' ' ' CYS . . . . . 0.646 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 5.9 p 170.52 89.67 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.996 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 71.07 -174.81 40.0 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.734 178.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 155' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -77.66 -18.36 56.77 Favored 'General case' 0 N--CA 1.463 0.208 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.044 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 156' ' ' GLY . . . . . 0.451 ' O ' HG21 ' A' ' 68' ' ' VAL . . . -108.33 31.27 8.01 Favored Glycine 0 CA--C 1.508 -0.349 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.321 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 157' ' ' HIS . . . . . 0.646 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 0.3 OUTLIER -66.41 -27.89 68.19 Favored 'General case' 0 C--N 1.318 -0.789 0 O-C-N 122.682 -0.305 . . . . 0.0 111.425 -179.337 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 2.6 pm0 -76.07 -17.67 59.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -178.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 159' ' ' ASN . . . . . 0.411 ' HB3' ' CG2' ' A' ' 68' ' ' VAL . 13.1 t30 -100.96 4.49 42.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.823 0.344 . . . . 0.0 111.038 -179.514 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 160' ' ' MET . . . . . . . . . . . . . 26.8 ttt -77.5 77.48 4.02 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 161' ' ' PHE . . . . . 0.53 ' HA ' ' O ' ' B' ' 147' ' ' ILE . 8.6 m-30 -115.8 109.89 18.3 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.427 -178.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 162' ' ' GLY . . . . . . . . . . . . . . . -80.4 165.31 48.29 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.921 -0.657 . . . . 0.0 111.598 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.08 127.06 53.04 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 117.377 0.589 . . . . 0.0 112.084 -178.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 40.8 mt -120.15 130.41 74.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 178.55 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 165' ' ' VAL . . . . . 0.61 ' O ' ' HA ' ' B' ' 96' ' ' GLU . 58.0 t -126.3 104.78 13.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 120.869 0.366 . . . . 0.0 110.643 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 166' ' ' VAL . . . . . 0.626 HG13 ' HA ' ' B' ' 142' ' ' PRO . 0.4 OUTLIER -86.74 127.56 40.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.563 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 30.5 mmtp -80.33 136.03 36.32 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.077 -178.419 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 168' ' ' GLU . . . . . 0.433 ' H ' ' CD ' ' B' ' 168' ' ' GLU . 1.3 pm0 . . . . . 0 C--O 1.248 0.995 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.129 179.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.336 0 CA-C-O 120.277 -0.18 . . . . 0.0 113.152 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.65 -38.65 77.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.997 0.398 . . . . 0.0 110.378 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.52 -34.44 77.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.55 179.186 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 50.7 mm -76.07 -35.16 28.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.358 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.402 ' HA ' ' SG ' ' A' ' 11' ' ' CYS . 68.3 t80 -65.71 -16.43 63.76 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.451 -179.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -58.91 -26.98 64.82 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.978 0.418 . . . . 0.0 110.982 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.43 HE22 HD21 ' A' ' 75' ' ' LEU . 60.0 mt-30 -77.11 -30.49 55.27 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.535 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.402 ' SG ' ' HA ' ' A' ' 8' ' ' TYR . 2.0 m -76.02 -25.87 56.12 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.152 -179.35 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.29 -18.24 48.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.948 -179.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.15 -20.77 80.05 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.795 -0.717 . . . . 0.0 113.277 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 77.0 m -130.43 -43.58 1.14 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 117.329 0.564 . . . . 0.0 111.971 -179.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 92.1 m-70 -91.42 -5.4 54.44 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 59.47 -172.11 0.12 Allowed 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.617 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -92.47 -9.67 40.63 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.093 -179.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 39.1 p30 -84.63 -8.31 58.93 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.623 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 72.67 20.32 79.58 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.498 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 64.3 mt-30 -117.4 -51.05 2.53 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.941 0.401 . . . . 0.0 110.282 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.623 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.77 -179.675 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.283 0 CA-C-O 120.547 0.213 . . . . 0.0 111.12 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -121.89 137.81 27.81 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.071 -179.186 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -76.16 147.64 30.01 Favored 'Trans proline' 0 C--O 1.24 0.597 0 C-N-CA 122.857 2.371 . . . . 0.0 112.14 179.056 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -80.81 155.5 20.51 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.856 2.371 . . . . 0.0 112.263 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.552 ' O ' HG23 ' A' ' 33' ' ' VAL . 67.4 mt -105.57 -43.75 4.86 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.655 179.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.91 120.02 11.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.431 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.25 12.7 82.88 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.783 -0.722 . . . . 0.0 111.998 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 58.0 t60 -127.62 -22.53 3.59 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.692 0.282 . . . . 0.0 110.899 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.552 HG23 ' O ' ' A' ' 29' ' ' LEU . 60.2 t -65.53 -45.43 92.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.924 0.392 . . . . 0.0 109.945 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -63.05 -31.34 72.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.441 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -65.08 -38.13 89.76 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.198 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.523 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 63.8 mt -78.47 -40.11 24.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.705 -179.595 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 85.8 mt -64.32 -27.32 68.95 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.137 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -79.79 4.58 15.99 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.603 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 59.0 mmtt -109.74 154.79 22.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.629 0.252 . . . . 0.0 110.407 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -66.49 112.6 4.17 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.718 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.55 14.76 77.57 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.009 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.523 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -61.07 -40.75 98.95 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 121.226 -0.511 . . . . 0.0 112.648 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.432 ' O ' HG13 ' A' ' 47' ' ' ILE . 12.7 ptm85 -66.58 -36.31 82.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.679 0.276 . . . . 0.0 110.538 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -67.52 -41.85 83.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.373 0.606 . . . . 0.0 109.52 178.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.485 ' O ' HG23 ' A' ' 49' ' ' VAL . 26.7 t80 -60.0 -43.88 94.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.109 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 35.5 mt -56.06 -45.6 79.21 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.106 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.432 HG13 ' O ' ' A' ' 43' ' ' ARG . 59.2 mt -62.13 -43.39 97.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.802 -179.704 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 62.8 mt -60.93 -38.22 85.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.963 0.411 . . . . 0.0 110.739 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.485 HG23 ' O ' ' A' ' 45' ' ' TYR . 81.0 t -65.6 -31.68 54.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.183 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.0 mp -84.04 -34.65 24.21 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.958 0.409 . . . . 0.0 110.845 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.7 mt -71.54 -56.97 4.87 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.992 -0.549 . . . . 0.0 112.097 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.576 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 55.6 m-85 -103.71 -37.23 7.57 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -178.017 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.457 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 119.51 -167.61 13.4 Favored Glycine 0 N--CA 1.445 -0.728 0 C-N-CA 119.878 -1.153 . . . . 0.0 113.438 178.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.469 ' H ' ' HB3' ' A' ' 69' ' ' MET . 4.6 tp -163.33 134.62 4.81 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.867 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . 0.523 ' HB2' ' HB3' ' B' ' 159' ' ' ASN . 0.0 OUTLIER -154.38 116.27 4.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.06 0.457 . . . . 0.0 111.862 179.779 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -162.97 -148.3 5.32 Favored Glycine 0 N--CA 1.442 -0.904 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.462 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -130.52 68.19 1.47 Allowed 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.3 pt -83.39 165.49 2.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.357 -178.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -140.77 113.76 8.4 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.468 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 42.9 t -110.89 116.8 53.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.63 -179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 16.2 mttp 61.38 28.06 17.57 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.521 179.268 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.46 -20.22 51.59 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.753 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.78 110.87 18.68 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.882 0.372 . . . . 0.0 110.738 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 19.1 mttp -81.45 134.3 35.52 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.69 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -119.73 151.13 39.26 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -156.84 82.54 0.95 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.095 0.474 . . . . 0.0 110.268 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -139.73 -150.73 5.55 Favored Glycine 0 N--CA 1.44 -1.07 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.427 ' HA ' ' HB3' ' A' ' 55' ' ' GLN . 58.8 t -143.06 118.28 4.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.791 0.329 . . . . 0.0 110.574 179.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . 0.469 ' HB3' ' H ' ' A' ' 54' ' ' LEU . 4.1 tpt -77.02 108.5 10.13 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -55.75 132.33 48.96 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.404 -0.816 . . . . 0.0 113.01 -178.214 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -71.14 121.4 18.25 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.896 178.795 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 36.6 m-85 -108.06 39.22 2.0 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.125 0.488 . . . . 0.0 111.034 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.02 -18.71 65.52 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.414 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.1 pm0 -68.23 -14.91 63.34 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.809 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.43 HD21 HE22 ' A' ' 10' ' ' GLN . 82.4 mt -87.35 147.69 25.37 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.888 179.298 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 53.4 mtpt -71.6 160.71 32.19 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.933 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 76.8 m-20 -53.97 -42.88 69.43 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.18 0.515 . . . . 0.0 110.356 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -63.6 -43.31 97.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.309 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 73.9 mt-10 -64.46 -42.79 95.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.368 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 97.6 mt -66.28 -40.45 86.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.969 0.414 . . . . 0.0 110.498 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.49 -35.85 75.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.884 179.448 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.32 -45.67 92.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.538 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 12.5 p -70.96 -34.49 55.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.619 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 15.7 mt -62.25 -45.49 93.05 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.263 0.554 . . . . 0.0 109.96 178.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 54.0 m-20 -69.32 -32.83 72.2 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.405 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 25.8 t60 -66.19 -51.09 61.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.749 -179.089 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 39.5 pt -63.63 -32.43 56.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -178.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.703 ' HB1' ' HB2' ' A' ' 94' ' ' ALA . . . -73.63 -33.39 64.53 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 112.034 0.383 . . . . 0.0 112.034 -179.397 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.9 p -91.47 -31.06 16.13 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 -178.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -52.25 -47.94 65.5 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 28.5 m-90 -100.38 10.28 41.45 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.902 0.382 . . . . 0.0 110.934 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 57.44 26.56 56.95 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.869 -0.605 . . . . 0.0 113.309 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.435 ' HA ' ' HD3' ' A' ' 96' ' ' LYS . 0.5 OUTLIER -71.41 -29.11 64.53 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.202 0.525 . . . . 0.0 109.998 -179.412 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.703 ' HB2' ' HB1' ' A' ' 88' ' ' ALA . . . -70.55 -15.44 62.77 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.162 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.2 mttm -80.63 -14.43 58.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.957 0.408 . . . . 0.0 110.632 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.435 ' HD3' ' HA ' ' A' ' 93' ' ' ASP . 40.6 mtpt -80.86 -21.04 41.04 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.377 -179.46 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 28.3 m -95.22 161.06 2.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 179.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -97.07 127.86 43.45 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.068 0.461 . . . . 0.0 110.967 -178.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 62.05 61.11 7.02 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.61 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 76.4 t80 -75.61 110.31 9.9 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.857 0.361 . . . . 0.0 110.457 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 95.6 mttt -84.56 124.08 73.75 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 115.683 -0.69 . . . . 0.0 109.737 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_exo -59.52 138.15 82.06 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.631 2.221 . . . . 0.0 111.923 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -65.77 129.28 39.23 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.258 179.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p -111.91 157.57 20.5 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.081 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -60.79 -32.03 71.38 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.484 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.0 mm-40 -66.54 -32.74 74.28 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.821 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -66.51 -38.55 87.45 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.167 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.408 ' HA ' HG21 ' A' ' 47' ' ' ILE . 21.1 t -71.21 -45.76 69.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.061 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 4.2 ttmp? -58.68 -38.33 77.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.713 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 25.8 ttpt -58.75 -46.46 87.4 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.328 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 40.0 mt -83.63 -15.94 47.08 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.564 -178.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 48.1 ttm-85 -69.98 -16.86 63.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.379 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -80.34 -38.52 30.4 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.066 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 45.6 tttp -81.62 95.65 7.24 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 19.7 tptm -66.05 114.03 4.91 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.2 0.524 . . . . 0.0 111.532 -179.178 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 79.6 mt -125.35 176.66 6.64 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.005 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.441 ' O ' HG23 ' A' ' 121' ' ' VAL . 61.2 p -124.43 157.57 64.53 Favored Pre-proline 0 C--N 1.319 -0.744 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.359 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.576 ' HG3' ' O ' ' A' ' 52' ' ' TYR . 50.1 Cg_exo -55.1 -30.61 71.39 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.545 2.163 . . . . 0.0 111.745 179.298 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 42.8 tp60 -74.34 -39.92 62.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.881 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' GLN . . . . . 0.423 ' HB2' ' H ' ' A' ' 117' ' ' THR . 44.8 mt-30 -67.02 -37.63 84.48 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.162 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 117' ' ' THR . 60.8 t -60.37 -31.81 49.46 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 CA-C-O 121.137 0.494 . . . . 0.0 110.18 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 23.9 tp . . . . . 0 C--N 1.331 -0.23 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.543 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 45.9 t80 . . . . . 0 N--CA 1.479 0.991 0 CA-C-O 120.787 0.327 . . . . 0.0 110.926 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 1.6 p -60.96 -36.15 78.65 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -178.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 74.6 mt -69.18 -24.33 64.04 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.763 0.316 . . . . 0.0 111.339 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -93.48 -5.37 49.32 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.14 0.495 . . . . 0.0 111.072 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . 0.403 HG22 ' H ' ' B' ' 40' ' ' HIS . 3.9 m -106.82 167.73 9.68 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.887 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 40' ' ' HIS . . . . . 0.403 ' H ' HG22 ' B' ' 39' ' ' THR . 6.0 p80 -65.18 -10.38 30.84 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.73 0.3 . . . . 0.0 111.564 -179.678 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.76 -17.63 64.76 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.932 0.396 . . . . 0.0 111.178 179.421 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.07 -4.35 24.62 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.611 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -66.36 -18.06 67.02 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.962 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 33.4 m -72.44 -12.11 15.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-O 120.927 0.394 . . . . 0.0 111.234 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 71.0 mt -88.72 125.78 61.84 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.727 179.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 46' ' ' PRO . . . . . 0.405 ' HA ' ' O ' ' B' ' 134' ' ' THR . 32.2 Cg_exo -58.08 149.11 73.6 Favored 'Trans proline' 0 C--O 1.234 0.301 0 C-N-CA 122.567 2.178 . . . . 0.0 112.197 179.736 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -62.51 142.82 57.76 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.749 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -73.37 -18.36 79.29 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.959 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 45.0 tttp -68.19 127.94 34.74 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.252 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 50' ' ' LEU . . . . . . . . . . . . . 84.2 mt -80.54 114.89 19.75 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.008 0.432 . . . . 0.0 110.488 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 51' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -116.82 103.53 10.41 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.772 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 52' ' ' ARG . . . . . 0.454 ' HD2' ' N ' ' B' ' 52' ' ' ARG . 0.4 OUTLIER -111.0 137.64 48.38 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.412 -178.981 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 10.4 m -133.02 170.47 19.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.886 179.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . 0.493 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 13.7 t70 -81.48 114.05 46.64 Favored Pre-proline 0 C--N 1.327 -0.408 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.371 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -80.18 19.32 1.06 Allowed 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 123.07 2.513 . . . . 0.0 113.576 -178.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.8 -47.94 3.1 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.238 0.542 . . . . 0.0 110.67 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 9.2 p -106.41 12.72 29.41 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.48 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 58' ' ' VAL . . . . . 0.493 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 14.7 p -60.63 -28.59 43.06 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.428 0 CA-C-O 120.944 0.402 . . . . 0.0 111.829 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 59' ' ' ARG . . . . . . . . . . . . . 29.3 ptt180 -97.05 13.19 29.92 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.843 0.354 . . . . 0.0 111.055 -179.535 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 79.0 mt-30 -130.9 -35.93 1.39 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.95 0.405 . . . . 0.0 110.813 -179.332 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -135.04 105.68 6.47 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.857 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 145.43 -179.22 22.67 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.862 -0.685 . . . . 0.0 111.884 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_exo -63.33 -27.54 71.61 Favored 'Trans proline' 0 CA--C 1.527 0.145 0 C-N-CA 122.834 2.356 . . . . 0.0 112.551 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 31.3 m-90 -85.03 6.4 25.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.534 -179.273 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -94.55 10.57 34.18 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.973 0.416 . . . . 0.0 110.951 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . 0.416 ' HB3' ' HB2' ' B' ' 69' ' ' GLN . 7.9 t70 -147.65 110.35 3.87 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.222 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_exo -62.39 -32.66 81.03 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.808 2.339 . . . . 0.0 112.915 -179.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.5 -46.13 20.35 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.539 -0.301 . . . . 0.0 111.086 -179.164 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 69' ' ' GLN . . . . . 0.416 ' HB2' ' HB3' ' B' ' 66' ' ' ASP . 13.6 mm100 -80.63 16.92 1.23 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.529 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -78.11 -24.56 47.43 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.992 0.425 . . . . 0.0 110.662 179.366 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 25.5 t -100.46 93.85 3.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.741 179.555 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 2.9 t -105.56 139.64 26.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -178.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 8.5 tt0 -81.51 122.86 28.08 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.023 179.496 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.18 -29.55 18.18 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.678 -179.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . 178.86 -162.54 29.64 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.438 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -61.7 107.72 0.55 Allowed 'Trans proline' 0 C--O 1.236 0.397 0 C-N-CA 123.077 2.518 . . . . 0.0 112.124 -179.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 45.2 t30 63.79 29.76 14.71 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.762 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -133.96 122.31 22.9 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.093 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -127.06 151.42 48.64 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.873 -179.411 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 91.4 m -119.82 121.58 39.41 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.332 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 50.0 t -110.56 117.2 54.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 121.053 0.454 . . . . 0.0 111.242 -178.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -86.39 106.09 17.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.647 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 83' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 28.8 t -98.36 122.43 50.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.191 0.52 . . . . 0.0 110.697 -179.398 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 57.4 tp -102.09 109.39 21.08 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.797 179.621 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 85' ' ' ALA . . . . . . . . . . . . . . . -96.6 73.16 2.72 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.153 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 86' ' ' PHE . . . . . 0.52 ' CZ ' ' HB2' ' B' ' 91' ' ' GLN . 0.1 OUTLIER -75.01 -169.77 0.98 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.999 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . . . . . . . . . . . -39.66 93.75 0.01 OUTLIER 'General case' 0 N--CA 1.462 0.127 0 O-C-N 124.316 1.01 . . . . 0.0 113.724 -178.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . 0.402 ' HA ' ' SD ' ' B' ' 160' ' ' MET . 4.9 m-85 53.26 27.73 6.41 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.698 -1.137 . . . . 0.0 112.976 178.22 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 89' ' ' GLY . . . . . . . . . . . . . . . -139.62 -178.4 16.62 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.016 -1.088 . . . . 0.0 112.978 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 90' ' ' TYR . . . . . 0.517 ' OH ' ' HB2' ' B' ' 149' ' ' CYS . 41.2 m-85 -140.32 133.65 29.81 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 91' ' ' GLN . . . . . 0.52 ' HB2' ' CZ ' ' B' ' 86' ' ' PHE . 31.7 tt0 -135.48 128.34 18.11 Favored Pre-proline 0 C--N 1.322 -0.608 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 178.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -79.95 170.88 64.94 Favored 'Cis proline' 0 CA--C 1.53 0.293 0 C-N-CA 123.386 -1.506 . . . . 0.0 112.451 -0.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 93' ' ' ASN . . . . . 0.405 ' HA ' ' HA ' ' B' ' 94' ' ' PRO . 58.6 t30 -159.76 120.19 1.72 Allowed Pre-proline 0 C--N 1.326 -0.456 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 94' ' ' PRO . . . . . 0.405 ' HA ' ' HA ' ' B' ' 93' ' ' ASN . 98.2 Cg_endo -78.85 151.39 88.06 Favored 'Cis proline' 0 C--O 1.233 0.264 0 C-N-CA 123.47 -1.471 . . . . 0.0 112.755 -0.363 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 40.2 mt -81.7 127.27 39.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.611 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 96' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -104.52 124.63 49.63 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.516 0.198 . . . . 0.0 110.839 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 4.8 m -141.22 153.7 66.79 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.101 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.49 161.45 14.77 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 122.718 2.279 . . . . 0.0 111.802 178.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.29 152.73 18.31 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.021 0.438 . . . . 0.0 111.378 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 78.03 8.72 87.32 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.564 -0.743 . . . . 0.0 113.135 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.29 155.26 26.53 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.838 0.351 . . . . 0.0 111.302 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 102' ' ' GLU . . . . . 0.556 ' OE2' ' HD3' ' B' ' 136' ' ' ARG . 77.8 tt0 -81.56 119.26 23.55 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 103' ' ' ILE . . . . . 0.437 HD12 ' HD1' ' B' ' 139' ' ' PHE . 7.8 mt -108.91 113.54 44.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.004 -179.107 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 21.5 t -91.98 101.14 12.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 105' ' ' PHE . . . . . 0.503 ' O ' ' HA ' ' B' ' 134' ' ' THR . 75.7 m-85 -82.24 122.18 27.59 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.09 -179.235 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -119.93 89.95 3.23 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 107' ' ' ILE . . . . . 0.491 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.2 mp -97.77 135.82 30.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.576 -178.111 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 4.9 t -133.8 154.21 51.17 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.515 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 109' ' ' SER . . . . . 0.702 ' O ' ' HA ' ' B' ' 129' ' ' PRO . 0.7 OUTLIER -122.7 126.28 26.15 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-O 120.652 0.263 . . . . 0.0 111.226 -178.932 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -89.24 -29.05 0.26 Allowed 'Trans proline' 0 N--CA 1.459 -0.547 0 C-N-CA 122.911 2.407 . . . . 0.0 112.808 178.455 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 111' ' ' ASP . . . . . 0.43 ' CG ' ' H ' ' B' ' 112' ' ' VAL . 8.2 p-10 -95.0 -111.76 0.12 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.863 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 112' ' ' VAL . . . . . 0.43 ' H ' ' CG ' ' B' ' 111' ' ' ASP . 17.0 m -99.86 -172.77 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 120.561 0.22 . . . . 0.0 110.533 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 21.0 mt -74.91 143.78 12.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-O 121.365 0.602 . . . . 0.0 111.543 -179.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 114' ' ' HIS . . . . . 0.466 ' HD2' ' OG ' ' B' ' 109' ' ' SER . 97.7 m-70 -136.95 179.39 6.41 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.461 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 115' ' ' GLY . . . . . 0.505 ' O ' ' HA ' ' B' ' 149' ' ' CYS . . . -134.06 134.78 7.61 Favored Glycine 0 N--CA 1.443 -0.845 0 C-N-CA 120.443 -0.885 . . . . 0.0 112.044 -179.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -104.56 85.28 2.3 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-O 121.028 0.442 . . . . 0.0 109.915 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 117' ' ' HIS . . . . . 0.462 ' HA ' ' O ' ' B' ' 123' ' ' ILE . 12.6 t-160 -113.82 109.97 19.39 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.635 179.228 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.457 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 44.5 t -88.04 113.83 25.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.241 0.543 . . . . 0.0 111.119 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -63.38 115.93 5.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.6 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 110.46 0.06 29.39 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.462 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 121' ' ' THR . . . . . 0.457 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 40.9 p -139.65 175.5 9.52 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 179.407 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -92.96 18.24 9.43 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.94 0.4 . . . . 0.0 110.365 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . 0.462 ' O ' ' HA ' ' B' ' 117' ' ' HIS . 53.6 mt -81.9 106.72 13.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.033 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -146.1 100.33 3.37 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 178.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 7.1 p -137.63 144.57 30.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.485 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -82.56 145.63 29.63 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.373 179.122 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 127' ' ' VAL . . . . . 0.503 HG12 ' HB2' ' B' ' 109' ' ' SER . 6.3 t -115.5 106.17 19.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.589 179.579 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 128' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' B' ' 129' ' ' PRO . 7.7 mp -96.52 153.24 38.9 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.38 -178.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . 0.702 ' HA ' ' O ' ' B' ' 109' ' ' SER . 27.5 Cg_exo -62.65 120.52 8.08 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.693 2.262 . . . . 0.0 112.614 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.68 -13.68 65.04 Favored Glycine 0 N--CA 1.451 -0.312 0 CA-C-N 115.897 -0.592 . . . . 0.0 113.103 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -94.55 148.37 22.32 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 132' ' ' VAL . . . . . . . . . . . . . 22.6 t -112.82 89.27 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 121.026 0.441 . . . . 0.0 110.21 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 5.0 m -62.68 105.59 0.67 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.031 179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 134' ' ' THR . . . . . 0.503 ' HA ' ' O ' ' B' ' 105' ' ' PHE . 23.2 m -102.34 115.48 30.64 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.539 -179.26 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 78.6 t -127.85 136.28 60.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.834 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 136' ' ' ARG . . . . . 0.556 ' HD3' ' OE2' ' B' ' 102' ' ' GLU . 51.2 mtt180 -110.58 113.45 26.08 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.747 0.308 . . . . 0.0 111.056 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 137' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -128.98 166.83 18.42 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.675 -179.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 73.1 m -134.51 110.55 9.44 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 178.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 139' ' ' PHE . . . . . 0.437 ' HD1' HD12 ' B' ' 103' ' ' ILE . 39.6 m-85 -84.3 112.97 20.79 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.383 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 78.9 mttt -105.31 -11.0 16.68 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.183 0.516 . . . . 0.0 110.509 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 141' ' ' ARG . . . . . 0.413 ' HB2' ' OH ' ' B' ' 145' ' ' TYR . 61.5 mtt180 -110.67 114.27 54.84 Favored Pre-proline 0 C--N 1.324 -0.511 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.783 179.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 142' ' ' PRO . . . . . 0.475 ' HA ' HG13 ' B' ' 166' ' ' VAL . 15.5 Cg_exo -68.67 155.84 67.49 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.906 2.404 . . . . 0.0 112.852 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 143' ' ' GLY . . . . . . . . . . . . . . . 139.38 -168.66 24.83 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.681 179.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 144' ' ' GLU . . . . . 0.413 ' HG2' HG22 ' B' ' 165' ' ' VAL . 49.3 mt-10 -109.39 119.71 40.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.72 0.295 . . . . 0.0 110.71 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . 0.413 ' OH ' ' HB2' ' B' ' 141' ' ' ARG . 31.1 m-85 -106.05 137.38 44.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.017 179.66 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.43 135.44 34.67 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.034 0.445 . . . . 0.0 111.636 -178.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 147' ' ' ILE . . . . . . . . . . . . . 40.3 mt -99.79 109.92 25.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 13.4 mt -103.11 119.22 51.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-O 120.817 0.341 . . . . 0.0 111.185 -179.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 149' ' ' CYS . . . . . 0.517 ' HB2' ' OH ' ' B' ' 90' ' ' TYR . 3.9 t -85.57 84.05 7.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.093 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 150' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -58.89 -17.51 24.86 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -179.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 32.1 tp60 -80.33 140.06 36.3 Favored 'General case' 0 C--O 1.25 1.102 0 CA-C-O 121.162 0.506 . . . . 0.0 111.928 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -57.25 155.35 8.93 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 114.816 -1.084 . . . . 0.0 110.778 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 153' ' ' CYS . . . . . 0.547 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 1.6 p -176.55 78.34 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.733 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 55.65 -140.93 39.91 Favored Glycine 0 C--N 1.331 0.264 0 O-C-N 123.432 0.458 . . . . 0.0 112.73 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 155' ' ' LEU . . . . . 0.434 HD13 HG22 ' A' ' 117' ' ' THR . 37.4 mt -92.58 -15.49 26.85 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.24 0.543 . . . . 0.0 110.318 179.303 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 156' ' ' GLY . . . . . . . . . . . . . . . -87.97 63.91 3.71 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.729 -0.668 . . . . 0.0 111.909 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 157' ' ' HIS . . . . . 0.547 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 62.9 t60 -131.71 -37.5 1.18 Allowed 'General case' 0 C--N 1.319 -0.752 0 O-C-N 122.61 -0.347 . . . . 0.0 111.212 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -64.99 -14.05 59.29 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 112.864 0.69 . . . . 0.0 112.864 -178.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 159' ' ' ASN . . . . . 0.523 ' HB3' ' HB2' ' A' ' 55' ' ' GLN . 8.5 t30 -132.99 15.09 4.25 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.879 0.371 . . . . 0.0 111.4 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 160' ' ' MET . . . . . 0.402 ' SD ' ' HA ' ' B' ' 88' ' ' PHE . 24.7 ttt -87.74 87.87 7.5 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 161' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -128.2 136.2 50.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.852 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 162' ' ' GLY . . . . . . . . . . . . . . . -105.87 176.37 22.05 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 11.7 m -144.38 131.51 20.57 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 117.762 0.781 . . . . 0.0 111.9 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 65.1 mt -114.44 113.11 42.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 165' ' ' VAL . . . . . 0.413 HG22 ' HG2' ' B' ' 144' ' ' GLU . 22.1 t -101.91 103.67 15.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.113 0.482 . . . . 0.0 110.746 -179.345 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 166' ' ' VAL . . . . . 0.475 HG13 ' HA ' ' B' ' 142' ' ' PRO . 1.3 p -90.88 123.63 43.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 178.69 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 28.4 mmtp -79.16 147.26 32.74 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.212 -178.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 168' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.245 0.827 0 CA-C-O 118.689 -0.672 . . . . 0.0 109.781 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.231 0 CA-C-O 120.475 -0.069 . . . . 0.0 113.165 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.01 -35.67 80.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.526 0.203 . . . . 0.0 111.128 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -66.17 -34.87 79.02 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.034 0.445 . . . . 0.0 110.533 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 31.9 mm -73.02 -38.06 54.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.054 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -63.08 -21.81 66.43 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.112 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -57.89 -31.85 67.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.989 0.424 . . . . 0.0 110.827 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 66.4 mt-30 -77.31 -32.19 55.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.06 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 15.7 m -70.87 -29.39 65.48 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.074 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.15 -17.58 64.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.415 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.31 5.98 39.84 Favored Glycine 0 N--CA 1.453 -0.21 0 C-N-CA 121.048 -0.596 . . . . 0.0 112.623 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.8 m -153.56 -51.13 0.1 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.602 0.239 . . . . 0.0 110.992 179.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.5 m-70 -85.96 7.01 26.01 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.87 -0.15 . . . . 0.0 111.094 -179.041 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 57.2 mm-40 61.41 -168.19 0.18 Allowed 'General case' 0 N--CA 1.465 0.275 0 O-C-N 123.492 0.495 . . . . 0.0 111.215 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 46.8 mt-30 -104.52 -5.56 21.43 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.908 0.385 . . . . 0.0 110.593 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 14.9 p30 -82.71 -4.46 57.89 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.091 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 75.74 19.18 79.25 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.468 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.468 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 44.6 mt-30 -124.73 -80.16 0.62 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.824 0.345 . . . . 0.0 110.561 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.786 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.905 -179.655 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.349 0 CA-C-O 120.686 0.279 . . . . 0.0 111.096 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -136.09 126.3 16.41 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.007 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.428 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 60.0 Cg_endo -75.72 134.73 16.98 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.395 2.063 . . . . 0.0 111.276 178.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 20' ' ' GLN . 17.1 Cg_exo -67.61 148.0 77.34 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.524 2.149 . . . . 0.0 112.599 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.482 ' O ' HG23 ' A' ' 33' ' ' VAL . 80.3 mt -97.22 -39.86 9.06 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.37 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.38 116.49 8.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.143 179.418 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.84 29.45 42.54 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.561 -0.828 . . . . 0.0 111.101 -178.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 43.9 t60 -146.06 -34.22 0.31 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.598 -0.301 . . . . 0.0 110.561 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.482 HG23 ' O ' ' A' ' 29' ' ' LEU . 97.2 t -62.48 -43.12 98.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.326 -0.397 . . . . 0.0 109.961 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -61.8 -35.9 79.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.541 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -63.45 -37.61 87.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.23 0.538 . . . . 0.0 110.278 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.51 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 61.7 mt -80.2 -39.32 19.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.142 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 45.9 mt -61.82 -25.27 67.4 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.376 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.5 -13.82 59.65 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.456 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -87.22 151.82 22.83 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.631 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -66.89 111.87 4.0 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.981 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.549 ' HA2' ' OE1' ' A' ' 44' ' ' GLU . . . 83.02 14.59 74.59 Favored Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 120.737 -0.744 . . . . 0.0 111.578 -178.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.51 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -61.58 -39.54 97.5 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.338 -0.458 . . . . 0.0 112.475 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.502 ' O ' HG13 ' A' ' 47' ' ' ILE . 12.7 ptm85 -65.12 -36.1 83.19 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.549 ' OE1' ' HA2' ' A' ' 41' ' ' GLY . 23.0 mp0 -67.66 -39.66 84.54 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.141 0.496 . . . . 0.0 109.775 178.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.415 ' O ' HG23 ' A' ' 49' ' ' VAL . 31.5 t80 -60.16 -44.2 95.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.099 179.258 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 41.4 mt -60.67 -40.4 91.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.923 179.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.502 HG13 ' O ' ' A' ' 43' ' ' ARG . 71.9 mt -64.91 -42.12 93.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.158 179.63 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 92.2 mt -62.16 -35.42 78.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.873 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.475 ' O ' ' HA2' ' A' ' 53' ' ' GLY . 61.0 t -66.08 -33.35 62.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.733 179.448 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 8.2 mp -83.63 -33.31 25.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.949 0.404 . . . . 0.0 110.496 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 18.3 mt -72.18 -57.02 4.58 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.976 -0.556 . . . . 0.0 112.012 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 39.8 m-85 -105.12 -37.88 6.76 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.973 -177.635 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 117.59 -168.13 12.89 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.051 -1.071 . . . . 0.0 113.671 178.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.466 ' H ' ' HB3' ' A' ' 69' ' ' MET . 25.6 tp -152.85 150.2 29.09 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . 0.481 HE22 ' NE2' ' B' ' 158' ' ' GLN . 13.1 pt20 -163.94 157.49 18.63 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.672 0.272 . . . . 0.0 111.114 -178.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 138.25 -118.38 1.61 Allowed Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.727 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.417 HE22 ' HB2' ' A' ' 66' ' ' ASN . 6.0 tp60 -161.82 82.8 0.58 Allowed 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 4.0 pt -96.4 148.14 5.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.036 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.407 ' HA ' ' O ' ' A' ' 63' ' ' MET . 1.8 tt0 -121.44 105.27 10.34 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.165 179.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.424 HG12 ' HG2' ' A' ' 61' ' ' LYS . 6.9 t -126.68 135.7 62.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 179.616 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.424 ' HG2' HG12 ' A' ' 60' ' ' VAL . 21.3 mmtp 60.11 28.14 17.66 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 121.079 0.466 . . . . 0.0 110.814 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.19 20.91 78.8 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.793 -0.639 . . . . 0.0 112.447 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . 0.407 ' O ' ' HA ' ' A' ' 59' ' ' GLU . 45.2 mtt -118.03 121.41 40.55 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -90.39 100.22 13.09 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.196 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -85.18 139.87 31.35 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.657 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . 0.417 ' HB2' HE22 ' A' ' 57' ' ' GLN . 3.8 t-20 -139.73 81.61 1.83 Allowed 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.434 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.9 -160.95 9.96 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.667 -0.777 . . . . 0.0 111.946 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 64.5 t -138.46 114.04 9.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.932 0.396 . . . . 0.0 110.29 179.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . 0.466 ' HB3' ' H ' ' A' ' 54' ' ' LEU . 5.0 tpt -69.73 114.91 8.38 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 178.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.5 m -63.48 135.07 56.63 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.779 -177.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -72.09 126.87 30.86 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.412 179.23 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 37.1 m-85 -110.36 34.35 3.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.122 0.487 . . . . 0.0 110.661 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -69.02 -8.49 45.49 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.843 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 18.0 pm0 -72.22 -20.19 61.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.86 0.362 . . . . 0.0 110.721 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 22.9 mt -82.09 159.06 23.49 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.255 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.449 ' HB2' ' HG3' ' A' ' 79' ' ' GLU . 22.5 mtpt -70.29 155.11 41.11 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.255 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 40.3 m-20 -61.51 -37.05 82.28 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.002 0.43 . . . . 0.0 110.31 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -69.29 -19.99 63.9 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.952 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . 0.449 ' HG3' ' HB2' ' A' ' 76' ' ' LYS . 41.1 mt-10 -89.23 -41.85 11.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.371 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 81.9 mt -62.93 -38.84 82.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.857 179.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.55 -28.4 64.89 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.161 178.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.13 -46.46 67.6 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.327 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 14.2 p -65.27 -36.93 78.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 C-N-CA 120.81 -0.356 . . . . 0.0 110.161 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 41.1 mt -63.41 -44.02 95.85 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.168 0.509 . . . . 0.0 109.829 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 50.1 m-20 -64.51 -43.15 94.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.891 178.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 44.5 t60 -61.09 -55.23 34.96 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.354 -178.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 46.6 pt -60.6 -35.65 65.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.476 0.547 . . . . 0.0 112.476 -177.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.62 ' HB1' ' HB2' ' A' ' 94' ' ' ALA . . . -73.39 -34.2 65.4 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 22.1 p -89.85 -35.05 15.87 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.631 0.604 . . . . 0.0 112.631 -178.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -59.32 -44.51 92.58 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 15.8 m-90 -91.35 2.21 56.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.813 0.339 . . . . 0.0 111.014 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 64.44 23.99 68.93 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.9 -0.591 . . . . 0.0 113.273 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.454 ' HA ' ' HD3' ' A' ' 96' ' ' LYS . 0.2 OUTLIER -75.28 -28.73 59.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.191 0.52 . . . . 0.0 109.976 -179.913 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.62 ' HB2' ' HB1' ' A' ' 88' ' ' ALA . . . -73.47 -6.43 46.37 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.919 179.416 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -91.03 -7.12 52.78 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.175 179.362 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.454 ' HD3' ' HA ' ' A' ' 93' ' ' ASP . 34.3 mtpt -96.43 11.21 35.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.34 -179.211 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 13.0 m -126.1 151.04 32.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.017 178.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.3 ptpt -86.46 122.85 30.98 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.061 0.458 . . . . 0.0 111.967 -179.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 64.42 62.05 5.44 Favored Glycine 0 N--CA 1.453 -0.232 0 CA-C-N 115.617 -0.72 . . . . 0.0 113.424 178.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -72.46 122.7 21.71 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.778 0.323 . . . . 0.0 110.508 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 78.5 mttt -96.69 125.16 47.9 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.848 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -57.24 132.65 52.43 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.362 2.042 . . . . 0.0 111.393 179.137 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -61.95 132.57 53.42 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.581 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -113.36 153.83 27.89 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.733 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -63.33 -30.33 71.49 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.051 0.453 . . . . 0.0 110.774 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.0 mm-40 -61.24 -32.06 71.85 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.954 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -68.23 -45.72 72.48 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.176 0.512 . . . . 0.0 110.199 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 11.7 t -65.0 -46.4 91.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.527 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 26.0 ttpt -62.91 -36.01 81.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.747 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 32.9 ttpt -63.94 -47.7 79.45 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.124 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 80.3 mt -74.21 -25.69 59.82 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.046 0.45 . . . . 0.0 110.876 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 21.0 ttm-85 -72.74 -9.02 58.16 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.689 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -70.13 -37.45 75.29 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.032 0.444 . . . . 0.0 110.027 179.062 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -92.47 103.77 16.16 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.453 179.144 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 25.9 tptp -68.25 99.68 0.94 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.3 0.571 . . . . 0.0 111.009 -179.182 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 72.7 mt -108.86 -174.74 2.59 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.901 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.423 HG22 HD13 ' B' ' 155' ' ' LEU . 1.3 p -138.47 163.04 49.85 Favored Pre-proline 0 C--N 1.32 -0.699 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.401 ' HB2' ' CD ' ' A' ' 55' ' ' GLN . 77.9 Cg_exo -50.87 -41.66 54.61 Favored 'Trans proline' 0 CA--C 1.533 0.472 0 C-N-CA 122.686 2.257 . . . . 0.0 112.841 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 35.7 tp60 -65.63 -32.41 73.97 Favored 'General case' 0 CA--C 1.53 0.212 0 CA-C-O 120.767 0.318 . . . . 0.0 110.856 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 57.8 mt-30 -73.43 -35.24 65.76 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.182 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 50.1 t -66.46 -36.6 77.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 20.3 tp . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.963 178.827 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 61.5 t80 . . . . . 0 N--CA 1.48 1.049 0 CA-C-O 120.464 0.173 . . . . 0.0 111.024 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 4.1 m -59.83 -40.81 89.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.029 0.443 . . . . 0.0 111.436 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 94.9 mt -80.86 -3.46 51.33 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.455 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -103.53 -6.3 21.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.028 0.442 . . . . 0.0 110.993 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.0 p -116.31 179.97 3.84 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.651 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 40' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -68.09 -8.63 39.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.549 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -61.37 -20.67 63.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.329 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -72.06 -8.86 57.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.198 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -70.3 -18.7 75.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.326 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 8.9 m -74.61 -11.24 14.32 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-O 121.136 0.494 . . . . 0.0 110.905 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 38.1 mt -86.82 131.93 43.71 Favored Pre-proline 0 C--N 1.322 -0.625 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.596 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 46' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -53.56 134.62 58.72 Favored 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.797 2.331 . . . . 0.0 112.288 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -56.54 140.21 47.15 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.24 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -68.69 -23.59 75.52 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.914 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 80.0 tttt -64.08 116.87 6.33 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.933 0.397 . . . . 0.0 110.303 179.311 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 50' ' ' LEU . . . . . . . . . . . . . 80.2 mt -91.66 93.28 8.83 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.01 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 51' ' ' GLU . . . . . 0.41 ' HB2' ' HB ' ' B' ' 132' ' ' VAL . 21.0 mt-10 -89.19 103.7 16.3 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 52' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -90.7 114.79 27.2 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.797 0.332 . . . . 0.0 110.72 -179.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.19 -173.48 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.735 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . 0.59 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 17.3 t70 -96.04 111.41 56.16 Favored Pre-proline 0 C--N 1.326 -0.435 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -78.06 17.43 1.02 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.752 2.301 . . . . 0.0 113.755 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.6 -55.99 2.16 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.442 0.639 . . . . 0.0 110.609 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.8 -2.03 55.5 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.092 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 58' ' ' VAL . . . . . 0.59 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 12.1 p -56.22 -28.37 25.56 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -179.316 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 59' ' ' ARG . . . . . . . . . . . . . 37.3 ptt180 -98.43 12.0 36.37 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.068 0.461 . . . . 0.0 111.031 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 58.8 mt-30 -124.41 -39.35 2.33 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.214 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -140.63 133.87 29.63 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.995 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.07 170.86 12.94 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.027 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -60.46 -28.19 86.26 Favored 'Trans proline' 0 CA--C 1.529 0.229 0 C-N-CA 122.682 2.255 . . . . 0.0 112.712 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 32.3 m-90 -84.55 -2.62 57.63 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.154 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.92 -1.12 57.86 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.91 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -122.69 105.07 35.9 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.592 -179.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_exo -69.06 -23.76 33.65 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.888 2.392 . . . . 0.0 112.625 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -83.81 -47.55 11.01 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.134 0.492 . . . . 0.0 110.371 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 69' ' ' GLN . . . . . . . . . . . . . 17.6 mm100 -86.19 20.92 2.17 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.764 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . 0.442 ' O ' ' HA ' ' B' ' 81' ' ' VAL . . . -71.74 -24.25 61.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.141 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 33.9 t -112.21 103.35 15.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.261 179.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 9.6 t -122.06 130.39 74.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.435 -0.348 . . . . 0.0 111.049 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 6.2 tt0 -78.08 105.15 9.1 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 178.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -78.57 -23.76 45.89 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.152 -0.476 . . . . 0.0 112.041 -178.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . -164.17 177.39 39.91 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.366 -0.921 . . . . 0.0 112.242 -179.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -55.92 115.84 2.75 Favored 'Trans proline' 0 C--O 1.235 0.366 0 C-N-CA 122.85 2.367 . . . . 0.0 112.414 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 18.1 t30 65.27 28.18 11.99 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.533 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 34.4 tt0 -135.64 120.25 18.24 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.839 0.352 . . . . 0.0 110.69 179.379 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 34.3 m-85 -119.97 126.28 50.48 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.94 -178.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 59.4 m -97.85 124.65 42.34 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 81' ' ' VAL . . . . . 0.442 ' HA ' ' O ' ' B' ' 70' ' ' ALA . 44.7 t -115.15 117.76 56.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 121.09 0.471 . . . . 0.0 111.081 -179.342 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -88.86 95.51 10.32 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.2 178.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 83' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 21.7 t -90.46 120.3 39.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.282 -179.152 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 58.0 tp -101.2 109.12 20.94 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.848 179.22 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.79 70.31 10.35 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 86' ' ' PHE . . . . . 0.472 ' CZ ' ' HA3' ' B' ' 89' ' ' GLY . 53.5 p90 -63.0 179.13 0.41 Allowed 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.952 -178.737 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.12 102.94 0.05 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.464 -178.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 64.11 26.96 14.05 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 114.845 -1.07 . . . . 0.0 113.005 178.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 89' ' ' GLY . . . . . 0.472 ' HA3' ' CZ ' ' B' ' 86' ' ' PHE . . . -156.53 -179.52 31.58 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 119.776 -1.202 . . . . 0.0 113.285 179.42 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 90' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -135.71 132.02 36.37 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 91' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -124.1 137.64 29.33 Favored Pre-proline 0 C--N 1.324 -0.525 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -80.12 174.46 48.54 Favored 'Cis proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.249 -1.563 . . . . 0.0 111.971 -0.362 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 93' ' ' ASN . . . . . 0.432 ' OD1' ' HA ' ' B' ' 94' ' ' PRO . 55.4 t30 -161.14 124.86 1.94 Allowed Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 94' ' ' PRO . . . . . 0.432 ' HA ' ' OD1' ' B' ' 93' ' ' ASN . 69.3 Cg_endo -74.55 151.82 97.45 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.371 -1.512 . . . . 0.0 113.162 0.182 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 66.0 mt -85.78 108.56 17.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.917 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 96' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -94.15 115.43 27.71 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.481 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 97' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 2.6 m -132.6 155.31 81.36 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.65 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -84.6 160.89 12.52 Favored 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.492 2.128 . . . . 0.0 112.524 179.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.05 146.02 27.98 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.836 0.35 . . . . 0.0 111.031 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.47 -5.32 84.83 Favored Glycine 0 N--CA 1.452 -0.266 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.497 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -105.07 157.45 17.24 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.762 0.315 . . . . 0.0 111.406 -179.341 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 102' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -84.86 116.61 23.41 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 103' ' ' ILE . . . . . . . . . . . . . 24.2 mt -104.02 120.65 54.54 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.092 0.472 . . . . 0.0 110.766 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 16.7 t -96.37 99.36 8.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.262 179.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 105' ' ' PHE . . . . . 0.466 ' O ' ' HA ' ' B' ' 134' ' ' THR . 66.0 m-85 -84.07 118.62 24.19 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.343 -178.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 54.7 mttm -115.76 95.69 5.25 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 177.678 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 107' ' ' ILE . . . . . 0.508 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.1 mp -102.46 137.01 32.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.173 -177.584 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 3.3 t -138.85 157.19 46.51 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 109' ' ' SER . . . . . 0.616 ' O ' ' HA ' ' B' ' 129' ' ' PRO . 39.4 t -125.69 138.05 31.18 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 111.846 0.314 . . . . 0.0 111.846 -178.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -93.52 -11.51 1.51 Allowed 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 123.118 2.546 . . . . 0.0 112.666 178.15 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 111' ' ' ASP . . . . . 0.544 ' CG ' ' H ' ' B' ' 112' ' ' VAL . 11.5 p-10 -115.84 -113.98 0.34 Allowed 'General case' 0 CA--C 1.537 0.454 0 O-C-N 122.271 -0.268 . . . . 0.0 111.493 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 112' ' ' VAL . . . . . 0.544 ' H ' ' CG ' ' B' ' 111' ' ' ASP . 20.1 m -93.11 -179.05 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.676 0.274 . . . . 0.0 110.544 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.1 mt -73.42 136.01 26.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.24 0.543 . . . . 0.0 110.554 179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 114' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -122.83 174.13 7.33 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 115' ' ' GLY . . . . . 0.556 ' O ' ' HA ' ' B' ' 149' ' ' CYS . . . -124.96 121.35 4.28 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.999 -179.613 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -96.83 80.57 3.04 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 117' ' ' HIS . . . . . . . . . . . . . 12.2 t-80 -113.79 110.27 19.88 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.57 179.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.536 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 21.6 t -88.64 113.56 25.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-O 120.966 0.412 . . . . 0.0 110.316 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -63.02 115.47 4.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.957 -179.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 110.08 1.74 29.99 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.686 179.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 121' ' ' THR . . . . . 0.536 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 31.7 p -138.36 178.96 6.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.652 0.263 . . . . 0.0 110.658 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -96.52 20.58 10.45 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.129 0.49 . . . . 0.0 110.646 179.297 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 34.2 mt -86.95 109.38 19.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.246 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -150.28 103.82 3.19 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.761 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 9.0 p -143.41 151.78 16.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.275 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.75 134.68 34.04 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.145 0.498 . . . . 0.0 110.419 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 127' ' ' VAL . . . . . . . . . . . . . 5.1 t -99.17 96.98 5.41 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.884 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 128' ' ' LEU . . . . . . . . . . . . . 4.8 mp -87.93 147.18 40.32 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.773 -179.131 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . 0.616 ' HA ' ' O ' ' B' ' 109' ' ' SER . 28.5 Cg_endo -63.78 118.07 5.03 Favored 'Trans proline' 0 N--CA 1.462 -0.336 0 C-N-CA 122.52 2.147 . . . . 0.0 112.307 179.831 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.93 -4.29 85.67 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.832 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -102.58 139.87 37.61 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 132' ' ' VAL . . . . . 0.41 ' HB ' ' HB2' ' B' ' 51' ' ' GLU . 59.8 t -101.63 92.31 2.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.251 0.548 . . . . 0.0 110.756 179.363 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 5.3 m -73.29 105.59 4.76 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.842 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 134' ' ' THR . . . . . 0.466 ' HA ' ' O ' ' B' ' 105' ' ' PHE . 24.6 m -100.66 121.18 41.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.387 -179.024 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 48.2 t -128.13 137.3 57.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.177 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 136' ' ' ARG . . . . . 0.402 HH11 ' HD3' ' B' ' 136' ' ' ARG . 68.6 mtt-85 -108.74 120.26 41.96 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.899 0.38 . . . . 0.0 110.663 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 137' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -136.81 151.55 49.29 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.954 0.407 . . . . 0.0 111.081 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 8.3 m -120.48 100.17 6.99 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.806 179.077 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 139' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -73.27 96.87 2.35 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.344 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 83.5 mttt -91.78 -5.55 53.32 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.01 0.433 . . . . 0.0 110.668 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 141' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 -122.79 113.56 30.17 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.097 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 142' ' ' PRO . . . . . 0.468 ' HA ' HG13 ' B' ' 166' ' ' VAL . 64.4 Cg_endo -72.59 167.45 27.07 Favored 'Trans proline' 0 C--O 1.236 0.409 0 C-N-CA 122.591 2.194 . . . . 0.0 112.342 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 143' ' ' GLY . . . . . 0.487 ' N ' HG13 ' B' ' 166' ' ' VAL . . . 137.29 -159.56 24.79 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.245 -179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 144' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -120.33 116.82 26.28 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.781 0.324 . . . . 0.0 110.349 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 51.4 m-85 -110.11 147.04 34.4 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.92 -179.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 12.5 mmt180 -110.22 133.12 53.55 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.064 0.459 . . . . 0.0 111.456 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 147' ' ' ILE . . . . . 0.431 HD12 ' HA3' ' B' ' 162' ' ' GLY . 40.5 mt -88.0 131.46 35.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.708 178.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 46.4 mt -115.53 115.14 48.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 120.951 0.405 . . . . 0.0 110.179 179.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 149' ' ' CYS . . . . . 0.556 ' HA ' ' O ' ' B' ' 115' ' ' GLY . 42.5 t -79.9 89.1 5.28 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.751 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 150' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -64.13 -25.09 67.94 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 10.2 tp60 -81.05 135.85 35.88 Favored 'General case' 0 C--O 1.247 0.94 0 CA-C-O 121.204 0.526 . . . . 0.0 111.764 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -53.53 161.85 0.94 Allowed 'General case' 0 N--CA 1.471 0.621 0 CA-C-N 114.893 -1.049 . . . . 0.0 112.386 -178.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 153' ' ' CYS . . . . . 0.403 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 1.6 p 176.44 65.17 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.914 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 52.79 -142.67 25.85 Favored Glycine 0 CA--C 1.518 0.262 0 O-C-N 123.464 0.478 . . . . 0.0 114.019 179.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 155' ' ' LEU . . . . . 0.423 HD13 HG22 ' A' ' 117' ' ' THR . 91.4 mt -72.91 -27.1 61.67 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.741 0.305 . . . . 0.0 111.527 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 156' ' ' GLY . . . . . . . . . . . . . . . -87.32 62.14 4.14 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.591 -0.814 . . . . 0.0 111.623 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 157' ' ' HIS . . . . . 0.403 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 69.2 t60 -127.78 -59.3 1.21 Allowed 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -178.831 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . 0.481 ' NE2' HE22 ' A' ' 55' ' ' GLN . 4.5 pm0 -57.71 -33.23 68.19 Favored 'General case' 0 C--N 1.328 -0.333 0 O-C-N 123.463 0.477 . . . . 0.0 112.188 -178.359 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 159' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -107.49 14.14 26.14 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.719 -0.392 . . . . 0.0 111.009 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 160' ' ' MET . . . . . . . . . . . . . 26.3 ttt -84.99 85.15 7.51 Favored 'General case' 0 C--O 1.237 0.426 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 161' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -112.66 -177.14 3.07 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.972 -179.282 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 162' ' ' GLY . . . . . 0.431 ' HA3' HD12 ' B' ' 147' ' ' ILE . . . -148.21 150.98 23.25 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 178.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 7.5 m -113.03 108.31 17.17 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 117.317 0.558 . . . . 0.0 111.659 -179.022 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 41.1 mt -102.5 111.86 33.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 165' ' ' VAL . . . . . . . . . . . . . 15.0 t -108.49 102.78 14.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 121.175 0.512 . . . . 0.0 110.451 -179.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 166' ' ' VAL . . . . . 0.487 HG13 ' N ' ' B' ' 143' ' ' GLY . 0.7 OUTLIER -88.06 120.75 37.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 179.209 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 51.9 mmtt -67.32 155.93 37.69 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.654 -178.354 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 168' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 . . . . . 0 C--O 1.249 1.035 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.094 -179.459 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.408 ' OD1' ' HB2' ' A' ' 6' ' ' LYS . 4.1 p-10 . . . . . 0 N--CA 1.481 1.095 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.452 ' HA3' ' HB2' ' A' ' 86' ' ' HIS . . . -71.72 -32.66 63.92 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.931 -0.652 . . . . 0.0 113.52 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.06 -39.4 75.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 117.186 0.493 . . . . 0.0 111.165 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.408 ' HB2' ' OD1' ' A' ' 3' ' ' ASP . 0.0 OUTLIER -60.06 -40.17 88.58 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.167 179.839 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.402 ' HB ' ' HB ' ' A' ' 83' ' ' VAL . 37.2 mm -80.3 -26.92 11.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.081 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -57.2 -29.34 63.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.923 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -59.57 -30.81 68.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.103 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.467 ' O ' HMC3 ' A' ' 132' ' ' HEC . 75.8 mt-30 -75.39 -36.16 60.93 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.284 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 20.6 m -67.42 -31.8 72.24 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-O 121.048 0.452 . . . . 0.0 110.516 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.51 -19.56 65.98 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.953 -179.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.95 -24.73 71.74 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.256 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 96.3 m -129.32 -40.2 1.46 Allowed 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -179.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -91.3 -7.2 51.72 Favored 'General case' 0 C--N 1.33 -0.253 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.341 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 16.1 mm-40 65.27 176.26 0.21 Allowed 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.892 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 20.3 mp0 -79.35 -8.57 59.17 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.631 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 23.8 p30 -90.93 -20.22 22.44 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.774 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 72.34 22.35 78.94 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.938 -0.648 . . . . 0.0 112.565 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 16.3 mt-30 -98.02 -32.29 11.71 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.978 0.418 . . . . 0.0 110.42 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 79.68 -154.65 38.24 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.786 179.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 43.2 mm -128.54 125.43 23.15 Favored Pre-proline 0 C--N 1.323 -0.552 0 C-N-CA 122.472 0.309 . . . . 0.0 110.587 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_exo -56.59 114.86 2.11 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.92 2.413 . . . . 0.0 112.573 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 92.27 4.35 66.51 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 116.037 -0.528 . . . . 0.0 113.334 179.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -139.81 -53.69 0.54 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.137 0.469 . . . . 0.0 112.125 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.613 ' CD1' HMD3 ' A' ' 132' ' ' HEC . 29.8 m-85 -128.29 123.91 22.68 Favored Pre-proline 0 C--N 1.327 -0.397 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.939 -178.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.3 158.65 44.62 Favored 'Trans proline' 0 C--O 1.239 0.531 0 C-N-CA 122.889 2.393 . . . . 0.0 113.0 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -78.76 158.7 28.06 Favored 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.782 2.322 . . . . 0.0 112.351 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.409 ' O ' HG23 ' A' ' 33' ' ' VAL . 65.8 mt -115.4 -38.04 3.88 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.347 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.39 120.3 11.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.127 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 73.43 33.45 58.63 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 -179.042 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 32.4 t60 -143.92 -32.99 0.43 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.585 -0.307 . . . . 0.0 110.548 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 29' ' ' LEU . 59.6 t -63.45 -41.12 91.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -62.04 -35.38 78.42 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.847 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -61.65 -37.58 84.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.513 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.47 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 19.4 mt -79.95 -38.53 18.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.525 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 46.5 mt -62.67 -23.59 67.19 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.556 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -82.7 -10.1 59.06 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.419 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 65.9 mmtt -90.7 154.02 19.86 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.739 0.304 . . . . 0.0 110.35 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -75.42 105.31 6.38 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.71 7.67 55.28 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -64.44 -34.79 90.85 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 121.255 -0.498 . . . . 0.0 112.105 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 11.4 ptm85 -67.77 -35.17 78.21 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.614 0.245 . . . . 0.0 110.394 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -67.0 -40.09 87.28 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -61.96 -40.67 96.36 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.393 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 86.6 mt -59.43 -34.09 72.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.011 179.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.4 mt -78.98 -42.19 23.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.999 0.428 . . . . 0.0 110.08 179.104 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.51 ' HG ' HD13 ' A' ' 111' ' ' LEU . 42.8 mt -63.3 -37.93 89.17 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.11 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.577 ' O ' ' HA2' ' A' ' 53' ' ' GLY . 0.8 OUTLIER -71.06 -15.47 18.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.013 -179.631 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.59 HD11 HMB2 ' A' ' 132' ' ' HEC . 3.0 mp -96.66 -44.5 7.09 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.852 0.358 . . . . 0.0 110.538 179.158 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.6 mt -66.69 -47.23 73.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.059 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 68.9 m-85 -111.92 -55.85 2.46 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.213 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.577 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 120.11 -158.46 15.36 Favored Glycine 0 N--CA 1.441 -1.009 0 C-N-CA 119.888 -1.148 . . . . 0.0 113.938 178.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.431 ' H ' ' HB2' ' A' ' 69' ' ' MET . 1.9 tp -152.52 150.01 29.12 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -179.192 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . 0.495 ' OE1' ' HB2' ' A' ' 118' ' ' PRO . 9.3 pt20 -151.09 111.16 4.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.864 0.364 . . . . 0.0 111.726 -179.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -177.37 -143.8 5.09 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.182 178.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.463 ' HA ' ' O ' ' A' ' 65' ' ' TYR . 19.8 mp0 -132.88 66.67 1.55 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.479 ' O ' ' HA ' ' A' ' 64' ' ' LYS . 33.1 pt -66.87 155.07 7.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.247 -178.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.408 ' OE1' ' HG3' ' A' ' 64' ' ' LYS . 23.7 tt0 -124.62 100.63 6.73 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.215 0.531 . . . . 0.0 110.817 -179.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 41.0 t -100.32 115.85 42.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.061 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 19.2 mmtp 62.96 23.82 14.22 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.508 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.91 -7.9 65.17 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.654 179.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -97.55 121.0 38.95 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 17.0 mttp -91.67 144.77 25.18 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.955 0.407 . . . . 0.0 110.914 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.463 ' O ' ' HA ' ' A' ' 57' ' ' GLN . 71.1 m-85 -120.96 177.43 5.11 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.058 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -156.38 71.98 0.73 Allowed 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -140.99 -161.99 8.92 Favored Glycine 0 N--CA 1.445 -0.725 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.766 179.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.67 ' HB ' ' CG ' ' B' ' 88' ' ' PHE . 41.4 t -146.77 136.39 16.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.222 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . 0.517 ' HG3' HG22 ' A' ' 49' ' ' VAL . 0.3 OUTLIER -71.19 142.07 50.66 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.527 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.451 ' OG ' HBC2 ' A' ' 132' ' ' HEC . 6.5 m -78.52 123.84 27.5 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.719 0.295 . . . . 0.0 110.75 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.5 m -70.78 95.19 1.1 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.351 179.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.466 ' CE2' HBB2 ' A' ' 132' ' ' HEC . 41.5 m-85 -84.5 45.83 1.17 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.229 0.538 . . . . 0.0 111.375 -179.192 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -74.12 -16.67 61.0 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.84 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 19.4 pm0 -76.12 -18.65 59.06 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.68 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 65.2 mt -83.48 155.31 23.45 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.889 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 25.0 mtpt -72.69 154.71 40.58 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -55.41 -41.72 73.11 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.715 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -63.17 -37.96 89.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.005 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 51.5 mt-10 -67.07 -45.17 78.14 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.652 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 89.9 mt -60.45 -42.48 91.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.379 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.39 -35.61 73.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.635 179.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.83 -46.39 88.17 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.701 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.402 ' HB ' ' HB ' ' A' ' 7' ' ' ILE . 9.8 p -66.42 -34.94 73.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 C-N-CA 120.485 -0.486 . . . . 0.0 110.669 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 35.2 mt -65.55 -44.82 85.63 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.157 0.503 . . . . 0.0 110.155 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 82.4 m-20 -66.33 -39.06 89.0 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.21 179.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . 0.452 ' HB2' ' HA3' ' A' ' 4' ' ' GLY . 32.3 t60 -63.73 -50.73 67.98 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.516 -0.766 . . . . 0.0 111.597 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.438 HG13 ' N ' ' A' ' 88' ' ' ALA . 41.8 pt -64.39 -39.53 85.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.561 ' HB1' ' HB2' ' A' ' 94' ' ' ALA . . . -63.62 -36.23 83.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.852 0.358 . . . . 0.0 111.663 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.5 p -89.28 -23.57 22.27 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.751 -179.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -61.43 -53.88 50.76 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.875 0.369 . . . . 0.0 111.527 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.415 ' CZ3' ' HB ' ' A' ' 87' ' ' ILE . 5.3 m-90 -86.32 -8.4 57.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.192 0.52 . . . . 0.0 110.566 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 77.56 17.89 78.4 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.493 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.59 -26.96 68.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.301 0.572 . . . . 0.0 110.187 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.561 ' HB2' ' HB1' ' A' ' 88' ' ' ALA . . . -73.53 -7.57 52.39 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.208 179.233 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -98.67 1.14 45.94 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.052 0.453 . . . . 0.0 110.476 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 39.4 mtpt -103.76 11.05 36.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.636 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 15.9 m -125.18 159.77 31.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.987 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.6 ptpt -93.1 112.91 25.02 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.823 0.344 . . . . 0.0 111.155 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 69.99 68.27 1.68 Allowed Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.85 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 65.1 t80 -73.17 124.68 26.09 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.827 0.346 . . . . 0.0 110.395 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 70.5 mttt -98.65 117.56 64.37 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.501 179.261 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -59.55 141.85 97.93 Favored 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.243 1.962 . . . . 0.0 111.374 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -69.83 126.64 30.3 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.306 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.6 p -109.15 152.52 25.01 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.663 -0.698 . . . . 0.0 110.457 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.05 -24.44 58.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 111.333 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 66.6 mm-40 -60.97 -43.21 99.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.894 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.473 ' O ' ' HG2' ' A' ' 110' ' ' LYS . 27.2 mt-10 -68.73 -29.64 68.1 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.006 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 24.3 t -76.98 -40.56 30.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-O 121.186 0.517 . . . . 0.0 109.919 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 9.2 tppt? -62.93 -44.21 96.7 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.814 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.473 ' HG2' ' O ' ' A' ' 107' ' ' GLU . 62.7 pttt -60.49 -32.0 71.01 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.711 0.291 . . . . 0.0 111.361 -179.031 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.51 HD13 ' HG ' ' A' ' 48' ' ' LEU . 97.4 mt -87.61 -30.48 20.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.214 -179.342 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 46.6 ttm-85 -66.56 -31.05 71.52 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.051 0.453 . . . . 0.0 110.457 179.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -71.46 -29.99 65.48 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.621 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -89.16 92.65 9.28 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.729 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 27.3 tptp -66.09 113.71 4.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.415 0.626 . . . . 0.0 111.473 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 81.5 mt -126.63 -174.97 3.26 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.245 179.102 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.45 ' O ' HG23 ' A' ' 121' ' ' VAL . 75.3 p -131.13 147.94 68.26 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.091 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.495 ' HB2' ' OE1' ' A' ' 55' ' ' GLN . 32.4 Cg_exo -58.01 -26.77 76.56 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.6 2.2 . . . . 0.0 112.118 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 11.5 tp60 -71.29 -29.91 65.62 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.447 179.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -80.07 -33.0 39.3 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.073 179.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.45 HG23 ' O ' ' A' ' 117' ' ' THR . 43.2 t -63.15 -25.72 39.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.344 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.416 ' HA ' HD11 ' A' ' 54' ' ' LEU . 26.7 tp -57.38 -40.67 78.65 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.215 178.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . 0.464 ' O ' ' HG3' ' A' ' 127' ' ' LYS . . . -67.88 -44.72 76.4 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.042 179.428 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 32.2 mm-40 -58.12 -40.55 81.53 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.698 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.473 ' HG2' ' HB2' ' A' ' 130' ' ' LEU . 67.0 ttt-85 -65.24 -46.25 81.34 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.45 179.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.409 ' HA ' ' O ' ' A' ' 130' ' ' LEU . 65.7 mttm -67.89 -27.49 66.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.21 -179.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.464 ' HG3' ' O ' ' A' ' 123' ' ' ALA . 92.2 mttt -65.43 -29.66 70.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.071 0.462 . . . . 0.0 109.97 178.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 96.0 mt -76.77 -6.6 52.91 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.549 179.102 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.44 -1.44 57.2 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 121.018 -0.611 . . . . 0.0 111.589 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.473 ' HB2' ' HG2' ' A' ' 125' ' ' ARG . 64.4 mt -81.18 112.27 18.36 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.9 0.381 . . . . 0.0 110.343 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 8.8 mptt . . . . . 0 C--O 1.252 1.214 0 CA-C-O 118.32 -0.848 . . . . 0.0 111.139 -179.355 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 86.4 t80 . . . . . 0 N--CA 1.481 1.105 0 CA-C-O 120.716 0.294 . . . . 0.0 110.932 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -35.35 80.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.86 0.362 . . . . 0.0 111.311 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 94.4 mt -76.79 -15.16 59.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.994 0.426 . . . . 0.0 110.675 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.81 13.02 30.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.824 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 1.8 p -139.89 178.04 7.54 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.314 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' HIS . . . . . . . . . . . . . 1.4 p80 -75.54 -6.43 50.21 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.349 0.595 . . . . 0.0 109.824 179.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . 0.476 ' O ' HG22 ' B' ' 44' ' ' VAL . 0.3 OUTLIER -64.4 -19.71 65.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.07 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.28 -10.92 47.18 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.276 179.445 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -66.11 -25.78 72.27 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.312 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . 0.476 HG22 ' O ' ' B' ' 41' ' ' THR . 11.8 m -70.62 -12.24 15.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-O 120.987 0.422 . . . . 0.0 111.094 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 38.1 mt -92.16 133.2 30.59 Favored Pre-proline 0 C--N 1.322 -0.602 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -52.62 145.02 39.96 Favored 'Trans proline' 0 C--N 1.347 0.482 0 C-N-CA 122.831 2.354 . . . . 0.0 112.613 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -60.24 152.55 24.51 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.492 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -84.98 -18.99 60.09 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.947 -0.644 . . . . 0.0 111.911 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 29.8 tttt -75.85 138.42 41.1 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 50' ' ' LEU . . . . . 0.427 HD23 ' HA ' ' B' ' 50' ' ' LEU . 13.2 mt -83.19 134.27 34.98 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.01 0.433 . . . . 0.0 110.272 179.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 51' ' ' GLU . . . . . 0.435 ' HB3' ' HB ' ' B' ' 132' ' ' VAL . 1.6 tt0 -133.46 74.82 1.58 Allowed 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 52' ' ' ARG . . . . . . . . . . . . . 23.2 ttm180 -95.78 132.45 41.0 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.092 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 6.8 m -136.16 -172.0 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 115.668 -0.697 . . . . 0.0 109.909 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . 0.549 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 28.2 t70 -93.07 114.62 63.22 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 179.161 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -72.1 -11.83 27.49 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.541 2.16 . . . . 0.0 112.952 -178.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.17 -52.11 9.83 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 111.887 0.328 . . . . 0.0 111.887 -179.277 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 12.6 p -98.51 0.02 44.25 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 -178.367 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 58' ' ' VAL . . . . . 0.549 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 8.4 p -61.84 -22.58 28.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-O 121.136 0.494 . . . . 0.0 111.104 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 59' ' ' ARG . . . . . 0.456 ' NH1' ' HB2' ' B' ' 110' ' ' PRO . 12.2 ptt180 -95.77 3.12 54.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.435 -179.707 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -124.04 -31.2 3.4 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.85 0.357 . . . . 0.0 111.095 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -140.23 118.37 11.97 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.448 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 137.79 -177.76 19.68 Favored Glycine 0 N--CA 1.441 -0.969 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.298 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -63.88 -13.2 35.8 Favored 'Trans proline' 0 CA--C 1.53 0.306 0 C-N-CA 123.17 2.58 . . . . 0.0 113.103 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 30.2 m-90 -104.18 12.66 33.57 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.978 0.418 . . . . 0.0 110.328 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -100.42 2.54 42.35 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.563 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -145.14 114.93 4.97 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.472 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -72.61 -9.97 24.62 Favored 'Trans proline' 0 C--O 1.234 0.293 0 C-N-CA 122.64 2.227 . . . . 0.0 112.985 -179.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -81.93 -54.93 4.93 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.848 0.356 . . . . 0.0 110.581 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 69' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -88.07 44.23 1.18 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.051 0.453 . . . . 0.0 110.989 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . 0.429 ' O ' ' HA ' ' B' ' 81' ' ' VAL . . . -84.15 -29.36 26.74 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.383 179.374 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 41.6 t -102.21 106.84 20.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.697 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 40.7 t -120.94 125.03 73.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.136 -179.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -65.93 127.4 31.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.843 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -123.58 20.85 9.43 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.875 -178.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . 158.33 177.81 31.77 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.359 -0.924 . . . . 0.0 112.125 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -61.45 108.69 0.63 Allowed 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.961 2.441 . . . . 0.0 111.729 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 38.8 t30 63.47 25.56 14.53 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.401 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -122.19 123.15 40.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.587 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 24.8 m-85 -129.37 127.42 40.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.725 0.298 . . . . 0.0 110.823 -179.085 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 100.0 m -93.37 125.37 37.94 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 178.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . 0.429 ' HA ' ' O ' ' B' ' 70' ' ' ALA . 55.8 t -114.52 116.98 54.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.097 0.475 . . . . 0.0 110.825 -179.261 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -85.36 118.48 24.92 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.557 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 83' ' ' VAL . . . . . 0.531 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 20.2 t -116.16 124.82 72.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.138 0.494 . . . . 0.0 110.986 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 34.6 tp -101.05 115.2 29.92 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.524 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 85' ' ' ALA . . . . . . . . . . . . . . . -100.46 90.93 4.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.641 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 86' ' ' PHE . . . . . 0.414 ' CZ ' ' HB2' ' B' ' 91' ' ' GLN . 0.2 OUTLIER -96.44 -163.82 1.09 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.011 0.434 . . . . 0.0 111.524 -179.535 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.41 ' H ' ' HB2' ' B' ' 86' ' ' PHE . . . -55.86 103.31 0.1 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.913 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . 0.67 ' CG ' ' HB ' ' A' ' 68' ' ' VAL . 9.2 m-85 56.34 27.66 12.27 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.085 -0.962 . . . . 0.0 113.071 177.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 89' ' ' GLY . . . . . . . . . . . . . . . -150.38 168.98 30.33 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 119.649 -1.262 . . . . 0.0 113.207 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 90' ' ' TYR . . . . . 0.408 ' O ' ' HB2' ' B' ' 93' ' ' ASN . 83.8 m-85 -138.78 131.39 28.98 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 91' ' ' GLN . . . . . 0.414 ' HB2' ' CZ ' ' B' ' 86' ' ' PHE . 5.3 tt0 -122.34 130.28 24.75 Favored Pre-proline 0 C--N 1.323 -0.567 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -82.03 172.14 52.91 Favored 'Cis proline' 0 N--CA 1.461 -0.385 0 C-N-CA 123.512 -1.453 . . . . 0.0 112.269 -0.197 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 93' ' ' ASN . . . . . 0.408 ' HB2' ' O ' ' B' ' 90' ' ' TYR . 3.7 t30 -152.09 130.07 6.04 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.788 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 94' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' B' ' 93' ' ' ASN . 73.0 Cg_endo -77.96 149.31 87.22 Favored 'Cis proline' 0 N--CA 1.461 -0.418 0 C-N-CA 122.925 -1.698 . . . . 0.0 111.481 -1.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.3 mt -75.65 96.22 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.472 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 96' ' ' GLU . . . . . 0.61 ' HA ' ' O ' ' B' ' 165' ' ' VAL . 41.2 mt-10 -88.32 120.5 29.75 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.449 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 3.2 m -138.29 149.82 64.57 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.692 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -78.99 149.07 22.39 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.747 2.298 . . . . 0.0 112.318 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -92.26 155.83 17.7 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.37 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.13 7.12 87.39 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.355 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -123.36 158.31 31.36 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.44 0.162 . . . . 0.0 110.847 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 102' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -86.26 111.71 20.7 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 103' ' ' ILE . . . . . . . . . . . . . 8.0 mt -100.51 116.42 43.89 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.631 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 20.0 t -90.5 95.66 5.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 105' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -79.83 122.74 27.01 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.204 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -121.02 92.55 3.78 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 107' ' ' ILE . . . . . 0.531 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.5 mp -100.85 137.65 27.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.493 -177.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 5.5 t -141.79 159.49 42.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.499 178.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 109' ' ' SER . . . . . . . . . . . . . 30.6 t -119.5 135.88 24.32 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-O 120.708 0.29 . . . . 0.0 111.18 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 110' ' ' PRO . . . . . 0.456 ' HB2' ' NH1' ' B' ' 59' ' ' ARG . 65.8 Cg_endo -96.67 -0.83 1.82 Allowed 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.212 2.608 . . . . 0.0 113.216 178.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 111' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -129.16 -97.71 0.37 Allowed 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -179.042 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 112' ' ' VAL . . . . . . . . . . . . . 14.6 m -107.7 -175.25 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.709 0.29 . . . . 0.0 111.469 -178.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 2.1 mt -68.26 144.19 14.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.707 0.765 . . . . 0.0 111.428 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 114' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -141.82 178.02 7.78 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.578 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 115' ' ' GLY . . . . . 0.446 ' HA3' ' OD1' ' B' ' 150' ' ' ASN . . . -141.79 141.81 11.33 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.537 -0.839 . . . . 0.0 111.579 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -110.66 76.66 0.99 Allowed 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.077 0.465 . . . . 0.0 110.343 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 117' ' ' HIS . . . . . 0.475 ' HA ' ' O ' ' B' ' 123' ' ' ILE . 15.1 t-160 -109.11 92.18 3.95 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.024 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.571 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 22.0 t -75.26 114.63 15.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.728 -179.203 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -64.67 119.21 10.11 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.538 -179.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 106.84 1.7 36.63 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.151 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 121' ' ' THR . . . . . 0.571 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 51.0 p -132.4 -174.68 3.52 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.836 0.351 . . . . 0.0 110.777 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -103.01 14.14 32.64 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 178.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' B' ' 117' ' ' HIS . 33.7 mt -83.44 109.37 17.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.572 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -144.54 80.15 1.62 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.437 -0.801 . . . . 0.0 108.957 179.498 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 14.6 p -124.76 148.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.0 -179.047 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -83.47 142.78 30.69 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.304 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 127' ' ' VAL . . . . . . . . . . . . . 46.8 t -116.16 103.84 15.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 128' ' ' LEU . . . . . . . . . . . . . 6.4 mt -92.2 156.57 41.82 Favored Pre-proline 0 C--N 1.322 -0.592 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.135 -178.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -66.59 119.17 6.17 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.725 2.283 . . . . 0.0 112.289 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 77.71 7.48 87.29 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.708 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -112.48 126.05 54.9 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 132' ' ' VAL . . . . . 0.435 ' HB ' ' HB3' ' B' ' 51' ' ' GLU . 35.1 t -93.94 103.73 15.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.191 0.519 . . . . 0.0 111.137 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 6.3 m -81.97 111.71 18.39 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.653 179.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 134' ' ' THR . . . . . . . . . . . . . 24.3 m -97.99 124.16 42.33 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.543 -179.083 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 40.4 t -136.12 130.99 48.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.932 179.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 136' ' ' ARG . . . . . . . . . . . . . 51.5 mtt180 -99.91 115.98 30.9 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.941 0.401 . . . . 0.0 110.404 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 137' ' ' TYR . . . . . 0.413 ' CZ ' ' HB ' ' B' ' 121' ' ' THR . 7.7 t80 -121.07 156.54 32.01 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.167 0.508 . . . . 0.0 111.272 -179.311 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 4.1 m -134.12 100.57 4.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.741 178.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 139' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -72.19 121.92 20.15 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.538 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -108.79 6.99 26.05 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.034 0.445 . . . . 0.0 110.444 179.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 141' ' ' ARG . . . . . . . . . . . . . 8.7 ptp180 -152.17 131.15 6.57 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.215 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 142' ' ' PRO . . . . . 0.626 ' HA ' HG13 ' B' ' 166' ' ' VAL . 92.1 Cg_endo -76.64 -177.33 3.68 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 123.134 2.556 . . . . 0.0 112.782 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 143' ' ' GLY . . . . . . . . . . . . . . . 123.43 179.58 15.82 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.93 -0.653 . . . . 0.0 112.44 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 144' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -101.25 127.04 48.03 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -119.07 143.01 47.37 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.739 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 2.8 tpt180 -108.18 133.01 53.04 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.799 0.333 . . . . 0.0 110.301 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 147' ' ' ILE . . . . . 0.53 ' O ' ' HA ' ' B' ' 161' ' ' PHE . 13.5 mt -87.27 125.22 41.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.655 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 69.7 mt -102.19 116.01 45.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.086 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 149' ' ' CYS . . . . . . . . . . . . . 37.5 t -85.39 90.21 7.88 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.418 179.387 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 150' ' ' ASN . . . . . 0.446 ' OD1' ' HA3' ' B' ' 115' ' ' GLY . 26.5 p-10 -59.36 -38.47 80.49 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -179.185 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -70.95 136.01 48.24 Favored 'General case' 0 C--O 1.25 1.098 0 CA-C-O 121.128 0.489 . . . . 0.0 111.793 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -53.63 164.35 0.55 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.067 -0.969 . . . . 0.0 111.993 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 153' ' ' CYS . . . . . 0.646 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 5.9 p 170.52 89.67 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.996 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 71.07 -174.81 40.0 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.734 178.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 155' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -77.66 -18.36 56.77 Favored 'General case' 0 N--CA 1.463 0.208 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.044 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 156' ' ' GLY . . . . . 0.451 ' O ' HG21 ' A' ' 68' ' ' VAL . . . -108.33 31.27 8.01 Favored Glycine 0 CA--C 1.508 -0.349 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.321 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 157' ' ' HIS . . . . . 0.646 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 0.3 OUTLIER -66.41 -27.89 68.19 Favored 'General case' 0 C--N 1.318 -0.789 0 O-C-N 122.682 -0.305 . . . . 0.0 111.425 -179.337 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 2.6 pm0 -76.07 -17.67 59.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -178.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 159' ' ' ASN . . . . . 0.411 ' HB3' ' CG2' ' A' ' 68' ' ' VAL . 13.1 t30 -100.96 4.49 42.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.823 0.344 . . . . 0.0 111.038 -179.514 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 160' ' ' MET . . . . . . . . . . . . . 26.8 ttt -77.5 77.48 4.02 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 161' ' ' PHE . . . . . 0.53 ' HA ' ' O ' ' B' ' 147' ' ' ILE . 8.6 m-30 -115.8 109.89 18.3 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.427 -178.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 162' ' ' GLY . . . . . . . . . . . . . . . -80.4 165.31 48.29 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.921 -0.657 . . . . 0.0 111.598 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.08 127.06 53.04 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 117.377 0.589 . . . . 0.0 112.084 -178.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 40.8 mt -120.15 130.41 74.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 178.55 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 165' ' ' VAL . . . . . 0.61 ' O ' ' HA ' ' B' ' 96' ' ' GLU . 58.0 t -126.3 104.78 13.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 120.869 0.366 . . . . 0.0 110.643 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 166' ' ' VAL . . . . . 0.626 HG13 ' HA ' ' B' ' 142' ' ' PRO . 0.4 OUTLIER -86.74 127.56 40.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.563 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 30.5 mmtp -80.33 136.03 36.32 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.077 -178.419 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 168' ' ' GLU . . . . . 0.433 ' H ' ' CD ' ' B' ' 168' ' ' GLU . 1.3 pm0 . . . . . 0 C--O 1.248 0.995 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.129 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' HEC . . . . . 0.97 HBC3 HMC1 ' A' ' 132' ' ' HEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 169' ' ' CUA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.421 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.7 OUTLIER . . . . . 0 N--CA 1.481 1.123 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.49 -37.05 91.55 Favored Glycine 0 C--N 1.334 0.453 0 C-N-CA 121.45 -0.405 . . . . 0.0 113.152 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.65 -38.65 77.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.997 0.398 . . . . 0.0 110.378 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.52 -34.44 77.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.55 179.186 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.421 HG12 ' O ' ' A' ' 3' ' ' ASP . 50.7 mm -76.07 -35.16 28.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.358 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.402 ' HA ' ' SG ' ' A' ' 11' ' ' CYS . 68.3 t80 -65.71 -16.43 63.76 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.451 -179.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -58.91 -26.98 64.82 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.978 0.418 . . . . 0.0 110.982 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.43 HE22 HD21 ' A' ' 75' ' ' LEU . 60.0 mt-30 -77.11 -30.49 55.27 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.535 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.402 ' SG ' ' HA ' ' A' ' 8' ' ' TYR . 2.0 m -76.02 -25.87 56.12 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.152 -179.35 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.29 -18.24 48.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.948 -179.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.15 -20.77 80.05 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.795 -0.717 . . . . 0.0 113.277 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 77.0 m -130.43 -43.58 1.14 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 117.329 0.564 . . . . 0.0 111.971 -179.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 92.1 m-70 -91.42 -5.4 54.44 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 59.47 -172.11 0.12 Allowed 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.617 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -92.47 -9.67 40.63 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.093 -179.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 39.1 p30 -84.63 -8.31 58.93 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.623 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 72.67 20.32 79.58 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.498 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 64.3 mt-30 -117.4 -51.05 2.53 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.941 0.401 . . . . 0.0 110.282 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.32 -154.45 28.7 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.77 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 42.3 mm -94.92 115.33 65.27 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-O 120.623 0.249 . . . . 0.0 110.452 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -59.45 128.56 27.7 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.739 2.292 . . . . 0.0 112.089 179.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.07 3.69 69.78 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.169 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -138.27 -48.43 0.54 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.547 0.213 . . . . 0.0 111.12 179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.642 ' CD1' HMD3 ' A' ' 132' ' ' HEC . 56.6 m-85 -121.89 137.81 27.81 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.071 -179.186 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -76.16 147.64 30.01 Favored 'Trans proline' 0 C--O 1.24 0.597 0 C-N-CA 122.857 2.371 . . . . 0.0 112.14 179.056 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -80.81 155.5 20.51 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.856 2.371 . . . . 0.0 112.263 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.552 ' O ' HG23 ' A' ' 33' ' ' VAL . 67.4 mt -105.57 -43.75 4.86 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.655 179.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.91 120.02 11.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.431 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.25 12.7 82.88 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.783 -0.722 . . . . 0.0 111.998 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 58.0 t60 -127.62 -22.53 3.59 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.692 0.282 . . . . 0.0 110.899 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.552 HG23 ' O ' ' A' ' 29' ' ' LEU . 60.2 t -65.53 -45.43 92.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.924 0.392 . . . . 0.0 109.945 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -63.05 -31.34 72.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.441 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -65.08 -38.13 89.76 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.198 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.523 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 63.8 mt -78.47 -40.11 24.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.705 -179.595 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 85.8 mt -64.32 -27.32 68.95 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.137 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -79.79 4.58 15.99 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.603 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 59.0 mmtt -109.74 154.79 22.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.629 0.252 . . . . 0.0 110.407 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -66.49 112.6 4.17 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.718 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.55 14.76 77.57 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.009 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.523 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -61.07 -40.75 98.95 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 121.226 -0.511 . . . . 0.0 112.648 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.432 ' O ' HG13 ' A' ' 47' ' ' ILE . 12.7 ptm85 -66.58 -36.31 82.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.679 0.276 . . . . 0.0 110.538 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -67.52 -41.85 83.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.373 0.606 . . . . 0.0 109.52 178.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.485 ' O ' HG23 ' A' ' 49' ' ' VAL . 26.7 t80 -60.0 -43.88 94.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.109 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 35.5 mt -56.06 -45.6 79.21 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.106 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.432 HG13 ' O ' ' A' ' 43' ' ' ARG . 59.2 mt -62.13 -43.39 97.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.802 -179.704 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 62.8 mt -60.93 -38.22 85.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.963 0.411 . . . . 0.0 110.739 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.485 HG23 ' O ' ' A' ' 45' ' ' TYR . 81.0 t -65.6 -31.68 54.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.183 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.627 HD21 HMB2 ' A' ' 132' ' ' HEC . 7.0 mp -84.04 -34.65 24.21 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.958 0.409 . . . . 0.0 110.845 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.7 mt -71.54 -56.97 4.87 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.992 -0.549 . . . . 0.0 112.097 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.576 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 55.6 m-85 -103.71 -37.23 7.57 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -178.017 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.457 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 119.51 -167.61 13.4 Favored Glycine 0 N--CA 1.445 -0.728 0 C-N-CA 119.878 -1.153 . . . . 0.0 113.438 178.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.469 ' H ' ' HB3' ' A' ' 69' ' ' MET . 4.6 tp -163.33 134.62 4.81 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.867 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . 0.523 ' HB2' ' HB3' ' B' ' 159' ' ' ASN . 0.0 OUTLIER -154.38 116.27 4.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.06 0.457 . . . . 0.0 111.862 179.779 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -162.97 -148.3 5.32 Favored Glycine 0 N--CA 1.442 -0.904 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.462 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -130.52 68.19 1.47 Allowed 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.3 pt -83.39 165.49 2.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.357 -178.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -140.77 113.76 8.4 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.468 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 42.9 t -110.89 116.8 53.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.63 -179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 16.2 mttp 61.38 28.06 17.57 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.521 179.268 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.46 -20.22 51.59 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.753 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.78 110.87 18.68 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.882 0.372 . . . . 0.0 110.738 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 19.1 mttp -81.45 134.3 35.52 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.69 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -119.73 151.13 39.26 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -156.84 82.54 0.95 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.095 0.474 . . . . 0.0 110.268 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -139.73 -150.73 5.55 Favored Glycine 0 N--CA 1.44 -1.07 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.515 ' N ' HMD2 ' A' ' 132' ' ' HEC . 58.8 t -143.06 118.28 4.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.791 0.329 . . . . 0.0 110.574 179.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . 0.606 ' HB2' ' C4D' ' A' ' 132' ' ' HEC . 4.1 tpt -77.02 108.5 10.13 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -55.75 132.33 48.96 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.404 -0.816 . . . . 0.0 113.01 -178.214 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -71.14 121.4 18.25 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.896 178.795 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.45 ' HE2' ' CHC' ' A' ' 132' ' ' HEC . 36.6 m-85 -108.06 39.22 2.0 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.125 0.488 . . . . 0.0 111.034 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.02 -18.71 65.52 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.414 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.1 pm0 -68.23 -14.91 63.34 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.809 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.43 HD21 HE22 ' A' ' 10' ' ' GLN . 82.4 mt -87.35 147.69 25.37 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.888 179.298 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 53.4 mtpt -71.6 160.71 32.19 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.933 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 76.8 m-20 -53.97 -42.88 69.43 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.18 0.515 . . . . 0.0 110.356 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -63.6 -43.31 97.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.309 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 73.9 mt-10 -64.46 -42.79 95.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.368 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 97.6 mt -66.28 -40.45 86.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.969 0.414 . . . . 0.0 110.498 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.49 -35.85 75.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.884 179.448 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.32 -45.67 92.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.538 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 12.5 p -70.96 -34.49 55.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.619 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 15.7 mt -62.25 -45.49 93.05 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.263 0.554 . . . . 0.0 109.96 178.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 54.0 m-20 -69.32 -32.83 72.2 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.405 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 25.8 t60 -66.19 -51.09 61.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.749 -179.089 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 39.5 pt -63.63 -32.43 56.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -178.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.703 ' HB1' ' HB2' ' A' ' 94' ' ' ALA . . . -73.63 -33.39 64.53 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 112.034 0.383 . . . . 0.0 112.034 -179.397 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.9 p -91.47 -31.06 16.13 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 -178.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -52.25 -47.94 65.5 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 28.5 m-90 -100.38 10.28 41.45 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.902 0.382 . . . . 0.0 110.934 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 57.44 26.56 56.95 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.869 -0.605 . . . . 0.0 113.309 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.435 ' HA ' ' HD3' ' A' ' 96' ' ' LYS . 0.5 OUTLIER -71.41 -29.11 64.53 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.202 0.525 . . . . 0.0 109.998 -179.412 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.703 ' HB2' ' HB1' ' A' ' 88' ' ' ALA . . . -70.55 -15.44 62.77 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.162 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.2 mttm -80.63 -14.43 58.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.957 0.408 . . . . 0.0 110.632 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.435 ' HD3' ' HA ' ' A' ' 93' ' ' ASP . 40.6 mtpt -80.86 -21.04 41.04 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.377 -179.46 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 28.3 m -95.22 161.06 2.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 179.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -97.07 127.86 43.45 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.068 0.461 . . . . 0.0 110.967 -178.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 62.05 61.11 7.02 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.61 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 76.4 t80 -75.61 110.31 9.9 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.857 0.361 . . . . 0.0 110.457 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 95.6 mttt -84.56 124.08 73.75 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 115.683 -0.69 . . . . 0.0 109.737 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_exo -59.52 138.15 82.06 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.631 2.221 . . . . 0.0 111.923 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -65.77 129.28 39.23 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.258 179.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p -111.91 157.57 20.5 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.081 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -60.79 -32.03 71.38 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.484 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.0 mm-40 -66.54 -32.74 74.28 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.821 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -66.51 -38.55 87.45 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.167 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.408 ' HA ' HG21 ' A' ' 47' ' ' ILE . 21.1 t -71.21 -45.76 69.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.061 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 4.2 ttmp? -58.68 -38.33 77.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.713 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 25.8 ttpt -58.75 -46.46 87.4 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.328 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 40.0 mt -83.63 -15.94 47.08 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.564 -178.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 48.1 ttm-85 -69.98 -16.86 63.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.379 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -80.34 -38.52 30.4 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.066 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 45.6 tttp -81.62 95.65 7.24 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 19.7 tptm -66.05 114.03 4.91 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.2 0.524 . . . . 0.0 111.532 -179.178 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 79.6 mt -125.35 176.66 6.64 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.005 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.441 ' O ' HG23 ' A' ' 121' ' ' VAL . 61.2 p -124.43 157.57 64.53 Favored Pre-proline 0 C--N 1.319 -0.744 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.359 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.576 ' HG3' ' O ' ' A' ' 52' ' ' TYR . 50.1 Cg_exo -55.1 -30.61 71.39 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.545 2.163 . . . . 0.0 111.745 179.298 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 42.8 tp60 -74.34 -39.92 62.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.881 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' GLN . . . . . 0.478 ' O ' ' HG2' ' A' ' 124' ' ' GLU . 44.8 mt-30 -67.02 -37.63 84.48 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.162 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 117' ' ' THR . 60.8 t -60.37 -31.81 49.46 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 CA-C-O 121.137 0.494 . . . . 0.0 110.18 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 23.9 tp -64.91 -38.33 90.61 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.543 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -68.52 -39.74 81.06 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.753 178.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.478 ' HG2' ' O ' ' A' ' 120' ' ' GLN . 10.9 mm-40 -59.97 -38.03 81.34 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.656 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.426 HH11 ' HD3' ' A' ' 125' ' ' ARG . 6.4 ttm-85 -61.01 -46.27 91.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.964 178.372 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.526 ' HA ' ' O ' ' A' ' 130' ' ' LEU . 67.0 mttm -68.57 -28.41 66.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.911 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -69.01 -29.24 67.38 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.096 0.474 . . . . 0.0 110.006 178.741 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 70.0 mt -78.28 0.92 23.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.821 179.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 89.46 18.39 52.61 Favored Glycine 0 N--CA 1.446 -0.697 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.209 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.526 ' O ' ' HA ' ' A' ' 126' ' ' LYS . 18.1 mt -105.7 169.26 8.58 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 12.1 mptt . . . . . 0 C--O 1.246 0.891 0 CA-C-O 118.863 -0.589 . . . . 0.0 109.836 179.521 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 45.9 t80 . . . . . 0 N--CA 1.479 0.991 0 CA-C-O 120.787 0.327 . . . . 0.0 110.926 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 1.6 p -60.96 -36.15 78.65 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -178.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 74.6 mt -69.18 -24.33 64.04 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.763 0.316 . . . . 0.0 111.339 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -93.48 -5.37 49.32 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.14 0.495 . . . . 0.0 111.072 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . 0.403 HG22 ' H ' ' B' ' 40' ' ' HIS . 3.9 m -106.82 167.73 9.68 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.887 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 40' ' ' HIS . . . . . 0.403 ' H ' HG22 ' B' ' 39' ' ' THR . 6.0 p80 -65.18 -10.38 30.84 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.73 0.3 . . . . 0.0 111.564 -179.678 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.76 -17.63 64.76 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.932 0.396 . . . . 0.0 111.178 179.421 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.07 -4.35 24.62 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.611 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -66.36 -18.06 67.02 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.962 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 33.4 m -72.44 -12.11 15.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-O 120.927 0.394 . . . . 0.0 111.234 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 71.0 mt -88.72 125.78 61.84 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.727 179.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 46' ' ' PRO . . . . . 0.405 ' HA ' ' O ' ' B' ' 134' ' ' THR . 32.2 Cg_exo -58.08 149.11 73.6 Favored 'Trans proline' 0 C--O 1.234 0.301 0 C-N-CA 122.567 2.178 . . . . 0.0 112.197 179.736 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -62.51 142.82 57.76 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.749 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -73.37 -18.36 79.29 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.959 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 45.0 tttp -68.19 127.94 34.74 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.252 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 50' ' ' LEU . . . . . . . . . . . . . 84.2 mt -80.54 114.89 19.75 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.008 0.432 . . . . 0.0 110.488 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 51' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -116.82 103.53 10.41 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.772 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 52' ' ' ARG . . . . . 0.454 ' HD2' ' N ' ' B' ' 52' ' ' ARG . 0.4 OUTLIER -111.0 137.64 48.38 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.412 -178.981 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 10.4 m -133.02 170.47 19.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.886 179.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . 0.493 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 13.7 t70 -81.48 114.05 46.64 Favored Pre-proline 0 C--N 1.327 -0.408 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.371 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -80.18 19.32 1.06 Allowed 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 123.07 2.513 . . . . 0.0 113.576 -178.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.8 -47.94 3.1 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.238 0.542 . . . . 0.0 110.67 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 9.2 p -106.41 12.72 29.41 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.48 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 58' ' ' VAL . . . . . 0.493 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 14.7 p -60.63 -28.59 43.06 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.428 0 CA-C-O 120.944 0.402 . . . . 0.0 111.829 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 59' ' ' ARG . . . . . . . . . . . . . 29.3 ptt180 -97.05 13.19 29.92 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.843 0.354 . . . . 0.0 111.055 -179.535 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 79.0 mt-30 -130.9 -35.93 1.39 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.95 0.405 . . . . 0.0 110.813 -179.332 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -135.04 105.68 6.47 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.857 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 145.43 -179.22 22.67 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.862 -0.685 . . . . 0.0 111.884 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_exo -63.33 -27.54 71.61 Favored 'Trans proline' 0 CA--C 1.527 0.145 0 C-N-CA 122.834 2.356 . . . . 0.0 112.551 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 31.3 m-90 -85.03 6.4 25.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.534 -179.273 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -94.55 10.57 34.18 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.973 0.416 . . . . 0.0 110.951 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . 0.416 ' HB3' ' HB2' ' B' ' 69' ' ' GLN . 7.9 t70 -147.65 110.35 3.87 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.222 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_exo -62.39 -32.66 81.03 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.808 2.339 . . . . 0.0 112.915 -179.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -78.5 -46.13 20.35 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.539 -0.301 . . . . 0.0 111.086 -179.164 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 69' ' ' GLN . . . . . 0.416 ' HB2' ' HB3' ' B' ' 66' ' ' ASP . 13.6 mm100 -80.63 16.92 1.23 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.529 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -78.11 -24.56 47.43 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.992 0.425 . . . . 0.0 110.662 179.366 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 25.5 t -100.46 93.85 3.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.741 179.555 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 2.9 t -105.56 139.64 26.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -178.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 8.5 tt0 -81.51 122.86 28.08 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.023 179.496 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.18 -29.55 18.18 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.678 -179.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . 178.86 -162.54 29.64 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.438 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -61.7 107.72 0.55 Allowed 'Trans proline' 0 C--O 1.236 0.397 0 C-N-CA 123.077 2.518 . . . . 0.0 112.124 -179.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 45.2 t30 63.79 29.76 14.71 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.762 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -133.96 122.31 22.9 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.093 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -127.06 151.42 48.64 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.873 -179.411 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 91.4 m -119.82 121.58 39.41 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.332 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . . . . . . . . . 50.0 t -110.56 117.2 54.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 121.053 0.454 . . . . 0.0 111.242 -178.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -86.39 106.09 17.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.647 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 83' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 28.8 t -98.36 122.43 50.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.191 0.52 . . . . 0.0 110.697 -179.398 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 57.4 tp -102.09 109.39 21.08 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.797 179.621 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 85' ' ' ALA . . . . . . . . . . . . . . . -96.6 73.16 2.72 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.153 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 86' ' ' PHE . . . . . 0.52 ' CZ ' ' HB2' ' B' ' 91' ' ' GLN . 0.1 OUTLIER -75.01 -169.77 0.98 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.999 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . . . . . . . . . . . -39.66 93.75 0.01 OUTLIER 'General case' 0 N--CA 1.462 0.127 0 O-C-N 124.316 1.01 . . . . 0.0 113.724 -178.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . 0.402 ' HA ' ' SD ' ' B' ' 160' ' ' MET . 4.9 m-85 53.26 27.73 6.41 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 114.698 -1.137 . . . . 0.0 112.976 178.22 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 89' ' ' GLY . . . . . . . . . . . . . . . -139.62 -178.4 16.62 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.016 -1.088 . . . . 0.0 112.978 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 90' ' ' TYR . . . . . 0.517 ' OH ' ' HB2' ' B' ' 149' ' ' CYS . 41.2 m-85 -140.32 133.65 29.81 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 91' ' ' GLN . . . . . 0.52 ' HB2' ' CZ ' ' B' ' 86' ' ' PHE . 31.7 tt0 -135.48 128.34 18.11 Favored Pre-proline 0 C--N 1.322 -0.608 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 178.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -79.95 170.88 64.94 Favored 'Cis proline' 0 CA--C 1.53 0.293 0 C-N-CA 123.386 -1.506 . . . . 0.0 112.451 -0.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 93' ' ' ASN . . . . . 0.405 ' HA ' ' HA ' ' B' ' 94' ' ' PRO . 58.6 t30 -159.76 120.19 1.72 Allowed Pre-proline 0 C--N 1.326 -0.456 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 94' ' ' PRO . . . . . 0.405 ' HA ' ' HA ' ' B' ' 93' ' ' ASN . 98.2 Cg_endo -78.85 151.39 88.06 Favored 'Cis proline' 0 C--O 1.233 0.264 0 C-N-CA 123.47 -1.471 . . . . 0.0 112.755 -0.363 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 40.2 mt -81.7 127.27 39.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.611 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 96' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -104.52 124.63 49.63 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.516 0.198 . . . . 0.0 110.839 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 4.8 m -141.22 153.7 66.79 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.101 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.49 161.45 14.77 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 122.718 2.279 . . . . 0.0 111.802 178.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.29 152.73 18.31 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.021 0.438 . . . . 0.0 111.378 -179.517 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 78.03 8.72 87.32 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.564 -0.743 . . . . 0.0 113.135 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.29 155.26 26.53 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.838 0.351 . . . . 0.0 111.302 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 102' ' ' GLU . . . . . 0.556 ' OE2' ' HD3' ' B' ' 136' ' ' ARG . 77.8 tt0 -81.56 119.26 23.55 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 103' ' ' ILE . . . . . 0.437 HD12 ' HD1' ' B' ' 139' ' ' PHE . 7.8 mt -108.91 113.54 44.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.004 -179.107 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 21.5 t -91.98 101.14 12.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 105' ' ' PHE . . . . . 0.503 ' O ' ' HA ' ' B' ' 134' ' ' THR . 75.7 m-85 -82.24 122.18 27.59 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.09 -179.235 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 45.8 mttm -119.93 89.95 3.23 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 107' ' ' ILE . . . . . 0.491 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.2 mp -97.77 135.82 30.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.576 -178.111 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 4.9 t -133.8 154.21 51.17 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.515 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 109' ' ' SER . . . . . 0.702 ' O ' ' HA ' ' B' ' 129' ' ' PRO . 0.7 OUTLIER -122.7 126.28 26.15 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-O 120.652 0.263 . . . . 0.0 111.226 -178.932 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -89.24 -29.05 0.26 Allowed 'Trans proline' 0 N--CA 1.459 -0.547 0 C-N-CA 122.911 2.407 . . . . 0.0 112.808 178.455 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 111' ' ' ASP . . . . . 0.43 ' CG ' ' H ' ' B' ' 112' ' ' VAL . 8.2 p-10 -95.0 -111.76 0.12 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.863 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 112' ' ' VAL . . . . . 0.43 ' H ' ' CG ' ' B' ' 111' ' ' ASP . 17.0 m -99.86 -172.77 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 120.561 0.22 . . . . 0.0 110.533 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 21.0 mt -74.91 143.78 12.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-O 121.365 0.602 . . . . 0.0 111.543 -179.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 114' ' ' HIS . . . . . 0.466 ' HD2' ' OG ' ' B' ' 109' ' ' SER . 97.7 m-70 -136.95 179.39 6.41 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.461 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 115' ' ' GLY . . . . . 0.505 ' O ' ' HA ' ' B' ' 149' ' ' CYS . . . -134.06 134.78 7.61 Favored Glycine 0 N--CA 1.443 -0.845 0 C-N-CA 120.443 -0.885 . . . . 0.0 112.044 -179.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -104.56 85.28 2.3 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-O 121.028 0.442 . . . . 0.0 109.915 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 117' ' ' HIS . . . . . 0.462 ' HA ' ' O ' ' B' ' 123' ' ' ILE . 12.6 t-160 -113.82 109.97 19.39 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.635 179.228 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.457 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 44.5 t -88.04 113.83 25.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.241 0.543 . . . . 0.0 111.119 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -63.38 115.93 5.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.6 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 110.46 0.06 29.39 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.462 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 121' ' ' THR . . . . . 0.457 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 40.9 p -139.65 175.5 9.52 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 179.407 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -92.96 18.24 9.43 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.94 0.4 . . . . 0.0 110.365 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . 0.462 ' O ' ' HA ' ' B' ' 117' ' ' HIS . 53.6 mt -81.9 106.72 13.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.033 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -146.1 100.33 3.37 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 178.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 7.1 p -137.63 144.57 30.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.485 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -82.56 145.63 29.63 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.373 179.122 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 127' ' ' VAL . . . . . 0.503 HG12 ' HB2' ' B' ' 109' ' ' SER . 6.3 t -115.5 106.17 19.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.589 179.579 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 128' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' B' ' 129' ' ' PRO . 7.7 mp -96.52 153.24 38.9 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.38 -178.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . 0.702 ' HA ' ' O ' ' B' ' 109' ' ' SER . 27.5 Cg_exo -62.65 120.52 8.08 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.693 2.262 . . . . 0.0 112.614 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.68 -13.68 65.04 Favored Glycine 0 N--CA 1.451 -0.312 0 CA-C-N 115.897 -0.592 . . . . 0.0 113.103 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -94.55 148.37 22.32 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 132' ' ' VAL . . . . . . . . . . . . . 22.6 t -112.82 89.27 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 121.026 0.441 . . . . 0.0 110.21 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 5.0 m -62.68 105.59 0.67 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.031 179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 134' ' ' THR . . . . . 0.503 ' HA ' ' O ' ' B' ' 105' ' ' PHE . 23.2 m -102.34 115.48 30.64 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.539 -179.26 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 78.6 t -127.85 136.28 60.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.834 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 136' ' ' ARG . . . . . 0.556 ' HD3' ' OE2' ' B' ' 102' ' ' GLU . 51.2 mtt180 -110.58 113.45 26.08 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.747 0.308 . . . . 0.0 111.056 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 137' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -128.98 166.83 18.42 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.675 -179.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 73.1 m -134.51 110.55 9.44 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 178.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 139' ' ' PHE . . . . . 0.437 ' HD1' HD12 ' B' ' 103' ' ' ILE . 39.6 m-85 -84.3 112.97 20.79 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.383 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 78.9 mttt -105.31 -11.0 16.68 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.183 0.516 . . . . 0.0 110.509 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 141' ' ' ARG . . . . . 0.413 ' HB2' ' OH ' ' B' ' 145' ' ' TYR . 61.5 mtt180 -110.67 114.27 54.84 Favored Pre-proline 0 C--N 1.324 -0.511 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.783 179.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 142' ' ' PRO . . . . . 0.475 ' HA ' HG13 ' B' ' 166' ' ' VAL . 15.5 Cg_exo -68.67 155.84 67.49 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.906 2.404 . . . . 0.0 112.852 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 143' ' ' GLY . . . . . . . . . . . . . . . 139.38 -168.66 24.83 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.681 179.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 144' ' ' GLU . . . . . 0.413 ' HG2' HG22 ' B' ' 165' ' ' VAL . 49.3 mt-10 -109.39 119.71 40.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.72 0.295 . . . . 0.0 110.71 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . 0.413 ' OH ' ' HB2' ' B' ' 141' ' ' ARG . 31.1 m-85 -106.05 137.38 44.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.017 179.66 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.43 135.44 34.67 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.034 0.445 . . . . 0.0 111.636 -178.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 147' ' ' ILE . . . . . . . . . . . . . 40.3 mt -99.79 109.92 25.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 13.4 mt -103.11 119.22 51.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-O 120.817 0.341 . . . . 0.0 111.185 -179.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 149' ' ' CYS . . . . . 0.517 ' HB2' ' OH ' ' B' ' 90' ' ' TYR . 3.9 t -85.57 84.05 7.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.093 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 150' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -58.89 -17.51 24.86 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -179.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 32.1 tp60 -80.33 140.06 36.3 Favored 'General case' 0 C--O 1.25 1.102 0 CA-C-O 121.162 0.506 . . . . 0.0 111.928 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -57.25 155.35 8.93 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 114.816 -1.084 . . . . 0.0 110.778 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 153' ' ' CYS . . . . . 0.547 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 1.6 p -176.55 78.34 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.733 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 55.65 -140.93 39.91 Favored Glycine 0 C--N 1.331 0.264 0 O-C-N 123.432 0.458 . . . . 0.0 112.73 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 155' ' ' LEU . . . . . 0.434 HD13 HG22 ' A' ' 117' ' ' THR . 37.4 mt -92.58 -15.49 26.85 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.24 0.543 . . . . 0.0 110.318 179.303 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 156' ' ' GLY . . . . . . . . . . . . . . . -87.97 63.91 3.71 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.729 -0.668 . . . . 0.0 111.909 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 157' ' ' HIS . . . . . 0.547 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 62.9 t60 -131.71 -37.5 1.18 Allowed 'General case' 0 C--N 1.319 -0.752 0 O-C-N 122.61 -0.347 . . . . 0.0 111.212 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -64.99 -14.05 59.29 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 112.864 0.69 . . . . 0.0 112.864 -178.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 159' ' ' ASN . . . . . 0.523 ' HB3' ' HB2' ' A' ' 55' ' ' GLN . 8.5 t30 -132.99 15.09 4.25 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.879 0.371 . . . . 0.0 111.4 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 160' ' ' MET . . . . . 0.402 ' SD ' ' HA ' ' B' ' 88' ' ' PHE . 24.7 ttt -87.74 87.87 7.5 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 161' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -128.2 136.2 50.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.852 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 162' ' ' GLY . . . . . . . . . . . . . . . -105.87 176.37 22.05 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 11.7 m -144.38 131.51 20.57 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 117.762 0.781 . . . . 0.0 111.9 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 65.1 mt -114.44 113.11 42.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 165' ' ' VAL . . . . . 0.413 HG22 ' HG2' ' B' ' 144' ' ' GLU . 22.1 t -101.91 103.67 15.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.113 0.482 . . . . 0.0 110.746 -179.345 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 166' ' ' VAL . . . . . 0.475 HG13 ' HA ' ' B' ' 142' ' ' PRO . 1.3 p -90.88 123.63 43.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 178.69 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 28.4 mmtp -79.16 147.26 32.74 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.212 -178.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 168' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.245 0.827 0 CA-C-O 118.689 -0.672 . . . . 0.0 109.781 179.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' HEC . . . . . 0.906 HBC3 HMC1 ' A' ' 132' ' ' HEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 169' ' ' CUA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . 0.434 ' O ' HG12 ' A' ' 7' ' ' ILE . 6.1 p-10 . . . . . 0 N--CA 1.478 0.97 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.16 -37.39 92.82 Favored Glycine 0 C--N 1.333 0.379 0 C-N-CA 121.136 -0.554 . . . . 0.0 113.165 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.01 -35.67 80.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.526 0.203 . . . . 0.0 111.128 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -66.17 -34.87 79.02 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.034 0.445 . . . . 0.0 110.533 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.434 HG12 ' O ' ' A' ' 3' ' ' ASP . 31.9 mm -73.02 -38.06 54.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.054 179.557 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -63.08 -21.81 66.43 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.112 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -57.89 -31.85 67.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.989 0.424 . . . . 0.0 110.827 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 66.4 mt-30 -77.31 -32.19 55.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.06 179.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 15.7 m -70.87 -29.39 65.48 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.074 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.15 -17.58 64.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.415 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.31 5.98 39.84 Favored Glycine 0 N--CA 1.453 -0.21 0 C-N-CA 121.048 -0.596 . . . . 0.0 112.623 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.8 m -153.56 -51.13 0.1 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.602 0.239 . . . . 0.0 110.992 179.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.5 m-70 -85.96 7.01 26.01 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.87 -0.15 . . . . 0.0 111.094 -179.041 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 57.2 mm-40 61.41 -168.19 0.18 Allowed 'General case' 0 N--CA 1.465 0.275 0 O-C-N 123.492 0.495 . . . . 0.0 111.215 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 46.8 mt-30 -104.52 -5.56 21.43 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.908 0.385 . . . . 0.0 110.593 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 14.9 p30 -82.71 -4.46 57.89 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.091 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 75.74 19.18 79.25 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.468 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.468 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 44.6 mt-30 -124.73 -80.16 0.62 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.824 0.345 . . . . 0.0 110.561 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 116.39 -123.07 5.72 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.905 -179.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 36.9 mm -129.25 115.91 18.67 Favored Pre-proline 0 C--N 1.323 -0.572 0 N-CA-C 110.554 -0.165 . . . . 0.0 110.554 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -57.77 99.38 0.09 OUTLIER 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.884 2.39 . . . . 0.0 111.443 178.561 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 126.59 -15.29 6.71 Favored Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 -179.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -124.41 -36.45 2.64 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.686 0.279 . . . . 0.0 111.096 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -136.09 126.3 16.41 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.007 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.428 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 60.0 Cg_endo -75.72 134.73 16.98 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.395 2.063 . . . . 0.0 111.276 178.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 20' ' ' GLN . 17.1 Cg_exo -67.61 148.0 77.34 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.524 2.149 . . . . 0.0 112.599 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.482 ' O ' HG23 ' A' ' 33' ' ' VAL . 80.3 mt -97.22 -39.86 9.06 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.37 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.38 116.49 8.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.143 179.418 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 80.84 29.45 42.54 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.561 -0.828 . . . . 0.0 111.101 -178.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' HIS . . . . . . . . . . . . . 43.9 t60 -146.06 -34.22 0.31 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.598 -0.301 . . . . 0.0 110.561 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.482 HG23 ' O ' ' A' ' 29' ' ' LEU . 97.2 t -62.48 -43.12 98.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.326 -0.397 . . . . 0.0 109.961 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -61.8 -35.9 79.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.541 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -63.45 -37.61 87.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.23 0.538 . . . . 0.0 110.278 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.51 ' O ' ' HA3' ' A' ' 42' ' ' GLY . 61.7 mt -80.2 -39.32 19.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.142 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 45.9 mt -61.82 -25.27 67.4 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.376 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.5 -13.82 59.65 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.456 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -87.22 151.82 22.83 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.631 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -66.89 111.87 4.0 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.981 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.549 ' HA2' ' OE1' ' A' ' 44' ' ' GLU . . . 83.02 14.59 74.59 Favored Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 120.737 -0.744 . . . . 0.0 111.578 -178.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.51 ' HA3' ' O ' ' A' ' 36' ' ' ILE . . . -61.58 -39.54 97.5 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.338 -0.458 . . . . 0.0 112.475 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.502 ' O ' HG13 ' A' ' 47' ' ' ILE . 12.7 ptm85 -65.12 -36.1 83.19 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.549 ' OE1' ' HA2' ' A' ' 41' ' ' GLY . 23.0 mp0 -67.66 -39.66 84.54 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.141 0.496 . . . . 0.0 109.775 178.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.415 ' O ' HG23 ' A' ' 49' ' ' VAL . 31.5 t80 -60.16 -44.2 95.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.099 179.258 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 41.4 mt -60.67 -40.4 91.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.923 179.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.502 HG13 ' O ' ' A' ' 43' ' ' ARG . 71.9 mt -64.91 -42.12 93.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.158 179.63 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 92.2 mt -62.16 -35.42 78.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.873 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.486 HG11 HAA1 ' A' ' 132' ' ' HEC . 61.0 t -66.08 -33.35 62.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.733 179.448 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 8.2 mp -83.63 -33.31 25.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.949 0.404 . . . . 0.0 110.496 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 18.3 mt -72.18 -57.02 4.58 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.976 -0.556 . . . . 0.0 112.012 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 39.8 m-85 -105.12 -37.88 6.76 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.973 -177.635 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 49' ' ' VAL . . . 117.59 -168.13 12.89 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.051 -1.071 . . . . 0.0 113.671 178.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.466 ' H ' ' HB3' ' A' ' 69' ' ' MET . 25.6 tp -152.85 150.2 29.09 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . 0.481 HE22 ' NE2' ' B' ' 158' ' ' GLN . 13.1 pt20 -163.94 157.49 18.63 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.672 0.272 . . . . 0.0 111.114 -178.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 138.25 -118.38 1.61 Allowed Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.727 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.417 HE22 ' HB2' ' A' ' 66' ' ' ASN . 6.0 tp60 -161.82 82.8 0.58 Allowed 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 4.0 pt -96.4 148.14 5.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.036 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.407 ' HA ' ' O ' ' A' ' 63' ' ' MET . 1.8 tt0 -121.44 105.27 10.34 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.165 179.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.424 HG12 ' HG2' ' A' ' 61' ' ' LYS . 6.9 t -126.68 135.7 62.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 179.616 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.424 ' HG2' HG12 ' A' ' 60' ' ' VAL . 21.3 mmtp 60.11 28.14 17.66 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 121.079 0.466 . . . . 0.0 110.814 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.19 20.91 78.8 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.793 -0.639 . . . . 0.0 112.447 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . 0.407 ' O ' ' HA ' ' A' ' 59' ' ' GLU . 45.2 mtt -118.03 121.41 40.55 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -90.39 100.22 13.09 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.196 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -85.18 139.87 31.35 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.657 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . 0.417 ' HB2' HE22 ' A' ' 57' ' ' GLN . 3.8 t-20 -139.73 81.61 1.83 Allowed 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.434 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.9 -160.95 9.96 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.667 -0.777 . . . . 0.0 111.946 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 64.5 t -138.46 114.04 9.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.932 0.396 . . . . 0.0 110.29 179.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . 0.608 ' HB2' ' C4D' ' A' ' 132' ' ' HEC . 5.0 tpt -69.73 114.91 8.38 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 178.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.5 m -63.48 135.07 56.63 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.779 -177.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -72.09 126.87 30.86 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.412 179.23 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 37.1 m-85 -110.36 34.35 3.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.122 0.487 . . . . 0.0 110.661 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -69.02 -8.49 45.49 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.843 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 18.0 pm0 -72.22 -20.19 61.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.86 0.362 . . . . 0.0 110.721 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 22.9 mt -82.09 159.06 23.49 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.255 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.449 ' HB2' ' HG3' ' A' ' 79' ' ' GLU . 22.5 mtpt -70.29 155.11 41.11 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.255 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 40.3 m-20 -61.51 -37.05 82.28 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.002 0.43 . . . . 0.0 110.31 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -69.29 -19.99 63.9 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.952 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . 0.449 ' HG3' ' HB2' ' A' ' 76' ' ' LYS . 41.1 mt-10 -89.23 -41.85 11.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.371 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 81.9 mt -62.93 -38.84 82.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.857 179.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.55 -28.4 64.89 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.161 178.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.13 -46.46 67.6 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.327 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 14.2 p -65.27 -36.93 78.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 C-N-CA 120.81 -0.356 . . . . 0.0 110.161 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 41.1 mt -63.41 -44.02 95.85 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.168 0.509 . . . . 0.0 109.829 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 50.1 m-20 -64.51 -43.15 94.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.891 178.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 44.5 t60 -61.09 -55.23 34.96 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.354 -178.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 46.6 pt -60.6 -35.65 65.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.476 0.547 . . . . 0.0 112.476 -177.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.62 ' HB1' ' HB2' ' A' ' 94' ' ' ALA . . . -73.39 -34.2 65.4 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 22.1 p -89.85 -35.05 15.87 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.631 0.604 . . . . 0.0 112.631 -178.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -59.32 -44.51 92.58 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 15.8 m-90 -91.35 2.21 56.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.813 0.339 . . . . 0.0 111.014 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 64.44 23.99 68.93 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.9 -0.591 . . . . 0.0 113.273 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.454 ' HA ' ' HD3' ' A' ' 96' ' ' LYS . 0.2 OUTLIER -75.28 -28.73 59.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.191 0.52 . . . . 0.0 109.976 -179.913 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.62 ' HB2' ' HB1' ' A' ' 88' ' ' ALA . . . -73.47 -6.43 46.37 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.919 179.416 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 46.1 mttm -91.03 -7.12 52.78 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.175 179.362 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.454 ' HD3' ' HA ' ' A' ' 93' ' ' ASP . 34.3 mtpt -96.43 11.21 35.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.34 -179.211 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 13.0 m -126.1 151.04 32.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.017 178.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.3 ptpt -86.46 122.85 30.98 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.061 0.458 . . . . 0.0 111.967 -179.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 64.42 62.05 5.44 Favored Glycine 0 N--CA 1.453 -0.232 0 CA-C-N 115.617 -0.72 . . . . 0.0 113.424 178.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -72.46 122.7 21.71 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.778 0.323 . . . . 0.0 110.508 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 78.5 mttt -96.69 125.16 47.9 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.848 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -57.24 132.65 52.43 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.362 2.042 . . . . 0.0 111.393 179.137 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -61.95 132.57 53.42 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.581 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -113.36 153.83 27.89 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.733 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -63.33 -30.33 71.49 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.051 0.453 . . . . 0.0 110.774 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.0 mm-40 -61.24 -32.06 71.85 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.954 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -68.23 -45.72 72.48 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.176 0.512 . . . . 0.0 110.199 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 11.7 t -65.0 -46.4 91.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.527 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 26.0 ttpt -62.91 -36.01 81.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.747 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 32.9 ttpt -63.94 -47.7 79.45 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.124 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 80.3 mt -74.21 -25.69 59.82 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.046 0.45 . . . . 0.0 110.876 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 21.0 ttm-85 -72.74 -9.02 58.16 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.689 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -70.13 -37.45 75.29 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.032 0.444 . . . . 0.0 110.027 179.062 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -92.47 103.77 16.16 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.453 179.144 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 25.9 tptp -68.25 99.68 0.94 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.3 0.571 . . . . 0.0 111.009 -179.182 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 72.7 mt -108.86 -174.74 2.59 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.901 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.423 HG22 HD13 ' B' ' 155' ' ' LEU . 1.3 p -138.47 163.04 49.85 Favored Pre-proline 0 C--N 1.32 -0.699 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.401 ' HB2' ' CD ' ' A' ' 55' ' ' GLN . 77.9 Cg_exo -50.87 -41.66 54.61 Favored 'Trans proline' 0 CA--C 1.533 0.472 0 C-N-CA 122.686 2.257 . . . . 0.0 112.841 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 35.7 tp60 -65.63 -32.41 73.97 Favored 'General case' 0 CA--C 1.53 0.212 0 CA-C-O 120.767 0.318 . . . . 0.0 110.856 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 57.8 mt-30 -73.43 -35.24 65.76 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.182 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 50.1 t -66.46 -36.6 77.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 20.3 tp -61.14 -36.56 80.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.963 178.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -64.87 -38.72 91.92 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.408 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.465 ' O ' ' HG ' ' A' ' 128' ' ' LEU . 58.4 mm-40 -62.98 -39.13 93.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.33 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 55.4 ttt-85 -61.89 -42.18 98.76 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.986 179.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.457 ' HA ' ' O ' ' A' ' 130' ' ' LEU . 68.1 mttm -68.64 -27.71 66.25 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.469 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 91.1 mttt -73.67 -15.26 61.24 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.236 0.541 . . . . 0.0 110.252 179.307 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.465 ' HG ' ' O ' ' A' ' 124' ' ' GLU . 59.8 mt -88.4 -1.42 58.03 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.578 178.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.21 -10.42 61.64 Favored Glycine 0 N--CA 1.449 -0.463 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.942 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.457 ' O ' ' HA ' ' A' ' 126' ' ' LYS . 20.7 mt -88.25 106.58 18.3 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.9 0.381 . . . . 0.0 110.82 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.443 ' H ' ' HD2' ' A' ' 131' ' ' LYS . 9.2 mptt . . . . . 0 C--O 1.246 0.904 0 CA-C-O 118.416 -0.802 . . . . 0.0 110.12 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 35' ' ' TYR . . . . . . . . . . . . . 61.5 t80 . . . . . 0 N--CA 1.48 1.049 0 CA-C-O 120.464 0.173 . . . . 0.0 111.024 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 36' ' ' THR . . . . . . . . . . . . . 4.1 m -59.83 -40.81 89.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.029 0.443 . . . . 0.0 111.436 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 37' ' ' LEU . . . . . . . . . . . . . 94.9 mt -80.86 -3.46 51.33 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.455 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -103.53 -6.3 21.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.028 0.442 . . . . 0.0 110.993 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 39' ' ' THR . . . . . . . . . . . . . 2.0 p -116.31 179.97 3.84 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.651 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 40' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -68.09 -8.63 39.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.549 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -61.37 -20.67 63.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.329 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 42' ' ' ALA . . . . . . . . . . . . . . . -72.06 -8.86 57.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.198 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 43' ' ' GLY . . . . . . . . . . . . . . . -70.3 -18.7 75.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.326 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 8.9 m -74.61 -11.24 14.32 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-O 121.136 0.494 . . . . 0.0 110.905 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 38.1 mt -86.82 131.93 43.71 Favored Pre-proline 0 C--N 1.322 -0.625 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.596 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 46' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -53.56 134.62 58.72 Favored 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.797 2.331 . . . . 0.0 112.288 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -56.54 140.21 47.15 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.24 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -68.69 -23.59 75.52 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.914 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 80.0 tttt -64.08 116.87 6.33 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.933 0.397 . . . . 0.0 110.303 179.311 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 50' ' ' LEU . . . . . . . . . . . . . 80.2 mt -91.66 93.28 8.83 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.01 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 51' ' ' GLU . . . . . 0.41 ' HB2' ' HB ' ' B' ' 132' ' ' VAL . 21.0 mt-10 -89.19 103.7 16.3 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 52' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -90.7 114.79 27.2 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.797 0.332 . . . . 0.0 110.72 -179.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 53' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.19 -173.48 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.735 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . 0.59 ' O ' ' HB ' ' B' ' 58' ' ' VAL . 17.3 t70 -96.04 111.41 56.16 Favored Pre-proline 0 C--N 1.326 -0.435 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -78.06 17.43 1.02 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.752 2.301 . . . . 0.0 113.755 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.6 -55.99 2.16 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.442 0.639 . . . . 0.0 110.609 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.8 -2.03 55.5 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.092 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 58' ' ' VAL . . . . . 0.59 ' HB ' ' O ' ' B' ' 54' ' ' ASP . 12.1 p -56.22 -28.37 25.56 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -179.316 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 59' ' ' ARG . . . . . . . . . . . . . 37.3 ptt180 -98.43 12.0 36.37 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.068 0.461 . . . . 0.0 111.031 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 60' ' ' GLN . . . . . . . . . . . . . 58.8 mt-30 -124.41 -39.35 2.33 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.214 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 61' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -140.63 133.87 29.63 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.995 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.07 170.86 12.94 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.027 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 63' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -60.46 -28.19 86.26 Favored 'Trans proline' 0 CA--C 1.529 0.229 0 C-N-CA 122.682 2.255 . . . . 0.0 112.712 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 64' ' ' TRP . . . . . . . . . . . . . 32.3 m-90 -84.55 -2.62 57.63 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.154 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.92 -1.12 57.86 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.91 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -122.69 105.07 35.9 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.592 -179.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 67' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_exo -69.06 -23.76 33.65 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.888 2.392 . . . . 0.0 112.625 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -83.81 -47.55 11.01 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.134 0.492 . . . . 0.0 110.371 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 69' ' ' GLN . . . . . . . . . . . . . 17.6 mm100 -86.19 20.92 2.17 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.764 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . 0.442 ' O ' ' HA ' ' B' ' 81' ' ' VAL . . . -71.74 -24.25 61.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.141 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 33.9 t -112.21 103.35 15.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.261 179.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 9.6 t -122.06 130.39 74.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.435 -0.348 . . . . 0.0 111.049 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 6.2 tt0 -78.08 105.15 9.1 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 178.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -78.57 -23.76 45.89 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.152 -0.476 . . . . 0.0 112.041 -178.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . -164.17 177.39 39.91 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.366 -0.921 . . . . 0.0 112.242 -179.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 76' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -55.92 115.84 2.75 Favored 'Trans proline' 0 C--O 1.235 0.366 0 C-N-CA 122.85 2.367 . . . . 0.0 112.414 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 77' ' ' ASN . . . . . . . . . . . . . 18.1 t30 65.27 28.18 11.99 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.533 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 78' ' ' GLN . . . . . . . . . . . . . 34.4 tt0 -135.64 120.25 18.24 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.839 0.352 . . . . 0.0 110.69 179.379 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 34.3 m-85 -119.97 126.28 50.48 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.94 -178.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . . . . . . . . . 59.4 m -97.85 124.65 42.34 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 81' ' ' VAL . . . . . 0.442 ' HA ' ' O ' ' B' ' 70' ' ' ALA . 44.7 t -115.15 117.76 56.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 121.09 0.471 . . . . 0.0 111.081 -179.342 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -88.86 95.51 10.32 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.2 178.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 83' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' B' ' 107' ' ' ILE . 21.7 t -90.46 120.3 39.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.282 -179.152 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 58.0 tp -101.2 109.12 20.94 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.848 179.22 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.79 70.31 10.35 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 86' ' ' PHE . . . . . 0.472 ' CZ ' ' HA3' ' B' ' 89' ' ' GLY . 53.5 p90 -63.0 179.13 0.41 Allowed 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.952 -178.737 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.475 ' HB3' ' CBC' ' A' ' 132' ' ' HEC . . . -52.12 102.94 0.05 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.316 -0.856 . . . . 0.0 112.464 -178.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 64.11 26.96 14.05 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 114.845 -1.07 . . . . 0.0 113.005 178.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 89' ' ' GLY . . . . . 0.472 ' HA3' ' CZ ' ' B' ' 86' ' ' PHE . . . -156.53 -179.52 31.58 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 119.776 -1.202 . . . . 0.0 113.285 179.42 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 90' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -135.71 132.02 36.37 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 91' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -124.1 137.64 29.33 Favored Pre-proline 0 C--N 1.324 -0.525 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 92' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -80.12 174.46 48.54 Favored 'Cis proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.249 -1.563 . . . . 0.0 111.971 -0.362 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 93' ' ' ASN . . . . . 0.432 ' OD1' ' HA ' ' B' ' 94' ' ' PRO . 55.4 t30 -161.14 124.86 1.94 Allowed Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 94' ' ' PRO . . . . . 0.432 ' HA ' ' OD1' ' B' ' 93' ' ' ASN . 69.3 Cg_endo -74.55 151.82 97.45 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.371 -1.512 . . . . 0.0 113.162 0.182 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 66.0 mt -85.78 108.56 17.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.917 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 96' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -94.15 115.43 27.71 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.481 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' B' ' 166' ' ' VAL . 2.6 m -132.6 155.31 81.36 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.65 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 98' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -84.6 160.89 12.52 Favored 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.492 2.128 . . . . 0.0 112.524 179.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.05 146.02 27.98 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.836 0.35 . . . . 0.0 111.031 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.47 -5.32 84.83 Favored Glycine 0 N--CA 1.452 -0.266 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.497 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 101' ' ' ALA . . . . . . . . . . . . . . . -105.07 157.45 17.24 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.762 0.315 . . . . 0.0 111.406 -179.341 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 102' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -84.86 116.61 23.41 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 103' ' ' ILE . . . . . . . . . . . . . 24.2 mt -104.02 120.65 54.54 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.092 0.472 . . . . 0.0 110.766 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 104' ' ' VAL . . . . . . . . . . . . . 16.7 t -96.37 99.36 8.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.262 179.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 105' ' ' PHE . . . . . 0.466 ' O ' ' HA ' ' B' ' 134' ' ' THR . 66.0 m-85 -84.07 118.62 24.19 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.343 -178.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 54.7 mttm -115.76 95.69 5.25 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 177.678 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 107' ' ' ILE . . . . . 0.508 ' HA ' ' O ' ' B' ' 83' ' ' VAL . 1.1 mp -102.46 137.01 32.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.173 -177.584 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 108' ' ' THR . . . . . . . . . . . . . 3.3 t -138.85 157.19 46.51 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 109' ' ' SER . . . . . 0.616 ' O ' ' HA ' ' B' ' 129' ' ' PRO . 39.4 t -125.69 138.05 31.18 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 111.846 0.314 . . . . 0.0 111.846 -178.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -93.52 -11.51 1.51 Allowed 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 123.118 2.546 . . . . 0.0 112.666 178.15 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 111' ' ' ASP . . . . . 0.544 ' CG ' ' H ' ' B' ' 112' ' ' VAL . 11.5 p-10 -115.84 -113.98 0.34 Allowed 'General case' 0 CA--C 1.537 0.454 0 O-C-N 122.271 -0.268 . . . . 0.0 111.493 -179.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 112' ' ' VAL . . . . . 0.544 ' H ' ' CG ' ' B' ' 111' ' ' ASP . 20.1 m -93.11 -179.05 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.676 0.274 . . . . 0.0 110.544 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 34.1 mt -73.42 136.01 26.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.24 0.543 . . . . 0.0 110.554 179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 114' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -122.83 174.13 7.33 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 115' ' ' GLY . . . . . 0.556 ' O ' ' HA ' ' B' ' 149' ' ' CYS . . . -124.96 121.35 4.28 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.999 -179.613 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 116' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -96.83 80.57 3.04 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 117' ' ' HIS . . . . . . . . . . . . . 12.2 t-80 -113.79 110.27 19.88 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.57 179.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.536 ' HB ' ' OG1' ' B' ' 121' ' ' THR . 21.6 t -88.64 113.56 25.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-O 120.966 0.412 . . . . 0.0 110.316 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 119' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -63.02 115.47 4.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.957 -179.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . 110.08 1.74 29.99 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.686 179.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 121' ' ' THR . . . . . 0.536 ' OG1' ' HB ' ' B' ' 118' ' ' VAL . 31.7 p -138.36 178.96 6.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.652 0.263 . . . . 0.0 110.658 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 122' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -96.52 20.58 10.45 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.129 0.49 . . . . 0.0 110.646 179.297 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 34.2 mt -86.95 109.38 19.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.246 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 124' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -150.28 103.82 3.19 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.761 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 9.0 p -143.41 151.78 16.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.275 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 126' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.75 134.68 34.04 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.145 0.498 . . . . 0.0 110.419 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 127' ' ' VAL . . . . . . . . . . . . . 5.1 t -99.17 96.98 5.41 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.884 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 128' ' ' LEU . . . . . . . . . . . . . 4.8 mp -87.93 147.18 40.32 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.773 -179.131 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . 0.616 ' HA ' ' O ' ' B' ' 109' ' ' SER . 28.5 Cg_endo -63.78 118.07 5.03 Favored 'Trans proline' 0 N--CA 1.462 -0.336 0 C-N-CA 122.52 2.147 . . . . 0.0 112.307 179.831 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.93 -4.29 85.67 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.832 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 131' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -102.58 139.87 37.61 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 132' ' ' VAL . . . . . 0.41 ' HB ' ' HB2' ' B' ' 51' ' ' GLU . 59.8 t -101.63 92.31 2.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.251 0.548 . . . . 0.0 110.756 179.363 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 133' ' ' SER . . . . . . . . . . . . . 5.3 m -73.29 105.59 4.76 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.842 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 134' ' ' THR . . . . . 0.466 ' HA ' ' O ' ' B' ' 105' ' ' PHE . 24.6 m -100.66 121.18 41.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.387 -179.024 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 135' ' ' VAL . . . . . . . . . . . . . 48.2 t -128.13 137.3 57.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.177 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 136' ' ' ARG . . . . . 0.402 HH11 ' HD3' ' B' ' 136' ' ' ARG . 68.6 mtt-85 -108.74 120.26 41.96 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.899 0.38 . . . . 0.0 110.663 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 137' ' ' TYR . . . . . . . . . . . . . 3.4 t80 -136.81 151.55 49.29 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.954 0.407 . . . . 0.0 111.081 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 138' ' ' THR . . . . . . . . . . . . . 8.3 m -120.48 100.17 6.99 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.806 179.077 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 139' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -73.27 96.87 2.35 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.344 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 83.5 mttt -91.78 -5.55 53.32 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.01 0.433 . . . . 0.0 110.668 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 141' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 -122.79 113.56 30.17 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.097 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 142' ' ' PRO . . . . . 0.468 ' HA ' HG13 ' B' ' 166' ' ' VAL . 64.4 Cg_endo -72.59 167.45 27.07 Favored 'Trans proline' 0 C--O 1.236 0.409 0 C-N-CA 122.591 2.194 . . . . 0.0 112.342 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 143' ' ' GLY . . . . . 0.487 ' N ' HG13 ' B' ' 166' ' ' VAL . . . 137.29 -159.56 24.79 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.245 -179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 144' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -120.33 116.82 26.28 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.781 0.324 . . . . 0.0 110.349 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 51.4 m-85 -110.11 147.04 34.4 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.92 -179.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 146' ' ' ARG . . . . . . . . . . . . . 12.5 mmt180 -110.22 133.12 53.55 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.064 0.459 . . . . 0.0 111.456 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 147' ' ' ILE . . . . . 0.431 HD12 ' HA3' ' B' ' 162' ' ' GLY . 40.5 mt -88.0 131.46 35.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.708 178.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 46.4 mt -115.53 115.14 48.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 120.951 0.405 . . . . 0.0 110.179 179.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 149' ' ' CYS . . . . . 0.556 ' HA ' ' O ' ' B' ' 115' ' ' GLY . 42.5 t -79.9 89.1 5.28 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.751 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 150' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -64.13 -25.09 67.94 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 151' ' ' GLN . . . . . . . . . . . . . 10.2 tp60 -81.05 135.85 35.88 Favored 'General case' 0 C--O 1.247 0.94 0 CA-C-O 121.204 0.526 . . . . 0.0 111.764 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 152' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -53.53 161.85 0.94 Allowed 'General case' 0 N--CA 1.471 0.621 0 CA-C-N 114.893 -1.049 . . . . 0.0 112.386 -178.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 153' ' ' CYS . . . . . 0.403 ' SG ' ' HB2' ' B' ' 157' ' ' HIS . 1.6 p 176.44 65.17 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.914 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 154' ' ' GLY . . . . . . . . . . . . . . . 52.79 -142.67 25.85 Favored Glycine 0 CA--C 1.518 0.262 0 O-C-N 123.464 0.478 . . . . 0.0 114.019 179.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 155' ' ' LEU . . . . . 0.423 HD13 HG22 ' A' ' 117' ' ' THR . 91.4 mt -72.91 -27.1 61.67 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.741 0.305 . . . . 0.0 111.527 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 156' ' ' GLY . . . . . . . . . . . . . . . -87.32 62.14 4.14 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.591 -0.814 . . . . 0.0 111.623 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 157' ' ' HIS . . . . . 0.403 ' HB2' ' SG ' ' B' ' 153' ' ' CYS . 69.2 t60 -127.78 -59.3 1.21 Allowed 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -178.831 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . 0.481 ' NE2' HE22 ' A' ' 55' ' ' GLN . 4.5 pm0 -57.71 -33.23 68.19 Favored 'General case' 0 C--N 1.328 -0.333 0 O-C-N 123.463 0.477 . . . . 0.0 112.188 -178.359 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 159' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -107.49 14.14 26.14 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.719 -0.392 . . . . 0.0 111.009 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 160' ' ' MET . . . . . . . . . . . . . 26.3 ttt -84.99 85.15 7.51 Favored 'General case' 0 C--O 1.237 0.426 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 161' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -112.66 -177.14 3.07 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.972 -179.282 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 162' ' ' GLY . . . . . 0.431 ' HA3' HD12 ' B' ' 147' ' ' ILE . . . -148.21 150.98 23.25 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 178.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 163' ' ' THR . . . . . . . . . . . . . 7.5 m -113.03 108.31 17.17 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 117.317 0.558 . . . . 0.0 111.659 -179.022 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 164' ' ' ILE . . . . . . . . . . . . . 41.1 mt -102.5 111.86 33.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 165' ' ' VAL . . . . . . . . . . . . . 15.0 t -108.49 102.78 14.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 121.175 0.512 . . . . 0.0 110.451 -179.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 166' ' ' VAL . . . . . 0.487 HG13 ' N ' ' B' ' 143' ' ' GLY . 0.7 OUTLIER -88.06 120.75 37.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 179.209 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 167' ' ' LYS . . . . . . . . . . . . . 51.9 mmtt -67.32 155.93 37.69 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.654 -178.354 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 168' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 . . . . . 0 C--O 1.249 1.035 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.094 -179.459 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' HEC . . . . . 0.827 HBC3 HMC1 ' A' ' 132' ' ' HEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 169' ' ' CUA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 stop_ save_